tranexamic acid has been researched along with Blood Loss, Surgical in 1488 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Blood Loss, Surgical: Loss of blood during a surgical procedure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Multiple doses of dexamethasone and tranexamic acid can inhibit postoperative inflammation and reduce fibrinolysis and perioperative blood loss in total knee arthroplasty." | 9.69 | Tourniquets can further reduce perioperative blood loss in patients on dexamethasone and tranexamic acid during cemented total knee arthritis: a single-center, double-blind, randomized controlled trial. ( Huang, Q; Jiang, W; Liu, M; Pei, F; Wang, X; Xie, J; Xu, H; Zhou, R; Zhou, Z, 2023) |
| " The purpose of this study was to assess the safety of tranexamic acid (TXA) utilization with respect to the incidence of deep venous thrombosis (DVT) in hemophiliacs undergoing total knee arthroplasty (TKA)." | 9.69 | Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study. ( Guo, JJ; Yu, Z; Zhang, Q; Zhao, L, 2023) |
| "Patients with non-traumatic epistaxis were evaluated in three treatment groups as topical lidocaine, epinephrine, and TXA." | 9.51 | Comparison of the therapeutic efficacy of topical tranexamic acid, epinephrine, and lidocaine in stopping bleeding in non-traumatic epistaxis: a prospective, randomized, double-blind study. ( Ekmekyapar, M; Gur, A; Sahin, L, 2022) |
| "Based upon Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), the authors collected fully published English literature on the administration of tranexamic acid for patients undergoing intracranial meningioma surgery using the keywords ["tranexamic acid" and "meningioma"] and its synonyms from Cochrane Central Database, the WHO International Clinical Trials Registry Platform (ICTRP), ClinicalTrials." | 9.41 | A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma. ( Chadid, DP; July, J; Quintero-Consuegra, M; Wijaya, JH, 2023) |
| "To compare the efficacy of different dosages of intravenous (IV) tranexamic acid (TXA) in the treatment of traumatic hip fractures against that of the control group of no TXA." | 9.41 | The Efficacy of Tranexamic Acid for the Treatment of Traumatic Hip Fractures: A Network Meta-Analysis. ( Bloom, DA; Chapman, CB; Konda, SR; Lin, CC; Manzi, JE; Mojica, ES; Telgheder, ZL, 2023) |
| "Meta-analyses on the use of tranexamic acid (TXA) in intertrochanteric fractures have shown inconsistent results due to variations in inclusion criteria and clinical heterogeneity." | 9.41 | Intravenous application of tranexamic acid in intramedullary nailing for the treatment of geriatric intertrochanteric fractures: a systematic review and meta-analysis. ( Fan, X; Wu, J; Yuan, X; Zhang, J; Zheng, Y, 2023) |
| "Tranexamic acid (TXA) has been widely used in orthopedic surgery, but its efficacy in adolescent scoliosis (AS) surgery remains unclear in the literature." | 9.41 | Tranexamic acid can reduce blood loss in adolescent scoliosis surgery: a systematic review and meta-analysis. ( Chen, K; Gao, Q; Masood, U; Song, Y; Wang, L; Yang, H; Zeng, Z, 2023) |
| " We included controlled trials, either randomized (RCT) or non-randomized studies of intervention (NRSI) comparing the effects of intravenous tranexamic acid (TXA) treatment with placebo/no treatment on postoperative blood loss, pain VAS score, elbow ROM, and complications, in patients who underwent open or closed elbow arthrolysis surgery." | 9.41 | Does tranexamic acid diminish hemorrhage and pain in open elbow arthrolysis? a systematic review and meta-analysis. ( Daliri, M; Ebrahimzadeh, MH; Khayami, A; Moradi, A; Nejat, MH; Sadeghi, M, 2023) |
| "To conduct the first-ever systematic review and meta-analysis of randomized controlled trials (RCTs) on the antihemorrhagic utility and safety of tranexamic acid (TXA) versus misoprostol for management (prevention and/or treatment) of postpartum hemorrhage (PPH)." | 9.41 | Tranexamic acid versus misoprostol for management of postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials. ( Abdulmalik, NA; Abu-Zaid, A; Abuzaid, M; Albadawi, MI; Alblewi, H; Albouq, B; Alomar, O; Alsehaimi, SO; Alyousef, A; Baradwan, S; Bukhari, IA; Ghazi, A; Khadawardi, K; Salem, H, 2023) |
| "Tranexamic acid (TXA) is widely used in surgery for adolescent idiopathic scoliosis (AIS) and has been proved to be efficacious in reducing intraoperative blood loss (IBL) and the transfusion rate." | 9.41 | The effect of multiple-dose oral versus intravenous tranexamic acid in reducing postoperative blood loss and transfusion rate after adolescent scoliosis surgery: a randomized controlled trial. ( Liu, LM; Song, YM; Wang, L; Wang, LN; Xiu, P; Yang, X; Zhang, Z; Zhou, ZJ, 2021) |
| "The objective of this study is to determine the efficacy of high-dose versus low-dose tranexamic acid (TXA) in adolescent idiopathic scoliosis (AIS) corrective surgery." | 9.41 | Tranexamic Acid in Pediatric Scoliosis Surgery: A Prospective Randomized Trial Comparing High-dose and Low-dose Tranexamic Acid in Adolescent Idiopathic Scoliosis Undergoing Posterior Spinal Fusion Surgery. ( Chan, CYW; Chiu, CK; Hasan, MS; Kwan, MK; Ng, CC; Yunus, SN, 2021) |
| "We aimed to determine the efficacy and safety of multiple doses of intravenous tranexamic acid (IV-TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA) who had undergone primary unilateral total knee arthroplasty (TKA)." | 9.41 | Multiple intravenous tranexamic acid doses in total knee arthroplasty in patients with rheumatoid arthritis: a randomized controlled study. ( Gao, CX; Gao, XJ; Kang, BX; Ma, YH; Sun, ST; Xiao, LB; Xie, J; Xu, H; Xu, XR; Zhai, WT; Zhang, J; Zhao, C; Zhong, S, 2021) |
| "To investigate the efficacy and safety of intravenous combined with topical administration of tranexamic acid (TXA) in reducing blood loss after intramedullary fixation of intertrochanteric femoral fractures by a prospective controlled trial." | 9.41 | [Efficacy and safety of intravenous combined with topical administration of tranexamic acid in reducing blood loss after intramedullary fixation of intertrochanteric femoral fractures]. ( Gong, D; Gou, Y; Li, H; Li, W; Liu, D; Tang, X; Wang, N; Wu, Y; Zhang, Y, 2021) |
| "To indicate whether combined topical and intravenous (IV) administration of tranexamic acid (TXA) could further reduce the blood loss after surgery for adolescent idiopathic scoliosis (AIS) compared with IV-TXA alone." | 9.41 | Combined topical and intravenous administration of tranexamic acid further reduces postoperative blood loss in adolescent idiopathic scoliosis patients undergoing spinal fusion surgery: a randomized controlled trial. ( Dong, Y; Li, Q; Liang, J; Shen, J; Tong, B; Zhao, H, 2021) |
| "The combined application of tranexamic acid and rivaroxaban significantly reduced the amount of blood loss and the transfusion rate during PLIF surgery and avoided an increase in the probability of thrombosis and the occurrence of epidural haematoma." | 9.34 | Combined use of tranexamic acid and rivaroxaban in posterior lumbar interbody fusion safely reduces blood loss and transfusion rates without increasing the risk of thrombosis-a prospective, stratified, randomized, controlled trial. ( Chen, Y; Guan, T; Jiao, G; Li, Y; Liu, D; Liu, H; Meng, C; Sun, Z; Wang, H; Wu, W; Xiao, X; Xue, H; Yue, H; Zhang, L; Zhou, H, 2020) |
| "This clinical trial is designed to evaluate the effect of multiple-dose tranexamic acid (TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA)." | 9.34 | Multiple-dose tranexamic acid for perioperative blood loss in total knee arthroplasty in patients with rheumatoid arthritis：a single-blinded, randomised, parallel-controlled study protocol in China. ( Gao, CX; Kang, BX; Ma, YH; Sun, ST; Xiao, LB; Xie, J; Xu, H; Zhai, WT; Zhang, J; Zhong, S, 2020) |
| "To investigate the effect of adjunctive intravenous tranexamic acid (TA) on blood loss during cesarean section (CS) in patients with placenta previa undergone bilateral uterine arteryligation (BUAL)." | 9.30 | Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean delivery for placenta previa: a randomized double-blind controlled trial. ( Abbas, AM; Sallam, HF; Shady, NW, 2019) |
| "We recently reported that tranexamic acid (TXA) evokes pain in rats by inhibiting γ-aminobutyric acid and glycine receptors on neurons in the spinal dorsal horn." | 9.24 | Administration of tranexamic acid to patients undergoing surgery for adolescent idiopathic scoliosis evokes pain and increases the infusion rate of remifentanil during the surgery. ( Endo, N; Kohno, T; Ohashi, M; Ohashi, N, 2017) |
| "To assess the effects of tranexamic acid among patients undergoing cesarean delivery who were at high risk of postpartum hemorrhage." | 9.22 | Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. ( Aneja, A; Hanjoora, VM; Kaur, R; Khanna, M; Sujata, N; Tobin, R, 2016) |
| "The aim of this study was to investigate the efficacy of tranexamic acid (TA) and methylprednisolone on periorbital edema, ecchymosis, and intraoperative bleeding in patients who underwent open septorhinoplasty (oSRP)." | 9.20 | The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty. ( Akyiğit, A; Düzer, S; Orhan, İ; Polat, C; Sakallioğlu, Ö; Soylu, E, 2015) |
| "Preincision administration of 10 mg/kg of tranexamic acid significantly improved the surgical field during cleft palate repair." | 9.20 | Evaluation of the Efficacy of Tranexamic Acid on the Surgical Field in Primary Cleft Palate Surgery on Children-A Prospective, Randomized Clinical Study. ( Durga, P; Gunnam, P; Gurajala, I; Raavula, P; Ramachandran, G; Reddy, M; Upputuri, O; Veerabathula, P, 2015) |
| "This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery." | 9.12 | The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021) |
| "The use of tranexamic acid (TXA) is established in the treatment of bleeding, especially of bleeding due to hyperfibrinolysis." | 9.12 | [Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?] ( Möhnle, P; Pekrul, I; Schachtner, T; Zwißler, B, 2021) |
| "Intraoperative administration of tranexamic acid significantly reduces blood loss during spinal surgery in children with scoliosis." | 9.11 | Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. ( Bacsik, J; Brustowicz, RM; Sethna, NF; Shapiro, F; Sullivan, LJ; Zurakowski, D, 2005) |
| "The administration of prophylactic tranexamic acid in patients with scoliosis who are undergoing posterior spinal fusion surgery has the potential to reduce perioperative blood transfusion requirements." | 9.09 | A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. ( Barrowman, NJ; Hall, L; Murto, K; Neilipovitz, DT; Splinter, WM, 2001) |
| "The effect of high dose tranexamic acid on blood loss after operations for acute aortic dissection was evaluated." | 9.08 | [The effect of intraoperative high-dose tranexamic acid on blood loss after operation for acute aortic dissection]. ( Hirayama, T; Misumi, H; Nakajima, M; Shimamura, Y; Shimokawa, T; Uemura, K; Uesugi, H, 1998) |
| "Objective To summarize cases of acute myocardial infarction (AMI) after tranexamic acid (TXA) administration." | 9.05 | Acute Myocardial Infarction After Tranexamic Acid: Review of Published Case Reports. ( Shao, K; Yao, YT; Yuan, X, 2020) |
| "To systematically examine the role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty." | 9.01 | Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis. ( Bezuhly, M; McGuire, C; Nurmsoo, S; Samargandi, OA, 2019) |
| "To evaluate the efficacy and safety of tranexamic acid (TXA) in patients with adolescent idiopathic scoliosis undergoing corrective surgery." | 9.01 | The Perioperative Efficacy and Safety of Tranexamic Acid in Adolescent Idiopathic Scoliosis. ( Cao, K; Lin, N; Lu, H; Wang, B; Zhong, J; Zhou, X, 2019) |
| "To investigate the results of tranexamic acid use to reduce intraoperative bleeding, postoperative eyelid edema, and periorbital ecchymosis in rhinoplasty." | 8.98 | Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis. ( de Aguiar Menezes, MV; de Souza Dantas, R; de Vasconcellos, SJA; do Nascimento-Júnior, EM; Martins-Filho, PRS; Tavares Mendes, ML, 2018) |
| "This meta-analysis aims to assess the efficacy and safety of tranexamic acid for reducing blood loss and transfusion requirements in patients with intertrochanteric fractures." | 8.95 | Tranexamic acid reduces blood loss in intertrochanteric fractures: A meta-analysis from randomized controlled trials. ( Wang, W; Yu, J, 2017) |
| "The purpose of this systematic review and meta-analysis of randomized controlled trials (RCTs) and non-RCTs was to gather data to evaluate the efficacy and safety of tranexamic acid (TXA) versus placebo after a scoliosis surgery." | 8.95 | Efficacy and safety of tranexamic acid in reducing blood loss in scoliosis surgery: a systematic review and meta-analysis. ( Xu, BS; Yuan, QM; Zhao, ZH, 2017) |
| "The aim of this meta-analysis was to assess whether tranexamic acid (TXA) therapy for adult cardiac surgery is associated with an increase in the risk of seizures, and we performed a meta-analysis of randomized controlled trials (RCTs) and non-randomized observational studies." | 8.95 | Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and non-randomized studies. ( Ando, T; Takagi, H; Umemoto, T, 2017) |
| "There has been an explosion of interest in the ability of tranexamic acid to reduce morbidity and mortality in surgical and traumatic bleeding." | 8.91 | The current place of tranexamic acid in the management of bleeding. ( Hunt, BJ, 2015) |
| "Intravenous tranexamic acid reduces bleeding in surgery, however, its effect on the risk of thromboembolic events is uncertain and an increased risk remains a theoretical concern." | 8.89 | Topical application of tranexamic acid for the reduction of bleeding. ( Beecher, D; Ker, K; Roberts, I, 2013) |
| "The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage." | 8.87 | Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011) |
| "We conducted a secondary analysis of the MAssive Transfusion in Children (MATIC), a prospectively collected database of children with life-threatening hemorrhage (LTH), and evaluated for risk of adverse events with either antifibrinolytic treatment, epsilon aminocaproic acid (EACA) or tranexamic acid (TXA)." | 8.31 | Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children. ( Josephson, CD; Kolodziej, JH; Leeper, CM; Leonard, JC; Spinella, PC; Zenati, MS, 2023) |
| "To evaluate the effects of administering tranexamic acid (TXA) after cardiopulmonary bypass, instead of after anesthesia induction, on postoperative seizures and blood transfusion requirements." | 8.12 | Tranexamic acid after cardiopulmonary bypass does not increase risk of postoperative seizures: a retrospective study. ( Chen, C; Du, L; Liu, J, 2022) |
| "The utility of tranexamic acid (TXA) in patients with Marfan syndrome (MFS) is uncertain given associated aberrations within the vasculature and clotting cascade." | 8.12 | Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome. ( Ikwuezunma, IA; Margalit, A; Sponseller, PD, 2022) |
| "Previous studies demonstrated the safety of tranexamic acid (TXA) use in cerebral palsy (CP) patients undergoing proximal femoral varus derotational osteotomy (VDRO), but were underpowered to determine if TXA alters transfusion rates or estimated blood loss (EBL)." | 8.12 | Tranexamic acid use decreases transfusion rate in children with cerebral palsy undergoing proximal femoral varus derotational osteotomy. ( Andras, L; Compton, E; Goldstein, RY; Kay, RM; Nazareth, A; Shymon, SJ, 2022) |
| "Background and Objectives: Previous studies regarding tranexamic acid (TXA) in total knee arthroplasty (TKA) investigated only symptomatic deep vein thrombosis (DVT), or did not include high risk patients." | 8.12 | Topical Tranexamic Acid Can Be Used Safely Even in High Risk Patients: Deep Vein Thrombosis Examination Using Routine Ultrasonography of 510 Patients. ( An, BK; Joo, YB; Kim, YM; Kwon, ST; Lee, CW; Song, JH, 2022) |
| "The administration of tranexamic acid (TXA) has been shown to be beneficial in reducing blood loss during surgery for adolescent idiopathic scoliosis (AIS), but optimal dosing has yet to be defined." | 8.12 | High- versus low-dose tranexamic acid as part of a Patient Blood Management strategy for reducing blood loss in patients undergoing surgery for adolescent idiopathic scoliosis. ( Bacon, A; Javidan, Y; Klineberg, E; Roberto, R; Stondell, C; Tafoya, S; Taylor, SL; Tumber, S, 2022) |
| " The purpose of this study was to compare the effects of intra-articular (IA) administration of tranexamic acid (TXA), an anti-fibrinolytic commonly used in TKA, and ALM chondroprotective solution on postoperative inflammation and joint tissue healing in a rat model of knee implant surgery." | 8.02 | Comparison of intra-articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty. ( Biros, E; Dlaska, C; Dobson, GP; Hazratwala, K; Letson, HL; McEwen, P; Morris, JL; Wilkinson, M, 2021) |
| "This case reminds clinicians that perioperative tranexamic acid administration may increase the risk of thrombosis, which needs focused attention from anesthesiologists." | 8.02 | Circulation collapse caused by intracardiac thrombosis associated with tranexamic acid administration: A case report. ( Gu, KP; Huang, CJ; Xie, Q; Yao, YX, 2021) |
| "Tranexamic acid (TXA) is an antifibrinolytic used for prophylaxis and treatment of acute bleeding." | 8.02 | Impact of Obesity on Tranexamic Acid Efficacy in Adult Patients With Major Bleeding. ( Farina, N; Franz, ND; Machado-Aranda, D; Miller, JT, 2021) |
| "Tranexamic acid (TXA) has gained increasing recognition in plastic surgery as a dependable adjunct capable of minimizing blood loss, ecchymosis, and edema." | 8.02 | Local Infiltration of Tranexamic Acid (TXA) in Liposuction: A Single-Surgeon Outcomes Analysis and Considerations for Minimizing Postoperative Donor Site Ecchymosis. ( Banuelos, J; Molinar, VE; Tran, NV; Weissler, JM, 2021) |
| "In cardiac surgery, use of the antifibrinolytic agent tranexamic acid (TXA) and acute perioperative stroke are both associated with convulsive seizures." | 8.02 | Associations of preoperative stroke and tranexamic acid administration with convulsive seizures in valvular open-heart surgery. ( Deutsch, MA; Gummert, JF; Hulde, N; Koster, A; von Dossow, V; Zittermann, A, 2021) |
| "Previous studies have demonstrated that the use of tranexamic acid (TXA) reduces blood loss and transfusion requirements in children undergoing scoliosis surgery." | 8.02 | A New Low Dose of Tranexamic Acid for Decreasing the Rate of Blood Loss in Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis. ( Bronson, WE; Halpern, LM; Kogan, CJ, 2021) |
| "This study aimed to investigate the effect of intravenous tranexamic acid (TXA) on blood loss and transfusion rates in children who underwent resection and endoprosthetic reconstruction of distal femoral osteosarcomas." | 8.02 | Efficacy and Safety of Tranexamic Acid in Resection and Endoprosthetic Reconstruction of Distal Femoral Osteosarcomas in Children: A Retrospective Cohort Study. ( Buyuktopcu, O; Erol, B; Kesimer, MD; Ozturk, O; Polat, M; Sofulu, O, 2021) |
| "Tranexamic acid (TXA) is an effective agent used for reducing perioperative blood loss and decreasing the potential for postoperative hemarthrosis." | 7.88 | Tranexamic Acid Reduces Perioperative Blood Loss and Hemarthrosis in Total Ankle Arthroplasty. ( Boyle, KK; Nodzo, SR; Pavlesen, S; Ritter, C, 2018) |
| "To investigate the effectiveness and safety of intravenous tranexamic acid for reducing perioperative blood loss in patients with multilevel thoracic spinal stenosis (TSS)." | 7.88 | The efficacy and safety of tranexamic acid in reducing perioperative blood loss in patients with multilevel thoracic spinal stenosis: A retrospective observational study. ( Huang, X; Huang, Y; Liu, T; Qiao, F; Xu, X; Xue, P; Yang, J, 2018) |
| "Our objective was to quantify blood loss and transfusion requirements for high-dose and low-dose tranexamic acid (TXA) dosing regimens in pediatric patients undergoing spinal fusion for correction of idiopathic scoliosis." | 7.85 | High-dose Versus Low-dose Tranexamic Acid to Reduce Transfusion Requirements in Pediatric Scoliosis Surgery. ( Frank, SM; Goobie, SM; Johnson, CC; Johnson, DJ; Nami, N; Sponseller, PD; Wetzler, JA, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic that is widely used to reduce surgical bleeding." | 7.83 | Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. ( Li, S; Liu, M; Peng, Y; Sessler, DI; Wu, Y; Yan, X; Yang, J; Zeng, M; Zhang, L; Zhou, D, 2024) |
| "Use of large dose tranexamic acid routinely seems to be effective and safe in reducing allogenic blood transfusion and blood loss in adolescent idiopathic scoliosis surgery." | 7.83 | Efficacy of tranexamic acid in reducing allogeneic blood products in adolescent idiopathic scoliosis surgery. ( Sui, WY; Yang, JL; Ye, F, 2016) |
| "We investigated the influence of intraoperative continuous tranexamic acid (TA) infusion on the amount of blood transfusion required in emergency surgery for type A acute aortic dissection." | 7.81 | Usefulness of intraoperative continuous infusion of tranexamic acid during emergency surgery for type A acute aortic dissection. ( Ahn, KT; Hirose, K; Ikarashi, J; Iwakura, A; Kusuhara, T; Nakatsuka, D; Yamanaka, K, 2015) |
| "We describe, for the first time, the use of topical tranexamic acid as an adjunct to traditional methods in the control of bleeding in burns surgery." | 7.78 | Use of tranexamic acid to reduce bleeding in burns surgery. ( Brooks, P; Chapman, TW; Tang, YM, 2012) |
| "A retrospective review of consecutive adult patients undergoing scoliosis correction surgery was performed to compare the effects of aprotinin and tranexamic acid in blood conservation and to define a comprehensive blood conservation strategy for such surgery." | 7.78 | Comparison of aprotinin and tranexamic acid in adult scoliosis correction surgery. ( Ahuja, S; Guha, A; Khurana, A; Pugh, S; Saxena, N, 2012) |
| "To assess the efficacy and safety of tranexamic acid (TXA) in decreasing operative blood loss and the need for transfusion during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents." | 7.78 | Does the intraoperative tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of adolescent idiopathic scoliosis? ( Fukuda, K; Hasegawa, J; Iizuka, S; Kaneko, S; Machida, M; Nagoshi, N; Shioda, M; Takemitsu, M; Yagi, M, 2012) |
| "We compared intraoperative blood loss and blood replacement during spinal fusion surgery for scoliosis in Duchenne muscular dystrophy (DMD) performed with and without the synthetic antifibrinolytic agent tranexamic acid (TXA)." | 7.74 | Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusions for duchenne muscular dystrophy scoliosis. ( Sethna, NF; Shapiro, F; Zurakowski, D, 2007) |
| "Tranexamic acid (TXA) has been widely applied in total knee arthroplasty (TKA) to significantly reduce perioperative blood loss and improve knee function recovery in patients after surgery." | 7.30 | Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study. ( Wang, CC; Wu, T; Zhang, GQ; Zhang, LT; Zhou, LB, 2023) |
| "No tranexamic acid was administered to the control group." | 7.30 | [Effects of Tranexamic Acid on Perioperative Blood Loss and Wound Hematoma Development in Lumbar Spine Surgery: a Prospective Randomized Study]. ( Hrabálek, L; Jablonský, J; Novák, V; Stejskal, P; Trnka, Š; Wanek, T, 2023) |
| "Tranexamic acid (TXA) has been proven to prevent thrombolysis and reduce bleeding and blood transfusion requirements in various surgical settings." | 7.30 | The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial. ( Jin, H; Li, M; Li, S; Liu, M; Liu, X; Ma, T; Peng, Y; Wang, J; Wu, Y; Yang, J; Yu, H; Zeng, M; Zhang, L; Zhang, X, 2023) |
| "The hemostatic effect of tranexamic acid (TXA) combined with carbazochrome sodium sulfonate (CSS) in total hip arthroplasty (THA) has not been determined." | 7.11 | Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial. ( Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022) |
| "Postoperative pneumonia is a major cause of morbidity and mortality following cardiac surgery." | 7.11 | Characterisation of Plasma Mitochondrial DNA, MMP-9 and Neutrophil Elastase in Patients Undergoing Coronary Artery Bypass Grafting: Effects of Tranexamic Acid and Postoperative Pneumonia. ( Bain, CR; Draxler, DF; Gruen, RL; Hauser, CJ; Ho, H; Medcalf, RL; Myles, PS; Sandler, N; Smith, JA, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery." | 7.11 | Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. ( Abubakirov, M; Aguado, HJ; Alfonsi, P; Amir, M; Astrakov, SV; Ayad, S; Balasubramanian, K; Bangdiwala, SI; Belley-Cote, E; Bhatt, K; Biccard, B; Borges, FK; Chan, MTV; Cheong, CC; Conen, D; Copland, I; de Nadal, M; Devereaux, PJ; Duceppe, E; Efremov, S; Eikelboom, J; Fleischmann, E; Garg, AX; Gross, PL; Guyatt, G; Iglesisas, PP; Jayaram, R; Kirov, M; Kleinlugtenbelt, YV; Kurz, A; Lamy, A; Landoni, G; Leslie, K; Likhvantsev, V; Lomivorotov, VV; Marcucci, M; Martínez Zapata, MJ; McGillion, M; McIntyre, W; Meyhoff, CS; Ofori, SN; Painter, TW; Parlow, JL; Patel, A; Petit, S; Polanczyk, CA; Rao, M; Richards, T; Roshanov, P; Ruetzler, K; Schmartz, D; Sessler, D; Short, TG; Spence, J; Srinathan, S; Stillo, D; Szczeklik, W; Tandon, V; Torres, D; VanHelder, T; Vincent, J; Wang, CY; Wang, MK; Whitlock, RP; Wittmann, M; Wu, WKK; Xavier, D; Yusuf, S, 2022) |
| " However, postoperative seizure, as one of the major adverse effects of TXA infusion, has been a concern that restricts its utility in neurosurgery." | 7.11 | Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial. ( Dong, J; Li, R; Li, S; Liu, X; Ma, T; Peng, Y; Wang, J; Yan, X; Zeng, M; Zhang, X, 2022) |
| " The current study aimed to determine whether tranexamic acid (TXA) in combination with pressure dressing reduce the amount of blood loss, the rate of incision-related complications, and the rate of readmission for patients undergoing surgeries to release GMC." | 7.11 | Tranexamic acid combined with compression dressing reduces blood loss in gluteal muscle contracture surgery. ( Huang, Q; Huang, Z; Ma, J; Pei, F; Shen, B; Zhou, Z, 2022) |
| "Tranexamic acid (TXA) has been shown to reduce intraoperative bleeding and the need for post-operative allogenic blood transfusion requirement in surgery." | 7.11 | A single dose of tranexamic acid infusion is safe and effective to reduce total blood loss during proximal femoral nailing for intertrochanteric fractures: A prospective randomized study. ( Ekinci, M; Ersin, M; Günen, E; Kocazeybek, E; Ok, M; Sırma, SÖ; Yılmaz, M, 2022) |
| "Tranexamic Acid (TXA) has been used in medical and surgical practice to reduce haemorrhage." | 7.01 | Tranexamic acid use in meningioma surgery - A systematic review and meta-analysis. ( Bakhsh, A; Brodbelt, AR; Clynch, AL; Gillespie, CS; Islim, AI; Jenkinson, MD; Keshwara, SM; Kumar, S; Mills, SJ; Millward, CP; Mustafa, MA; Richardson, GE; Zakaria, R, 2023) |
| "Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects." | 7.01 | Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis. ( Cheah, S; Cheong, CC; Mong, SXY; Ng, KT; Tsan, SEH; Viknaswaran, NL; Wang, CY, 2023) |
| "Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in elective orthopedic surgery." | 7.01 | Topical tranexamic acid in hip fractures: a randomized, placebo-controlled double-blinded study. ( Cheong, Y; Costain, D; Elder, G; Fera, L; Fraser, B; Kelly, A; Slagel, B, 2021) |
| "A total of 100 patients with intertrochanteric fractures undergoing surgery were enrolled and randomly allocated to the TXA group in which patients (75." | 6.90 | Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single-Blind Randomized Controlled Trial. ( Huang, Y; Jiang, LF; Wu, LD; Xu, NW; Zhang, JJ; Zhang, Y; Zhou, D; Zhou, XD, 2019) |
| " Other secondary variables were total blood loss, hidden blood loss, transfusion rate, average hospital stay, complications, adverse events, and mortality." | 6.90 | Prevention of postoperative bleeding in hip fractures treated with prosthetic replacement: efficacy and safety of fibrin sealant and tranexamic acid. A randomised controlled clinical trial (TRANEXFER study). ( Aguilera, X; Bosch, A; Camacho-Carrasco, P; Castillón, P; González, JC; Hernández, JA; Jordan, M; Martínez-Zapata, MJ; Mora, JM; Prat-Fabregat, S; Rodriguez-Arias, A; Ruiz, L; Salomó, M, 2019) |
| "Radical cystectomy for bladder cancer is associated with a high risk of needing red blood cell transfusion." | 6.87 | Tranexamic Acid versus Placebo to Prevent Blood Transfusion during Radical Cystectomy for Bladder Cancer (TACT): Study Protocol for a Randomized Controlled Trial. ( Breau, RH; Bryson, G; Cagiannos, I; Cnossen, S; Fergusson, DA; Kanji, S; Knoll, G; Lavallée, LT; Mallick, R; Momoli, F; Morash, C; Turgeon, A; Witiuk, K; Zarychanski, R, 2018) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss." | 6.87 | Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery: A Randomized Placebo-Controlled Trial. ( Brustowicz, RM; Emans, JB; Glotzbecker, MP; Goobie, SM; Hedequist, D; Hresko, MT; Karlin, LI; McCann, ME; Sethna, NF; Zurakowski, D, 2018) |
| "Usually, TXA-associated seizures persist for a few minutes with no progression into status epilepticus." | 6.82 | Tranexamic acid-associated fatal status epilepticus in a paediatric non-cardiac surgery: A case report and literature review. ( Aboul-Fotouh, S; Habib, MZ; Hassan, BEE; Magdy, SM, 2022) |
| " (3) The appropriate, empirically established, dosage and administration patterns of TEA for CDH repair during ECMO seem to be one bolus of 4 mg/kg TEA intravenously 30 minutes before the anticipated CDH repair and a continuous infusion of 1 mg/kg/h TEA during the 24 hours after CDH repair." | 6.68 | Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid. ( de Haan, AF; Festen, C; Geven, WB; van der Staak, FH, 1997) |
| "We failed to observe a difference in infection risk after adjustment for confounders and surgeon differences (hazard ratio [HR] 1." | 5.91 | Tranexamic acid is not associated with decreased infection risk after primary shoulder arthroplasty: a cohort study of 9276 patients. ( Chan, PH; Gorbaty, J; McElvany, MD; Prentice, HA; Yian, EH, 2023) |
| "Bleeding complications are not uncommon after breast reduction surgery, and recently, tranexamic acid (TXA) as an antifibrinolytic agent has been used in various surgical specialties as a way to minimizes such adverse outcomes." | 5.91 | The Usage of Intravenous Tranexamic Acid in Reduction Mammaplasty Safely Reduces Hematoma Rates. ( Kebede, S; Losken, A; Marxen, T; Om, A, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to reduce blood loss following surgery." | 5.91 | Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection. ( Foster, D; Garner, H; Goulding, K; Houdek, M; Sebro, R; Spaulding, AC; Stanborough, R; Wilke, B, 2023) |
| "Tranexamic acid (TXA) has gained increasing recognition as a valuable pharmacologic agent within plastic surgery." | 5.72 | Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty. ( Alsayed, A; Antezana, L; Banuelos, J; Curiel, D; Harless, CA; Kerivan, L; Kuruoglu, D; Martinez-Jorge, J; Nguyen, MT; Sharaf, BA; Tran, NV; Vijayasekaran, A; Weissler, JM, 2022) |
| "High-dose tranexamic acid is more effective in reducing blood loss and blood transfusion without increasing the risk of postoperative complications." | 5.69 | Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial. ( Chai, M; He, Z; Wu, X; Xia, L; Yang, X; Zhang, J, 2023) |
| "Prophylactic use of tranexamic acid during cesarean delivery did not lead to a significantly lower risk of a composite outcome of maternal death or blood transfusion than placebo." | 5.69 | Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery. ( Bailit, JL; Chauhan, SP; Clifton, RG; Dalton, W; Grobman, WA; Gyamfi-Bannerman, C; Longo, M; Macones, GA; Metz, TD; Pacheco, LD; Parry, S; Rood, K; Rouse, DJ; Saade, GR; Salazar, A; Simhan, HN; Thorp, JM; Tita, ATN; Weiner, SJ, 2023) |
| "Multiple doses of dexamethasone and tranexamic acid can inhibit postoperative inflammation and reduce fibrinolysis and perioperative blood loss in total knee arthroplasty." | 5.69 | Tourniquets can further reduce perioperative blood loss in patients on dexamethasone and tranexamic acid during cemented total knee arthritis: a single-center, double-blind, randomized controlled trial. ( Huang, Q; Jiang, W; Liu, M; Pei, F; Wang, X; Xie, J; Xu, H; Zhou, R; Zhou, Z, 2023) |
| " The purpose of this study was to assess the safety of tranexamic acid (TXA) utilization with respect to the incidence of deep venous thrombosis (DVT) in hemophiliacs undergoing total knee arthroplasty (TKA)." | 5.69 | Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study. ( Guo, JJ; Yu, Z; Zhang, Q; Zhao, L, 2023) |
| " The purpose of this study was to determine if TXA is safe to use in patients with a history of CAD or coronary stents." | 5.62 | Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty. ( Rozell, JC; Schwarzkopf, R; Sharan, M; Tang, A; Waren, D; Zak, SG, 2021) |
| "Tranexamic acid (TXA) has been used extensively to minimize blood loss in cardiac surgery and more recently in orthopedic surgery." | 5.56 | Tranexamic acid administration during total joint arthroplasty surgery is not associated with an increased risk of perioperative seizures: a national database analysis. ( Fiasconaro, M; Kirksey, MA; Liu, J; Memtsoudis, SG; Poeran, J; Wilson, LA, 2020) |
| "This study was carried out to evaluate role of intravenous tranexamic acid (TXA) in reducing blood loss during tangential excision of burns." | 5.51 | Effect of single dose intravenous tranexamic acid on blood loss in tangential excision of burn wounds - A double blind randomised controlled trial. ( K S, A; Kumar, P; Sharma, RK; Subair, M, 2022) |
| "Patients with non-traumatic epistaxis were evaluated in three treatment groups as topical lidocaine, epinephrine, and TXA." | 5.51 | Comparison of the therapeutic efficacy of topical tranexamic acid, epinephrine, and lidocaine in stopping bleeding in non-traumatic epistaxis: a prospective, randomized, double-blind study. ( Ekmekyapar, M; Gur, A; Sahin, L, 2022) |
| "To assess the efficacy and safety of single-dose tranexamic acid on the blood transfusion rate and outcomes of patients with complex kidney stones undergoing percutaneous nephrolithotomy (PCNL)." | 5.51 | Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial. ( Batagello, CA; Coelho, RF; Danilovic, A; Marchini, GS; Mazzucchi, E; Miller, AW; Monga, M; Nahas, WC; Srougi, M; Torricelli, FCM; Vicentini, FC, 2022) |
| "Pediatric craniosynostosis repair with cranial vault reconstructive surgery can be associated with significant blood loss." | 5.51 | Ulnar Artery Thrombosis Following Tranexamic Acid Administration for Craniosynostosis Repair. ( Chung, E; Karlberg, HI, 2019) |
| "The combined use of intraarticular topical TXA with rivaroxaban in patients undergoing TKA is a safe and effective method to reduce blood loss, the need for transfusion, and wound complications without elevating the risk of DVT." | 5.48 | Combined use of topical intraarticular tranexamic acid and rivaroxaban in total knee arthroplasty safely reduces blood loss, transfusion rates, and wound complications without increasing the risk of thrombosis. ( Kang, MW; Kim, JI; Kim, YT; Lee, JK; Lee, YM, 2018) |
| " The best administration route and dosage should be further studied." | 5.48 | [Preliminary analysis of the effect of different administration routes of tranexamic acid on blood loss after total hip arthroplasty for female femur neck fractures]. ( Lin, ZQ; Luo, GG; Xie, HF; Yao, JC; Zhang, HZ, 2018) |
| "Tranexamic acid is an anti-fibrinolytic agent frequently used in pediatric surgery." | 5.46 | Anaphylactic reaction to tranexamic acid in an adolescent undergoing posterior spinal fusion. ( Chiem, J; Ivanova, I; Jimenez, N; Krengel, W; Parker, A, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that can be used to reduce blood loss in total knee arthroplasty (TKA) patients." | 5.43 | Intraarticular Administration of Tranexamic Acid is Safe and Effective in Total Knee Arthroplasty Patients at High-Risk for Thromboembolism. ( Chughtai, M; Delanois, RE; Gwam, C; Khlopas, A; Mistry, JB; Mont, MA; Mudaliar, PP; Tangri, V; Thomas, M, 2016) |
| "Based upon Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), the authors collected fully published English literature on the administration of tranexamic acid for patients undergoing intracranial meningioma surgery using the keywords ["tranexamic acid" and "meningioma"] and its synonyms from Cochrane Central Database, the WHO International Clinical Trials Registry Platform (ICTRP), ClinicalTrials." | 5.41 | A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma. ( Chadid, DP; July, J; Quintero-Consuegra, M; Wijaya, JH, 2023) |
| "To compare the efficacy of different dosages of intravenous (IV) tranexamic acid (TXA) in the treatment of traumatic hip fractures against that of the control group of no TXA." | 5.41 | The Efficacy of Tranexamic Acid for the Treatment of Traumatic Hip Fractures: A Network Meta-Analysis. ( Bloom, DA; Chapman, CB; Konda, SR; Lin, CC; Manzi, JE; Mojica, ES; Telgheder, ZL, 2023) |
| "Tranexamic acid is a cost-effective intervention for the prevention of postpartum hemorrhage among women who undergo cesarean delivery, but the evidence to support its use is conflicting." | 5.41 | Tranexamic acid for the prevention of blood loss after cesarean section: an updated systematic review and meta-analysis of randomized controlled trials. ( Ahmad, AB; Ayyan, M; Azeem, S; Cheema, HA; Ehsan, M; Hussain, A; Laganà, AS; Mikuš, M; Nashwan, AJ; Shahid, A, 2023) |
| "In this meta-analysis, the combination of TXA and DEX has positive impacts on the usage of oxycodone and metoclopramide, postoperative range of motion, postoperative nausea and vomiting and reduces the length of hospital stay." | 5.41 | Effects of combined dexamethasone and tranexamic acid in lower limb total arthroplasty: a systematic review and meta-analysis of randomized clinical trials. ( Gopal Subramaniam, A; Hau, R; Tan, TK, 2023) |
| "Meta-analyses on the use of tranexamic acid (TXA) in intertrochanteric fractures have shown inconsistent results due to variations in inclusion criteria and clinical heterogeneity." | 5.41 | Intravenous application of tranexamic acid in intramedullary nailing for the treatment of geriatric intertrochanteric fractures: a systematic review and meta-analysis. ( Fan, X; Wu, J; Yuan, X; Zhang, J; Zheng, Y, 2023) |
| "Tranexamic acid (TXA) has been widely used in orthopedic surgery, but its efficacy in adolescent scoliosis (AS) surgery remains unclear in the literature." | 5.41 | Tranexamic acid can reduce blood loss in adolescent scoliosis surgery: a systematic review and meta-analysis. ( Chen, K; Gao, Q; Masood, U; Song, Y; Wang, L; Yang, H; Zeng, Z, 2023) |
| " We included controlled trials, either randomized (RCT) or non-randomized studies of intervention (NRSI) comparing the effects of intravenous tranexamic acid (TXA) treatment with placebo/no treatment on postoperative blood loss, pain VAS score, elbow ROM, and complications, in patients who underwent open or closed elbow arthrolysis surgery." | 5.41 | Does tranexamic acid diminish hemorrhage and pain in open elbow arthrolysis? a systematic review and meta-analysis. ( Daliri, M; Ebrahimzadeh, MH; Khayami, A; Moradi, A; Nejat, MH; Sadeghi, M, 2023) |
| "To conduct the first-ever systematic review and meta-analysis of randomized controlled trials (RCTs) on the antihemorrhagic utility and safety of tranexamic acid (TXA) versus misoprostol for management (prevention and/or treatment) of postpartum hemorrhage (PPH)." | 5.41 | Tranexamic acid versus misoprostol for management of postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials. ( Abdulmalik, NA; Abu-Zaid, A; Abuzaid, M; Albadawi, MI; Alblewi, H; Albouq, B; Alomar, O; Alsehaimi, SO; Alyousef, A; Baradwan, S; Bukhari, IA; Ghazi, A; Khadawardi, K; Salem, H, 2023) |
| "Tranexamic acid (TXA) is widely used in surgery for adolescent idiopathic scoliosis (AIS) and has been proved to be efficacious in reducing intraoperative blood loss (IBL) and the transfusion rate." | 5.41 | The effect of multiple-dose oral versus intravenous tranexamic acid in reducing postoperative blood loss and transfusion rate after adolescent scoliosis surgery: a randomized controlled trial. ( Liu, LM; Song, YM; Wang, L; Wang, LN; Xiu, P; Yang, X; Zhang, Z; Zhou, ZJ, 2021) |
| "The objective of this study is to determine the efficacy of high-dose versus low-dose tranexamic acid (TXA) in adolescent idiopathic scoliosis (AIS) corrective surgery." | 5.41 | Tranexamic Acid in Pediatric Scoliosis Surgery: A Prospective Randomized Trial Comparing High-dose and Low-dose Tranexamic Acid in Adolescent Idiopathic Scoliosis Undergoing Posterior Spinal Fusion Surgery. ( Chan, CYW; Chiu, CK; Hasan, MS; Kwan, MK; Ng, CC; Yunus, SN, 2021) |
| "We aimed to determine the efficacy and safety of multiple doses of intravenous tranexamic acid (IV-TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA) who had undergone primary unilateral total knee arthroplasty (TKA)." | 5.41 | Multiple intravenous tranexamic acid doses in total knee arthroplasty in patients with rheumatoid arthritis: a randomized controlled study. ( Gao, CX; Gao, XJ; Kang, BX; Ma, YH; Sun, ST; Xiao, LB; Xie, J; Xu, H; Xu, XR; Zhai, WT; Zhang, J; Zhao, C; Zhong, S, 2021) |
| "To investigate the efficacy and safety of intravenous combined with topical administration of tranexamic acid (TXA) in reducing blood loss after intramedullary fixation of intertrochanteric femoral fractures by a prospective controlled trial." | 5.41 | [Efficacy and safety of intravenous combined with topical administration of tranexamic acid in reducing blood loss after intramedullary fixation of intertrochanteric femoral fractures]. ( Gong, D; Gou, Y; Li, H; Li, W; Liu, D; Tang, X; Wang, N; Wu, Y; Zhang, Y, 2021) |
| " Tranexamic acid (TXA) is most commonly given as a single preoperative dose only and is often withheld from patients with a history of thromboembolic disease as they are perceived to be "high-risk" with respect to postoperative venous thromboembolism (VTE)." | 5.41 | Oral tranexamic acid for an additional 24 hours postoperatively versus a single preoperative intravenous dose for reducing blood loss in total hip arthroplasty: results of a randomized controlled trial (TRAC-24). ( Bell, J; Benson, G; Beverland, D; Bryce, L; Campbell, C; Dorman, A; Gardner, E; Hill, JC; Hogg, R; Magill, P; Martin, U; McFarland, M, 2021) |
| "To indicate whether combined topical and intravenous (IV) administration of tranexamic acid (TXA) could further reduce the blood loss after surgery for adolescent idiopathic scoliosis (AIS) compared with IV-TXA alone." | 5.41 | Combined topical and intravenous administration of tranexamic acid further reduces postoperative blood loss in adolescent idiopathic scoliosis patients undergoing spinal fusion surgery: a randomized controlled trial. ( Dong, Y; Li, Q; Liang, J; Shen, J; Tong, B; Zhao, H, 2021) |
| "Tranexamic acid is an antifibrinolytic drug." | 5.39 | Tranexamic acid and thrombosis. ( , 2013) |
| "Postoperative seizures occurred significantly more frequently in TXA patients (7." | 5.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
| "All patients with seizures did not have permanent neurological abnormalities." | 5.36 | High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. ( Burt, C; Chu, M; Falter, F; Granton, J; Murkin, JM; Young, B, 2010) |
| "The aim of this study was to evaluate the effects of a high initial-dose (60 mg/kg) intravenous tranexamic acid (IV-TXA) on fibrinolysis and inflammation after total knee arthroplasty (TKA)." | 5.34 | The antifibrinolytic and anti-inflammatory effects of a high initial-dose tranexamic acid in total knee arthroplasty: a randomized controlled trial. ( Huang, Q; Huang, W; Lei, YT; Pei, FX; Xie, JW, 2020) |
| "The combined application of tranexamic acid and rivaroxaban significantly reduced the amount of blood loss and the transfusion rate during PLIF surgery and avoided an increase in the probability of thrombosis and the occurrence of epidural haematoma." | 5.34 | Combined use of tranexamic acid and rivaroxaban in posterior lumbar interbody fusion safely reduces blood loss and transfusion rates without increasing the risk of thrombosis-a prospective, stratified, randomized, controlled trial. ( Chen, Y; Guan, T; Jiao, G; Li, Y; Liu, D; Liu, H; Meng, C; Sun, Z; Wang, H; Wu, W; Xiao, X; Xue, H; Yue, H; Zhang, L; Zhou, H, 2020) |
| "This clinical trial is designed to evaluate the effect of multiple-dose tranexamic acid (TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA)." | 5.34 | Multiple-dose tranexamic acid for perioperative blood loss in total knee arthroplasty in patients with rheumatoid arthritis：a single-blinded, randomised, parallel-controlled study protocol in China. ( Gao, CX; Kang, BX; Ma, YH; Sun, ST; Xiao, LB; Xie, J; Xu, H; Zhai, WT; Zhang, J; Zhong, S, 2020) |
| "An initial retrospective study suggested that tranexamic acid (TXA) administration increased the incidence of seizures in paediatric patients undergoing cardiac surgery." | 5.30 | Safety and efficacy of tranexamic acid in paediatric cardiac surgery: study protocol for a double-blind randomised controlled trial. ( Hu, S; Hua, Z; Jia, Y; Li, S; Liu, J; Ran, J; Shi, J; Wang, R; Wang, X; Wang, Y; Yan, F; Yan, J; Yuan, S; Zhang, Y; Zhang, Z; Zhao, Y; Zheng, Z, 2019) |
| "We examined the blood conserving effect of tranexamic acid in total hip arthroplasty using the direct anterior approach with enoxaparin as deep vein thrombosis (DVT) chemoprophylaxis, and whether this translates to an effect on functional outcomes in the perioperative period." | 5.30 | OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial. ( Duggan, J; Duncan, S; Fraval, A; Murray, T; Tirosh, O; Tran, P, 2019) |
| "To investigate the effect of adjunctive intravenous tranexamic acid (TA) on blood loss during cesarean section (CS) in patients with placenta previa undergone bilateral uterine arteryligation (BUAL)." | 5.30 | Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean delivery for placenta previa: a randomized double-blind controlled trial. ( Abbas, AM; Sallam, HF; Shady, NW, 2019) |
| "The objective of this study was to ascertain whether combined intravenous (IV) and intra-articular (IA) administration of tranexamic acid (TXA) is beneficial for reducing blood loss and the prevalence of deep venous thrombosis (DVT) in primary simultaneous bilateral total knee arthroplasty compared with IV only administration of TXA." | 5.27 | Comparative Efficacy of Intravenous With Intra-articular Versus Intravenous Only Administration of Tranexamic Acid to Reduce Blood Loss in Knee Arthroplasty. ( Kim, JS; Kim, YH; Pandey, K; Park, JW, 2018) |
| "The aim of this randomized double-blind study was to evaluate the efficacy of Tranexamic acid (TXA) on intraoperative bleeding, postoperative eyelid edema, and postoperative periorbital ecchymosis in rhinoplasty." | 5.24 | Efficacy of tranexamic acid on side effects of rhinoplasty: A randomized double-blind study. ( Chavoshzadeh, MA; Ghavimi, MA; Ghoreishizadeh, A; Taheri Talesh, K; Zarandi, A, 2017) |
| "Systemic administration of TXA can effectively reduce the postoperative blood loss which results in lower rate of transfusion requirement and wound hematoma in minimally invasive TKA patients when rivaroxaban is used for thromboprophylaxis." | 5.24 | The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial. ( Chen, B; Huang, CC; Kuo, FC; Lin, PC; Wang, JW; Yen, SH, 2017) |
| "We recently reported that tranexamic acid (TXA) evokes pain in rats by inhibiting γ-aminobutyric acid and glycine receptors on neurons in the spinal dorsal horn." | 5.24 | Administration of tranexamic acid to patients undergoing surgery for adolescent idiopathic scoliosis evokes pain and increases the infusion rate of remifentanil during the surgery. ( Endo, N; Kohno, T; Ohashi, M; Ohashi, N, 2017) |
| "Compared with intravenous application, topical application of tranexamic acid could also effectively reduce total blood loss and hidden blood loss, postoperative blood transfusion rate in primary total hip arthroplasty, while does not increase the risk of DVT." | 5.22 | [Comparison of different modes of using tranexamic acid administration on reducing hidden blood loss in total hip arthroplasty]. ( Chen, XJ; Ni, JR; Wang, LX, 2016) |
| "To evaluate the efficacy of tranexamic acid (TA) in decreasing blood loss during and after open myomectomy for patients with 3 or more uterine fibroids." | 5.22 | Efficacy of Tranexamic Acid on Myomectomy-Associated Blood Loss in Patients With Multiple Myomas: A Randomized Controlled Clinical Trial. ( Ahmed, MR; Dardeer, HH; Farhan, RE; Shaaban, MM, 2016) |
| "To assess the effects of tranexamic acid among patients undergoing cesarean delivery who were at high risk of postpartum hemorrhage." | 5.22 | Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. ( Aneja, A; Hanjoora, VM; Kaur, R; Khanna, M; Sujata, N; Tobin, R, 2016) |
| " The use of tranexamic acid to control surgical bleeding and aspirin for venous thromboembolism prophylaxis has gained popularity." | 5.22 | Closed Suction Drainage Has No Benefits in Anterior Hip Arthroplasty: A Prospective, Randomized Trial. ( Barksdale, LC; Calvo, C; McNamara, CA; Patel, PD; Suarez, JC; Szubski, CR, 2016) |
| "The aim of this study was to investigate the efficacy of tranexamic acid (TA) and methylprednisolone on periorbital edema, ecchymosis, and intraoperative bleeding in patients who underwent open septorhinoplasty (oSRP)." | 5.20 | The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty. ( Akyiğit, A; Düzer, S; Orhan, İ; Polat, C; Sakallioğlu, Ö; Soylu, E, 2015) |
| "Preincision administration of 10 mg/kg of tranexamic acid significantly improved the surgical field during cleft palate repair." | 5.20 | Evaluation of the Efficacy of Tranexamic Acid on the Surgical Field in Primary Cleft Palate Surgery on Children-A Prospective, Randomized Clinical Study. ( Durga, P; Gunnam, P; Gurajala, I; Raavula, P; Ramachandran, G; Reddy, M; Upputuri, O; Veerabathula, P, 2015) |
| " The primary aim of this study was to determine the efficacy of intraoperative tranexamic acid, epsilon-aminocaproic acid, and placebo at reducing perioperative blood loss and the transfusion rate in patients with adolescent idiopathic scoliosis undergoing posterior spinal arthrodesis." | 5.19 | The relative efficacy of antifibrinolytics in adolescent idiopathic scoliosis: a prospective randomized trial. ( Boenigk, K; Diefenbach, C; Dryer, J; Errico, T; Hoelscher, C; Huncke, T; Lonner, BS; Peters, A; Verma, K, 2014) |
| "There was no statistically significant reduction in bleeding volume with the use of tranexamic acid (mean ± standard deviation, 135." | 5.16 | Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial. ( Brum, MR; Castro, SF; Lima, LH; Lubianca Neto, JF; Machado, GM; Miura, MS, 2012) |
| "Tranexamic acid (TXA) is one of the measures indicated to reduce bleeding and the need for volume replacement." | 5.12 | Tranexamic acid in Neurosurgery: a controversy indication-review. ( Costa E Silva, LT; da Silva Brito, J; de Faria, JL; de Souza, NB; Figueiredo, EG; Kilesse, CTSM; Pereira, CU; Rabelo, NN, 2021) |
| "This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery." | 5.12 | The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021) |
| "The use of tranexamic acid (TXA) is established in the treatment of bleeding, especially of bleeding due to hyperfibrinolysis." | 5.12 | [Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?] ( Möhnle, P; Pekrul, I; Schachtner, T; Zwißler, B, 2021) |
| "Tranexamic acid is an efficacious and safe pharmacological-based blood conservation technique in the management of clinically significant hemorrhage." | 5.12 | Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery. ( George, RB; Hanley, CM; Jerath, A; Saliba, C; Wong, J; Yee, DA, 2021) |
| "Intraoperative administration of tranexamic acid significantly reduces blood loss during spinal surgery in children with scoliosis." | 5.11 | Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. ( Bacsik, J; Brustowicz, RM; Sethna, NF; Shapiro, F; Sullivan, LJ; Zurakowski, D, 2005) |
| "The administration of prophylactic tranexamic acid in patients with scoliosis who are undergoing posterior spinal fusion surgery has the potential to reduce perioperative blood transfusion requirements." | 5.09 | A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. ( Barrowman, NJ; Hall, L; Murto, K; Neilipovitz, DT; Splinter, WM, 2001) |
| "The effect of high dose tranexamic acid on blood loss after operations for acute aortic dissection was evaluated." | 5.08 | [The effect of intraoperative high-dose tranexamic acid on blood loss after operation for acute aortic dissection]. ( Hirayama, T; Misumi, H; Nakajima, M; Shimamura, Y; Shimokawa, T; Uemura, K; Uesugi, H, 1998) |
| " Tranexamic acid (TXA) is one of the most commonly used and widely researched antifibrinolytic agents; its role in postpartum hemorrhage, menorrhagia, trauma-associated hemorrhage, and surgical bleeding has been well defined." | 5.05 | The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. ( Al-Samkari, H; Cai, J; DeLoughery, TG; Olson, S; Raghunathan, V; Ribkoff, J; Shatzel, JJ, 2020) |
| "Objective To summarize cases of acute myocardial infarction (AMI) after tranexamic acid (TXA) administration." | 5.05 | Acute Myocardial Infarction After Tranexamic Acid: Review of Published Case Reports. ( Shao, K; Yao, YT; Yuan, X, 2020) |
| "To systematically examine the role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty." | 5.01 | Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis. ( Bezuhly, M; McGuire, C; Nurmsoo, S; Samargandi, OA, 2019) |
| "To evaluate the efficacy and safety of tranexamic acid (TXA) in patients with adolescent idiopathic scoliosis undergoing corrective surgery." | 5.01 | The Perioperative Efficacy and Safety of Tranexamic Acid in Adolescent Idiopathic Scoliosis. ( Cao, K; Lin, N; Lu, H; Wang, B; Zhong, J; Zhou, X, 2019) |
| "To investigate the results of tranexamic acid use to reduce intraoperative bleeding, postoperative eyelid edema, and periorbital ecchymosis in rhinoplasty." | 4.98 | Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis. ( de Aguiar Menezes, MV; de Souza Dantas, R; de Vasconcellos, SJA; do Nascimento-Júnior, EM; Martins-Filho, PRS; Tavares Mendes, ML, 2018) |
| "This meta-analysis aims to assess the efficacy and safety of tranexamic acid for reducing blood loss and transfusion requirements in patients with intertrochanteric fractures." | 4.95 | Tranexamic acid reduces blood loss in intertrochanteric fractures: A meta-analysis from randomized controlled trials. ( Wang, W; Yu, J, 2017) |
| "The purpose of this systematic review and meta-analysis of randomized controlled trials (RCTs) and non-RCTs was to gather data to evaluate the efficacy and safety of tranexamic acid (TXA) versus placebo after a scoliosis surgery." | 4.95 | Efficacy and safety of tranexamic acid in reducing blood loss in scoliosis surgery: a systematic review and meta-analysis. ( Xu, BS; Yuan, QM; Zhao, ZH, 2017) |
| "The aim of this meta-analysis was to assess whether tranexamic acid (TXA) therapy for adult cardiac surgery is associated with an increase in the risk of seizures, and we performed a meta-analysis of randomized controlled trials (RCTs) and non-randomized observational studies." | 4.95 | Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and non-randomized studies. ( Ando, T; Takagi, H; Umemoto, T, 2017) |
| "There has been an explosion of interest in the ability of tranexamic acid to reduce morbidity and mortality in surgical and traumatic bleeding." | 4.91 | The current place of tranexamic acid in the management of bleeding. ( Hunt, BJ, 2015) |
| "This systematic review was undertaken to answer three specific questions relating to the clinical values of tranexamic acid (TNA) in total knee arthroplasty (TKA): (1) Whether there are differences in blood-saving effects between the systemic and topical administrations; (2) Whether blood-saving effects of TNA differ by doses and timings of administration; and (3) Whether the use of TNA is safe at all reported doses, timings, and routes of administration with respect to the incidences of symptomatic deep-vein thrombosis (DVT) and pulmonary embolism (PE)." | 4.90 | Practical issues for the use of tranexamic acid in total knee arthroplasty: a systematic review. ( Chang, CB; Kim, TK; Koh, IJ, 2014) |
| " The aim of this study was to review the literature on the use of lysine analogs to prevent bleeding and blood transfusion during pelvic surgery." | 4.90 | The effects of lysine analogs during pelvic surgery: a systematic review and meta-analysis. ( Beck, A; Breau, RH; Buenaventura, C; Cagiannos, I; Cowan, J; Fergusson, DA; Knoll, G; Kokolo, MB; Momoli, F; Morash, C; Niznick, N; Punjani, N; Ruzicka, M; Schachkina, S; Tinmouth, A; Xie, HY, 2014) |
| "Intravenous tranexamic acid reduces bleeding in surgery, however, its effect on the risk of thromboembolic events is uncertain and an increased risk remains a theoretical concern." | 4.89 | Topical application of tranexamic acid for the reduction of bleeding. ( Beecher, D; Ker, K; Roberts, I, 2013) |
| "Tranexamic acid safely reduces mortality in bleeding trauma patients without increasing the risk of adverse events." | 4.88 | Antifibrinolytic drugs for acute traumatic injury. ( Coats, T; Ker, K; Roberts, I; Shakur, H, 2012) |
| "The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage." | 4.87 | Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011) |
| "A systematic review of the literature was conducted to identify all randomized controlled trials of aprotinin, tranexamic acid, and aminocaproic acid involving children undergoing cardiac or scoliosis surgery." | 4.85 | The effect of aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in major pediatric surgery: a meta-analysis. ( Bollen, CW; Jansen, NJ; Schouten, AN; Schouten, ES; Turner, NM; van de Pol, AC, 2009) |
| "Tranexamic acid (TXA) has been widely utilized to reduce blood loss and allogeneic transfusions in patients who undergo lower limb arthroplasty." | 4.40 | Tranexamic acid administration for the prevention of periprosthetic joint infection and surgical site infection: a systematic review and meta-analysis. ( Choe, H; Imanishi, K; Inaba, Y; Kamono, E; Kobayashi, N; Kumagai, K; Takagawa, S; Yukizawa, Y, 2023) |
| " Two multivariable logistic regression models, for postoperative anemia (hemoglobin < 10 g/dL) and allogeneic blood transfusion included 8 variables: age, sex, body mass index, preoperative hemoglobin level, tranexamic acid total dose, American Society of Anesthesiologists level, operative time, and drain use." | 4.31 | Predicting Postoperative Anemia and Blood Transfusion Following Total Knee Arthroplasty. ( Ast, MP; Chalmers, BP; Della Valle, AG; Kolin, DA; Landy, DC; Lyman, S, 2023) |
| "We conducted a secondary analysis of the MAssive Transfusion in Children (MATIC), a prospectively collected database of children with life-threatening hemorrhage (LTH), and evaluated for risk of adverse events with either antifibrinolytic treatment, epsilon aminocaproic acid (EACA) or tranexamic acid (TXA)." | 4.31 | Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children. ( Josephson, CD; Kolodziej, JH; Leeper, CM; Leonard, JC; Spinella, PC; Zenati, MS, 2023) |
| "The use of tranexamic acid (TXA) in posterior lumbar interbody fusion (PLIF) surgery is believed to be beneficial for reducing intraoperative blood loss, postoperative drainage volume (PDV), and length of hospital stay (LOS)." | 4.31 | Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study. ( Ji, X; Shi, L; Tian, F; Wang, X, 2023) |
| "To evaluate the effects of administering tranexamic acid (TXA) after cardiopulmonary bypass, instead of after anesthesia induction, on postoperative seizures and blood transfusion requirements." | 4.12 | Tranexamic acid after cardiopulmonary bypass does not increase risk of postoperative seizures: a retrospective study. ( Chen, C; Du, L; Liu, J, 2022) |
| "The utility of tranexamic acid (TXA) in patients with Marfan syndrome (MFS) is uncertain given associated aberrations within the vasculature and clotting cascade." | 4.12 | Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome. ( Ikwuezunma, IA; Margalit, A; Sponseller, PD, 2022) |
| "Previous studies demonstrated the safety of tranexamic acid (TXA) use in cerebral palsy (CP) patients undergoing proximal femoral varus derotational osteotomy (VDRO), but were underpowered to determine if TXA alters transfusion rates or estimated blood loss (EBL)." | 4.12 | Tranexamic acid use decreases transfusion rate in children with cerebral palsy undergoing proximal femoral varus derotational osteotomy. ( Andras, L; Compton, E; Goldstein, RY; Kay, RM; Nazareth, A; Shymon, SJ, 2022) |
| "Treatment with tranexamic acid (TxA) significantly reduces maternal death due to postpartum hemorrhage." | 4.12 | The effect of prophylactic use of tranexamic acid for cesarean section. ( Binyamin, Y; Erez, O; Frank, D; Frenkel, A; Gruzman, I; Heesen, M; Ioscovich, A; Lerman, S; Orbach-Zinger, S; Zlotnik, A, 2022) |
| "Tranexamic acid (TXA) has become a widely used antifibrinolytic drug for reducing bleeding in surgery." | 4.12 | Safety and efficacy of intravenous or topical tranexamic acid administration in surgery: a protocol for a systematic review and network meta-analysis. ( Han, R; Liang, F; Wang, X; Yu, Y, 2022) |
| "This multicenter international experience of pediatric craniofacial surgery reports no increase in seizures or thromboembolic events in those that received antifibrinolytics (tranexamic acid and epsilon-aminocaproic acid) versus those that did not." | 4.12 | Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group. ( Benzon, HA; Goobie, SM; King, MR; Nelson, O; Pérez-Pradilla, C; Staffa, SJ; Stricker, PA, 2022) |
| "Background and Objectives: Previous studies regarding tranexamic acid (TXA) in total knee arthroplasty (TKA) investigated only symptomatic deep vein thrombosis (DVT), or did not include high risk patients." | 4.12 | Topical Tranexamic Acid Can Be Used Safely Even in High Risk Patients: Deep Vein Thrombosis Examination Using Routine Ultrasonography of 510 Patients. ( An, BK; Joo, YB; Kim, YM; Kwon, ST; Lee, CW; Song, JH, 2022) |
| "The administration of tranexamic acid (TXA) has been shown to be beneficial in reducing blood loss during surgery for adolescent idiopathic scoliosis (AIS), but optimal dosing has yet to be defined." | 4.12 | High- versus low-dose tranexamic acid as part of a Patient Blood Management strategy for reducing blood loss in patients undergoing surgery for adolescent idiopathic scoliosis. ( Bacon, A; Javidan, Y; Klineberg, E; Roberto, R; Stondell, C; Tafoya, S; Taylor, SL; Tumber, S, 2022) |
| "To determine whether locally injected tranexamic acid (TXA) used in the surgical treatment of fragility hip fractures can lower transfusion rates without increasing the risk of complications." | 4.12 | Efficacy and Safety of Locally Injected Tranexamic Acid in Hip Fracture Patients: A Retrospective Review. ( Davis, S; Kumar, M; Shearier, E; Solomito, MJ; Witmer, D, 2022) |
| " The PBM protocol consisted of epoetin (EPO) alfa therapy prescribed by the surgeon, routine administration of tranexamic acid (TXA), an avascular approach to the hip and postoperative prophylaxis of thromboembolism." | 4.02 | Application of an adjusted patient blood management protocol in patients undergoing elective total hip arthroplasty: towards a zero-percent transfusion rate in renal patients-results from an observational cohort study. ( Fennema, P; Hourlier, H, 2021) |
| " The purpose of this study was to compare the effects of intra-articular (IA) administration of tranexamic acid (TXA), an anti-fibrinolytic commonly used in TKA, and ALM chondroprotective solution on postoperative inflammation and joint tissue healing in a rat model of knee implant surgery." | 4.02 | Comparison of intra-articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty. ( Biros, E; Dlaska, C; Dobson, GP; Hazratwala, K; Letson, HL; McEwen, P; Morris, JL; Wilkinson, M, 2021) |
| "This case reminds clinicians that perioperative tranexamic acid administration may increase the risk of thrombosis, which needs focused attention from anesthesiologists." | 4.02 | Circulation collapse caused by intracardiac thrombosis associated with tranexamic acid administration: A case report. ( Gu, KP; Huang, CJ; Xie, Q; Yao, YX, 2021) |
| "Tranexamic acid (TXA) is an antifibrinolytic used for prophylaxis and treatment of acute bleeding." | 4.02 | Impact of Obesity on Tranexamic Acid Efficacy in Adult Patients With Major Bleeding. ( Farina, N; Franz, ND; Machado-Aranda, D; Miller, JT, 2021) |
| "Tranexamic acid (TXA) has gained increasing recognition in plastic surgery as a dependable adjunct capable of minimizing blood loss, ecchymosis, and edema." | 4.02 | Local Infiltration of Tranexamic Acid (TXA) in Liposuction: A Single-Surgeon Outcomes Analysis and Considerations for Minimizing Postoperative Donor Site Ecchymosis. ( Banuelos, J; Molinar, VE; Tran, NV; Weissler, JM, 2021) |
| "The aim of this pre and post interventional study looks at the effects of intravenous administration of tranexamic acid on induction for elderly patients undergoing hemiarthroplasty or intramedullary nail fixation for hip fractures." | 4.02 | The efficacy of intravenous tranexamic acid administration at induction in definitive hip fracture surgery: Is there a role? ( Chakravarty, D; Guhan, B; Kanthasamy, S; Parker, MJ, 2021) |
| "In cardiac surgery, use of the antifibrinolytic agent tranexamic acid (TXA) and acute perioperative stroke are both associated with convulsive seizures." | 4.02 | Associations of preoperative stroke and tranexamic acid administration with convulsive seizures in valvular open-heart surgery. ( Deutsch, MA; Gummert, JF; Hulde, N; Koster, A; von Dossow, V; Zittermann, A, 2021) |
| "Previous studies have demonstrated that the use of tranexamic acid (TXA) reduces blood loss and transfusion requirements in children undergoing scoliosis surgery." | 4.02 | A New Low Dose of Tranexamic Acid for Decreasing the Rate of Blood Loss in Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis. ( Bronson, WE; Halpern, LM; Kogan, CJ, 2021) |
| "This study aimed to investigate the effect of intravenous tranexamic acid (TXA) on blood loss and transfusion rates in children who underwent resection and endoprosthetic reconstruction of distal femoral osteosarcomas." | 4.02 | Efficacy and Safety of Tranexamic Acid in Resection and Endoprosthetic Reconstruction of Distal Femoral Osteosarcomas in Children: A Retrospective Cohort Study. ( Buyuktopcu, O; Erol, B; Kesimer, MD; Ozturk, O; Polat, M; Sofulu, O, 2021) |
| "The specific method and dose of tranexamic acid (TXA) topically applied for intertrochanteric fractures have not been well established." | 4.02 | Effect and safety of topical application of tranexamic acid to reduce perioperative blood loss in elderly patients with intertrochanteric fracture undergoing PFNA. ( He, J; Huang, T; Wei, H; Xia, M; Xian, S; Xiao, Q; Xu, W, 2021) |
| " A standard blood management protocol that consisted of hypotensive anesthesia, local and systemic administration of tranexamic acid (TXA) and intraoperative cell salvage was applied to all patients." | 3.96 | Does tourniquet use decrease blood loss following primary total knee arthroplasty in Jehovah's Witness patients? ( Çıtak, M; Gehrke, T; Köse, Ö; Levent, A; Linke, P, 2020) |
| "We investigated the clinical application of auricular point sticking (APS) combined with tranexamic acid in perioperative hemostasis in elderly patients with intertrochanteric fractures of the femur." | 3.91 | Clinical application of auricular point sticking in perioperative hemostasis for elderly patients with intertrochanteric fractures of the femur. ( Er, Z; Yin, C; Zhang, J, 2019) |
| "Geriatric hip fracture patients are particularly susceptible to blood loss and venous thromboembolism (VTE) during hemiarthroplasty, yet relatively few studies have examined the safety and efficacy of tranexamic acid (TXA) in these patients." | 3.91 | Efficacy and safety of tranexamic acid in geriatric hip fracture with hemiarthroplasty: a retrospective cohort study. ( Chen, G; Hu, Q; Huang, Q; Pei, F; Xie, J; Zhou, Z, 2019) |
| "Antifibrinolytics such as tranexamic acid reduce operative blood loss and blood product transfusion requirements in patients undergoing surgical correction of scoliosis." | 3.88 | Effect of Tranexamic Acid on Blood Loss, D-Dimer, and Fibrinogen Kinetics in Adult Spinal Deformity Surgery. ( Edwards, A; Herodes, M; Leveque, JA; Pong, RP; Sethi, RK; Wright, AK; Yanamadala, V, 2018) |
| "Tranexamic acid (TXA) is an effective agent used for reducing perioperative blood loss and decreasing the potential for postoperative hemarthrosis." | 3.88 | Tranexamic Acid Reduces Perioperative Blood Loss and Hemarthrosis in Total Ankle Arthroplasty. ( Boyle, KK; Nodzo, SR; Pavlesen, S; Ritter, C, 2018) |
| "To investigate the effectiveness and safety of intravenous tranexamic acid for reducing perioperative blood loss in patients with multilevel thoracic spinal stenosis (TSS)." | 3.88 | The efficacy and safety of tranexamic acid in reducing perioperative blood loss in patients with multilevel thoracic spinal stenosis: A retrospective observational study. ( Huang, X; Huang, Y; Liu, T; Qiao, F; Xu, X; Xue, P; Yang, J, 2018) |
| "Our objective was to quantify blood loss and transfusion requirements for high-dose and low-dose tranexamic acid (TXA) dosing regimens in pediatric patients undergoing spinal fusion for correction of idiopathic scoliosis." | 3.85 | High-dose Versus Low-dose Tranexamic Acid to Reduce Transfusion Requirements in Pediatric Scoliosis Surgery. ( Frank, SM; Goobie, SM; Johnson, CC; Johnson, DJ; Nami, N; Sponseller, PD; Wetzler, JA, 2017) |
| " Tranexamic acid (TA), an anti-fibrinolytic agent, has been shown to reduce peri-operative blood loss without increasing the risk of myocardial infarction (MI); however, no large study has examined the association between TA treatment and post-CABG myonecrosis." | 3.85 | Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery. ( Alexander, JH; Carrier, M; Lopes, RD; Merrill, PD; Podgoreanu, M; Tardif, JC; van Diepen, S, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic that is widely used to reduce surgical bleeding." | 3.83 | Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. ( Li, S; Liu, M; Peng, Y; Sessler, DI; Wu, Y; Yan, X; Yang, J; Zeng, M; Zhang, L; Zhou, D, 2024) |
| "Tranexamic acid is significantly less expensive than FE or EPO as a treatment option for total joint arthroplasty patients presenting with preoperative anemia." | 3.83 | Cost Analysis of Tranexamic Acid in Anemic Total Joint Arthroplasty Patients. ( Ani, F; Phan, DL; Schwarzkopf, R, 2016) |
| "Use of large dose tranexamic acid routinely seems to be effective and safe in reducing allogenic blood transfusion and blood loss in adolescent idiopathic scoliosis surgery." | 3.83 | Efficacy of tranexamic acid in reducing allogeneic blood products in adolescent idiopathic scoliosis surgery. ( Sui, WY; Yang, JL; Ye, F, 2016) |
| "We investigated the influence of intraoperative continuous tranexamic acid (TA) infusion on the amount of blood transfusion required in emergency surgery for type A acute aortic dissection." | 3.81 | Usefulness of intraoperative continuous infusion of tranexamic acid during emergency surgery for type A acute aortic dissection. ( Ahn, KT; Hirose, K; Ikarashi, J; Iwakura, A; Kusuhara, T; Nakatsuka, D; Yamanaka, K, 2015) |
| "The aim of this study was to compare transfusion requirements in patients before and after the introduction of tranexamic acid as standard in patients undergoing spinal surgery for idiopathic scoliosis in a national orthopaedic hospital." | 3.81 | Eliminating the use of allogeneic blood products in adolescent idiopathic scoliosis surgery. ( Berney, MJ; Connolly, P; Dawson, PH; Lui, DF; Phillips, M, 2015) |
| "We describe, for the first time, the use of topical tranexamic acid as an adjunct to traditional methods in the control of bleeding in burns surgery." | 3.78 | Use of tranexamic acid to reduce bleeding in burns surgery. ( Brooks, P; Chapman, TW; Tang, YM, 2012) |
| "A retrospective review of consecutive adult patients undergoing scoliosis correction surgery was performed to compare the effects of aprotinin and tranexamic acid in blood conservation and to define a comprehensive blood conservation strategy for such surgery." | 3.78 | Comparison of aprotinin and tranexamic acid in adult scoliosis correction surgery. ( Ahuja, S; Guha, A; Khurana, A; Pugh, S; Saxena, N, 2012) |
| "To assess the efficacy and safety of tranexamic acid (TXA) in decreasing operative blood loss and the need for transfusion during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents." | 3.78 | Does the intraoperative tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of adolescent idiopathic scoliosis? ( Fukuda, K; Hasegawa, J; Iizuka, S; Kaneko, S; Machida, M; Nagoshi, N; Shioda, M; Takemitsu, M; Yagi, M, 2012) |
| "Sequential cohort study analysing hemoglobin titers, transfusion rates, and the occurrence of venous thromboembolism in patients undergoing hip and knee replacements with and without the administration of tranexamic acid at the time of induction." | 3.78 | The routine use of tranexamic acid in hip and knee replacements. ( Chegini, S; Kucheria, R; Lobban, C; Panchmatia, JR; Shah, G; Smallman, JM; Stapleton, C, 2012) |
| " Postoperatively, a higher incidence of seizures in the first 48 hours was seen with tranexamic acid compared with aprotinin (11% versus 4%, p = 0." | 3.76 | Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients. ( Berman, M; Cardone, D; Dunning, J; Gerrard, C; Jenkins, D; Klein, A; Sharples, L; Tsui, S; Vuylsteke, A, 2010) |
| "Factor VIII:C, epsilon amino-caproic acid or tranexamic acid are prophylactic agents used in preventing hemorrhage pre-operatively in patients with hemophilia A." | 3.75 | Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation. ( Günaldi, M; Helvaci, A; Kiskaç, M; Küçükkaya, RD; Yildirim, ND, 2009) |
| "We compared intraoperative blood loss and blood replacement during spinal fusion surgery for scoliosis in Duchenne muscular dystrophy (DMD) performed with and without the synthetic antifibrinolytic agent tranexamic acid (TXA)." | 3.74 | Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusions for duchenne muscular dystrophy scoliosis. ( Sethna, NF; Shapiro, F; Zurakowski, D, 2007) |
| "The use of rFIX, rFVIIa, erythropoetin, iron, and tranexamic acid before, during and after scoliosis surgery may be a viable and safe option for hemophilia patients with inhibitors, who refuse blood products." | 3.74 | [A Jehovah's Witness child with hemophilia B and factor IX inhibitors undergoing scoliosis surgery]. ( Ansermino, M; Chau, A; Purdy, R; Tredwell, S; Wu, J, 2008) |
| "Knee arthritis is the primary cause of disability in middle-aged and older adults." | 3.30 | Value of Tranexamic Acid and Progressive Nursing in Accelerating Postoperative Rehabilitation After Total Knee Arthroplasty. ( Li, L; Liu, G; Pan, H; Wang, F; Wang, J; Zheng, S, 2023) |
| "Tranexamic acid is a drug thought to reduce blood loss." | 3.30 | Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial. ( Aoba, T; Ebata, T; Hayashi, D; Hiramatsu, K; Ishii, K; Kinoshita, F; Kurumiya, Y; Kuwatsuka, Y; Maeda, A; Minami, T; Natsume, S; Okuno, M; Sato, F; Seita, K; Shimizu, Y; Sugawara, G; Yamaguchi, R; Yokoyama, Y; Yonekawa, Y, 2023) |
| "Tranexamic acid (TXA) has been widely applied in total knee arthroplasty (TKA) to significantly reduce perioperative blood loss and improve knee function recovery in patients after surgery." | 3.30 | Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study. ( Wang, CC; Wu, T; Zhang, GQ; Zhang, LT; Zhou, LB, 2023) |
| "Tranexamic acid (TXA) has been shown to reduce intraoperative blood loss and improve the visual field." | 3.30 | Tranexamic acid does not significantly lower postoperative bleeding after endoscopic sinus and nasal surgery. ( Chan, E; Hwang, PH; Khanwalkar, A; Kim, D; Ma, Y; Nayak, JV; Patel, ZM; Roozdar, P, 2023) |
| "Tranexamic acid (TXA) has been shown to be effective in reducing blood loss for patients undergoing THA, but few studies focus on its alleviation of postoperative local pain symptoms." | 3.30 | Topical use of tranexamic acid can reduce opioid consumption compared with intravenous use for patients undergoing primary total hip arthroplasty: a prospective randomized controlled trial. ( Jiang, Z; Shen, L; Wang, Q; Xu, W, 2023) |
| "No tranexamic acid was administered to the control group." | 3.30 | [Effects of Tranexamic Acid on Perioperative Blood Loss and Wound Hematoma Development in Lumbar Spine Surgery: a Prospective Randomized Study]. ( Hrabálek, L; Jablonský, J; Novák, V; Stejskal, P; Trnka, Š; Wanek, T, 2023) |
| "To evaluate the efficacy and safety of perioperative cryotherapy combined with intra-articular injection of tranexamic acid (TXA) in total knee arthroplasty (TKA) and explore a new strategy of enhanced recovery after TKA." | 3.30 | Efficacy of perioperative cryotherapy combined with intra-articular injection of tranexamic acid in total knee arthroplasty. ( Huang, W; Huang, X; Li, F; Liu, W; Shi, W; Yin, D, 2023) |
| "However, uterine fibroids are highly vascular tumors and, consequently, extremely susceptible to problems from myomectomy-related hemorrhage." | 3.30 | Oxytocin versus a combination of tranexamic acid and ethamsylate in reducing intraoperative bleeding during abdominal myomectomy: a randomized clinical trial. ( Abd-ElGawad, M; Abdel-Hakam, F; Abdelaziz, DFM; Abdelhamed, SA; Abdelmonem, H; Abdou, AM; Afiffi, IK; Bosilah, AH; Eldesouky, E; Elhalim, AEMA; Ellaban, M; Elrashedy, AA; Elsayed, HGA; Elsror, AGA; Farag, E; Kamel, MA; Marai, AAE; Marie, H; Mohammed, A; Shaaban, A, 2023) |
| "Tranexamic acid (TXA) has been proven to prevent thrombolysis and reduce bleeding and blood transfusion requirements in various surgical settings." | 3.30 | The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial. ( Jin, H; Li, M; Li, S; Liu, M; Liu, X; Ma, T; Peng, Y; Wang, J; Wu, Y; Yang, J; Yu, H; Zeng, M; Zhang, L; Zhang, X, 2023) |
| "This study aimed to evaluate the effect of temperature intervention combined with tranexamic acid (TXA) on perioperative blood loss during spinal fusion and accelerated rehabilitation." | 3.30 | The efficacy of temperature intervention combined with tranexamic acid in reducing blood loss and accelerating recovery during spinal fusion. ( Huang, X; Huang, Y; Li, F; Liang, B; Yin, D, 2023) |
| "Tranexamic acid has been found to be effective in reducing peri-operative blood loss and is widely used across surgical specialties including orthopaedic surgery." | 3.11 | Comparison of single versus double tranexamic acid dose regimens in reducing post-operative blood loss following intramedullary nailing of femoral fracture nonunions. ( Ajiboye, LO; Arojuraye, SA; Ibrahim, SS; James, JA; Jatto, HI; Ramat, AM; Shodipo, OM; Toluse, AM, 2022) |
| "The hemostatic effect of tranexamic acid (TXA) combined with carbazochrome sodium sulfonate (CSS) in total hip arthroplasty (THA) has not been determined." | 3.11 | Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial. ( Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022) |
| "Postoperative pneumonia is a major cause of morbidity and mortality following cardiac surgery." | 3.11 | Characterisation of Plasma Mitochondrial DNA, MMP-9 and Neutrophil Elastase in Patients Undergoing Coronary Artery Bypass Grafting: Effects of Tranexamic Acid and Postoperative Pneumonia. ( Bain, CR; Draxler, DF; Gruen, RL; Hauser, CJ; Ho, H; Medcalf, RL; Myles, PS; Sandler, N; Smith, JA, 2022) |
| "The primary outcome was postoperative blood loss, and the secondary outcomes were postoperative PRC transfusion and complications." | 3.11 | Adjunctive Topical Tranexamic Acid for Blood Salvage Does Not Reduce Postoperative Blood Loss Compared with Placebo in Patients Who Undergo Palliative Decompressive Spinal Metastasis Surgery: A Randomized Controlled Trial. ( Atthakomol, P; Maethungkul, R; Murakami, H; Phanphaisarn, A; Phinyo, P; Sangsin, A, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery." | 3.11 | Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. ( Abubakirov, M; Aguado, HJ; Alfonsi, P; Amir, M; Astrakov, SV; Ayad, S; Balasubramanian, K; Bangdiwala, SI; Belley-Cote, E; Bhatt, K; Biccard, B; Borges, FK; Chan, MTV; Cheong, CC; Conen, D; Copland, I; de Nadal, M; Devereaux, PJ; Duceppe, E; Efremov, S; Eikelboom, J; Fleischmann, E; Garg, AX; Gross, PL; Guyatt, G; Iglesisas, PP; Jayaram, R; Kirov, M; Kleinlugtenbelt, YV; Kurz, A; Lamy, A; Landoni, G; Leslie, K; Likhvantsev, V; Lomivorotov, VV; Marcucci, M; Martínez Zapata, MJ; McGillion, M; McIntyre, W; Meyhoff, CS; Ofori, SN; Painter, TW; Parlow, JL; Patel, A; Petit, S; Polanczyk, CA; Rao, M; Richards, T; Roshanov, P; Ruetzler, K; Schmartz, D; Sessler, D; Short, TG; Spence, J; Srinathan, S; Stillo, D; Szczeklik, W; Tandon, V; Torres, D; VanHelder, T; Vincent, J; Wang, CY; Wang, MK; Whitlock, RP; Wittmann, M; Wu, WKK; Xavier, D; Yusuf, S, 2022) |
| " However, postoperative seizure, as one of the major adverse effects of TXA infusion, has been a concern that restricts its utility in neurosurgery." | 3.11 | Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial. ( Dong, J; Li, R; Li, S; Liu, X; Ma, T; Peng, Y; Wang, J; Yan, X; Zeng, M; Zhang, X, 2022) |
| " There were no serious adverse events associated with the interventions in this study." | 3.11 | Safety and efficacy of aprotinin versus tranexamic acid for reducing absolute blood loss and transfusion in pediatric patients undergoing craniosynostosis surgery: a randomized, double-blind, three-arm controlled trial. ( Dabbagh Ohadi, MA; Ebrahim Soltani, A; Ebrahim Soltani, Z; Habibi, Z; Hanaei, S; Khademi, S; Maroufi, SF; Nejat, F; Tayebi Meybodi, K; Yaghmaei, B, 2022) |
| " The current study aimed to determine whether tranexamic acid (TXA) in combination with pressure dressing reduce the amount of blood loss, the rate of incision-related complications, and the rate of readmission for patients undergoing surgeries to release GMC." | 3.11 | Tranexamic acid combined with compression dressing reduces blood loss in gluteal muscle contracture surgery. ( Huang, Q; Huang, Z; Ma, J; Pei, F; Shen, B; Zhou, Z, 2022) |
| "Preoperative TXA is safe and effective in reducing blood loss during and after high-risk CD." | 3.11 | Safety and efficacy of preoperative tranexamic acid in reducing intraoperative and postoperative blood loss in high-risk women undergoing cesarean delivery: a randomized controlled trial. ( Al-Asmar, A; Al-Mohamady, M; El Mahy, M; Maged, AM; Rund, NMA; Shalaby, MA, 2022) |
| "Tranexamic acid is a good choice to reduce blood loss during this type of surgery." | 3.11 | Is intravenous tranexamic acid effective in reduction of blood loss during pelvic and acetabular surgery? ( El-Deeb, YM; Sharaby, MMF, 2022) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic effective in reducing blood loss in orthopedic surgery." | 3.11 | Randomized, controlled trial of two tranexamic acid dosing protocols in adult spinal deformity surgery. ( Clohisy, JCF; Dafrawy, MHE; Frazier, E; Kelly, MP; Lenke, LG; Wolfe, RC, 2022) |
| "Tranexamic acid is a lysine synthetic derivate that inhibits fibrinolysis and diminishes the bleeding by blocking the five lysine-binding sites for plasminogen." | 3.11 | Use of Tranexamic Acid in Liposculpture: A Double-Blind, Multicenter, Randomized Clinical Trial. ( Bayter, JE; Cala, L; Cardenas-Camarena, L; Domínguez-Millan, R; Duran, H; Hoyos, AE; Lopez, A; Mogollon, IR; Perez, M; Talleri, G, 2022) |
| " DISCUSSION Consensus on optimal TXA dosing regime in primary hip and knee arthroplasties is still missing." | 3.11 | Comparison of Intravenous and Topical Tranexamic Acid in Total Joint Arthroplasty. ( Masaryk, J; Melus, V; Steno, B; Vidan, J, 2022) |
| "Tranexamic acid (TXA) has been shown to reduce intraoperative bleeding and the need for post-operative allogenic blood transfusion requirement in surgery." | 3.11 | A single dose of tranexamic acid infusion is safe and effective to reduce total blood loss during proximal femoral nailing for intertrochanteric fractures: A prospective randomized study. ( Ekinci, M; Ersin, M; Günen, E; Kocazeybek, E; Ok, M; Sırma, SÖ; Yılmaz, M, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the conversion of plasminogen to plasmin, thus preventing the binding and degradation of fibrin." | 3.11 | Efficacy and Safety of Tranexamic Acid for the Control of Surgical Bleeding in Patients Under Liposuction. ( Álvarez-Trejo, HJ; Bonilla-Catalán, PV; de Andrea, GT; Dorado-Hernández, E; Fierro-Rodríguez, DA; García-Valenzuela, SE; Jiménez-Pavón, KE; Medina-Quintana, VM; Morfin-Meza, KE; Ramos-Maciel, J; Rodríguez-García, FA; Romero-Algara, E; Sánchez-Peña, MA; Torres-Salazar, QL; Villarreal-Salgado, JL, 2022) |
| "Tranexamic acid (TXA) has shown significant reductions in blood loss and transfusion rates in total knee arthroplasty (TKA)." | 3.01 | Multimodal Peri-articular Injection with Tranexamic Acid can reduce postoperative blood loss versus Intravenous Tranexamic Acid in Total Knee Arthroplasty: A Randomized Controlled Trial. ( Lin, J; Peng, HM; Qian, WW; Wang, W; Wang, WD; Weng, XS, 2021) |
| "Tranexamic acid was used systemically by IV application (15mg/kg) in IV group, locally in the surgical field (2g) in local group as well as combined systemic and local together in combined group." | 3.01 | The efficacy, safety, and cost-effectives of combined administration of Intravenous and Local Tranexamic Acid in the management of Patients Undergoing Primary Total Hip Arthroplasty: A prospective, blinded and randomized clinical study. ( Çaylak, R; Örs, Ç, 2021) |
| "Tranexamic acid (TXA) has been studied extensively during the last 5-8 years." | 3.01 | Tranexamic Acid: When is It Indicated in Orthopaedic Surgery? ( Viberg, B, 2023) |
| "Osteoporotic hip fractures are a major health problem in developed countries." | 3.01 | Intravenous tranexamic acid and thromboembolic events in hip fracture surgery: A systematic review and meta-analysis. ( Leverett, GD; Marriott, A, 2023) |
| "Surgical correction of craniosynostosis can involve significant blood loss." | 3.01 | Optimizing Blood Loss and Management in Craniosynostosis Surgery: A Systematic Review of Outcomes Over the Last 40 Years. ( Coombs, DM; Knackstedt, R; Patel, N, 2023) |
| "Tranexamic acid (TXA) has been considered effective in preventing anemia in total hip arthroplasty, but its role in hemiarthroplasty is debated." | 3.01 | Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis. ( Augustinus, S; Gardenbroek, TJ; Goslings, JC; Mulders, MAM, 2023) |
| "Tranexamic acid (TXA) has been found to reduce mortality and blood transfusion in surgical and trauma patients." | 3.01 | Is tranexamic acid associated with decreased need for blood transfusion in percutaneous nephrolithotomy: a systematic review and meta-analysis. ( Devana, SK; Kumar, S; Prasad, S; Sharma, G; Sharma, S, 2023) |
| "Tranexamic Acid (TXA) has been used in medical and surgical practice to reduce haemorrhage." | 3.01 | Tranexamic acid use in meningioma surgery - A systematic review and meta-analysis. ( Bakhsh, A; Brodbelt, AR; Clynch, AL; Gillespie, CS; Islim, AI; Jenkinson, MD; Keshwara, SM; Kumar, S; Mills, SJ; Millward, CP; Mustafa, MA; Richardson, GE; Zakaria, R, 2023) |
| "Tranexamic acid (TXA) has drawn growing interest over the last decade for its benefit in optimizing post-operative bleeding, yet its role in bariatric surgery is poorly understood." | 3.01 | Role of Tranexamic Acid (TXA) in Preventing Bleeding Following Sleeve Gastrectomy: a Systematic Review and Meta-analysis. ( Karmali, S; Koloszvari, N; Kung, J; Mocanu, V; Neville, A; Verhoeff, K; Walsh, C; Wilson, H, 2023) |
| "Its role in reducing postoperative blood loss in breast surgery remains unclear." | 3.01 | The Effects of Tranexamic Acid in Breast Surgery: A Systematic Review and Meta-Analysis. ( Huynh, MNQ; McRae, MC; McRae, MH; Voineskos, S; Wong, CR, 2023) |
| "Intraoperative and postoperative blood loss is a major risk in head and neck (H&N) surgery." | 3.01 | A systematic review on the efficacy of tranexamic acid in head and neck surgery. ( Coulson, C; Jamshaid, M; Jamshaid, W; Muzaffar, J; Nieto, H; Sharma, N, 2023) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic that has been shown to reduce surgical blood losses; however, its use in burn surgery is not well established." | 3.01 | Tranexamic acid in burn surgery: A systematic review and meta-analysis. ( Boctor, MJ; Fijany, AJ; Gandhi, RR; Givechian, KB; Olsson, SE; Pekarev, M; Zago, I, 2023) |
| "Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects." | 3.01 | Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis. ( Cheah, S; Cheong, CC; Mong, SXY; Ng, KT; Tsan, SEH; Viknaswaran, NL; Wang, CY, 2023) |
| "Tranexamic acid (TXA) has been reported to reduce perioperative blood loss in hip or knee arthroplasty." | 3.01 | Efficacy and safety of single- and double-dose intravenous tranexamic acid in hip and knee arthroplasty: a systematic review and meta-analysis. ( Cheng, QH; Guo, HZ; Yang, X; Yang, YZ; Zhang, AR; Zhang, ZZ, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug associated with reduced blood loss in a range of surgical specialties, including neurosurgery, orthopedic surgery, and cardiac surgery." | 3.01 | Systematic review and meta-analysis of topical tranexamic acid in spine surgery. ( Ambati, VS; Chan, AK; Chou, D; Izima, C; Sampath, SG; Tang, AJ, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent shown to decrease intraoperative bleeding, reduce transfusions, and improve outcomes across multiple specialties." | 3.01 | Effects of Intravenous Tranexamic Acid During Rhytidectomy: A Randomized, Controlled, Double-Blind Pilot Study. ( Alloju, LM; Cohen, JC; Glasgold, MJ; Glasgold, RA, 2021) |
| "This study aimed to evaluate the optimal dosage of topical tranexamic acid (TXA) considering the efficacy and safety for controlling bleeding after total knee arthroplasty (TKA)." | 3.01 | Optimal dose of topical tranexamic acid considering efficacy and safety in total knee arthroplasty: a randomized controlled study. ( Han, HS; Kim, JK; Lee, DY; Lee, MC; Park, JY; Ro, DH, 2021) |
| "Tranexamic acid (TXA) has been widely used in hip and knee arthroplasty to decrease perioperative blood loss." | 3.01 | A single dose of tranexamic acid reduces blood loss after reverse and anatomic shoulder arthroplasty: a randomized controlled trial. ( Borner, B; Cass, B; Cunningham, G; Hughes, J; Mattern, O; Smith, MM; Taha, ME; Young, AA, 2021) |
| "Tranexamic acid (TXA) has become a routine part of perioperative care in TKAs." | 3.01 | Prospective, randomised, controlled study on the efficacy and safety of different strategies of tranexamic acid with total blood loss, blood transfusion rate and thrombogenic biomarkers in total knee arthroplasty: study protocol. ( Ding, D; He, J; Jin, Q; Jin, Y; Wang, F; Wang, Z; Yang, H; Yang, K; Yang, Y; Zhao, X, 2021) |
| "Tranexamic acid is a fibrinolysis suppressor that is used for a variety of bleeding control procedures such as hematuria, surgery bleeding, and trauma caused bleeding." | 3.01 | The Effects of Tranexamic Acid on Bleeding Control During and after Percutaneous Nephrolithotomy (PCNL): A Randomized Clinical Trial. ( Abedi, F; Farshid, S; Modresi, P; Mokhtari, MR, 2021) |
| "Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in elective orthopedic surgery." | 3.01 | Topical tranexamic acid in hip fractures: a randomized, placebo-controlled double-blinded study. ( Cheong, Y; Costain, D; Elder, G; Fera, L; Fraser, B; Kelly, A; Slagel, B, 2021) |
| "Tranexamic acid (TXA) has been widely used to prevent excessive blood loss perioperatively." | 2.94 | Comparison of hemocoagulase atrox versus tranexamic acid used in primary total knee arthroplasty: A randomized controlled trial. ( Lin, Y; Qin, JZ; Shi, L; Wang, SJ; Xia, C; Zhao, HH; Zheng, XP, 2020) |
| "Tranexamic acid (TXA) has been shown to be effective in reducing blood loss after total knee replacement." | 2.94 | Topical tranexamic acid in cemented primary total knee arthroplasty without tourniquet: a prospective randomized study. ( Bustamante Suarez de Puga, D; Martínez Gimenez, E; Mas Martinez, J; Morales Santias, M; Sanz-Reig, J; Verdu Román, C, 2020) |
| "Tranexamic acid is a synthetic lysine derivative with antifibrinolytic activity used in other surgical disciplines to reduce blood loss during surgery." | 2.94 | Intraoperative tranexamic acid to decrease blood loss during myomectomy: a randomized, double-blind, placebo-controlled trial. ( Maasen, MS; Marfori, CQ; Moawad, G; Opoku-Anane, J; Robinson, JK; Vargas, MV, 2020) |
| "However, there was significantly lower postoperative blood loss with TXA (29." | 2.94 | Tranexamic acid for the Latarjet procedure: a randomized controlled trial. ( Hurley, ET; Lim Fat, D; Mullett, H; Pauzenberger, L, 2020) |
| "Tranexamic acid (TXA) has been widely used in hip and knee arthroplasty to reduce perioperative blood loss and blood transfusion, but the dosage and efficacy of TXA in posterior lumbar spinal surgery are not fully clear." | 2.94 | Two Doses of Tranexamic Acid Reduce Blood Loss in Primary Posterior Lumbar Fusion Surgery: A Randomized-controlled Trial. ( Guo, K; Li, D; Li, H; Shi, Q; Wu, J; Zheng, X; Zhu, X, 2020) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that has been used to reduce blood loss in orthopedic surgery." | 2.94 | Randomized prospective evaluation of the use of tranexamic acid and effects on blood loss for proximal humeral fracture surgery. ( Cuff, DJ; Gorman, RA; Simon, P, 2020) |
| "Deep venous thrombosis (DVT) and pulmonary embolism (PE) events were monitored and recorded." | 2.94 | Combined use of intravenous and topical tranexamic acid efficiently reduces blood loss in patients aged over 60 operated with a 2-level lumbar fusion. ( Bai, T; Huang, Y; Li, J; Liu, Y; Wang, L, 2020) |
| "Tranexamic acid (TXA) has been shown to reduce blood loss and transfusion requirements in patients undergoing orthopaedic surgery." | 2.94 | Intravenous tranexamic acid reduces blood loss and transfusion requirements after periacetabular osteotomy. ( DelPizzo, K; Dodwell, E; Levack, AE; McLawhorn, AS; Nguyen, J; Sink, E, 2020) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent, which reduces bleeding in numerous scenarios, however, its prophylactic use in mitigating post-TBLB bleeding has not been investigated." | 2.94 | Prophylactic use of tranexamic acid for prevention of bleeding during transbronchial lung biopsies - A randomized, double-blind, placebo-controlled trial. ( Abu Rmeileh, A; Abutbul, A; Berkman, N; Cohen Goichman, P; Fridlender, ZG; Huszti, E; Kuint, R; Levy, L; Shriki, O, 2020) |
| "The purpose of this multicenter, randomized trial was to determine the optimal dosing regimen of tranexamic acid (TXA) to minimize perioperative blood loss in revision total hip arthroplasty." | 2.94 | The Optimal Dosing Regimen for Tranexamic Acid in Revision Total Hip Arthroplasty: A Multicenter Randomized Clinical Trial. ( Abdel, MP; Culvern, C; Della Valle, CJ; Fillingham, YA; Malkani, AL; Nahhas, C; Nam, D; Padgett, DE; Schwarzkopf, R; Sershon, RA; Vail, TP, 2020) |
| " There was no evidence of any serious side effect of tranexamic acid." | 2.94 | Safety and Efficacy of Using Tranexamic Acid at the Beginning of Robotic-Assisted Radical Prostatectomy in a Double-Blind Prospective Randomized Pilot Study. ( Balík, M; Broďák, M; Čečka, F; Hušek, P; Košina, J, 2020) |
| "A total of 100 patients with intertrochanteric fractures undergoing surgery were enrolled and randomly allocated to the TXA group in which patients (75." | 2.90 | Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single-Blind Randomized Controlled Trial. ( Huang, Y; Jiang, LF; Wu, LD; Xu, NW; Zhang, JJ; Zhang, Y; Zhou, D; Zhou, XD, 2019) |
| "Tranexamic acid (TXA) has long been used to reduce blood loss associated with total knee arthroplasty (TKA)." | 2.90 | Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial. ( Bernaitis, N; Dare, W; King, L; Randle, R, 2019) |
| "Uterine fibroids are the commonest tumour of the female genital tract; about one third are symptomatic and require management." | 2.90 | Adjunctive use of tranexamic acid to tourniquet in reducing haemorrhage during abdominal myomectomy - A randomized controlled trial. ( Abdul, IF; Adesina, KT; Amadu, MB; Olarinoye, AO; Omokanye, LO, 2019) |
| "Tranexamic acid appears to be an effective haemostat in endoscopic ear surgery, thus improving surgical field visualisation, especially during manipulation of the external auditory canal soft tissues." | 2.90 | Does tranexamic acid improve intra-operative visualisation in endoscopic ear surgery? A double-blind, randomised, controlled trial. ( Das, A; Ghosh, D; Kumar, S; Mitra, S; Sengupta, A, 2019) |
| "Tranexamic acid was reported to reduce bleeding in patients undergoing percutaneous nephrolithotomy (PCNL)." | 2.90 | Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy: a randomized clinical trial. ( Gholipour, F; Kazemi, R; Mohammadi Sichani, M; Nouri-Mahdavi, K, 2019) |
| " Other secondary variables were total blood loss, hidden blood loss, transfusion rate, average hospital stay, complications, adverse events, and mortality." | 2.90 | Prevention of postoperative bleeding in hip fractures treated with prosthetic replacement: efficacy and safety of fibrin sealant and tranexamic acid. A randomised controlled clinical trial (TRANEXFER study). ( Aguilera, X; Bosch, A; Camacho-Carrasco, P; Castillón, P; González, JC; Hernández, JA; Jordan, M; Martínez-Zapata, MJ; Mora, JM; Prat-Fabregat, S; Rodriguez-Arias, A; Ruiz, L; Salomó, M, 2019) |
| "Tranexamic acid (TXA) reduces surgical blood loss and alleviates inflammatory response in total hip arthroplasty." | 2.90 | Effect of Multiple Doses of Oral Tranexamic Acid on Haemostasis and Inflammatory Reaction in Total Hip Arthroplasty: A Randomized Controlled Trial. ( He, C; Li, Q; Luo, ZY; Pei, FX; Wang, D; Yang, Y; Zeng, WN; Zhou, ZK, 2019) |
| "Tranexamic acid (TXA) is an efficient antifibrinolytic agent, but the mode and timing of its administration remain controversial." | 2.90 | A randomized, double-blind, placebo-controlled trial on the efficacy of tranexamic acid combined with rivaroxaban thromboprophylaxis in reducing blood loss after primary cementless total hip arthroplasty. ( Baynat, C; Clavé, A; Danguy des Déserts, M; Gatineau, F; Gérard, R; Lacroix, J; Mottier, D, 2019) |
| "Tranexamic acid (TXA) has been routinely delivered in multisegmental spinal decompression and bone graft fusion surgeries with satisfactory outcomes in minimizing gross blood loss and transfusion demands." | 2.90 | Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries (TARGETS): study protocol for a prospective, randomized, double-blind, non-inferiority trial. ( Chen, X; Huang, Y; Hui, S; Li, S; Mahmood, F; Ren, Z; Sheng, L; Tao, L; Xu, D; Zhuang, Q, 2019) |
| "Tranexamic acid (TXA) has been widely used in total knee arthroplasty (TKA) for blood loss reduction." | 2.90 | Intra-Articular Tranexamic Acid Mitigates Blood Loss and Morphine Use After Total Knee Arthroplasty. A Randomized Controlled Trial. ( Galassi, M; Laoruengthana, A; Pongpirul, K; Rasamimongkol, S; Rattanaprichavej, P; Weerakul, S, 2019) |
| "Eligible patients with trochanteric fractures surgically treated by dynamic hip screw and proximal anti-rotating intramedullary nail between March 2016 and October 2017 were enrolled in the study." | 2.90 | Efficacy and safety of perioperative tranexamic acid in elderly patients undergoing trochanteric fracture surgery: a randomised controlled trial. ( Chen, F; Jiang, Z; Li, M; Zhu, X, 2019) |
| "Additional reduction of postoperative blood loss may further reduce exposure to allogeneic blood products." | 2.90 | Reduced perioperative blood loss in children undergoing craniosynostosis surgery using prolonged tranexamic acid infusion: a randomised trial. ( D'Amore Lindholm, A; Fenger-Eriksen, C; Hvas, AM; Juul, N; Krogh, L; Nørholt, SE; Rasmussen, M; Tarpgaard, M; von Oettingen, G, 2019) |
| "Tranexamic acid (TXA) is proven to reduce blood loss following total knee arthroplasty (TKA), but there are limited data on the impact of similar dosing regimens in revision TKA." | 2.90 | 2019 Mark Coventry Award: A multicentre randomized clinical trial of tranexamic acid in revision total knee arthroplasty: does the dosing regimen matter?. ( Abdel, MP; Bini, S; Calkins, TE; Culvern, C; Darrith, B; Della Valle, CJ; Fillingham, YA; Malkani, AL; Padgett, DE; Schwarzkopf, R; Sershon, RA, 2019) |
| "Outcomes assessed are intraoperative and postoperative blood loss, hematocrit, allogenic blood transfusion, and deep vein thrombosis (DVT), postoperatively." | 2.87 | Effectiveness and Safety of Batroxobin, Tranexamic Acid and a Combination in Reduction of Blood Loss in Lumbar Spinal Fusion Surgery. ( Dumpa, SR; Kanna, RM; Nagabhushan, RM; Shanmuganathan, R; Shetty, AP; Subramanian, B, 2018) |
| "Tranexamic acid (TXA) has demonstrated efficacy in reducing blood loss, reduction in hemoglobin, and blood transfusion requirements in primary total hip arthroplasty (THA)." | 2.87 | Oral vs Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Study. ( Luo, ZY; Pei, FX; Wang, D; Wang, HY; Zhou, K; Zhou, ZK, 2018) |
| "The purpose of this study was to compare the effects of three dosage regimens of intravenous tranexamic acid and normal saline placebo on blood loss and the requirement for transfusion during bimaxillary osteotomy." | 2.87 | The effect of different dosage regimens of tranexamic acid on blood loss in bimaxillary osteotomy: a randomized, double-blind, placebo-controlled study. ( Apipan, B; Narainthonsaenee, T; Rummasak, D, 2018) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent, decreasing blood loss in hip arthroplasty." | 2.87 | Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokinetic-pharmacodynamic study. ( Delavenne, X; Hodin, S; Lanoiselée, J; Ollier, E; Zufferey, PJ, 2018) |
| " TA efficiency and optimal dosage in haemorrhagic caesarean section (CS) has not been yet determined." | 2.87 | Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial. ( Allorge, D; Baptiste, AS; Bouthors, AS; Duhamel, A; Hennart, B; Jeanpierre, E; Lannoy, D; Saidi, I; Simon, E; Susen, S, 2018) |
| " In order to avoid adverse effects associated with intravenous administration, topical use has been proposed as an alternative." | 2.87 | Efficacy and safety of topical tranexamic acid in knee arthroplasty. ( Dauder-Gallego, C; Ferreño-Márquez, D; López-Hualda, Á; Martínez-Martín, J, 2018) |
| "Tranexamic acid has been shown to be effective for minimizing perioperative blood loss in liposuction." | 2.87 | Use of Tranexamic Acid to Reduce Blood Loss in Liposuction. ( Cansancao, AL; Cansancao, B; Condé-Green, A; David, JA; Vidigal, RA, 2018) |
| "Radical cystectomy for bladder cancer is associated with a high risk of needing red blood cell transfusion." | 2.87 | Tranexamic Acid versus Placebo to Prevent Blood Transfusion during Radical Cystectomy for Bladder Cancer (TACT): Study Protocol for a Randomized Controlled Trial. ( Breau, RH; Bryson, G; Cagiannos, I; Cnossen, S; Fergusson, DA; Kanji, S; Knoll, G; Lavallée, LT; Mallick, R; Momoli, F; Morash, C; Turgeon, A; Witiuk, K; Zarychanski, R, 2018) |
| "No episodes of deep venous thrombosis or pulmonary embolism occurred in all cases." | 2.87 | Multiple-Dose Intravenous Tranexamic Acid Further Reduces Hidden Blood Loss After Total Hip Arthroplasty: A Randomized Controlled Trial. ( Chen, G; Huang, Q; Huang, Z; Lei, Y; Pei, F; Xie, J, 2018) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that has shown promise in reducing blood loss during total hip arthroplasty (THA)." | 2.87 | Tranexamic acid use during total hip arthroplasty: A single center retrospective analysis. ( Ackermann, W; Bergese, SD; Ellis, T; Glassman, A; Granger, J; Joseph, N; Mahmoud, AR; Moran, K; Niermeyer, W; Rogers, B; Ryan, J; Salon, N; Stoicea, N, 2018) |
| "TRAC-24 will help to determine whether an extended TXA dosing regimen can further reduce blood loss following primary THA and TKA." | 2.87 | Assessment of the effect of addition of 24 hours of oral tranexamic acid post-operatively to a single intraoperative intravenous dose of tranexamic acid on calculated blood loss following primary hip and knee arthroplasty (TRAC-24): a study protocol for a ( Adams, C; Agus, A; Bell, J; Benson, G; Beverland, D; Bryce, L; Campbell, C; Dorman, A; Eggleton, A; Gardner, E; Hill, J; Hogg, R; Magill, P; Martin, U; McFarland, M; Mockford, B; Molloy, D; Murphy, L; O'Hagan, S; Phair, G, 2018) |
| "Only one patient in IV group exhibited deep venous thrombosis." | 2.87 | Tranexamic acid in primary total knee arthroplasty without tourniquet: a randomized, controlled trial of oral versus intravenous versus topical administration. ( Cao, C; Li, DH; Li, LL; Meng, WK; Pei, FX; Wang, D; Wang, HY; Zeng, WN; Zhou, ZK, 2018) |
| "To compare the efficacy and safety of intra-articular combined with intravenous administration of tranexamic acid (TXA) with different dosage for reducing blood loss in primary total knee arthroplasty (TKA)." | 2.87 | [Comparison of combined intravenous and topical use of tranexamic acid with different dosage in primary total knee arthroplasty]. ( Chen, Y; Deng, J; Li, G; Wu, J; Zhang, C, 2018) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss." | 2.87 | Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery: A Randomized Placebo-Controlled Trial. ( Brustowicz, RM; Emans, JB; Glotzbecker, MP; Goobie, SM; Hedequist, D; Hresko, MT; Karlin, LI; McCann, ME; Sethna, NF; Zurakowski, D, 2018) |
| " Secondary outcomes were calculated blood loss, number of units transfused during hospitalization, and incidence of adverse events at 30 and 90 days including thromboembolic event, wound complications, reoperation, hospital readmission, and all-cause mortality." | 2.84 | Tranexamic Acid Safely Reduced Blood Loss in Hemi- and Total Hip Arthroplasty for Acute Femoral Neck Fracture: A Randomized Clinical Trial. ( Cross, WW; Houdek, MT; Pagnano, MW; Sems, SA; Watts, CD, 2017) |
| "Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in total knee arthroplasty (TKA)." | 2.84 | Tranexamic Acid in Knee Surgery Study-A Multicentered, Randomized, Controlled Trial. ( Aoina, J; Hill, AG; Munro, JT; Poutawera, V; Stowers, MDJ; Vane, A, 2017) |
| "No deep venous thrombosis or other severe complications had occurred." | 2.84 | Intra-articular Application is More Effective Than Intravenous Application of Tranexamic Acid in Total Knee Arthroplasty: A Prospective Randomized Controlled Trial. ( Wang, J; Wang, Q; Zhang, X, 2017) |
| "Tranexamic acid is a proven drug used for reduction of intraoperative blood loss in spinal surgery." | 2.84 | The effectiveness of low-dose and high-dose tranexamic acid in posterior lumbar interbody fusion: a double-blinded, placebo-controlled randomized study. ( Hey, HWD; Hong, SJ; Juh, HS; Kim, CK; Kim, HJ; Kim, HS; Kim, KT; Kim, YC, 2017) |
| "The total blood loss and postoperative blood loss were significantly lower in groups B and C without any difference between them." | 2.84 | Efficacy of a Single Dose and an Additional Dose of Tranexamic Acid in Reduction of Blood Loss in Total Knee Arthroplasty. ( Cai, M; Ge, W; Li, S; Sun, Q; Wu, J; Yu, X, 2017) |
| "v, a maintenance dosage of 2 mg/kg/h TA, or an equivalent volume of normal saline." | 2.84 | Tranexamic acid reduces perioperative blood loss of posterior lumbar surgery for stenosis or spondylolisthesis: A randomized trial. ( Jiang, D; Ou, Y; Quan, Z; Shi, H; Zhao, Z; Zhu, Y, 2017) |
| " combined with topical administration of TXA decreases postoperative blood loss and transfusion rates after THA." | 2.84 | Intravenous Combined with Topical Administration of Tranexamic Acid in Primary Total Hip Arthroplasty: A Randomized Controlled Trial. ( Kang, PD; Pei, FX; Shen, B; Si, HB; Yang, J; Zeng, Y; Zhou, ZK, 2017) |
| "The combined (IV (intravenous) + topical) use of tranexamic acid (TXA) has been shown to be a safe method and more effective than single (IV or topical) application." | 2.84 | The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty. ( Akkaya, M; Basaran, SH; Bozkurt, M; Cankaya, D; Dasar, U; Satilmis, AB, 2017) |
| "Tranexamic acid results in lower bleeding irrespective of the mode of administration compared to control group." | 2.84 | A randomized control trial to evaluate the effectiveness of intravenous, intra-articular and topical wash regimes of tranexamic acid in primary total knee arthroplasty. ( Jin, C; Park, YJ; Prakash, J; Seon, JK; Song, EK, 2017) |
| "Tranexamic acid is an antifibrinolytic that has been shown to reduce blood loss and the need for transfusions when administered intravenously in total hip arthroplasty." | 2.84 | Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial. ( Della Valle, CJ; Fillingham, YA; Gerlinger, TL; Kayupov, E; Moric, M; Okroj, K; Plummer, DR, 2017) |
| " However, in infants less than 1 year of age, the optimal dosing based on pharmacokinetic (PK) considerations is still under discussion." | 2.84 | Pharmacokinetics of tranexamic acid in neonates and infants undergoing cardiac surgery. ( Braun, S; Burg, S; Gertler, R; Grassin-Delyle, S; Gruber, M; Martin, K; Tassani-Prell, P; Urien, S; Wiesner, G, 2017) |
| " Antifibrinolytic drugs are part of a multifaceted approach aimed at reducing bleeding, though sufficiently sized pediatric studies are sparse, and dosing algorithms are heterogeneous." | 2.82 | Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis. ( Hunt, BJ; Murdoch, IA; Sangaran, DP; Siemens, K; Tibby, SM, 2022) |
| "This meta-analysis provides strong evidence that TXA is a safe and effective agent to reduce perioperative blood loss in hip fracture surgery." | 2.82 | Efficacy and safety of tranexamic acid in hip fracture surgery. How does dosage affect outcomes: A meta-analysis of randomized controlled trials. ( Antoniou, G; Masouros, P; Nikolaou, VS, 2022) |
| " Then, subgroup and meta-regression analyses were conducted to disclose the influence of geographic area, fracture type, administration route, frequency and dosage of TXA, blood transfusion threshold, and follow-up duration on the overall effect." | 2.82 | Tranexamic acid usage in hip fracture surgery: a meta-analysis and meta-regression analysis of current practice. ( Deng, S; Liang, J; Liu, W, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent associated with reduced blood loss and mortality in a wide range of procedures, including spine surgery, traumatic brain injury, and craniosynostosis." | 2.82 | Association of tranexamic acid with decreased blood loss in patients undergoing laminectomy and fusion with posterior instrumentation: a systematic review and meta-analysis. ( Brown, NJ; Chan, A; Choi, EH; Gendreau, JL; Himstead, A; Lien, BV; Oh, MY; Ong, V; Ransom, SC; Sahyouni, R; Shahrestani, S; Tafreshi, AR; Tran, K, 2022) |
| " Unease regarding possible systemic adverse effects prevents widespread systemic use, but local use of tranexamic acid is gaining popularity among plastic surgeons." | 2.82 | Safety and Efficacy of Local Tranexamic Acid for the Prevention of Surgical Bleeding in Soft-Tissue Surgery: A Review of the Literature and Recommendations for Plastic Surgery. ( Ausen, K; Fossmark, R; Pleym, H; Spigset, O, 2022) |
| "Tranexamic acid has been increasingly used for blood conservation in cardiac surgery." | 2.82 | Tranexamic acid reduces postoperative blood loss in Chinese pediatric patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis. ( He, LX; Yao, YT; Zou, ZY, 2022) |
| "Usually, TXA-associated seizures persist for a few minutes with no progression into status epilepticus." | 2.82 | Tranexamic acid-associated fatal status epilepticus in a paediatric non-cardiac surgery: A case report and literature review. ( Aboul-Fotouh, S; Habib, MZ; Hassan, BEE; Magdy, SM, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug primarily used for reducing blood loss in patients with major bleedings." | 2.82 | Tranexamic Acid and Its Potential Anti-Inflammatory Effect: A Systematic Review. ( Hvas, AM; Krog, J; Okholm, SH, 2022) |
| "Tranexamic acid (TXA) has been widely used for bleeding reduction in spinal surgery." | 2.82 | Optimal administration strategies of tranexamic acid to minimize blood loss during spinal surgery: results of a Bayesian network meta-analysis. ( Cao, Z; Guo, J; Li, Q; Li, Y; Wu, J, 2022) |
| "Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood loss and allogeneic red blood cell transfusion in several clinical settings." | 2.82 | Update on Applications and Limitations of Perioperative Tranexamic Acid. ( Butwick, AJ; Goobie, SM; Hare, GMT; Mazer, CD; Patel, PA; Pivalizza, EG; Wyrobek, JA, 2022) |
| "Tranexamic acid (TXA) has been widely used in various orthopaedic subspecialities to decrease blood loss, transfusions, and wound complications." | 2.82 | Tranexamic Acid Utilization in Foot and Ankle Surgery: A Meta-analysis. ( Attia, AK; Blankenhorn, B; El Khatib, S; Hantouly, A; Hsu, R; Salameh, M, 2022) |
| "TXA can considerably decrease surgical blood loss, postoperative drainage, reduce operative times, hospital stays, and transfusion rates." | 2.82 | The Safety and Effectiveness of Tranexamic Acid in Lumbar Interbody Fusion Surgery: An Updated Meta-analysis of Randomized Controlled Trials. ( Chen, CM; Lin, GX; Zheng, L; Zhu, MT, 2022) |
| "Tranexamic acid (TXA) has been investigated further in patients with hip surgery and shows reduction of bleeding." | 2.82 | Patient blood management and patient safety. ( Steinbicker, AU; Zacharowski, K; Zoller, H, 2022) |
| "Tranexamic acid (TXA) has become a commonly used perioperative intervention in total joint arthroplasty, shoulder and knee arthroscopy, and spinal procedures in order to minimize blood loss, hematoma formation, hemarthrosis, and wound healing complications." | 2.82 | Tranexamic Acid in Foot and Ankle Surgery: A Topical Review and Value Analysis. ( Gonzalez, TA; Jackson, B; Johns, WL; Walley, KC, 2022) |
| "Tranexamic acid is an antifibrinolytic agent that has shown to effectively reduce bleeding complications within other surgical and medical areas." | 2.82 | Anti-hemorrhagic effect of prophylactic tranexamic acid in benign hysterectomy-a double-blinded randomized placebo-controlled trial. ( Bergholt, T; Moeller, C; Ottesen, B; Ravn, P; Schouenborg, L; Settnes, A; Topsoee, MF, 2016) |
| "Tranexamic acid can be effective at decreasing blood loss and transfusion requirements associated with total hip arthroplasty (THA), but few studies have compared the efficacy of different intravenous dosing regimes." | 2.82 | Single-dose tranexamic acid for reducing bleeding and transfusions in total hip arthroplasty: A double-blind, randomized controlled trial of different doses. ( Kang, P; Ma, J; Pei, F; Wang, C; Xie, J; Yue, C, 2016) |
| "Fixed dose of TXA for patients undergoing simultaneous bilateral TKAs was effective and safe in reducing total blood loss and allogeneic blood transfusion needs without any additional thromboembolic risk." | 2.82 | Effectiveness and Safety of Fixed-Dose Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Randomized Double-Blind Controlled Trial. ( Cao, X; Chen, X; Guo, K; Yang, C; Zhu, J; Zhu, Q, 2016) |
| "No pulmonary embolism was observed and no significant differences were found in other complications between the 2 groups." | 2.82 | The Efficacy and Safety of Combination of Intravenous and Topical Tranexamic Acid in Revision Hip Arthroplasty: A Randomized, Controlled Trial. ( Cao, F; Shen, B; Si, HB; Wu, YG; Yang, TM; Zeng, Y, 2016) |
| "The optimal dosage and timing of tranexamic acid (TXA) in total knee arthroplasty (TKA) are undetermined." | 2.82 | Multiple Boluses of Intravenous Tranexamic Acid to Reduce Hidden Blood Loss After Primary Total Knee Arthroplasty Without Tourniquet: A Randomized Clinical Trial. ( Ma, J; Pei, F; Xie, J; Yao, H; Yue, C, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that decreases bleeding in various settings, but has not been well studied in patients undergoing liver resection." | 2.82 | Major liver resection, systemic fibrinolytic activity, and the impact of tranexamic acid. ( Coburn, NG; Hallet, J; Karanicolas, PJ; Law, CH; Lin, Y; McCluskey, SA; Nascimento, B; Pawliszyn, J; Tarshis, J, 2016) |
| "No deep vein thrombosis was detected through Doppler ultrasound examination." | 2.80 | The reduction in blood loss with intra-articular injection of tranexamic acid in unilateral total knee arthroplasty without operative drains: a randomized controlled trial. ( Ding, PJ; Li, J; Lv, YM; Yang, Y; Ying-Ze, Z, 2015) |
| "Tranexamic Acid (TXA) has been used in cardiac and orthopedic surgeries, including major spinal surgeries, to reduce blood loss and transfusion requirements for decades." | 2.80 | Preliminary investigation of high-dose tranexamic acid for controlling intraoperative blood loss in patients undergoing spine correction surgery. ( Lenke, LG; Li, T; Si, Y; Wang, Y; Xiao, J; Xie, J; Zhang, Y; Zhao, Z, 2015) |
| "TXA treatment without drainage during TKA reduces the amount of blood transfusions required without increasing the rate of adverse events." | 2.80 | Safety and efficacy of intra-articular tranexamic acid injection without drainage on blood loss in total knee arthroplasty: A randomized clinical trial. ( Cao, JG; Li, ZJ; Liu, J; Sun, ZH; Wang, CG, 2015) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that has been shown to significantly reduce blood loss and transfusion requirements after total knee and hip arthroplasty." | 2.80 | Neer Award 2015: A randomized, prospective evaluation on the effectiveness of tranexamic acid in reducing blood loss after total shoulder arthroplasty. ( Gillespie, R; Gobezie, R; Joseph, S; Shishani, Y; Streit, JJ, 2015) |
| "Tranexamic acid is an antifibrinolytic agent which blocks plasmin-mediated fibrin degradation." | 2.80 | [The Effect of Tranexamic Acid on Blood Loss after Primary Unilateral Total Knee Arthroplasty. Prospective Single-Centre Study]. ( Mezera, V; Musil, D; Pertlíček, J; Sadovský, P; Stehlík, J, 2015) |
| "Tranexamic acid resulted in a lower mean maximum decline in postoperative hemoglobin levels when compared to placebo (P = 0." | 2.79 | Topical administration of tranexamic acid in primary total hip and total knee arthroplasty. ( Cassatt, KB; Garton, AS; Kincaid-Cinnamon, KA; Lemke, JH; Martin, JG; Westendorf, DS, 2014) |
| " However, dosing based on pharmacokinetic data to optimally inhibit fibrinolysis is unknown." | 2.79 | Effect of two doses of tranexamic acid on fibrinolysis evaluated by thromboelastography during cardiac surgery: a randomised, controlled study. ( Barvais, L; Cacheux, C; Faraoni, D; Ickx, BE; Levy, JH; Van Aelbrouck, C, 2014) |
| "Tranexamic acid is an antifibrinolytic drug used widely to prevent bleeding." | 2.79 | Comparison between intravenous and intra-articular regimens of tranexamic acid in reducing blood loss during total knee arthroplasty. ( Bhatty, S; Gulati, A; Paul, R; Rajoli, SR; Saini, R; Soni, A, 2014) |
| "234." | 2.78 | Effect of tranexamic acid on reducing postoperative blood loss in combined hypotensive epidural anesthesia and general anesthesia for total hip replacement. ( Cho, CH; Kim, JS; Lee, YC; Park, SJ, 2013) |
| "Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that has been successfully used intravenously to stop bleeding after total knee replacement." | 2.78 | Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K). ( Alshryda, S; Anand, S; Hungin, AP; Logishetty, R; Maheswaran, S; Mason, J; Nargol, A; Sarda, P; Stothart, B; Tulloch, C; Vaghela, M, 2013) |
| "Tranexamic acid is a synthetic antifibrinolytic agent that has been successfully used intravenously to control bleeding after total hip replacement." | 2.78 | Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H). ( Ahmad, H; Alshryda, S; Cooke, N; Hungin, AP; Logishetty, R; Mason, J; McPartlin, L; Nargol, A; Sarda, P; Tang, S; Vaghela, M, 2013) |
| "Ecallantide is a recombinant peptide in the same class as aprotinin that inhibits plasma kallikrein, a major component of the contact coagulation and inflammatory cascades." | 2.77 | A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). ( Bokesch, PM; Grocott, HP; Levy, JH; Mazer, CD; Smith, PK; Szabo, G; Vetticaden, S; Wheeler, A; Wojdyga, R, 2012) |
| " In this study, we investigated the efficacy of temporary clamping of the drain either or not in combination with tranexamic acid administration for controlling blood loss after TKA." | 2.77 | Temporary clamping of drain combined with tranexamic acid reduce blood loss after total knee arthroplasty: a prospective randomized controlled trial. ( Chareancholvanich, K; Narkbunnam, R; Pornrattanamaneewong, C; Siriwattanasakul, P, 2012) |
| "Forty consecutive patients with cervical compressive myelopathy were prospectively randomized into groups that received 15 mg/kg body weight of TXA or placebo intravenously before the skin incision was made." | 2.76 | Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study. ( Misawa, H; Ohta, H; Shimogata, M; Tsutsumimoto, T; Yoda, I; Yui, M, 2011) |
| "Surgical correction of craniosynostosis in children is associated with substantial intraoperative bleeding." | 2.76 | Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study. ( Bigorre, M; Bringuier, S; Canaud, N; Capdevila, X; Dadure, C; Raux, O; Rochette, A; Sauter, M, 2011) |
| "No patient in either group developed deep vein thrombosis or pulmonary embolism up to 3 months." | 2.75 | Effects of tranexamic acid on blood loss during total hip arthroplasty. ( Ballal, MS; Denn, PG; Mitchell, P; Singh, J, 2010) |
| "Tranexamic acid has been used to reduce blood loss and the subsequent need for transfusion in orthopedic, spinal, and cardiac surgery." | 2.74 | The effect of tranexamic acid on blood loss during orthognathic surgery: a randomized controlled trial. ( Choi, WS; Irwin, MG; Samman, N, 2009) |
| "Tranexamic acid is a fibrinolytic inhibitor which reduces blood loss in total knee replacement." | 2.74 | The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. ( Ahmad, M; Biant, LC; Field, RE; Rajesparan, K, 2009) |
| "Tranexamic acid does not seem to be a useful adjunct in myomectomy if given according to the described protocol in this study." | 2.73 | Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study. ( Caglar, GS; Haberal, A; Kayikcioglu, F; Tasci, Y, 2008) |
| "Tranexamic acid was used to reduce postoperative drainage and allogenic blood transfusion requirements in patients undergoing on-pump primary coronary bypass surgery." | 2.73 | Tranexamic acid and primary coronary artery bypass surgery: a prospective study. ( Maddali, MM; Rajakumar, MC, 2007) |
| " In Group A, 1 g of tranexamic acid dissolved in 250 ml of normal saline was intravenously infused before deflation of the tourniquet; another intravenous administration of the same drug of the same dosage was given 3 hours later." | 2.73 | [Clinical comparative studies on effect of tranexamic acid on blood loss associated with total knee arthroplasty]. ( Gao, Z; Yu, J; Zhang, F, 2007) |
| "Tranexamic acid (TXA) combined with rivaroxaban (RA) has been widely used in total knee replacement (TKA)." | 2.72 | Efficacy and Safety of Tranexamic Acid Combined with Rivaroxaban in Primary Total Knee Arthroplasty: A Meta-Analysis of Randomized Controlled Trials. ( Du, C; Liu, Z; Ma, J; Meng, B; Zhang, G, 2021) |
| "Tranexamic acid (TXA) is an effective and commonly used hemostatic agent for perioperative blood loss in various surgical specialties." | 2.72 | Advances in surgical hemostasis: a comprehensive review and meta-analysis on topical tranexamic acid in spinal deformity surgery. ( Barra, ME; Fatima, N; Hadzipasic, M; Massaad, E; Roberts, RJ; Shankar, GM; Shin, JH, 2021) |
| "The primary outcome was surgical blood loss." | 2.72 | A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis. ( Heyns, M; Knight, P; Steve, AK; Yeung, JK, 2021) |
| "Tranexamic acid (TXA) was conducive in total knee arthroplasty (TKA) to reduce blood loss and transfusion demand." | 2.72 | What is the ideal route of administration of tranexamic acid in total knee arthroplasty? A meta-analysis based on randomized controlled trials. ( Guo, W; Lu, F; Sun, X; Wang, W; Zhang, Q, 2021) |
| "Tranexamic acid (TXA) use has expanded across many surgical specialties." | 2.72 | The Use of Tranexamic Acid in Hip and Pelvic Fracture Surgeries. ( Adams, JD; Marshall, WA, 2021) |
| " No adverse drug reactions or in-hospital deaths were reported." | 2.72 | Safety and efficacy of tranexamic acid in minimizing perioperative bleeding in extrahepatic abdominal surgery: meta-analysis. ( Adiamah, A; Gomez, D; Koh, A; Sanyal, S, 2021) |
| " Few studies found adverse events, and no difference in incidence or type of adverse events was seen between the antifibrinolytic and the placebo group." | 2.72 | Efficacy and Safety of Antifibrinolytic Drugs in Pediatric Surgery: A Systematic Review. ( Fenger-Eriksen, C; Hansen, AK; Hovgesen, NT; Hvas, AM; Larsen, JB, 2021) |
| "Tranexamic acid (TXA) is a kind of antifibrinolytic agent that has been widely used in spinal surgery." | 2.72 | The Efficacy and Safety of Topical Tranexamic Acid for Spinal Surgery. ( Feng, H; Guo, T; Ma, X; Wang, J; Xuan, W, 2021) |
| "Treatment with tranexamic acid was not associated with a higher incidence of myocardial ischemia or other thrombotic events." | 2.71 | Tranexamic acid reduces bleeding after off-pump coronary artery bypass grafting. ( Brucek, P; Jares, M; Straka, Z; Vanek, T, 2003) |
| "Tranexamic acid (TA) has less side-effects, but data regarding its efficacy are controversial." | 2.71 | Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial. ( Geissler, HJ; Hekmat, K; Kampe, S; Kasper, SM; Mehlhorn, U; Weber, HJ; Zimmermann, T, 2004) |
| "The volume of postoperative blood loss was recorded at two-hour intervals for the first twelve hours and then again at twenty-four hours, and the values were compared between the two groups." | 2.71 | Tranexamic acid reduces postoperative blood loss in cementless total hip arthroplasty. ( Fuji, T; Masuhara, K; Yamasaki, S, 2005) |
| "Tranexamic acid appears to be an effective and economic drug for reduction of blood loss in cemented primary hip arthroplasty for osteoarthritis." | 2.71 | Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis. ( Korkala, OL; Niskanen, RO, 2005) |
| "Tranexamic acid 10 mg kg-1 was given at conclusion of surgery and again 3 h later." | 2.70 | Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study. ( Juelsgaard, P; Madsen, F; Sørensen, JV; Veien, M, 2002) |
| "Case material included 25 patients with hemophilia (9 children and 16 adults) with high-responding inhibitors and 3 patients with acquired factor VIII inhibitors." | 2.70 | Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. ( Baudo, F; Gringeri, A; Morfini, M; Rocino, A; Santagostino, E; Scaraggi, FA, 2001) |
| "Tranexamic acid was as effective and as safe as high dose aprotinin." | 2.68 | [Fibrinolytic inhibitors and prevention of bleeding in cardiac valve surgery. Comparison of tranexamic acid and high dose aprotinin]. ( Benmosbah, L; Boughenou, F; Carpentier, A; Cousin, MT; Madi-Jebara, S; Massonnet-Castel, S, 1995) |
| " This study explored the dose-response relationship of tranexamic acid for hemostatic efficacy after cardiac operation." | 2.68 | The dose-response relationship of tranexamic acid. ( Grunewald, KE; Horrow, JC; Parmet, JL; Strong, MD; Van Riper, DF, 1995) |
| " (3) The appropriate, empirically established, dosage and administration patterns of TEA for CDH repair during ECMO seem to be one bolus of 4 mg/kg TEA intravenously 30 minutes before the anticipated CDH repair and a continuous infusion of 1 mg/kg/h TEA during the 24 hours after CDH repair." | 2.68 | Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid. ( de Haan, AF; Festen, C; Geven, WB; van der Staak, FH, 1997) |
| "When tranexamic acid was administered immediately after the operation, it had a minor beneficial effect." | 2.68 | Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial. ( Brown, RS; Mongan, PD; Thwaites, BK, 1997) |
| "The tranexamic acid dose was 10 mg infused in 500 mL of normal saline." | 2.68 | Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery. ( Ansley, DM; Dryden, PJ; Jamieson, WR; Merrick, PM; O'Connor, JP; Sadeghi, H, 1997) |
| "Tranexamic acid was an effective drug in bleeding control and in reducing blood transfusion in the postoperative of patients submitted to myocardial revascularization." | 2.67 | [Use of tranexamic acid for bleeding control in myocardial revascularization]. ( Cordeiro, CO; Couto, WJ; Freitas, M; Gregori Júnior, F; Ketzer, JL; Rosa, V; Silva, L; Silva, SS; Wanderley, WR, 1994) |
| " Tranexamic acid dosing regimens should be decreased in patients with chronic kidney dysfunction secondary to reduced clearance and drug accumulation." | 2.66 | Current Evidence and Future Directions of Tranexamic Acid Use, Efficacy, and Dosing for Major Surgical Procedures. ( Choi, S; Jerath, A; Karanicolas, P; Pang, KS; Taam, J; Wasowicz, M; Yang, QJ, 2020) |
| "Tranexamic acid (TXA) has been demonstrated to reduce blood loss following primary total knee and hip arthroplasty." | 2.66 | Comparison of efficacy and safety between oral and intravenous administration of tranexamic acid for primary total knee/hip replacement: a meta-analysis of randomized controlled trial. ( Fei, Y; Gao, X; Li, XL; Liu, WF; Liu, Y; Ye, W, 2020) |
| "Tranexamic acid is a safe and effective treatment modality, and consideration should be given to use multiple doses and combine different modes of administration." | 2.66 | Controversial Topics in Total Knee Arthroplasty: A Five-Year Update (Part 2). ( Mastel, MS; van der Merwe, JM, 2020) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic agent that acts by inhibiting plasminogen activation and fibrinolysis." | 2.66 | The never ending success story of tranexamic acid in acquired bleeding. ( Franchini, M; Mannucci, PM, 2020) |
| "Tranexamic acid (TXA) is a widely used antifibrinolytic agent worldwide and whether TXA influences ACT value in cardiac surgical patients remains unknown." | 2.66 | The effect of tranexamic acid on the values of activated clotting time in patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis. ( He, LX; Tan, JC; Yao, YT, 2020) |
| "Oral tranexamic acid (TXA) has been demonstrated to reduce the blood loss in primary total knee and hip arthroplasty, but the optimal regimen of oral TXA administration is still unknown." | 2.66 | The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial. ( Li, XL; Liu, WF; Liu, Y; Shao, J; Ye, W, 2020) |
| "The optimal dosage and administration approach of tranexamic acid (TXA) in primary total knee arthroplasty (TKA) remains controversial." | 2.66 | Intra-articular vs. intravenous administration: a meta-analysis of tranexamic acid in primary total knee arthroplasty. ( Hong, P; Li, J; Liu, R; Rai, S; Tang, X; Ze, R, 2020) |
| " The results of subgroup analysis revealed that hemostatic techniques, which could substantially decrease the rate of ABT, were cell salvage with the transfusion trigger of 9 mg/dl, fibrin sealant with a dosage of 10 ml, and postoperative flexion position." | 2.61 | Hemostatic techniques to reduce blood transfusion after primary TKA: a meta-analysis and systematic review. ( Dong, Z; Han, L; Qi, J; Song, Y; Wang, F, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug, which has demonstrated a significant reduction in perioperative blood loss in many pediatric surgical procedures such as cardiac surgery and scoliosis surgery." | 2.61 | Reducing blood loss in pediatric craniosynostosis surgery by use of tranexamic acid. ( Eustache, G; Riffaud, L, 2019) |
| " For prophylactic perioperative administration, different dosage regimens exist for adults." | 2.61 | [Prophylactic use of tranexamic acid in noncardiac surgery : Update 2017]. ( Schefold, JC; Stueber, F; Waskowski, J, 2019) |
| " Furthermore, it is safe and does not increase the risk of thrombotic events." | 2.61 | The Efficacy and Safety of Intravenous Tranexamic Acid in Reducing Surgical Blood Loss in Posterior Lumbar Interbody Fusion for the Adult: A Systematic Review and a Meta-Analysis. ( Chen, L; Chen, R; Gong, M; Liu, G; Xiang, Z, 2019) |
| "The surgical removal of fibroids can be associated with excessive blood loss requiring transfusion." | 2.61 | The Effectiveness of Tranexamic Acid at Reducing Blood Loss and Transfusion Requirement for Women Undergoing Myomectomy: A Systematic Review and Meta-analysis. ( Boutet, M; Chen, I; Fergusson, D; Fusca, L; Perelman, I, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic which has been shown to decrease such a burden in particular surgeries." | 2.61 | Tranexamic Acid Decreases Blood Transfusion Burden in Open Craniosynostosis Surgery Without Operative Compromise. ( Daniels, DJ; Goyal, A; Lu, VM, 2019) |
| "Tranexamic acid (TXA) is an inexpensive therapy effective at minimizing perioperative blood loss and transfusion." | 2.61 | Exclusion criteria and adverse events in perioperative trials of tranexamic acid: a systematic review and meta-analysis. ( Khair, S; Lampron, J; Perelman, I; Saidenberg, E; Taylor, J; Tinmouth, A; Yates, J, 2019) |
| " Recent data on TXA's use in spine surgery suggest that TXA remains both efficacious and safe, although the ideal dosing and timing of administration is still a point of disagreement." | 2.61 | The Use of Tranexamic Acid to Reduce Surgical Blood Loss: A Review Basic Science, Subspecialty Studies, and The Evolution of Use in Spine Deformity Surgery. ( Kark, J; Slattery, C; Verma, K; Wagner, T, 2019) |
| "Tranexamic acid has a limited effect on reducing operative time (p < 0." | 2.61 | Comprehensive assessment of tranexamic acid during orthognathic surgery: A systematic review and meta-analysis of randomized, controlled trials. ( Liu, S; Ma, C; Wu, Z; Zhao, H, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that reduces bleeding and transfusion in a broad number of adult and pediatric surgeries, as well as in trauma and obstetrics." | 2.61 | Tranexamic acid and perioperative bleeding in children: what do we still need to know? ( Faraoni, D; Goobie, SM, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic, and it was used to reduce the perioperative bleeding." | 2.61 | Role of tranexamic acid in nasal surgery: A systemic review and meta-analysis of randomized control trial. ( Li, F; Lu, HS; Ping, WD; Sun, HF; Zhao, QM, 2019) |
| "Tranexamic acid is an effective treatment to reduce the volume of bleeding during menstruation." | 2.61 | Applications of Tranexamic acid in benign gynecology. ( Ingraham, CF; Klebanoff, JS; Marfori, CQ; Moawad, GN; Wu, CZ, 2019) |
| "Secondary outcomes were length of stay, deep venous thrombosis (DVT) and/or pulmonary embolism (PE)." | 2.61 | Transfusions and cost-benefit of oral versus intravenous tranexamic acid in primary total hip arthroplasty: A meta-analysis of randomized controlled trials. ( Chen, H; Ji, M; Liu, W; Tang, J; Wang, N; Xiong, X; Xu, L; Yang, T; Yang, Y, 2019) |
| " Nevertheless, TXA remains underutilized because of concerns regarding development of adverse events." | 2.61 | Exclusion criteria and adverse events in perioperative trials of tranexamic acid in cardiac surgery: a systematic review and meta-analysis. ( Khair, S; Lampron, J; Perelman, I; Saidenberg, E; Taylor, J; Tinmouth, A; Yates, J, 2019) |
| "Tranexamic acid (TXA) has been used to treat peripartum hemorrhage, while preoperative use of TXA in cesarean section (CS) remains controversial." | 2.61 | Prophylactic use of tranexamic acid reduces blood loss and transfusion requirements in patients undergoing cesarean section: A meta-analysis. ( He, L; Liu, S; Wang, Y, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic medication that can reduce perioperative blood loss in TKA." | 2.58 | Intra-articular Tranexamic Acid in Primary Total Knee Arthroplasty: Meta-analysis. ( Capps, SG; Moskal, JT, 2018) |
| "Tranexamic acid (TXA) has been shown to be effective in patients with total knee arthroplasty (TKA) in clinical studies with no consensus with regard to the most appropriate route of administration." | 2.58 | Tranexamic Acid in Total Knee Arthroplasty: Mixed Treatment Comparisons and Recursive Cumulative Meta-Analysis of Randomized, Controlled Trials and Cohort Studies. ( Sivaramakrishnan, G; Sridharan, K, 2018) |
| "Tranexamic acid is an antifibrinolytic agent that has been widely used in other surgical specialties, especially in cardiac, orthopedic, and trauma surgery." | 2.58 | The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations. ( Cho, MJ; Rohrich, RJ, 2018) |
| " Other severe drug-related adverse events occurred very rarely (0." | 2.58 | Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials. ( Franchini, M; Liumbruno, GM; Mannucci, PM; Marano, G; Marietta, M; Mengoli, C; Pupella, S; Vaglio, S, 2018) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug widely used as a blood-sparing technique in total knee arthroplasty (TKA), and it is usually administrated by intravenous or intraarticular injection." | 2.58 | Efficacy and safety of oral tranexamic acid in total knee arthroplasty: A systematic review and meta-analysis. ( Cheng, L; Gao, F; Guo, P; Guo, W; He, Z; Li, Z; Sun, W; Wang, Y, 2018) |
| "Prostate cancer and benign prostatic hyperplasia have an increased incidence with aging." | 2.58 | Systematic review and meta-analyses of tranexamic acid use for bleeding reduction in prostate surgery. ( Cavalheiro, BT; de Oliveira Filho, GR; Longo, MA, 2018) |
| " IV TXA dosing varied, as 14 (39%) of the studies used a weight-based approach while 22 (61%) used a standard dose." | 2.58 | Reduction of Blood Loss by Tranexamic Acid Following Total Hip and Knee Arthroplasty: A Meta-Analysis. ( Gianakos, AL; Haring, RS; Hurley, ET; Liporace, FA; Yoon, RS, 2018) |
| " Use of repeat IV and oral TXA dosing and higher doses of IV and topical TXA did not significantly reduce blood loss or risk of transfusion." | 2.58 | The Efficacy of Tranexamic Acid in Total Knee Arthroplasty: A Network Meta-Analysis. ( Bini, SA; Clarke, HD; Della Valle, CJ; Fillingham, YA; Jevsevar, DS; Johnson, RL; Memtsoudis, SG; Mullen, K; Ramkumar, DB; Sah, AP; Sayeed, SA; Schemitsch, E; Shores, P; Yates, AJ, 2018) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent commonly used to reduce blood loss in total hip arthroplasty (THA)." | 2.58 | The Efficacy of Tranexamic Acid in Total Hip Arthroplasty: A Network Meta-analysis. ( Bini, SA; Clarke, HD; Della Valle, CJ; Fillingham, YA; Jevsevar, DS; Johnson, RL; Memtsoudis, SG; Mullen, K; Ramkumar, DB; Sah, AP; Sayeed, SA; Schemitsch, E; Shores, P; Yates, AJ, 2018) |
| "Tranexamic acid has an important ability to decrease intraoperative blood loss and hospitalization for lumbar spinal fusion surgery." | 2.58 | The Efficacy of Tranexamic Acid on Blood Loss from Lumbar Spinal Fusion Surgery: A Meta-Analysis of Randomized Controlled Trials. ( Du, Y; Feng, C, 2018) |
| "Tranexamic acid (TXA) has been widely used to decrease transfusion rate in joint replacement surgery." | 2.58 | A systematic review of tranexamic acid usage in patients undergoing femoral fracture surgery. ( Bai, J; Chen, P; He, J; Liang, Y; Wang, J; Zhang, P, 2018) |
| "Tranexamic acid (TXA) has been demonstrated to minimize blood loss after total hip arthroplasty." | 2.58 | Optimal use of tranexamic acid for total hip arthroplasty: A network meta-analysis. ( Ha, YC; Kim, TY; Ko, YS; Koo, KH; Lee, YK; Yoon, BH, 2018) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic agent successfully preventing blood loss when using intravenously (IV) in total hip arthroplasty (THA) and total knee arthroplasty (TKA)." | 2.58 | Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis. ( Gong, G; Han, N; Han, X; Liu, M, 2018) |
| "A total of 59 participants with haemophilia undergoing dental extraction were involved." | 2.55 | Preventing perioperative bleeding in patients with inherited bleeding disorders. ( Beacher, N; Watterson, C, 2017) |
| " Secondary outcomes were other adverse events, blood transfusion, and blood loss." | 2.55 | The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis. ( Breau, RH; Cagiannos, I; Cnossen, S; Fergusson, DA; Fergusson, NA; Hutton, B; Lavallée, LT; Montroy, J; Morash, C, 2017) |
| "Tranexamic acid (TXA) has been proven to be effective in reducing blood loss and transfusion rate after total knee arthroplasty (TKA) without increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE)." | 2.55 | Is combined use of intravenous and intraarticular tranexamic acid superior to intravenous or intraarticular tranexamic acid alone in total knee arthroplasty? A meta-analysis of randomized controlled trials. ( Liu, G; Liu, J; Liu, Y; Lv, H; Mi, B; Wu, Q; Zha, K, 2017) |
| "Tranexamic acid (TXA) has been widely used to decrease blood loss and transfusion rates in joint replacement surgery." | 2.55 | Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: A meta-analysis. ( Chen, P; Fang, Y; He, J; Liang, Y; Wang, J; Zhang, P, 2017) |
| "20), or incidence of adverse effects such as deep venous thrombosis (odds ratio 1." | 2.55 | Efficiency and safety of tranexamic acid in reducing blood loss in total shoulder arthroplasty: A systematic review and meta-analysis. ( Du, GY; He, SW; Mi, LD; Sun, CX; Sun, XG; Zhang, L, 2017) |
| " In addition, no adverse effect was identified in treatment groups." | 2.55 | The efficiency and safety of tranexamic acid for reducing blood loss in open myomectomy: A meta-analysis of randomized controlled trials. ( Lin, X; Wang, D; Wang, L; Wang, Y, 2017) |
| "Treatment with tranexamic acid (TXA) by intravenous application has been discussed extensively." | 2.55 | Comparison of oral versus intravenous application of tranexamic acid in total knee and hip arthroplasty: A systematic review and meta-analysis. ( Kuang, MJ; Lu, B; Ma, JX; Ma, XL; Sun, L; Wang, Y; Zhang, LK; Zhao, J, 2017) |
| " Further research is necessary to evaluate the efficacy of TXA in revision shoulder arthroplasty and to identify the optimal dosing and route of administration of TXA in shoulder arthroplasty." | 2.55 | Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis. ( Bedi, A; Bhandari, M; Horner, N; Khan, M; Kirsch, JM; Koueiter, DM; Miller, BS; Pauzenberger, L; Wiater, JM, 2017) |
| "In patients with orthopaedic trauma, TXA reduces the risk of blood transfusion, reduces perioperative blood loss, and has no significant effect on the risk of symptomatic thromboembolic events." | 2.55 | Tranexamic Acid in Orthopaedic Trauma Surgery: A Meta-Analysis. ( Boone, MD; Gausden, EB; Lorich, DG; OʼGara, B; Qudsi, R; Ruzbarsky, JJ, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries." | 2.55 | Efficacy and Safety of Tranexamic Acid in Orthopaedic Fracture Surgery: A Meta-Analysis and Systematic Literature Review. ( Amer, K; Amer, KM; Haydel, C; Rehman, S, 2017) |
| "Tranexamic acid (TA) is a potent drug to reduce surgical blood loss in surgery, therefore, as a potential drug for application in THA." | 2.55 | Efficacy and safety of tranexamic acid in total hip replacement: A PRISMA-compliant meta-analysis of 25 randomized controlled trials. ( Hu, Y; Lei, P; Su, W; Zeng, M; Zhu, J; Zhu, Y, 2017) |
| "Tranexamic acid (TXA) is a synthetic anti-fibrinolytic agent commonly used for the prevention and treatment of bleeding disorders." | 2.55 | Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature. ( Chow, KM; Kwan, BC; Leung, CB; Li, PK; Ma, TK; Szeto, CC, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug used widely to prevent bleeding in total knee arthroplasty (TKA)." | 2.55 | Topical versus intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. ( An, Y; Gao, X; Wang, S, 2017) |
| "Ovarian cancer is the third most common gynaecological cancer worldwide, with an age-standardised incidence rate of 6." | 2.53 | Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. ( Kietpeerakool, C; Laopaiboon, M; Lumbiganon, P; Supoken, A, 2016) |
| "81) or and incidence of adverse effects such as infection (P = 0." | 2.53 | Efficiency and Safety of Intravenous Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Systematic Review and Meta-analysis. ( Jiang, X; Ma, JX; Ma, XL, 2016) |
| "Tranexamic acid (TXA) has been reported to reduce perioperative blood loss in hip joint arthroplasty." | 2.53 | Intravenous versus topical tranexamic acid in primary total hip replacement: A meta-analysis. ( Chen, P; Fang, Y; He, J; Liang, Y; Wang, J; Zhang, P, 2016) |
| " The dose and timing to administration TXA is different, and more randomized controlled trials are warranted to clarify the optimal dosing and time to administration TXA." | 2.53 | Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis. ( Jiang, XQ; Jie, L; Li, HB; Lin, C; Ma, L; Qi, Y; Qin, L; Zhang, ZH; Zhao, XC, 2016) |
| " No significant difference in deep vein thrombosis (DVT), pulmonary embolism, or other adverse events among the study groups." | 2.52 | Is tranexamic acid clinically effective and safe to prevent blood loss in total knee arthroplasty? A meta-analysis of 34 randomized controlled trials. ( Liu, SL; Meng, T; Wang, P; Wu, Q; Zhang, HA; Zhou, X, 2015) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug used to reduce bleeding in mortality risk situations such as trauma." | 2.52 | Efficiency of tranexamic acid in perioperative blood loss in hip arthroplasty: a systematic literature review and meta-analysis. ( Díaz Quijano, DM; Pinzón-Florez, CE; Vélez Cañas, KM, 2015) |
| "In people with haemophilia or other congenital bleeding disorders undergoing surgical interventions, haemostatic treatment is needed in order to correct the underlying coagulation abnormalities and minimise the bleeding risk." | 2.52 | Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. ( Coppola, A; Di Minno, MN; Tufano, A; Windyga, J; Yeung, C, 2015) |
| "Uncontrolled bleeding is an important cause of death in trauma victims." | 2.52 | Antifibrinolytic drugs for acute traumatic injury. ( Coats, TJ; Ker, K; Roberts, I; Shakur, H, 2015) |
| " The question addressed was: what dose of tranexamic acid is most effective and safe for adult patients undergoing cardiac surgery? Altogether 586 papers were found using the reported search, of which 12 represented the best evidence to answer the clinical question." | 2.52 | What dose of tranexamic acid is most effective and safe for adult patients undergoing cardiac surgery? ( Dearman, C; Hodgson, S; Larvin, JT, 2015) |
| " To further investigate the safe and effective role of using tranexamic acid (TA) in reducing transfusion rate and blood loss in total knee arthroplasty." | 2.52 | Safety and Efficacy of Tranexamic Acid in Total Knee Arthroplasty. ( Li, W; Liu, J; Qiu, Y; Xu, P; Yu, X; Zhu, Y, 2015) |
| " Both topical and intravenous administration of TXA, in a variety of dosing regimens, has proven effective." | 2.52 | Tranexamic Acid in Hip and Knee Arthroplasty. ( Melvin, JS; Sierra, RJ; Stryker, LS, 2015) |
| "Fibrin sealant also has this potential, but is not more potent than tranexamic acid." | 2.52 | Prevention of post-operative anaemia in hip and knee arthroplasty--a systematic review. ( Husted, H; Khan, N; Troelsen, A, 2015) |
| "The present meta-analysis indicated that intra-articular injection of TXA in patients undergoing TKA may reduce total blood loss and the need for blood transfusions, particularly when a high dosage of TXA is used (≥30 mg/ml), without any increase in the risk of post-operative DVT." | 2.50 | Reduced blood loss after intra-articular tranexamic acid injection during total knee arthroplasty: a meta-analysis of the literature. ( Wei, C; Yan, G; Ying-Ze, Z; Yuejv, L; Zhao-Yu, C, 2014) |
| "Tranexamic acid was intra-articularly injected in total knee arthroplasty (TKA) to reduce blood loss and transfusion." | 2.50 | Safety and efficacy of intra-articular injection of tranexamic acid in total knee arthroplasty. ( Fu, X; Li, YM; Li, ZJ; Liu, WX; Ma, XL; Zhang, Y, 2014) |
| "Tranexamic acid has been shown to reduce the need for a blood transfusion in adult patients undergoing elective surgery but its effects in patients undergoing emergency or urgent surgery is unclear." | 2.49 | Tranexamic acid for reducing mortality in emergency and urgent surgery. ( Ker, K; Morales Uribe, CH; Perel, P; Roberts, I, 2013) |
| "Meanwhile TA is recommended to reduce deep vein thrombosis and pulmonary embolism following TKA." | 2.49 | Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Chen, C; Fu, DJ; Guo, L; Yang, L, 2013) |
| "To evaluate the effectiveness and safety of tranexamic acid (TEA) treatment in reducing perioperative blood loss and transfusion for patients receiving primary unilateral total knee arthroplasty (TKA) and to explore the most effective and safe protocol." | 2.49 | A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty. ( Chen, C; Chen, H; Huang, W; Liu, Q; Tan, J, 2013) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug used as a blood-sparing technique in many surgical specialties." | 2.49 | Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. ( Evans, HM; Gandhi, R; Mahomed, NN; Mahomed, SR, 2013) |
| " It reduces total blood loss and the need for blood transfusion, particularly in the using of high dosage of TXA (≥ 15 mg/kg), yet does not increase the risk of postoperative DVT." | 2.49 | Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials. ( Fu, X; Li, ZJ; Ma, XL; Xing, D; Zang, JC; Zhang, HF, 2013) |
| " Although TXA is a long known drug available on the market for more than 50 years, the studies connecting factors of indication, dosage regimen and safety are limited especially in children and infants." | 2.49 | [Hemostasis and antifibrinolytic therapy in major pediatric surgery]. ( Hertfelder, HJ; Schindler, E, 2013) |
| "Tranexamic acid is a safe drug to treat hyperfibrinolysis during prostate resection." | 2.49 | [Current strategies to minimize of blood loss during radical prostatectomy]. ( Hachenberg, T; Strang, CM, 2013) |
| "Surgical correction of craniosynostosis in children is associated with substantial intraoperative bleeding." | 2.49 | Tranexamic Acid reducing blood transfusion in children undergoing craniosynostosis surgery. ( Feng, G; Hu, J; Li, J; Li, Y; Luo, E; Song, G; Yang, P; Zhu, S, 2013) |
| " There was marked variability in the dosage and infusion schemes used in different studies." | 2.48 | Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis. ( De Hert, S; Faraoni, D; Melot, C; Van der Linden, P; Willems, A, 2012) |
| "The meta-analysis shows that the use of tranexamic acid for patients undergoing total knee arthroplasty is effective and safe for the reduction of blood loss." | 2.48 | Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. ( Chen, WP; Wu, LD; Yang, ZG, 2012) |
| "Uncontrolled bleeding is an important cause of death in trauma victims." | 2.47 | Antifibrinolytic drugs for acute traumatic injury. ( Coats, T; Ker, K; Roberts, I; Shakur, H, 2011) |
| " A total of 19 trials were eligible: 18 used intravenous administration, one also evaluated oral dosing and one trial evaluated topical use." | 2.47 | Tranexamic acid in total knee replacement: a systematic review and meta-analysis. ( Alshryda, S; Blenkinsopp, J; Mason, JM; Nargol, A; Sarda, P; Sukeik, M, 2011) |
| "Tranexamic acid and aprotinin have been shown to reduce blood loss and transfusions in clinical trials with variable results." | 2.43 | The use of antifibrinolytic agents in total hip arthroplasty: a meta-analysis. ( Gill, JB; Rosenstein, A, 2006) |
| "Tranexamic acid does not increase the risk of thromboembolic complications such as deep vein thrombosis, pulmonary embolism, thrombotic cerebral vascular accident, or myocardial infarction (OR 0." | 2.42 | Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. ( Ho, KM; Ismail, H, 2003) |
| "Tranexamic acid was usually added for mucosal surgery." | 2.41 | Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. ( Griffioen, A; Harrington, C; Lee, CA; Nitu-Whalley, IC, 2001) |
| "We failed to observe a difference in infection risk after adjustment for confounders and surgeon differences (hazard ratio [HR] 1." | 1.91 | Tranexamic acid is not associated with decreased infection risk after primary shoulder arthroplasty: a cohort study of 9276 patients. ( Chan, PH; Gorbaty, J; McElvany, MD; Prentice, HA; Yian, EH, 2023) |
| "Tranexamic acid is an effective treatment to reduce blood loss." | 1.91 | The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan. ( Chen, JW; Hou, SM; Hsu, HW; Hsu, LI; Wei, ST, 2023) |
| " Further studies are needed to adjust dosage of EACA to make better comparison of the two drugs." | 1.91 | Combination of Intravenous and Intra-Articular Application of Tranexamic Acid and Epsilon-Aminocaproic Acid in Primary Total Knee Arthroplasty: A Prospective Randomized Controlled Trial. ( Li, M; Liu, Y; Ma, J; Shen, B; Si, H; Xu, J; Zheng, C, 2023) |
| "Surgical resection of posterior fossa tumors (PFT) in the pediatric age group often results in significant intraoperative blood loss." | 1.91 | Effect of administration of tranexamic acid on blood loss and transfusion requirements in children undergoing posterior fossa tumor excision: a retrospective cohort study. ( George, SE; Moorthy, RK; Singh, G; Thakkar, K; Yadav, B, 2023) |
| " Although the use of TXA for multilevel spine surgery is increasing, there remains widespread equivocality regarding ideal dosing regimens." | 1.91 | The Administration of Tranexamic Acid For Complex Spine Surgery. ( Cosgrove, MS; Jockel, K; Lee, A; Reilly, D; Wijesekera, S, 2023) |
| "Bleeding complications are not uncommon after breast reduction surgery, and recently, tranexamic acid (TXA) as an antifibrinolytic agent has been used in various surgical specialties as a way to minimizes such adverse outcomes." | 1.91 | The Usage of Intravenous Tranexamic Acid in Reduction Mammaplasty Safely Reduces Hematoma Rates. ( Kebede, S; Losken, A; Marxen, T; Om, A, 2023) |
| "The aim of the study was to evaluate the efficacy of aggressive warming combined with tranexamic acid (TXA) during total hip arthroplasty (THA)." | 1.91 | The efficacy of aggressive warming combined with tranexamic acid during total hip arthroplasty: a single-center retrospective study from southern China. ( Huang, WW; Huang, X; Huang, Y; Li, FL; Liu, WH; Mo, BF; Yin, D, 2023) |
| "However, hemarthrosis is the most common complication in arthroscopic surgery, which has potential adverse effects on postoperative rehabilitation." | 1.91 | Topical administration of tranexamic acid reduces postoperative blood loss and inflammatory response in knee arthroscopic arthrolysis: a retrospective comparative study. ( Chen, G; Fu, W; Li, J; Li, Q; Tang, X; Xiong, Y; Yao, L; You, M, 2023) |
| "Tranexamic acid (TXA) has been popularized as an adjunct to decrease the risk of bleeding and subsequent bruising and edema in aesthetic surgery." | 1.91 | Wound Healing Complications With Tranexamic Acid: Not the Silver Bullet After All. ( Auersvald, A; Azizzadeh, B; Frankel, AS; Talei, B; Yalamanchili, S, 2023) |
| "The primary outcomes were postoperative blood loss and the composite incidence of mortality and morbidities during hospitalization." | 1.91 | The efficacy and safety of intravenous administration of tranexamic acid in patients undergoing cardiac surgery: Evidence from a single cardiovascular center. ( He, LX; Jiang, JJ; Lin, PS; Ma, J; Tian, LJ; Yao, YT; Yu, YP; Zhang, Y, 2023) |
| " The following guidelines provide updated recommendations based on the current state of knowledge on TXA optimal timing, routes of administration and dosing regimen." | 1.91 | Die perioperative Gabe von Tranexamsäure. ( Kaufner, L; Lier, H; Perka, C; Treskatsch, S; von Heymann, C, 2023) |
| "Tranexamic acid (TXA) has long been the antifibrinolytic hemostatic drug of choice for orthopedic surgery." | 1.91 | Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs. ( Haibier, A; Qin, Q; Ran, J; Ren, Z; Yusufu, A; Zhang, Z; Zhou, Y, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to reduce blood loss following surgery." | 1.91 | Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection. ( Foster, D; Garner, H; Goulding, K; Houdek, M; Sebro, R; Spaulding, AC; Stanborough, R; Wilke, B, 2023) |
| " Weight-based administration of tranexamic acid (TXA) has the potential to reduce blood loss and related complications in spinal surgery; however, evidence for standardized dosing is lacking." | 1.91 | Examining the safety profile of a standard dose tranexamic acid regimen in spine surgery. ( Adida, S; Dalton, J; Fourman, MS; Lee, JY; Mirvish, A; Sadhwani, S; Setliff, J; Shaw, JD; Tang, MY; Wawrose, R, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that reduces blood loss in patients that undergo Total knee arthroplasty (TKA)." | 1.91 | Benefits of Tranexamic Acid in Total Knee Arthroplasty: A Classification and Regression Tree Analysis in Function of Instrumentation, BMI, and Gender. ( Carvalho, MM; Cruz, H; Fontes, AP; Marreiros, A; Oliveira, T; Pereira, EG; Sacramento, T; Sousa, JP; Viegas, R, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent for reducing blood loss and allogenic blood transfusion." | 1.72 | The Efficiency of Simultaneous Systemic and Topical Use of Tranexamic Acid in Spinal Fusion Surgery. ( Akbas, A; Erdogan, U; Sari, S, 2022) |
| "001) with no associations with blood exposure or adverse events." | 1.72 | Blood conservation outcomes and safety of tranexamic acid in coronary artery bypass graft surgery. ( Chen, W; Hu, S; Wang, E; Wang, Y; Yuan, S; Yuan, X; Zhou, X, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that has achieved significant reduction in perioperative blood loss and the quantity of blood transfused in many pediatric surgical procedures, without morbidity." | 1.72 | Importance of tranexamic acid in pediatric monosutural craniosynostosis surgery. ( Aillet, S; Aouaissia, S; Delahaye Larralde, S; Eustache, G; Nardi, N; Riffaud, L; Rousseau, C; Wodey, E, 2022) |
| "Tranexamic acid (TXA) has gained increasing recognition as a valuable pharmacologic agent within plastic surgery." | 1.72 | Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty. ( Alsayed, A; Antezana, L; Banuelos, J; Curiel, D; Harless, CA; Kerivan, L; Kuruoglu, D; Martinez-Jorge, J; Nguyen, MT; Sharaf, BA; Tran, NV; Vijayasekaran, A; Weissler, JM, 2022) |
| "Tranexamic acid (TXA) has shown to significantly reduce perioperative blood loss in elective orthopedic joint replacement surgery but is yet not implemented in acute hip fracture surgery for elderly patients who are particularly vulnerable to perioperative blood loss and postoperative anemia." | 1.72 | Clinical outcomes of tranexamic acid in acute hip hemiarthroplasties in frail geriatric patients. ( de Jong, L; Kuijper, TM; Roukema, GR; van Rijckevorsel, VAJIM, 2022) |
| "Tranexamic acid (TXA) is a synthetic lysine analog that reduces perioperative blood loss by blocking lysine-binding sites on plasminogen molecules." | 1.72 | Local tranexamic acid reduces surgical blood loss. ( Bolton, L, 2022) |
| "Intraoperative blood loss and postoperative drain collection of the TXA group, ANH combined with TXA group were statistically lower than those in the control group and ANH group (P < 0." | 1.72 | Acute normovolemic hemodilution in combination with tranexamic acid is an effective strategy for blood management in lumbar spinal fusion surgery. ( Fang, X; Li, Y; Zhang, Y, 2022) |
| "Tranexamic acid (TXA) has been used to treat severe bleeding events for nearly 60 years and is on the list of World Health Organization essential medicines." | 1.72 | Editorial Commentary: The Current Evidence in Support of Tranexamic Acid in Arthroscopic Surgery Is Poor. ( Hohmann, E, 2022) |
| "To assess the efficacy and safety of hypotensive anesthesia (HA) combined with tranexamic acid (TXA) for reducing perioperative blood loss in simultaneous bilateral total hip arthroplasty (SBTHA)." | 1.72 | Hypotensive Anesthesia Combined with Tranexamic Acid Reduces Perioperative Blood Loss in Simultaneous Bilateral Total Hip Arthroplasty: A Retrospective Cohort Study. ( Huang, K; Liao, R; Wang, MY; Xie, HQ; Yang, J; Yin, SJ; Zeng, Y; Zhang, QY, 2022) |
| "Tranexamic acid (TXA) has been shown to decrease perioperative blood loss, transfusions, and cost in patients undergoing resection of aggressive bone tumors and endoprosthetic reconstruction." | 1.72 | Tranexamic acid improves early postoperative mobilization in cancer patients undergoing endoprosthetic reconstruction. ( Bombardier, B; Haase, DR; Kimbrel, B; Mersereau, EJ; Rosenthal, HG; Sweeney, KR; Templeton, KJ, 2022) |
| " However, both the cause of this and the appropriate measures to determine antifibrinolytic efficacy during high-blood-loss spine surgery are unknown, making clinical trials to optimize antifibrinolytic dosing in PSF difficult." | 1.72 | Variable Response to Antifibrinolytics Correlates with Blood-loss and Transfusion in Posterior Spinal Fusion. ( Benvenuti, TA; Borst, AJ; Duvernay, MT; Emerson, BR; Gibson, BHY; Martus, JE; McKeithan, LJ; Mencio, GA; Moore-Lotridge, SN; Schoenecker, JG; Warhoover, TA, 2022) |
| " To date, the most efficacious dosing protocol in this setting has not yet been ascertained." | 1.72 | No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA. ( Bugbee, WD; Copp, SN; Evans, AS; Ezzet, KA; McCauley, JC; Rosen, AS; Walker, RH; Wilde, JM, 2022) |
| "Tranexamic acid (TXA) has rapidly gained popularity in aesthetic surgery." | 1.72 | Local Infiltration of Tranexamic Acid During Facelift Improves Operating Room Efficiency: A Matched Patient Study. ( Coombs, DM; Jin, A; Kwiecien, GJ; Sinclair, NR; Zins, JE, 2022) |
| "This study aimed to evaluate the efficacy and safety of intravenous combined with topical application of tranexamic acid (TXA) in reducing blood loss in opening wedge high tibial osteotomy (OWHTO)." | 1.72 | Efficacy and safety of intravenous combined with topical administration of tranexamic acid in reducing blood loss in opening wedge high tibial osteotomy procedure: A retrospective case-control study. ( Fu, X; Huang, JM; Luo, W; Ma, XL; Wu, J, 2022) |
| "The aim of the study is to compare weight-based versus standard dosing of intravenous (IV) tranexamic acid (TXA) for blood loss and transfusion amount in total knee arthroplasty (TKA) without a tourniquet." | 1.72 | Comparison of weight-based versus standard dosing of tranexamic acid for blood loss and transfusion amount in knee arthroplasty without tourniquet. ( Çarkcı, E; Çerci, MH; Guler, O; Gümüşsuyu, G; Öztürk, Ç, 2022) |
| "This study suggests that TXA administration safely and effectively reduces blood loss, in particular for wide resection, with no increase in the rate of adverse events." | 1.72 | Efficacy and safety of tranexamic acid in patients undergoing surgery for bone and soft tissue tumors: a propensity score matching analysis. ( Endo, M; Fujiwara, T; Iida, K; Matsumoto, Y; Nabeshima, A; Nakashima, Y; Oyama, R; Setsu, N, 2022) |
| "Tranexamic acid (TXA) has been shown to be effective at reducing peri-operative blood loss and haemarthrosis in arthroplasty and arthroscopic soft tissue reconstructions." | 1.72 | Cytotoxicity of tranexamic acid to tendon and bone in vitro: Is there a safe dosage? ( Bolam, SM; Callon, KE; Coleman, B; Cornish, J; Dalbeth, N; Konar, S; Monk, AP; Munro, JT; Musson, DS; O'Regan-Brown, A, 2022) |
| "Ninety-two hemophilia A patients who underwent total knee arthroplasty in our center were included." | 1.72 | Hidden blood loss of total knee arthroplasty in hemophilia arthritis: an analysis of influencing factors. ( Lv, SJ; Shen, SN; Tong, PJ; Wu, DX, 2022) |
| " However, concerns regarding potential adverse reactions, specifically postoperative seizures and thrombotic events, still exist." | 1.72 | Evaluation of the safety of tranexamic acid use in pediatric patients undergoing spinal fusion surgery: a retrospective comparative cohort study. ( Chang, PS; Chatterjee, A; Geiselmann, MT; Ivasyk, I; Jordan, C; Kamel, H; Khormaee, S, 2022) |
| " Weight-based TXA dosing regimens have been compared to fixed-dose regimens of EACA with variable outcomes in perioperative blood product transfusions and chest tube output." | 1.72 | Comparison of trauma-dosed tranexamic acid versus aminocaproic acid in cardiac surgery in the setting of drug shortage. ( Cook, BM; Dannemiller, RE; Goodberlet, MZ; Kelly, JM; Knowles, DM; Malloy, R, 2022) |
| " The intervention increased the use of TXA for both TKA and THA and shifted the dosage to better align with evidence-based practice guidelines." | 1.72 | The effectiveness of a multifaceted, group-facilitated audit and feedback intervention to increase tranexamic acid use during total joint arthroplasty. ( Baghirzada, L; Burak, KW; Cooke, LJ; Dowling, SK; Endersby, RVW; Gjata, I; Law, S; Olivieri, L; Solbak, NM; Weaver, CGW, 2022) |
| "Tranexamic acid (TXA) has been proven to reduce perioperative blood loss and the incidence of allogeneic blood transfusion in total joint arthroplasty (TJA)." | 1.72 | Combination effect of intraoperative and postoperative intravenous tranexamic acid in hip hemiarthroplasty. A propensity score matched analysis. ( Chang, Q; Li, C; Li, Y; Zhang, W, 2022) |
| " 'Consideration of tranexamic acid use' should be included in the safe surgery checklist." | 1.72 | Tranexamic acid for safer surgery: the time is now. ( Grocott, MPW; Murphy, M; Roberts, I; Sayers, R; Toh, CH, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that can be used to treat and prevent bleeding." | 1.72 | ( Bosselmann, K; Keck, M; Lohmeyer, JA; Müller-Wittig, S; Wittig, KS, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that has been increasingly used in THA in recent years to reduce blood loss and the need for transfusion." | 1.72 | The Effect of Systemic Tranexamic Acid on Blood Loss and Blood Transfusion Requirement in Elective Total Hip Arthroplasty. ( Akalın, Y; Avcı, Ö; Çevik, N; Öztürk, A; Sağlıcak, H; Şahin, H, 2022) |
| "The use of tranexamic acid is effective in reduction of blood loss and rates of blood transfusion, without an apparent increase in adverse thromboembolic events." | 1.72 | Efficacy and safety of tranexamic acid in hip fracture surgery: A comparative study of 613 patients. ( AlSumadi, M; Ashour, R; Banim, R; Kharma, L; Mahmood, A; Whittam, D, 2022) |
| " The estimated bioavailability for intra-articular administration was 81%." | 1.72 | Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement. ( Aguilera Roig, X; González Osuna, A; Lamas, C; Martínez-Zapata, MJ; Pla-Junca, F; Rojas, LF; Valle, M; Videla, S, 2022) |
| "To evaluate the effectiveness and safety of tranexamic acid (TXA) combined with intraoperative controlled hypotension (ICH) for reducing perioperative blood loss in primary total hip arthroplasty (THA)." | 1.62 | [Effectiveness and safety of tranexamic acid combined with intraoperative controlled hypotension on reducing perioperative blood loss in primary total hip arthroplasty]. ( Huang, K; Liao, R; Wang, M; Xie, H; Yang, J; Yin, S; Zeng, Y; Zhang, Q, 2021) |
| "Tranexamic acid (TXA) has been shown to reduce blood loss and postoperative transfusions in total knee arthroplasty (TKA)." | 1.62 | One Versus Two Doses of Intravenous Tranexamic Acid in Total Knee Arthroplasty. ( Bernstein, JA; Charette, RS; Kamath, AF; Nchako, CM; Nelson, CL; Sloan, M, 2021) |
| "Nineteen patients had metopic synostosis, 11 had unicoronal synostosis, and 6 had bicoronal synostosis." | 1.62 | A protocol of situation-dependent transfusion, erythropoietin and tranexamic acid reduces transfusion in fronto-orbital advancement for metopic and coronal craniosynostosis. ( Chinnadurai, S; Escher, PJ; Kearney, SL; Kebriaei, MA; Linabery, AM; Petronio, JA; Tibesar, RJ; Tu, AD, 2021) |
| "Tranexamic acid (TXA) has been shown to decrease blood loss and transfusion in shoulder arthroplasty." | 1.62 | Intravenous tranexamic acid vs. topical thrombin in total shoulder arthroplasty: a comparative study. ( Anakwenze, O; Belay, ES; Flamant, E; Hinton, Z; Klifto, CS; O'Donnell, J, 2021) |
| "Tranexamic acid (TXA) has been shown to reduce blood loss and transfusion risk in various orthopedic surgeries including shoulder arthroplasty." | 1.62 | Administration of tranexamic acid during total shoulder arthroplasty is not associated with increased risk of complications in patients with a history of thrombotic events. ( Cagle, PJ; Carbone, A; Chan, J; Galatz, LM; Mazumdar, M; Parsons, BO; Poeran, J; Zubizarreta, N, 2021) |
| "Despite its widespread use, a single formulation or dosing regimen of tranexamic acid (TXA) has not been universally agreed on for total joint arthroplasty." | 1.62 | One Dose Versus Two Doses of Intravenous Tranexamic Acid in Total Joint Arthroplasty. ( Adams, WH; Brown, NM; Davis, BJ; Golz, AG; Yee, HK, 2021) |
| " The exact mechanisms and ideal dosage by which TXA can contribute to such a reduction need further study." | 1.62 | Tranexamic Acid Administration is Associated With a Decreased Odds of Prosthetic Joint Infection Following Primary Total Hip and Primary Total Knee Arthroplasty: A National Database Analysis. ( Hong, GJ; Liu, J; Memtsoudis, SG; Wilson, LA, 2021) |
| "Tranexamic acid (TXA) has proven to be safe in elective and traumatic femoral hemiarthroplasty; however, its use has not been investigated in oncologic patients." | 1.62 | Use of tranexamic acid is not associated with complications following bipolar hemiarthroplasty for metastatic disease. ( Houdek, MT; Owen, A; Rose, PS; Wellings, EP; Wyles, CC; Yuan, BJ, 2021) |
| "Tranexamic acid (TXA) has proven to be effective in reducing the blood loss associated with total knee arthroplasty (TKA) in patients with osteoarthritis." | 1.62 | Is there a role of tranexamic acid in rheumatoid arthritis with total knee arthroplasty? Findings from a multicenter prospective cohort study in China. ( Huang, Q; Huang, W; Lei, Y; Pei, F; Xie, J, 2021) |
| " Nous avons décrit le pourcentage de patients qui ont reçu de l’ATX par chirurgie individuelle, les détails du dosage de l’ATX, et avons estimé l’effet des anesthésiologistes et des chirurgiens sur l’ATX prophylactique en réalisant des analyses de régression logistique multivariées à effets mixtes." | 1.62 | Variation in prophylactic tranexamic acid administration among anesthesiologists and surgeons in orthopedic surgery: a retrospective cohort study. ( Ariano, R; Balshaw, R; Blankstein, A; Bohm, E; Breau, RH; Falk, J; Fergusson, DA; Garland, A; Houston, BL; Houston, DS; Jacobsohn, E; Krupka, E; McIsaac, DI; Perelman, I; Rimmer, E; Tinmouth, A; Turgeon, AF; Zarychanski, R, 2021) |
| " Thus, we conclude that it is safe to use TXA in this patient group." | 1.62 | Is tranexamic acid use in patients with a hip fracture safe? ( Andersen, LR; Clemmensen, SB; Gundtoft, PH; Halekoh, U; Lauritsen, J; Madsen, CF; Overgaard, S; Pedersen, L; Schønnemann, JO; Titlestad, K; Viberg, B, 2021) |
| " For each surgery, we evaluated the percentage of patients who received TXA as well as the specifics of TXA dosing and administration." | 1.62 | Prophylactic tranexamic acid use in non-cardiac surgeries at high risk for transfusion. ( Ariano, RE; Balshaw, R; Breau, RH; Falk, J; Fergusson, DA; Garland, A; Houston, BL; Houston, DS; Jacobsohn, E; Krupka, E; McIsaac, DI; Perelman, I; Rimmer, E; Tinmouth, A; Turgeon, AF; Zarychanski, R, 2021) |
| "0, was employed to analyze demographics including surgical traits, blood loss, drainage, length of hospital stays (LOS), blood biochemical indices, prethrombotic state molecular markers, coagulation function, and adverse events." | 1.62 | Safety and Efficacy of Topical Administration of Tranexamic Acid in High-Risk Patients Undergoing Posterior Lumbar Interbody Fusion Surgery. ( Cai, T; Chen, D; Feng, X; Shi, P; Wang, J; Wang, S; Wang, Y; Zhang, L; Zhang, W, 2021) |
| " The purpose of this study was to determine if TXA is safe to use in patients with a history of CAD or coronary stents." | 1.62 | Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty. ( Rozell, JC; Schwarzkopf, R; Sharan, M; Tang, A; Waren, D; Zak, SG, 2021) |
| "Tranexamic acid (TXA) has been widely used as an antifibrinolytic in dentoalveolar surgery and only recently has its effects been explored in facial procedures." | 1.62 | The Use of Tranexamic Acid in Facial Cosmetic Surgery Procedures: A Technical Note. ( Christensen, BJ; Fathimani, K; Perenack, J, 2021) |
| "Tranexamic acid (TXA) is a drug used to control hemorrhage by preventing the breakdown of fibrin." | 1.62 | The Efficacy and Safety of Tranexamic Acid Treatment in Orthopaedic Trauma Surgery. ( Egol, KA; Littlefield, CP; Perskin, CR; Umeh, U; Wang, C, 2021) |
| "Tranexamic acid (TXA) is an effective blood management strategy, as it competitively inhibits the activation process of plasminogen and prevents fibrinolytic enzymes from degrading fibrin." | 1.62 | Comparison of topical and intravenous Tranexamic acid for high tibial osteotomy: A retrospective study. ( Bian, J; Deng, B; Li, S; Wang, G; Wang, Z; Yuan, L; Zhang, Y; Zhao, X, 2021) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic agent whose safety and efficacy in reducing bleeding are well documented." | 1.56 | Local Infiltration of Tranexamic Acid With Local Anesthetic Reduces Intraoperative Facelift Bleeding: A Preliminary Report. ( Charafeddine, A; Couto, RA; Nayak, LM; Sinclair, NR; Zins, JE, 2020) |
| "Tranexamic acid (TXA) has reduced blood transfusion following total hip arthroplasty (THA)." | 1.56 | Topical Tranexamic Acid Increases Early Postoperative Pain After Total Hip Arthroplasty. ( Deckard, ER; Meneghini, RM; Wurtz, JW; Wurtz, LD; Ziemba-Davis, M, 2020) |
| " The outcomes were evaluated by hidden blood loss (HBL), total blood loss (TBL), intraoperative blood loss (IBL), transfusion rate, maximum hemoglobin (Hb) drop, prethrombotic state molecular markers, liver and renal function, coagulation function, inflammatory factor and adverse events." | 1.56 | The efficacy and safety of multiple-dose intravenous tranexamic acid in reducing perioperative blood loss in patients with thoracolumbar burst fracture. ( Cheng, X; Feng, X; Nan, L; Tao, Y; Wang, F; Wang, Y; Yang, J; Zhang, L; Zhang, S, 2020) |
| " Our study indicates that the local administration of TXA/DEP is safe and more effective than the administration of TXA alone in treating trochanteric femoral fractures." | 1.56 | Safety and efficacy of tranexamic acid with epinephrine for prevention of blood loss following surgery for trochanteric femoral fractures. ( Hu, Y; Xie, L; Xu, X; Yu, H, 2020) |
| "Tranexamic acid bolus was administered before the skin incision and continued throughout the operation." | 1.56 | Perioperative anesthetic management in a patient with factor XI deficiency undergoing coronary artery bypass graft surgery. ( Ince, ME; Ors, N; Ozkan, G; Yildirim, V, 2020) |
| "Tranexamic acid (TXA) has been used extensively to minimize blood loss in cardiac surgery and more recently in orthopedic surgery." | 1.56 | Tranexamic acid administration during total joint arthroplasty surgery is not associated with an increased risk of perioperative seizures: a national database analysis. ( Fiasconaro, M; Kirksey, MA; Liu, J; Memtsoudis, SG; Poeran, J; Wilson, LA, 2020) |
| "Tranexamic acid (TXA) is a medication that has been shown to decrease blood loss and risk of blood transfusion in total knee and total hip arthroplasty." | 1.56 | Effect of Tranexamic Acid on Wound Complications and Blood Loss in Total Ankle Arthroplasty. ( Falcon, S; Haleem, AM; Hollabaugh, K; Luick, L; Ringus, V; Steinmetz, RG; Stoner, J; Tkach, S, 2020) |
| " Previous studies have established the efficacy of TXA in TKA, however here are limited direct comparison studies available and the dosing regimens vary." | 1.56 | Higher doses of topical tranexamic acid safely improves immediate functional outcomes and reduces transfusion requirement in total knee arthroplasty. ( Tan, C; Wang, L; Wu, C, 2020) |
| "Tranexamic acid is an antifibrinolytic used to counteract blood loss." | 1.56 | Effectiveness of administering tranexamic acid to high-risk hip and knee arthroplasty patients: a systematic review protocol. ( Kuster, M; Lockwood, C; Yapa, S, 2020) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent." | 1.56 | The effects of intravenous and local tranexamic acid on bone healing: An experimental study in the rat tibia fracture model. ( Balkanlı, B; Çopuroğlu, C; Çopuroğlu, E, 2020) |
| "Tranexamic acid use in craniosynostosis surgery has increased dramatically since 2010." | 1.56 | Tranexamic Acid in Infantile Craniosynostosis Surgery: Friend or Foe? ( Bennett, WE; Cook, JA; Danforth, RM; Gerety, PA; Tholpady, SS, 2020) |
| " Perioperative blood loss, vascular events, wound complications, and adverse reactions were compared among the three groups." | 1.56 | Comparison of the effectiveness and safety of intravenous and topical regimens of tranexamic acid in complex tibial plateau fracture: a retrospective study. ( Li, Z; Lu, Y; Ma, T; Ren, C; Song, L; Wang, Q; Wang, Z; Yang, J; Zhang, B; Zhang, K, 2020) |
| "There was no significant difference in postoperative blood loss between the tranexamic acid group and the control group." | 1.56 | [Analysis of hemostatic effect of intra-articular injection of tranexamic acid after minimally invasive unicompartmental knee arthroplasty]. ( Dong, F; Qian, PK; Sun, BF; Wu, XF; Xu, F; Yin, ZF; Zhang, JB, 2020) |
| "Patients suffered from acute spinal cord compression caused by spinal tumor manifestation (n = 5), empyema (n = 4), degenerative spinal stenosis (n = 1), hematoma (n = 1), and vertebral body fracture/dislocation (n = 2)." | 1.51 | Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants. ( Beynon, C; Gumbinger, C; Olivares, A; Unterberg, AW; Younsi, A; Zweckberger, K, 2019) |
| "Thirty-four patients with haemophilia A undergoing 24 TKA and 18 THA were evaluated in this retrospective study (No." | 1.51 | Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia. ( Huang, Q; Huang, ZY; Ma, J; Pei, FX; Shen, B; Zeng, HJ; Zhou, ZK, 2019) |
| " A single very low dose of rFVIIa along with TXA is a simple and safe treatment to control hemostasis in severe FXI-deficient patients undergoing diverse type of surgical procedure at various sites." | 1.51 | Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery. ( Avishai, E; Bashari, D; Budnik, I; Dardik, R; Livnat, T; Salomon, O; Tamarin, I, 2019) |
| "Tranexamic acid is an antifibrinolytic with proven efficacy in major surgeries." | 1.51 | Tranexamic acid in cardiac surgery: a systematic review and meta-analysis (protocol). ( Ainswoth, C; Alaifan, T; Alenazy, A; Belley-Cote, E; Fernando, SM; Fox-Robichaud, A; Karachi, T; Kyeremanteng, K; Rochwerg, B; Spence, J; Whitlock, R; Xiang Wang, D; Zarychanski, R, 2019) |
| "Topical administration of tranexamic acid (TXA) reduces bleeding from surgical wounds similarly to intravenous use, but with negligible risk of adverse systemic events." | 1.51 | Cytotoxicity and effect on wound re-epithelialization after topical administration of tranexamic acid. ( Ausen, K; Eikebrokk, TA; Gravastrand, C; Pukstad, B; Spigset, O; Vassmyr, BS, 2019) |
| "Tranexamic acid (TXA) is an effective blood salvage agent that reduces perioperative blood loss in conventional total knee arthroplasty (TKA)." | 1.51 | Tranexamic Acid Reduces Total Blood Loss and Inflammatory Response in Computer-Assisted Navigation Total Knee Arthroplasty. ( Chou, WY; Hsu, YH; Ko, JY; Kuo, SJ; Siu, KK; Wu, KT, 2019) |
| "Pediatric craniosynostosis repair with cranial vault reconstructive surgery can be associated with significant blood loss." | 1.51 | Ulnar Artery Thrombosis Following Tranexamic Acid Administration for Craniosynostosis Repair. ( Chung, E; Karlberg, HI, 2019) |
| "Tranexamic acid (TXA) has been shown to reduce blood loss and transfusion requirements in patients undergoing total hip arthroplasty (THA)." | 1.51 | Transfusion rates with intravenous tranexamic acid in total hip arthroplasty performed using the direct anterior approach. ( Allen, P; Free, MD; Harvie, P; Owen, DH; Pascoe, E; Yang, L, 2019) |
| "The incidence of deep vein thrombosis in the topical group (1." | 1.51 | Comparison of three routes of administration of tranexamic acid in primary unilateral total knee arthroplasty: Analysis of a national database. ( Hu, Q; Huang, Z; Pei, F; Xie, J; Zhou, Z, 2019) |
| " The differences concern the systemic and local application, dosage and time of administration." | 1.51 | [Evaluation of Efficacy of Systemic Administration of Tranexamic Acid (Exacyl) in Total Hip and Knee Arthroplasty - Prospective Cohort Study]. ( Kubát, P; Longin, P; Mannová, J; Pospíchal, M, 2019) |
| "Tranexamic acid (TXA) has been shown to significantly reduce transfusion rates in primary total hip arthroplasties (THAs), but high-quality evidence is limited in the revision setting." | 1.51 | Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total hip arthroplasty. ( Abdel, MP; Amundson, AW; Hernandez, NM; Hines, JT; Pagnano, MW; Sierra, RJ, 2019) |
| " The incidence of adverse events was evaluated in the perioperative period and at 1 month follow-up." | 1.51 | Short-term safety of tranexamic acid use in posterior cervical decompression and fusion surgery. ( Burks, JD; Gjolaj, JP; Green, BA; Lugo-Pico, JG; Madhavan, K; Perez-Roman, RJ; Sheinberg, D, 2019) |
| "Tranexamic acid was used arbitrarily in 36 of them, while the other 47 did not receive TXA." | 1.51 | Blood loss and perioperative transfusions related to surgery for spinal tumors. Relevance of tranexamic acid. ( Damade, C; Foulongne, E; Gauthé, R; Gilard, V; Ould-Slimane, M; Tesson, G; Vigny, S, 2019) |
| " Although previous studies have established the efficacy of tranexamic acid (TXA), data evaluating the widely variable dosing regimens remains sparse." | 1.51 | The use of tranexamic acid in adult spinal deformity: is there an optimal dosing strategy? ( Buckland, AJ; Errico, TJ; Raman, T; Varlotta, C; Vasquez-Montes, D, 2019) |
| "Tranexamic acid (TXA) was found to be more effective at reducing total blood loss compared with epsilon-aminocaproic acid (AM) than placebo." | 1.48 | Antifibrinolytic Therapy in Surgery for Adolescent Idiopathic Scoliosis Does the Level 1 Evidence Translate to Practice? ( Asghar, J; Lonner, BS; Newton, PO; Ren, Y; Samdani, AF; Shah, SA, 2018) |
| "Tranexamic acid (TA) is an antifibrinolytic agent that prevents perioperative blood loss in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA)." | 1.48 | Comparison of Oral and Intravenous Tranexamic Acid for Prevention of Perioperative Blood Loss in Total Knee and Total Hip Arthroplasty. ( Allen, B; Cunningham, K; Forsyth, R; Gortemoller, MA; Theiss, K; Tucker, C, 2018) |
| "Blood loss during craniosynostosis surgery can be substantial, ranging from 20% to 500% of total circulating volume with a high associated risk of transfusion-related adverse events." | 1.48 | Perioperative Blood Loss and Transfusion in Craniosynostosis Surgery. ( Eccles, S; Hare, A; Miranda, BH; Ong, J; Park, C; Wormald, J, 2018) |
| "Consensus does not exist regarding the best dosage regimen for using tranexamic acid (TXA) for patients undergoing open calvarial vault remodeling in craniosynostosis surgery." | 1.48 | Craniosynostosis Surgery and the Impact of Tranexamic Acid Dosing. ( Bristol, R; Do, A; Kurnik, NM; Pflibsen, LR; Singh, DJ, 2018) |
| "Tranexamic acid (TXA) is a potent fibrinolysis inhibitor which has been extensively used at the surgical incision and closure to lower overall blood loss in adult reconstruction surgery." | 1.48 | Additional Dose of Intravenous Tranexamic Acid after Primary Total Knee Arthroplasty Further Reduces Hidden Blood Loss. ( Li, ZJ; Zeng, L; Zhao, MW, 2018) |
| "Tranexamic acid has been shown to be effective in reducing blood loss after total hip replacement." | 1.48 | Matched cohort study of topical tranexamic acid in cementless primary total hip replacement. ( Bustamante Suarez de Puga, D; Martínez Gimenez, E; Mas Martinez, J; Morales Santias, M; Sanz-Reig, J; Verdu Román, C, 2018) |
| "Tranexamic acid (TXA) helps to prevent excessive blood loss during total hip arthroplasty (THA) and total knee arthroplasty (TKA), but the most efficacious dosing protocol has not been ascertained." | 1.48 | One Dose of Intravenous Tranexamic Acid Is Equivalent to Two Doses in Total Hip and Knee Arthroplasty. ( Bugbee, WD; Copp, SN; McCauley, JC; Wilde, JM, 2018) |
| "The combined use of intraarticular topical TXA with rivaroxaban in patients undergoing TKA is a safe and effective method to reduce blood loss, the need for transfusion, and wound complications without elevating the risk of DVT." | 1.48 | Combined use of topical intraarticular tranexamic acid and rivaroxaban in total knee arthroplasty safely reduces blood loss, transfusion rates, and wound complications without increasing the risk of thrombosis. ( Kang, MW; Kim, JI; Kim, YT; Lee, JK; Lee, YM, 2018) |
| "Tranexamic acid usage was associated with decreased blood loss." | 1.48 | Patients With Infected Total Hip Arthroplasty Undergoing 2-Stage Exchange Arthroplasty Experience Massive Blood Loss. ( Buckley, P; Goel, R; Parvizi, J; Sterbis, E, 2018) |
| "The intravenous TXA would reduce postoperative blood loss and transfusion requirements without increasing thromboembolic complications in open-wedge HTO." | 1.48 | Tranexamic acid is effective for blood management in open-wedge high tibial osteotomy. ( Bae, SH; Kim, GB; Kim, HJ; Kim, KI, 2018) |
| "Male appeared to suffer more surgical blood loss than female." | 1.48 | Blood loss of total knee arthroplasty in osteoarthritis: an analysis of influential factors. ( Hu, Y; Li, Q; Shi, ZJ; Torsha, TT; Wei, BG; Xiao, J; Zhang, XS, 2018) |
| " The best administration route and dosage should be further studied." | 1.48 | [Preliminary analysis of the effect of different administration routes of tranexamic acid on blood loss after total hip arthroplasty for female femur neck fractures]. ( Lin, ZQ; Luo, GG; Xie, HF; Yao, JC; Zhang, HZ, 2018) |
| "Tranexamic acid was administered during 62% of the arthroplasties in the ATT+ group and to 90% in the ATT- group." | 1.48 | Tranexamic acid use and risk of thrombosis in regular users ofantithrombotics undergoing primary total knee arthroplasty: a prospectivecohort study. ( Fennema, P; Hourlier, H, 2018) |
| "Tranexamic acid is an anti-fibrinolytic agent frequently used in pediatric surgery." | 1.46 | Anaphylactic reaction to tranexamic acid in an adolescent undergoing posterior spinal fusion. ( Chiem, J; Ivanova, I; Jimenez, N; Krengel, W; Parker, A, 2017) |
| "Tranexamic acid (TXA) has been associated with decreased blood loss and transfusion after total hip arthroplasty (THA) and total knee arthroplasty (TKA)." | 1.46 | Process Improvement Project Using Tranexamic Acid Is Cost-Effective in Reducing Blood Loss and Transfusions After Total Hip and Total Knee Arthroplasty. ( Barfield, WR; Demos, HA; Lin, ZX; Pellegrini, VD; Robertson, DC; Wilson, SH, 2017) |
| "TISSEEL fibrin sealant does not reduce postoperative blood loss or transfusions; however, IV TXA reduced postoperative transfusions compared with TISSEEL and control." | 1.46 | An Aprotinin Containing Fibrin Sealant Does Not Reduce Blood Loss in Total Hip Arthroplasty. ( Bohl, DD; Kearns, SM; Kuhar, HN; Levine, BR, 2017) |
| " Although numerous studies demonstrate the efficacy of intravenous and topical TXA in these patients, few demonstrate the effectiveness and appropriate dosing recommendations of oral formulations." | 1.46 | Oral Tranexamic Acid Reduces Transfusions in Total Knee Arthroplasty. ( Fournier, CA; Junghans, RP; Mattingly, DA; Perreault, RE; Talmo, CT, 2017) |
| "Parameters associated with postoperative blood loss were compared to the prolongation of closure time and medication use." | 1.46 | Limitations of Preoperative PFA-200 as a Predictor of Postoperative Blood Loss in Total Knee Arthroplasty: According to Use of Tranexamic Acid. ( Jeon, Y; Kang, SY; Kim, MH; Lee, WI, 2017) |
| "Tranexamic acid has also been used to decrease blood loss by stabilizing clot formation." | 1.46 | Use of a Tourniquet in Total Knee Arthroplasty Causes a Paradoxical Increase in Total Blood Loss. ( Papillon, N; Rees, H; Schnettler, T, 2017) |
| "This study aimed to compare the efficacy of intravenous administration of tranexamic acid for reducing blood loss in total knee arthroplasty at different dosage time." | 1.46 | The Efficacy Comparison of Tranexamic Acid for Reducing Blood Loss in Total Knee Arthroplasty at Different Dosage Time. ( Cai, M; Gong, J; Nie, X; Sun, Q; Yu, X, 2017) |
| "Tranexamic acid (TXA) has been shown to be effective in reducing blood loss, hemoglobin drop, and blood transfusion in primary total hip arthroplasty." | 1.46 | Blood-Sparing Efficacy of Oral Tranexamic Acid in Primary Total Hip Arthroplasty. ( Chang, WY; Lee, QJ; Wong, YC, 2017) |
| "Intra- and postoperative blood loss was compared between the groups." | 1.46 | High-dose tranexamic acid reduces intraoperative and postoperative blood loss in posterior lumbar interbody fusion. ( Iwasaki, M; Kushioka, J; Maeno, T; Matsumoto, T; Okuda, S; Yamasaki, R; Yamashita, T, 2017) |
| "Tranexamic acid was superior to fibrin sealant in decreasing allogeneic transfusion requirements (0 vs." | 1.46 | Tranexamic acid versus fibrin sealant in primary total hip replacement: a comparative study. ( Borbora, A; Kumar, G; Mahmood, A; Peter, V; Sawalha, S, 2017) |
| "The aim was to utilize the Pediatric Craniofacial Surgery Perioperative Registry database to identify the safety profile of antifibrinolytic therapy for cranial vault reconstructive surgery by reporting the incidence of adverse events as they relate to exposure to tranexamic acid and aminocaproic acid compared to no exposure to antifibrinolytics." | 1.46 | Safety of antifibrinolytics in cranial vault reconstructive surgery: a report from the pediatric craniofacial collaborative group. ( Cladis, FP; Fernandez, AM; Glover, CD; Goobie, SM; Huang, H; Reddy, SK; Stricker, PA; Zurakowski, D, 2017) |
| "Tranexamic acid (TXA) has been reported to demonstrate efficacy in reducing blood loss during arthroplasty procedures." | 1.43 | Intravenous administration of tranexamic acid effectively reduces blood loss in primary total knee arthroplasty in a 610-patient consecutive case series. ( Pitta, M; Rubinstein, A; Verstraete, R; Zawadsky, M, 2016) |
| "Tranexamic acid has been reported to be safer with topical administration than with intravenous administration in total knee arthroplasty." | 1.43 | Comparison between topical and intravenous administration of tranexamic acid in primary total hip arthroplasty. ( Fukumori, N; Kawano, S; Kitajima, M; Mawatari, M; Sonohata, M; Ueno, M, 2016) |
| "Tranexamic acid (TXA) has proven its efficacy in reducing blood loss and the need for blood transfusions in patients who have undergone a total knee arthroplasty (TKA) surgical procedure." | 1.43 | Does tranexamic acid reduce blood loss and transfusion rates in unicompartmental knee arthroplasty? ( Pongcharoen, B; Ruetiwarangkoon, C, 2016) |
| "The incidence of symptomatic deep vein thrombosis and pulmonary embolism was evaluated." | 1.43 | Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis. ( Chen, AF; Heller, S; Parvizi, J; Secrist, E; Shahi, A, 2016) |
| "Tranexamic acid (TXA) has proven efficacy in decreasing blood loss in general trauma patients as well as patients undergoing elective orthopaedic surgery." | 1.43 | Tranexamic acid in hip fracture patients: a protocol for a randomised, placebo controlled trial on the efficacy of tranexamic acid in reducing blood loss in hip fracture patients. ( Flores, E; Garner, MR; Gausden, EB; Levack, A; Lorich, DG; Nellestein, AM; Tedore, T; Warner, SJ, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic that blocks lysine-binding sites of fibrinogen and fibrin, preventing the breakdown of existing clots." | 1.43 | Tranexamic Acid in Anesthetic Management of Surgical Procedures. ( Alwon, K; Collins, S; Hewer, I; Mayeux, J, 2016) |
| "Of a total of 259 patients with craniosynostosis, 187 had nonsyndromic single-suture involvement; 69 of these patients (36." | 1.43 | Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis. ( Diggs, B; Esmonde, N; Gries, H; Koh, J; Kuang, AA; Martin, DT; Schreiber, M; Selden, NR, 2016) |
| " TXA use was also associated with reduced risk of readmission among total hip arthroplasty patients and reduced risk of VTE among total knee arthroplasty patients, and did not have an adverse effect on cardiovascular complications in either group." | 1.43 | The Michigan Experience with Safety and Effectiveness of Tranexamic Acid Use in Hip and Knee Arthroplasty. ( Cowen, ME; Hallstrom, B; Hughes, RE; Roberts, KC; Singal, B, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that can be used to reduce blood loss in total knee arthroplasty (TKA) patients." | 1.43 | Intraarticular Administration of Tranexamic Acid is Safe and Effective in Total Knee Arthroplasty Patients at High-Risk for Thromboembolism. ( Chughtai, M; Delanois, RE; Gwam, C; Khlopas, A; Mistry, JB; Mont, MA; Mudaliar, PP; Tangri, V; Thomas, M, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin." | 1.42 | Single perioperative dose of tranexamic acid in primary hip and knee arthroplasty. ( George, DA; Nwaboku, H; Sarraf, KM, 2015) |
| "Tranexamic acid (TXA) is a synthetic antifibrinolytic drug that competitively decreases the conversion of plasminogen to plasmin, thereby suppressing fibrinolysis." | 1.42 | Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction. ( Claiborne, JR; Couture, DE; Crantford, JC; David, LR; Ririe, DG; Thompson, JT; Wood, BC, 2015) |
| "Tranexamic acid is a safe and effective antifibrinolytic agent used systemically and topically to reduce blood loss and transfusion rate in patients having TKA or THA." | 1.42 | Topical tranexamic Acid does not affect electrophysiologic or neurovascular sciatic nerve markers in an animal model. ( Dang, P; Gupta, R; Luu, M; Mozaffar, T; Schwarzkopf, R, 2015) |
| "Tranexamic acid (TXA) has shown safety and efficacy in reducing blood loss associated with various surgical procedures." | 1.42 | Does Tranexamic Acid Reduce Blood Loss and Transfusion Requirements Associated With the Periacetabular Osteotomy? ( Baca, GR; Clohisy, JC; Keith, AD; Schoenecker, PL; Wingerter, SA, 2015) |
| "A total of 33 children with metopic synostosis were operated on using standardized FOA, of which 16 patients (48." | 1.42 | The value of tranexamic acid during fronto-orbital advancement in isolated metopic craniosynostosis. ( Bodem, JP; Busch, CJ; Engel, M; Freudlsperger, C; Hoffmann, J; Horn, D; Mertens, C, 2015) |
| "Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in elective lower limb arthroplasty surgery." | 1.42 | The efficacy of tranexamic acid in hip hemiarthroplasty surgery: an observational cohort study. ( Edmondson, M; Freeman, R; Lee, C; Rogers, BA, 2015) |
| "Low-dose IA-TXA application in TKR with prolonged clamping drain method is a safe and effective blood conservative technique with only minimal systemic absorption and without significant increase in systemic absorption over time." | 1.42 | An In Vivo Study of Low-Dose Intra-Articular Tranexamic Acid Application with Prolonged Clamping Drain Method in Total Knee Replacement: Clinical Efficacy and Safety. ( Angchaisukisiri, P; Aryurachai, K; Chanplakorn, P; Jittorntam, P; Kawinwonggowit, V; Panpikoon, T; Sa-ngasoongsong, P; Uthadorn, K; Wongsak, S, 2015) |
| "Although TXA seemed safe and effective in this database review of patients with severe medical comorbidities, a larger prospective trial is warranted to confirm these results." | 1.40 | Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. ( Duncan, C; Gillette, BP; Pagnano, MW; Sierra, RJ; Smith, H; Whiting, DR, 2014) |
| "Tranexamic acid (TA) has been reported to reduce blood loss after total joint arthroplasty; however, the literature is sparse in evaluating its efficacy in simultaneous bilateral total knee arthroplasty (TKA)." | 1.40 | Evaluation of the efficacy and safety of tranexamic acid for reducing blood loss in bilateral total knee arthroplasty. ( Bloomfield, MR; DiIorio, TM; Irizarry, AM; Karam, JA; Sharkey, PF, 2014) |
| "Tranexamic acid has been used for many years to minimise blood loss during surgery and, more recently, to reduce morbidity after major trauma." | 1.40 | Perioperative tranexamic acid in day-case paediatric tonsillectomy. ( Robb, PJ; Thorning, G, 2014) |
| "Tranexamic acid (TXA) has been used successfully in primary total knee arthroplasty (TKA) to minimize blood loss and transfusions." | 1.40 | Decreased blood transfusion following revision total knee arthroplasty using tranexamic acid. ( Falls, TD; Malkani, AL; Samujh, C; Smith, L; Wessel, R, 2014) |
| "Tranexamic acid was effective in reducing the need for blood transfusions while not increasing the risk of complications, including thromboembolic events and renal failure." | 1.40 | Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. ( Boettner, F; Danninger, T; Mazumdar, M; Memtsoudis, SG; Opperer, M; Poeran, J; Rasul, R; Suzuki, S, 2014) |
| "Tranexamic acid (TA) has been shown to reduce perioperative blood loss and blood transfusion." | 1.39 | Economic impact of tranexamic acid in healthy patients undergoing primary total hip and knee arthroplasty. ( Duncan, CM; Gillette, BP; Maradit Kremers, H; Pagnano, MW; Sierra, RJ; Smith, HM; Trousdale, RT, 2013) |
| "Tranexamic acid has been shown to reduce perioperative blood loss without increasing the risk of venous thromboembolism after total knee replacement." | 1.39 | Cerebrovascular infarction following bilateral total knee arthroplasty and tranexamic acid administration. ( Baker, J; Bruce-Brand, R; Dragomir, R; Harty, J, 2013) |
| "Tranexamic acid is an antifibrinolytic drug." | 1.39 | Tranexamic acid and thrombosis. ( , 2013) |
| "Tranexamic acid (TXA) has been proven to be safe and effective in preventing blood loss in primary TKA." | 1.39 | One dose of tranexamic acid is safe and effective in revision knee arthroplasty. ( Berta, DM; Howard, JL; Naudie, DD; Ralley, FE; Smit, KM, 2013) |
| "The tranexamic acid dose was higher in the combined group (5." | 1.39 | A retrospective analysis of blood loss with combined topical and intravenous tranexamic acid after coronary artery bypass graft surgery. ( Arellano, R; Hamilton, A; Mahaffey, R; Phelan, R; Wang, L, 2013) |
| " However, few studies have reported the optimum timing and dosage for administration of TXA." | 1.39 | Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty. ( Hamada, M; Hideki, Y; Iwai, T; Sugamoto, K; Tomita, T; Tsuji, S, 2013) |
| "Tranexamic acid has long been used in orthopaedic surgery as an antifibrinolytic agent." | 1.38 | [Tranexamic acid reduces blood loss after major elective orthopaedic operations]. ( Eschen, CT; Husted, H; Tengberg, PT; Troelsen, A, 2012) |
| "Tranexamic acid (TA) is an inexpensive antifibrinolytic agent that is little used in orthopaedic surgery due to the absence of standardised optimal administration regimens." | 1.38 | Tranexamic acid reduces blood loss and financial cost in primary total hip and knee replacement surgery. ( Argenson, JN; Hémon, Y; Irisson, E; Kerbaul, F; Parratte, S; Pauly, V, 2012) |
| "Average preoperative major deformity (kyphosis or scoliosis) was 97° ± 31°." | 1.38 | Antifibrinolytic agents reduce blood loss during pediatric vertebral column resection procedures. ( Bastrom, TP; Emans, JB; Lenke, LG; Newton, PO; Shah, SA; Shufflebarger, HL; Sponseller, PD; Sucato, DJ, 2012) |
| "The rate of avoidance of ABTs, postoperative blood loss, and complications (DVT/PE, skin problems) were examined." | 1.37 | Efficient strategy for controlling postoperative hemorrhage in total knee arthroplasty. ( Hoshino, Y; Sasanuma, H; Sekiya, H; Sugimoto, N; Takada, H; Takatoku, K, 2011) |
| "Blood conservation; the area of greatest clinical variability was seen in dosing regimes for Tranexamic acid." | 1.37 | Blood conservation and pain control in scoliosis corrective surgery: an online survey of UK practice. ( Bird, S; McGill, N, 2011) |
| "Postoperative seizures occurred significantly more frequently in TXA patients (7." | 1.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
| "Tranexamic acid was given concomitantly every 8 h." | 1.37 | rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency. ( Holme, PA; Paus, A; Tjønnfjord, GE; Tran, HT, 2011) |
| "Its use for craniosynostosis surgery warrants investigation." | 1.37 | Comparative analysis of tranexamic acid use in minimally invasive versus open craniosynostosis procedures. ( Istaphanous, G; Martin, D; Maugans, TA; Salisbury, S; Taylor, J, 2011) |
| "All patients with seizures did not have permanent neurological abnormalities." | 1.36 | High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. ( Burt, C; Chu, M; Falter, F; Granton, J; Murkin, JM; Young, B, 2010) |
| " However, many of the dosing schedules in these studies are not ideally suited for routine application." | 1.36 | One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty. ( Berta, D; Binns, V; Howard, J; Naudie, DD; Ralley, FE, 2010) |
| " Further confirmatory prospective studies evaluating the efficacy and safety profile of TXA are urgently needed to find a safe dosage for this antifibrinolytic drug." | 1.36 | Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. ( Martiny, V; Rosenthal, C; Sander, M; Spies, CD; von Heymann, C; Wernecke, KD, 2010) |
| "IV tranexamic acid was also administered to reduce intraoperative blood loss." | 1.35 | Routine preoperative coagulation screening detects a rare bleeding disorder. ( Anne, KK; Durga, P; Jonnavithula, N; Pochiraju, R; Ramachandran, G, 2009) |
| " All the patients received specific hemostasis/coagulation management based on (a) routine use of tranexamic acid, (b) heparin dose-response monitoring, thromboelastography, platelet (PLT) function analysis in a select population of patients, and (c) use of fresh frozen plasma (FFP), PLTs, and desmopressin according to the hemostasis/coagulation profile." | 1.35 | Living without aprotinin: the results of a 5-year blood saving program in cardiac surgery. ( Ballotta, A; Castelvecchio, S; Conti, D; Isgrò, G; Ranucci, M; Romitti, F, 2009) |
| "Glanzmann thrombasthenia is a rare congenital platelet disorder characterized by spontaneous mucocutaneous bleeding and severe bleeding complications during major surgery." | 1.35 | Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery. ( Heindl, B; Lison, S; Spannagl, M, 2009) |
| "However, thrombosis has occurred in three of 12 such patients." | 1.35 | Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. ( Bar-Zakay, B; Horowitz, Z; Korianski, Y; Livnat, T; Mor, Y; Salomon, O; Seligsohn, U; Tamarin, I; Winckler, H, 2009) |
| "The tranexamic acid group has received 30 mg kg-1 the acid tranexamic and the aprotinin group has received a low regimen as 500,000 UIK of aprotinin." | 1.32 | [Tranexamic acid versus aprotinin for the prevention of bleeding during mitral valve surgery ]. ( Ait Houssa, M; Amahzoune, B; Arji, M; Azendour, H; Boulahya, A; Elbekkali, Y; Elkirat, A; Ibbat, D; Jabrani, K; Mamoun, F; Selkane, C; Wahid, FA, 2003) |
| " The goal of this study was to determine if acute normovolemic hemodilution combined with fibrinolytic inhibition and the use of cell saver can reduce the need for homologous blood transfusion in total hip arthroplasty compared to the cellsaver technique alone." | 1.32 | [Acute normovolemic hemodilution combined with inhibition of fibrinolysis and use of cell saver in total hip arthroplasty]. ( Erichsen, H; Gravesen, HS; Lauritsen, AØ; Øberg, BL, 2003) |
| " The dosing of tranexamic acid may require adjustment for renal insufficiency." | 1.31 | Plasma tranexamic acid concentrations during cardiopulmonary bypass. ( Dong, Y; Ereth, MH; Fiechtner, BK; Johnson, ME; Nuttall, GA; Oliver, WC; Oyen, LJ; Sarpal, RS; Sujirattanawimol, N, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 55 (3.70) | 18.2507 |
| 2000's | 133 (8.94) | 29.6817 |
| 2010's | 721 (48.45) | 24.3611 |
| 2020's | 579 (38.91) | 2.80 |
| Authors | Studies |
|---|---|
| Jozefowicz, E | 1 |
| Sabourdin, N | 1 |
| Lambelin, V | 1 |
| Lejeune, V | 1 |
| Delassus, R | 1 |
| Tavernier, B | 1 |
| Cho, MR | 1 |
| Jun, CM | 1 |
| Song, SK | 1 |
| Choi, WK | 2 |
| Peng, HM | 2 |
| Wang, W | 4 |
| Lin, J | 2 |
| Weng, XS | 1 |
| Qian, WW | 1 |
| Wang, WD | 1 |
| Laikhter, E | 1 |
| Comer, CD | 1 |
| Shiah, E | 1 |
| Manstein, SM | 1 |
| Bain, PA | 1 |
| Lin, SJ | 1 |
| Kuo, CC | 1 |
| DeGiovanni, JC | 1 |
| Carr, MM | 1 |
| Zhang, Q | 4 |
| Yin, S | 2 |
| Huang, K | 2 |
| Wang, M | 2 |
| Xie, H | 4 |
| Liao, R | 3 |
| Zeng, Y | 12 |
| Yang, J | 13 |
| Shodipo, OM | 1 |
| Jatto, HI | 1 |
| Ramat, AM | 1 |
| Ibrahim, SS | 1 |
| Ajiboye, LO | 1 |
| Arojuraye, SA | 1 |
| James, JA | 1 |
| Toluse, AM | 1 |
| Chen, C | 8 |
| Liu, J | 20 |
| Du, L | 1 |
| Lee, MJ | 1 |
| Kim, JK | 2 |
| Tang, J | 2 |
| Ming, JM | 1 |
| Chua, ME | 1 |
| Haase, DR | 2 |
| Kimbrel, B | 2 |
| Bombardier, B | 2 |
| Templeton, KJ | 2 |
| Rosenthal, HG | 2 |
| Sweeney, KR | 2 |
| Afzali, SL | 1 |
| Panahi, H | 1 |
| Ganji, F | 1 |
| Ziaei, S | 1 |
| Sedaghat, N | 1 |
| Magill, P | 3 |
| Hill, JC | 2 |
| Bryce, L | 3 |
| Martin, U | 3 |
| Dorman, A | 3 |
| Hogg, R | 3 |
| Campbell, C | 3 |
| Gardner, E | 3 |
| McFarland, M | 3 |
| Bell, J | 4 |
| Benson, G | 3 |
| Beverland, D | 3 |
| Luo, Y | 4 |
| Releken, Y | 2 |
| Yang, D | 1 |
| Yue, Y | 2 |
| Liu, Z | 2 |
| Kang, P | 8 |
| Jiang, W | 4 |
| Fu, M | 5 |
| Dong, W | 1 |
| Zhou, N | 1 |
| Shen, J | 5 |
| Zhang, X | 11 |
| Hao, J | 2 |
| Schwaiger, M | 1 |
| Wallner, J | 1 |
| Zemann, W | 1 |
| Aichner, S | 1 |
| Zrnc, T | 1 |
| Metzler, P | 1 |
| Ikwuezunma, IA | 1 |
| Margalit, A | 1 |
| Sponseller, PD | 4 |
| Sandler, N | 1 |
| Ho, H | 1 |
| Draxler, DF | 1 |
| Bain, CR | 1 |
| Smith, JA | 2 |
| Hauser, CJ | 1 |
| Gruen, RL | 3 |
| Myles, PS | 3 |
| Medcalf, RL | 1 |
| Siemens, K | 1 |
| Sangaran, DP | 1 |
| Hunt, BJ | 3 |
| Murdoch, IA | 1 |
| Tibby, SM | 1 |
| Ahlers, CG | 1 |
| Lan, M | 1 |
| Schoenecker, JG | 2 |
| Borst, AJ | 3 |
| Goldstein, K | 1 |
| Jones, C | 1 |
| Kay, J | 1 |
| Shin, J | 1 |
| de Sa, D | 1 |
| Alsubaie, HM | 1 |
| Abu-Zaid, A | 4 |
| Sayed, SI | 1 |
| Pathak, KA | 1 |
| Almayouf, MA | 1 |
| Albarrak, M | 1 |
| Aldhahri, SF | 1 |
| Al-Qahtani, KH | 1 |
| Azboy, I | 1 |
| Cheng, JF | 1 |
| Qian, WQ | 1 |
| Yishake, M | 1 |
| Shen, JW | 1 |
| Pan, Z | 1 |
| Xu, T | 1 |
| Masouros, P | 3 |
| Antoniou, G | 1 |
| Nikolaou, VS | 3 |
| Yap, D | 1 |
| Shakir, A | 1 |
| Hunt, A | 1 |
| Liu, W | 6 |
| Deng, S | 1 |
| Liang, J | 2 |
| Örs, Ç | 1 |
| Çaylak, R | 1 |
| Brown, NJ | 2 |
| Choi, EH | 2 |
| Gendreau, JL | 2 |
| Ong, V | 2 |
| Himstead, A | 1 |
| Lien, BV | 1 |
| Shahrestani, S | 2 |
| Ransom, SC | 1 |
| Tran, K | 1 |
| Tafreshi, AR | 1 |
| Sahyouni, R | 2 |
| Chan, A | 1 |
| Oh, MY | 1 |
| Wang, Z | 9 |
| Huang, Q | 19 |
| Liu, L | 1 |
| Lu, Y | 3 |
| Zhang, C | 7 |
| Ma, T | 5 |
| Li, Z | 11 |
| Wang, Q | 13 |
| Xue, H | 3 |
| Zhang, K | 4 |
| Koh, A | 2 |
| Adiamah, A | 2 |
| Gomez, D | 2 |
| Sanyal, S | 2 |
| Sun, X | 5 |
| Li, W | 7 |
| Zhang, M | 2 |
| Atasever, AG | 1 |
| Eerens, M | 1 |
| Van den Eynde, R | 1 |
| Faraoni, D | 6 |
| Rex, S | 1 |
| Erdogan, U | 1 |
| Sari, S | 1 |
| Akbas, A | 1 |
| Xu, H | 10 |
| Xie, J | 18 |
| Huang, Z | 11 |
| Wang, D | 12 |
| Pei, F | 27 |
| Emrah, K | 1 |
| Ali, AH | 1 |
| Utku, O | 1 |
| Murat, K | 1 |
| Kenan, S | 1 |
| Deniz, B | 1 |
| Maethungkul, R | 1 |
| Atthakomol, P | 1 |
| Phinyo, P | 1 |
| Phanphaisarn, A | 1 |
| Murakami, H | 1 |
| Sangsin, A | 1 |
| Öztürk, A | 5 |
| Akalin, Y | 5 |
| Çevik, N | 5 |
| Avcı, Ö | 3 |
| Çetin, O | 1 |
| Sağlicak, H | 4 |
| Hourlier, H | 3 |
| Fennema, P | 3 |
| MacDonald, M | 1 |
| Ilie, G | 1 |
| Power, L | 1 |
| Whalen, S | 1 |
| Parker, R | 1 |
| Skinner, TA | 1 |
| Powers, AGL | 1 |
| Sarpong, NO | 2 |
| Chiu, YF | 3 |
| Rodriguez, JA | 2 |
| Boettner, F | 10 |
| Westrich, GH | 3 |
| Chalmers, BP | 7 |
| Yee, DK | 1 |
| Wong, JSH | 1 |
| Fang, E | 1 |
| Wong, TM | 1 |
| Fang, C | 2 |
| Leung, F | 1 |
| Viberg, B | 2 |
| Lei, Y | 11 |
| Liao, J | 2 |
| Liang, X | 3 |
| Hu, N | 3 |
| Huang, W | 12 |
| Wang, E | 2 |
| Yuan, X | 5 |
| Wang, Y | 21 |
| Chen, W | 2 |
| Zhou, X | 3 |
| Hu, S | 3 |
| Yuan, S | 4 |
| Hanreich, C | 2 |
| Cushner, F | 2 |
| Krell, E | 1 |
| Gausden, E | 1 |
| Cororaton, A | 2 |
| Gonzalez Della Valle, A | 5 |
| Zins, JE | 5 |
| Dutton, JW | 2 |
| Ausen, K | 3 |
| Eikebrokk, T | 1 |
| Vassmyr, B | 1 |
| Gravastrand, C | 2 |
| Spigset, O | 3 |
| Pukstad, B | 2 |
| Wang, F | 8 |
| Wang, SG | 1 |
| Yang, Q | 2 |
| Nan, LP | 1 |
| Cai, TC | 1 |
| Wu, DS | 1 |
| Zhang, L | 12 |
| Morris, JL | 2 |
| Letson, HL | 2 |
| McEwen, P | 2 |
| Biros, E | 1 |
| Dlaska, C | 1 |
| Hazratwala, K | 2 |
| Wilkinson, M | 2 |
| Dobson, GP | 2 |
| Huang, L | 2 |
| Li, P | 1 |
| Gu, X | 1 |
| Zhao, R | 1 |
| Ma, X | 4 |
| Wei, X | 1 |
| Takahashi, R | 1 |
| Kajita, Y | 1 |
| Iwahori, Y | 1 |
| Harada, Y | 1 |
| Zapata-Copete, JA | 1 |
| Gómez-Ospina, JC | 1 |
| García-Perdomo, HA | 1 |
| Caycedo, DJ | 1 |
| Eustache, G | 2 |
| Nardi, N | 1 |
| Rousseau, C | 1 |
| Aouaissia, S | 1 |
| Aillet, S | 1 |
| Delahaye Larralde, S | 1 |
| Wodey, E | 1 |
| Riffaud, L | 2 |
| K S, A | 1 |
| Kumar, P | 1 |
| Subair, M | 1 |
| Sharma, RK | 1 |
| Xie, Q | 1 |
| Huang, CJ | 1 |
| Gu, KP | 1 |
| Yao, YX | 1 |
| Wilson, B | 1 |
| Yang, CY | 1 |
| Himstead, AS | 1 |
| Shlobin, NA | 1 |
| Reardon, T | 1 |
| Birkenbeuel, J | 1 |
| Cohn, SJ | 1 |
| Yang, I | 1 |
| Su, E | 1 |
| Lyman, S | 2 |
| Jungwirth-Weinberger, A | 2 |
| Violette, PD | 1 |
| Compton, E | 1 |
| Goldstein, RY | 1 |
| Nazareth, A | 1 |
| Shymon, SJ | 1 |
| Andras, L | 1 |
| Kay, RM | 1 |
| Weissler, JM | 2 |
| Kuruoglu, D | 1 |
| Antezana, L | 1 |
| Curiel, D | 1 |
| Kerivan, L | 1 |
| Alsayed, A | 1 |
| Banuelos, J | 2 |
| Harless, CA | 1 |
| Sharaf, BA | 1 |
| Vijayasekaran, A | 1 |
| Martinez-Jorge, J | 1 |
| Tran, NV | 2 |
| Nguyen, MT | 1 |
| Sun, C | 1 |
| Ma, Q | 1 |
| Tu, Y | 1 |
| Cai, X | 1 |
| Zhou, Y | 4 |
| Binyamin, Y | 1 |
| Orbach-Zinger, S | 1 |
| Gruzman, I | 1 |
| Frenkel, A | 1 |
| Lerman, S | 1 |
| Zlotnik, A | 1 |
| Frank, D | 1 |
| Ioscovich, A | 1 |
| Erez, O | 1 |
| Heesen, M | 1 |
| Baccaglini, W | 1 |
| Rodrigues, AF | 1 |
| Glina, FPA | 1 |
| DallAqua, V | 1 |
| Glina, S | 1 |
| Neto, ACL | 1 |
| Wang, H | 10 |
| Wu, X | 4 |
| van Rijckevorsel, VAJIM | 1 |
| Roukema, GR | 1 |
| Kuijper, TM | 1 |
| de Jong, L | 1 |
| Marcucci, M | 3 |
| Painter, TW | 2 |
| Conen, D | 1 |
| Leslie, K | 2 |
| Lomivorotov, VV | 1 |
| Sessler, D | 1 |
| Chan, MTV | 1 |
| Borges, FK | 1 |
| Martínez Zapata, MJ | 1 |
| Wang, CY | 3 |
| Xavier, D | 1 |
| Ofori, SN | 1 |
| Landoni, G | 3 |
| Efremov, S | 1 |
| Kleinlugtenbelt, YV | 1 |
| Szczeklik, W | 1 |
| Schmartz, D | 1 |
| Garg, AX | 1 |
| Short, TG | 1 |
| Wittmann, M | 1 |
| Meyhoff, CS | 1 |
| Amir, M | 1 |
| Torres, D | 1 |
| Patel, A | 1 |
| Duceppe, E | 1 |
| Ruetzler, K | 1 |
| Parlow, JL | 1 |
| Tandon, V | 1 |
| Wang, MK | 1 |
| Fleischmann, E | 1 |
| Polanczyk, CA | 1 |
| Jayaram, R | 1 |
| Astrakov, SV | 1 |
| Rao, M | 1 |
| VanHelder, T | 2 |
| Wu, WKK | 1 |
| Cheong, CC | 2 |
| Ayad, S | 1 |
| Abubakirov, M | 1 |
| Kirov, M | 1 |
| Bhatt, K | 1 |
| de Nadal, M | 1 |
| Likhvantsev, V | 1 |
| Iglesisas, PP | 1 |
| Aguado, HJ | 1 |
| McGillion, M | 1 |
| Lamy, A | 2 |
| Whitlock, RP | 1 |
| Roshanov, P | 1 |
| Stillo, D | 1 |
| Copland, I | 1 |
| Vincent, J | 1 |
| Balasubramanian, K | 2 |
| Bangdiwala, SI | 1 |
| Biccard, B | 1 |
| Kurz, A | 1 |
| Srinathan, S | 1 |
| Petit, S | 1 |
| Eikelboom, J | 1 |
| Richards, T | 2 |
| Gross, PL | 1 |
| Alfonsi, P | 2 |
| Guyatt, G | 2 |
| Belley-Cote, E | 2 |
| Spence, J | 2 |
| McIntyre, W | 1 |
| Yusuf, S | 1 |
| Devereaux, PJ | 2 |
| Bolton, L | 1 |
| Li, S | 12 |
| Yan, X | 2 |
| Li, R | 3 |
| Zeng, M | 4 |
| Dong, J | 1 |
| Wang, J | 19 |
| Liu, X | 4 |
| Peng, Y | 4 |
| Li, Y | 9 |
| Zhang, Y | 15 |
| Fang, X | 1 |
| Hohmann, E | 1 |
| Zhang, QY | 1 |
| Yin, SJ | 1 |
| Wang, MY | 1 |
| Xie, HQ | 1 |
| Ebrahim Soltani, Z | 1 |
| Hanaei, S | 1 |
| Dabbagh Ohadi, MA | 1 |
| Maroufi, SF | 1 |
| Tayebi Meybodi, K | 1 |
| Khademi, S | 1 |
| Yaghmaei, B | 1 |
| Ebrahim Soltani, A | 1 |
| Nejat, F | 1 |
| Habibi, Z | 1 |
| Ma, J | 18 |
| Zhou, Z | 10 |
| Shen, B | 16 |
| Shah, N | 1 |
| Khetan, V | 1 |
| Sivanadan, H | 1 |
| Cohen-Levy, WB | 2 |
| Klemt, C | 1 |
| Tirumala, V | 1 |
| Burns, JC | 1 |
| Barghi, A | 1 |
| Habibi, Y | 1 |
| Kwon, YM | 1 |
| Fossmark, R | 1 |
| Pleym, H | 2 |
| Karanicolas, PJ | 4 |
| Lin, Y | 5 |
| McCluskey, S | 1 |
| Roke, R | 2 |
| Tarshis, J | 2 |
| Thorpe, KE | 1 |
| Ball, CG | 1 |
| Chaudhury, P | 1 |
| Cleary, SP | 1 |
| Dixon, E | 1 |
| Eeson, G | 1 |
| Moulton, CA | 1 |
| Nanji, S | 1 |
| Porter, G | 1 |
| Ruo, L | 1 |
| Skaro, AI | 1 |
| Tsang, M | 1 |
| Wei, AC | 1 |
| Mersereau, EJ | 1 |
| Puri, S | 1 |
| Sculco, PK | 6 |
| Zou, ZY | 1 |
| He, LX | 3 |
| Yao, YT | 4 |
| Aboul-Fotouh, S | 1 |
| Habib, MZ | 1 |
| Magdy, SM | 1 |
| Hassan, BEE | 1 |
| Gibson, BHY | 1 |
| Duvernay, MT | 1 |
| McKeithan, LJ | 1 |
| Benvenuti, TA | 1 |
| Warhoover, TA | 1 |
| Martus, JE | 1 |
| Mencio, GA | 1 |
| Emerson, BR | 1 |
| Moore-Lotridge, SN | 1 |
| Zha, GC | 1 |
| Zhu, XR | 1 |
| Wang, L | 14 |
| Li, HW | 1 |
| Lier, H | 3 |
| Kammerer, T | 3 |
| Knapp, J | 2 |
| Hofer, S | 2 |
| Maegele, M | 2 |
| Fries, D | 2 |
| von Heymann, C | 4 |
| Eaker, L | 1 |
| Selverian, SR | 1 |
| Hodo, LN | 1 |
| Gal, J | 1 |
| Gangadharan, S | 1 |
| Meyers, J | 1 |
| Dolgopolov, S | 1 |
| Lonner, B | 2 |
| Shalaby, MA | 1 |
| Maged, AM | 2 |
| Al-Asmar, A | 1 |
| El Mahy, M | 1 |
| Al-Mohamady, M | 1 |
| Rund, NMA | 1 |
| Kim, CH | 2 |
| Lim, EJ | 1 |
| Kim, S | 2 |
| Kim, JW | 1 |
| Wilde, JM | 2 |
| Copp, SN | 2 |
| Ezzet, KA | 1 |
| Rosen, AS | 1 |
| Walker, RH | 1 |
| McCauley, JC | 2 |
| Evans, AS | 1 |
| Bugbee, WD | 2 |
| Berg, AJ | 1 |
| Naylor, T | 1 |
| Johnson, DS | 1 |
| Zhang, Z | 8 |
| Li, J | 17 |
| Huang, B | 1 |
| Jiang, Z | 3 |
| Pan, Y | 1 |
| He, T | 1 |
| Hu, Y | 4 |
| Tapking, C | 1 |
| Hundeshagen, G | 1 |
| Kirchner, M | 1 |
| Fischer, S | 1 |
| Kneser, U | 1 |
| Bliesener, B | 1 |
| Bierke, S | 1 |
| Häner, M | 1 |
| Bentzin, M | 1 |
| Park, HU | 1 |
| Petersen, W | 1 |
| Coombs, DM | 3 |
| Kwiecien, GJ | 2 |
| Sinclair, NR | 3 |
| Jin, A | 1 |
| Xiao, K | 1 |
| Zhuo, X | 1 |
| Peng, X | 1 |
| Wu, Z | 3 |
| Li, B | 1 |
| Akti, S | 1 |
| Zeybek, H | 1 |
| Bilekli, AB | 1 |
| Çelebi, NÖ | 1 |
| Erdem, Y | 1 |
| Çankaya, D | 2 |
| Okuzu, Y | 1 |
| Goto, K | 1 |
| Kuroda, Y | 1 |
| Kawai, T | 1 |
| Matsuda, S | 1 |
| Achour, I | 1 |
| Ben Rhaiem, Z | 1 |
| Thabet, W | 1 |
| Jdidi, J | 1 |
| Mnejja, M | 1 |
| Hammami, B | 1 |
| Chakroun, A | 1 |
| Charfeddine, I | 1 |
| Tan, TK | 2 |
| Lee, JY | 2 |
| Tay, A | 1 |
| Kuster, M | 2 |
| Luo, W | 2 |
| Fu, X | 4 |
| Huang, JM | 1 |
| Wu, J | 9 |
| Ma, XL | 8 |
| Lim, GB | 1 |
| Qu, W | 1 |
| Zhou, H | 2 |
| Tian, P | 3 |
| Qin, X | 1 |
| Shen, W | 1 |
| Zhang, D | 1 |
| Kong, Q | 1 |
| Zhang, B | 5 |
| Feng, P | 1 |
| Wu, Y | 12 |
| Guo, C | 1 |
| Fowler, H | 1 |
| Law, J | 1 |
| Tham, SM | 1 |
| Gunaravi, SA | 1 |
| Houghton, N | 1 |
| Clifford, RE | 1 |
| Fok, M | 1 |
| Barker, JA | 1 |
| Vimalachandran, D | 1 |
| Guler, O | 1 |
| Çarkcı, E | 1 |
| Çerci, MH | 1 |
| Gümüşsuyu, G | 1 |
| Öztürk, Ç | 1 |
| Sharaby, MMF | 1 |
| El-Deeb, YM | 1 |
| Oyama, R | 1 |
| Setsu, N | 1 |
| Matsumoto, Y | 1 |
| Endo, M | 1 |
| Fujiwara, T | 1 |
| Iida, K | 1 |
| Nabeshima, A | 1 |
| Nakashima, Y | 1 |
| Cherian, NJ | 1 |
| Hanish, SJ | 1 |
| Ohnoutka, CJ | 1 |
| Keeney, JA | 1 |
| Wang, X | 11 |
| Liang, F | 1 |
| Yu, Y | 2 |
| Han, R | 1 |
| Zhang, J | 15 |
| Yang, ZQ | 2 |
| Bolam, SM | 1 |
| O'Regan-Brown, A | 1 |
| Konar, S | 1 |
| Callon, KE | 1 |
| Coleman, B | 1 |
| Dalbeth, N | 1 |
| Monk, AP | 1 |
| Musson, DS | 1 |
| Cornish, J | 1 |
| Munro, JT | 3 |
| Ekmekyapar, M | 1 |
| Sahin, L | 1 |
| Gur, A | 1 |
| Cui, Y | 1 |
| Sun, L | 2 |
| Ren, C | 2 |
| Okholm, SH | 1 |
| Krog, J | 2 |
| Hvas, AM | 4 |
| Leverett, GD | 1 |
| Marriott, A | 1 |
| Tan, G | 1 |
| Xie, LW | 1 |
| Yi, SJ | 1 |
| Chen, Y | 6 |
| Zhang, H | 7 |
| Alfitian, J | 1 |
| Scheyerer, MJ | 1 |
| Rohde, A | 1 |
| Schick, V | 1 |
| Schier, R | 1 |
| Shen, SN | 1 |
| Wu, DX | 1 |
| Lv, SJ | 1 |
| Tong, PJ | 1 |
| Clohisy, JCF | 1 |
| Lenke, LG | 4 |
| Dafrawy, MHE | 1 |
| Wolfe, RC | 1 |
| Frazier, E | 1 |
| Kelly, MP | 1 |
| Hoyos, AE | 1 |
| Duran, H | 1 |
| Cardenas-Camarena, L | 1 |
| Bayter, JE | 1 |
| Cala, L | 1 |
| Perez, M | 1 |
| Lopez, A | 1 |
| Talleri, G | 1 |
| Domínguez-Millan, R | 1 |
| Mogollon, IR | 1 |
| Porter, SB | 2 |
| Spaulding, AC | 3 |
| Duncan, CM | 4 |
| Wilke, BK | 1 |
| Pagnano, MW | 7 |
| Abdel, MP | 5 |
| Ling, T | 2 |
| Ivasyk, I | 1 |
| Chatterjee, A | 1 |
| Jordan, C | 1 |
| Geiselmann, MT | 1 |
| Chang, PS | 1 |
| Kamel, H | 1 |
| Khormaee, S | 1 |
| Ye, YY | 1 |
| Chen, YF | 1 |
| Yang, XX | 1 |
| Liang, JQ | 1 |
| Liang, GY | 1 |
| Zheng, XQ | 1 |
| Chang, YB | 1 |
| Baradwan, S | 2 |
| Hafidh, B | 1 |
| Latifah, HM | 1 |
| Gari, A | 1 |
| Sabban, H | 1 |
| Abduljabbar, HH | 1 |
| Tawfiq, A | 1 |
| Hakeem, GF | 1 |
| Alkaff, A | 1 |
| AlSghan, R | 1 |
| Alshahrani, MS | 1 |
| Badghish, E | 1 |
| Kanhere, AP | 1 |
| Lambrechts, MJ | 1 |
| Issa, TZ | 1 |
| Karamian, BA | 1 |
| Hendow, CJ | 1 |
| Reddy, YC | 1 |
| Slota, PJ | 1 |
| D'Antonio, ND | 1 |
| Kaye, ID | 1 |
| Canseco, JA | 1 |
| Woods, BI | 1 |
| Hilibrand, AS | 1 |
| Kepler, CK | 1 |
| Vaccaro, AR | 1 |
| Schroeder, GD | 1 |
| Alphonsus, CS | 1 |
| Swanevelder, J | 1 |
| Biccard, BM | 1 |
| Qin, C | 1 |
| Du, KL | 1 |
| Guo, PY | 1 |
| Gong, HD | 1 |
| Zhang, CQ | 1 |
| Liu, ZG | 1 |
| Yang, F | 2 |
| Zhu, YH | 1 |
| Liu, GC | 1 |
| Zhu, QS | 1 |
| Zhang, BY | 1 |
| Fenwick, A | 1 |
| Antonovska, I | 1 |
| Pfann, M | 1 |
| Mayr, J | 1 |
| Wiedl, A | 1 |
| Nuber, S | 1 |
| Förch, S | 1 |
| Mayr, E | 1 |
| Cao, Z | 1 |
| Li, Q | 11 |
| Guo, J | 1 |
| Hwang, J | 1 |
| Lee, SJ | 1 |
| Yoon, PW | 1 |
| Yoon, KS | 1 |
| Dannemiller, RE | 1 |
| Knowles, DM | 1 |
| Cook, BM | 1 |
| Goodberlet, MZ | 1 |
| Kelly, JM | 1 |
| Malloy, R | 1 |
| Gjata, I | 1 |
| Olivieri, L | 1 |
| Baghirzada, L | 1 |
| Endersby, RVW | 1 |
| Solbak, NM | 1 |
| Weaver, CGW | 1 |
| Law, S | 1 |
| Cooke, LJ | 1 |
| Burak, KW | 1 |
| Dowling, SK | 1 |
| Wagener, G | 1 |
| Goldklang, MP | 1 |
| Gerber, A | 1 |
| Elisman, K | 1 |
| Eiseman, KA | 1 |
| Fonseca, LD | 1 |
| D'Armiento, JM | 1 |
| Knackstedt, R | 1 |
| Patel, N | 1 |
| Fang, Q | 1 |
| Xiong, W | 1 |
| Tang, Y | 3 |
| Wang, G | 5 |
| Li, C | 2 |
| Zhang, W | 5 |
| Chang, Q | 1 |
| King, MR | 1 |
| Staffa, SJ | 2 |
| Stricker, PA | 3 |
| Pérez-Pradilla, C | 1 |
| Nelson, O | 1 |
| Benzon, HA | 1 |
| Goobie, SM | 12 |
| Li, L | 8 |
| He, L | 2 |
| Yao, Y | 1 |
| Pan, H | 1 |
| Liu, G | 4 |
| Zheng, S | 1 |
| Lu, C | 1 |
| Corbett, C | 1 |
| Elliott, JE | 1 |
| Evans, D | 1 |
| Patel, PA | 2 |
| Wyrobek, JA | 1 |
| Butwick, AJ | 1 |
| Pivalizza, EG | 1 |
| Hare, GMT | 1 |
| Mazer, CD | 6 |
| Qi, MT | 1 |
| Wang, SY | 1 |
| Wang, LT | 1 |
| Chen, XW | 1 |
| Zhan, WH | 1 |
| Zhu, XF | 1 |
| Salameh, M | 1 |
| Attia, AK | 1 |
| El Khatib, S | 1 |
| Hantouly, A | 1 |
| Hsu, R | 1 |
| Blankenhorn, B | 1 |
| Combs, DB | 1 |
| Hummel, A | 1 |
| Nishioka, ST | 1 |
| Andrews, SN | 1 |
| Nakasone, CK | 1 |
| Seifert, SM | 1 |
| Fields, KG | 1 |
| Farber, MK | 1 |
| McDonald, C | 1 |
| Feeley, I | 1 |
| Flynn, S | 1 |
| Farrell, A | 1 |
| Kelly, M | 1 |
| Sheehan, E | 1 |
| Heckmann, ND | 1 |
| Haque, TF | 1 |
| Piple, AS | 1 |
| Mayfield, CK | 1 |
| Bouz, GJ | 1 |
| Mayer, LW | 1 |
| Oakes, DA | 1 |
| Lieberman, JR | 1 |
| Christ, AB | 1 |
| Sen, RK | 1 |
| Attar, MU | 1 |
| Saini, G | 1 |
| Tripathy, SK | 2 |
| Tekin, SB | 1 |
| Demir, IH | 1 |
| Bozgeyik, B | 1 |
| Mert, A | 1 |
| Fujikawa, T | 1 |
| Baker, EC | 1 |
| Anwar, S | 1 |
| Masaryk, J | 2 |
| Melus, V | 1 |
| Vidan, J | 2 |
| Steno, B | 2 |
| Grocott, MPW | 4 |
| Murphy, M | 5 |
| Roberts, I | 14 |
| Sayers, R | 4 |
| Toh, CH | 4 |
| Stöckle, M | 1 |
| Khadivi, M | 1 |
| Saghebdoust, S | 1 |
| Moghadam, N | 1 |
| Zarei, M | 1 |
| Moosavi, M | 1 |
| Ataei, H | 1 |
| Jafarieh, A | 1 |
| Borghei, A | 1 |
| Shafizadeh, M | 1 |
| Eslamian, M | 1 |
| Jouibari, MF | 1 |
| Kordi, R | 1 |
| Rostami, M | 1 |
| Baghaie, H | 1 |
| Shukla, K | 1 |
| Stone, J | 1 |
| Breik, O | 1 |
| Munn, Z | 1 |
| Lin, GX | 1 |
| Chen, CM | 2 |
| Zhu, MT | 1 |
| Zheng, L | 1 |
| Lu, E | 1 |
| Huang, T | 2 |
| Tan, Y | 2 |
| Keck, M | 1 |
| Bosselmann, K | 1 |
| Müller-Wittig, S | 1 |
| Wittig, KS | 1 |
| Lohmeyer, JA | 1 |
| Huang, Y | 7 |
| Ye, P | 1 |
| Deng, P | 1 |
| Chen, J | 5 |
| Qi, X | 1 |
| Zeng, J | 1 |
| Feng, W | 3 |
| Kim, MK | 1 |
| Ko, SH | 1 |
| Nam, YC | 1 |
| Jeon, YS | 1 |
| Kwon, DG | 1 |
| Ryu, DJ | 1 |
| Hung, CM | 1 |
| Hung, KC | 1 |
| Lee, PH | 1 |
| Tsai, IT | 1 |
| Lee, HM | 1 |
| Chiu, CC | 1 |
| Miangul, S | 1 |
| Oluwaremi, T | 1 |
| El Haddad, J | 1 |
| Adra, M | 1 |
| Pinnawala, N | 1 |
| Nakanishi, H | 1 |
| Matar, RH | 1 |
| Than, CA | 1 |
| Stewart, TM | 1 |
| Abdou, M | 1 |
| Kwon, JW | 1 |
| Kim, HJ | 3 |
| Lee, B | 1 |
| Choi, YS | 1 |
| Moon, SH | 1 |
| Lee, BH | 1 |
| Li, TQ | 1 |
| Ma, TC | 1 |
| Ma, ZS | 1 |
| Alam, MS | 1 |
| Barh, A | 1 |
| Kundu, D | 1 |
| Zacharowski, K | 3 |
| Zoller, H | 1 |
| Steinbicker, AU | 1 |
| Turan, K | 1 |
| Muratoğlu, OG | 1 |
| Ergün, T | 1 |
| Çabuk, H | 1 |
| Ertürer, RE | 1 |
| Gorbaty, J | 1 |
| Chan, PH | 1 |
| McElvany, MD | 1 |
| Prentice, HA | 1 |
| Yian, EH | 1 |
| Tang, S | 2 |
| Shi, X | 2 |
| Brito, RM | 1 |
| Oliveira, CMB | 1 |
| Moura, ECR | 1 |
| Campelo, GP | 1 |
| Lima, RC | 1 |
| Fe, CSM | 1 |
| Sousa, TM | 1 |
| Oliveira, EJSG | 1 |
| Dibai Filho, AV | 1 |
| Leal, PDC | 1 |
| Ekinci, M | 3 |
| Ok, M | 1 |
| Ersin, M | 2 |
| Günen, E | 1 |
| Kocazeybek, E | 1 |
| Sırma, SÖ | 1 |
| Yılmaz, M | 1 |
| Zhao, CC | 1 |
| Chen, LY | 1 |
| Chen, CJ | 2 |
| Wang, QR | 2 |
| Li, QH | 1 |
| Kang, PD | 3 |
| Hanke, J | 1 |
| Mendel, T | 1 |
| Wingert, M | 1 |
| Schenk, P | 1 |
| Heinecke, M | 1 |
| Wilharm, A | 1 |
| Liu, Y | 17 |
| Li, YM | 2 |
| Li, ZJ | 6 |
| Xu, GJ | 2 |
| Ishii, K | 4 |
| Yokoyama, Y | 4 |
| Yonekawa, Y | 4 |
| Hayashi, D | 3 |
| Kinoshita, F | 3 |
| Kuwatsuka, Y | 3 |
| Okuno, M | 3 |
| Natsume, S | 3 |
| Minami, T | 3 |
| Sugawara, G | 3 |
| Seita, K | 3 |
| Sato, F | 3 |
| Aoba, T | 3 |
| Shimizu, Y | 3 |
| Kurumiya, Y | 3 |
| Maeda, A | 3 |
| Yamaguchi, R | 3 |
| Hiramatsu, K | 3 |
| Ebata, T | 4 |
| Hsu, LI | 3 |
| Hsu, HW | 3 |
| Chen, JW | 3 |
| Wei, ST | 3 |
| Hou, SM | 3 |
| Weng, N | 3 |
| Gou, Y | 4 |
| Kuang, F | 3 |
| Agius, C | 3 |
| Cole, E | 3 |
| Mifsud, MG | 3 |
| Vasireddy, A | 3 |
| Yang, YS | 3 |
| Tian, SM | 3 |
| Wang, BJ | 3 |
| Fu, WM | 3 |
| Cheng, LL | 3 |
| Jiang, NN | 3 |
| Gu, G | 3 |
| Zhao, DW | 3 |
| Jones, AL | 3 |
| Lotan, R | 2 |
| Lengenova, S | 2 |
| Rijini, N | 2 |
| Hershkovich, O | 2 |
| Douglas, ZH | 2 |
| Piccirillo, JF | 2 |
| Schneider, J | 2 |
| Roland, LT | 2 |
| Farrell, NF | 2 |
| Augustinus, S | 2 |
| Mulders, MAM | 2 |
| Gardenbroek, TJ | 2 |
| Goslings, JC | 2 |
| Şahin, H | 2 |
| DeFrancesco, CJ | 2 |
| Reichel, JF | 2 |
| Gbaje, E | 2 |
| Popovic, M | 2 |
| Freeman, C | 2 |
| Wong, M | 2 |
| DeMeo, D | 2 |
| Ranawat, A | 2 |
| Cross, M | 2 |
| Haskins, S | 2 |
| Kim, D | 3 |
| Maalouf, D | 2 |
| Kirksey, M | 2 |
| Jules-Elysee, K | 2 |
| Soffin, EM | 2 |
| Kumar, K | 2 |
| Beathe, J | 2 |
| Figgie, M | 2 |
| Inglis, A | 2 |
| Garvin, S | 2 |
| Alexiades, M | 2 |
| DelPizzo, K | 3 |
| Russell, LA | 3 |
| Sideris, A | 2 |
| Saleh, J | 2 |
| Zhong, H | 3 |
| Memtsoudis, SG | 9 |
| Zheng, C | 5 |
| Xu, J | 6 |
| Wu, L | 3 |
| Alrajhi, AA | 1 |
| Alghamdi, AS | 1 |
| Baali, MH | 1 |
| Altowairqi, AF | 1 |
| Khan, MF | 1 |
| Alharthi, AS | 1 |
| Albazee, E | 1 |
| Ye, L | 1 |
| Guan, J | 2 |
| Chen, X | 12 |
| Lu, H | 5 |
| Xiao, Y | 1 |
| Dai, X | 1 |
| Wu, M | 2 |
| Ma, S | 1 |
| Xia, Y | 2 |
| Joo, YB | 1 |
| Kim, YM | 1 |
| An, BK | 1 |
| Lee, CW | 1 |
| Kwon, ST | 1 |
| Song, JH | 1 |
| Calpin, GG | 1 |
| McAnena, PF | 1 |
| Davey, MG | 1 |
| Calpin, P | 1 |
| Kerin, MJ | 1 |
| McInerney, N | 1 |
| Walsh, SR | 1 |
| Lowery, AJ | 1 |
| Si, H | 2 |
| Li, M | 6 |
| Thakkar, K | 1 |
| Moorthy, RK | 1 |
| Yadav, B | 1 |
| George, SE | 1 |
| Singh, G | 1 |
| Shi, J | 5 |
| Zhou, C | 2 |
| Zheng, Z | 5 |
| Koster, A | 4 |
| Hulde, N | 3 |
| Zittermann, A | 3 |
| Bian, T | 1 |
| Man, S | 1 |
| Li, H | 9 |
| Dou, Y | 1 |
| Bailey, CR | 1 |
| Zhou, LB | 1 |
| Wang, CC | 1 |
| Zhang, LT | 1 |
| Wu, T | 1 |
| Zhang, GQ | 1 |
| Luan, H | 1 |
| Liu, K | 1 |
| Peng, C | 1 |
| Tian, Q | 1 |
| Song, X | 1 |
| Khanwalkar, A | 1 |
| Chan, E | 1 |
| Roozdar, P | 1 |
| Ma, Y | 1 |
| Hwang, PH | 1 |
| Nayak, JV | 1 |
| Patel, ZM | 1 |
| Wijaya, JH | 1 |
| July, J | 1 |
| Quintero-Consuegra, M | 1 |
| Chadid, DP | 1 |
| Kolin, DA | 2 |
| Della Valle, AG | 1 |
| Ast, MP | 2 |
| Landy, DC | 1 |
| Prasad, S | 1 |
| Sharma, G | 1 |
| Devana, SK | 1 |
| Kumar, S | 4 |
| Sharma, S | 1 |
| Jockel, K | 1 |
| Lee, A | 1 |
| Cosgrove, MS | 1 |
| Reilly, D | 1 |
| Wijesekera, S | 1 |
| Powell-Bowns, MFR | 1 |
| Olley, RK | 1 |
| McCann, C | 1 |
| Balfour, JR | 1 |
| Brennan, CM | 1 |
| Peh, J | 1 |
| Duckworth, AD | 1 |
| Scott, CEH | 1 |
| Liechti, R | 1 |
| van de Wall, BJM | 1 |
| Hug, U | 1 |
| Fritsche, E | 1 |
| Franchi, A | 1 |
| Om, A | 1 |
| Marxen, T | 1 |
| Kebede, S | 1 |
| Losken, A | 1 |
| Hmidan Simsam, M | 1 |
| Delorme, L | 1 |
| Grimm, D | 1 |
| Priestap, F | 1 |
| Bohnert, S | 1 |
| Descoteaux, M | 1 |
| Hilsden, R | 1 |
| Laverty, C | 1 |
| Mickler, J | 1 |
| Parry, N | 1 |
| Rochwerg, B | 3 |
| Sherman, C | 1 |
| Smith, S | 1 |
| Toole, J | 1 |
| Vogt, K | 1 |
| Wilson, S | 1 |
| Ball, I | 1 |
| Anyaehie, UE | 1 |
| Eyichukwu, GO | 1 |
| Muoghalu, ON | 1 |
| Emina, BK | 1 |
| Ede, O | 1 |
| Anetekhai, WI | 1 |
| G Nwosu, AD | 1 |
| Hindman, BJ | 1 |
| Gold, CJ | 1 |
| Ray, E | 1 |
| Wendt, LH | 1 |
| Ten Eyck, P | 1 |
| Berger, JI | 1 |
| Olinger, CR | 1 |
| Banks, MI | 1 |
| Sanders, RD | 1 |
| Howard, MA | 1 |
| Woodroffe, RW | 1 |
| Clynch, AL | 1 |
| Gillespie, CS | 1 |
| Richardson, GE | 1 |
| Mustafa, MA | 1 |
| Islim, AI | 1 |
| Keshwara, SM | 1 |
| Bakhsh, A | 1 |
| Zakaria, R | 1 |
| Millward, CP | 1 |
| Mills, SJ | 1 |
| Brodbelt, AR | 1 |
| Jenkinson, MD | 1 |
| Wang, S | 6 |
| Lin, L | 2 |
| Fan, X | 2 |
| Zheng, Y | 2 |
| Bloom, DA | 1 |
| Lin, CC | 1 |
| Manzi, JE | 1 |
| Mojica, ES | 1 |
| Telgheder, ZL | 1 |
| Chapman, CB | 1 |
| Konda, SR | 1 |
| Tripković, B | 1 |
| Jakovina Blažeković, S | 1 |
| Bratić, V | 1 |
| Tripković, M | 1 |
| Safran, T | 1 |
| Vorstenbosch, J | 1 |
| Viezel-Mathieu, A | 1 |
| Davison, P | 1 |
| Dionisopoulos, T | 1 |
| Alsabani, MH | 1 |
| Sibai, A | 1 |
| Alharbi, SF | 1 |
| Olayan, LH | 1 |
| Samman, AA | 1 |
| Al Harbi, MK | 1 |
| Nichols, G | 1 |
| Andrade, E | 1 |
| Gregoski, M | 1 |
| Herrera, FA | 1 |
| Armstrong, MB | 1 |
| Colson, P | 1 |
| Fellahi, JL | 1 |
| Gaudard, P | 1 |
| Provenchère, S | 2 |
| Rozec, B | 2 |
| Li, FL | 1 |
| Huang, X | 6 |
| Mo, BF | 1 |
| Liu, WH | 1 |
| Huang, WW | 1 |
| Yin, D | 4 |
| Patel, S | 1 |
| Iseki, T | 3 |
| Kanto, R | 1 |
| Onishi, S | 1 |
| Yoshiya, S | 2 |
| Tachibana, T | 1 |
| Nakayama, H | 1 |
| Pearson, ZC | 1 |
| Agarwal, AR | 1 |
| Elnemer, W | 1 |
| Thomas, J | 1 |
| Fox, H | 1 |
| Ahiarakwe, U | 1 |
| Best, MJ | 1 |
| Srikumaran, U | 1 |
| Hao, S | 1 |
| Liu, S | 6 |
| Meng, S | 1 |
| Yang, H | 7 |
| Dong, S | 1 |
| Mocanu, V | 1 |
| Wilson, H | 1 |
| Verhoeff, K | 1 |
| Kung, J | 1 |
| Walsh, C | 1 |
| Koloszvari, N | 1 |
| Neville, A | 1 |
| Karmali, S | 1 |
| Huynh, MNQ | 1 |
| Wong, CR | 1 |
| McRae, MC | 1 |
| Voineskos, S | 1 |
| McRae, MH | 1 |
| You, M | 1 |
| Yao, L | 2 |
| Fu, W | 2 |
| Chen, G | 5 |
| Tang, X | 5 |
| Xiong, Y | 1 |
| Morkos, K | 1 |
| Maingard, J | 1 |
| Barras, C | 1 |
| Kok, HK | 1 |
| Hall, J | 1 |
| Russell, J | 1 |
| Thijs, V | 1 |
| Slater, LA | 1 |
| Chong, W | 1 |
| Chandra, R | 1 |
| Jhamb, A | 1 |
| Brooks, M | 1 |
| Asadi, H | 1 |
| Yang, X | 4 |
| Chai, M | 1 |
| Xia, L | 1 |
| He, Z | 2 |
| Jamshaid, W | 1 |
| Jamshaid, M | 1 |
| Coulson, C | 1 |
| Sharma, N | 1 |
| Muzaffar, J | 1 |
| Nieto, H | 1 |
| Pacheco, LD | 1 |
| Clifton, RG | 1 |
| Saade, GR | 1 |
| Weiner, SJ | 1 |
| Parry, S | 1 |
| Thorp, JM | 1 |
| Longo, M | 1 |
| Salazar, A | 1 |
| Dalton, W | 1 |
| Tita, ATN | 1 |
| Gyamfi-Bannerman, C | 1 |
| Chauhan, SP | 1 |
| Metz, TD | 1 |
| Rood, K | 1 |
| Rouse, DJ | 1 |
| Bailit, JL | 1 |
| Grobman, WA | 1 |
| Simhan, HN | 1 |
| Macones, GA | 1 |
| Luetzenberg, FS | 1 |
| Lyford-Pike, S | 1 |
| Kolodziej, JH | 1 |
| Leeper, CM | 1 |
| Leonard, JC | 1 |
| Josephson, CD | 1 |
| Zenati, MS | 1 |
| Spinella, PC | 1 |
| Reyes-Sánchez, A | 1 |
| Domínguez-Soto, A | 1 |
| Zárate-Kalfópulos, B | 1 |
| Guerra-Garza, J | 1 |
| Gordillo-Pérez, R | 1 |
| Huffman, C | 1 |
| Rosales-Olivarez, LM | 1 |
| Alpízar-Aguirre, A | 1 |
| García-Ramos, CL | 1 |
| Liu, M | 5 |
| Zhou, R | 1 |
| Xiao, C | 4 |
| Gao, Z | 2 |
| Yu, W | 3 |
| Yao, K | 1 |
| Cao, Y | 1 |
| Long, N | 3 |
| Zhang, S | 13 |
| Jiang, Y | 5 |
| Cao, G | 7 |
| Quan, S | 1 |
| Cai, L | 1 |
| Yao, J | 1 |
| Tan, H | 1 |
| Tanis-Arens, CE | 1 |
| Mastropietro, CM | 1 |
| Walker, SG | 1 |
| Abbasi, RK | 1 |
| Meghpara, MM | 1 |
| Goh, GS | 2 |
| Ciesielka, KA | 1 |
| Fillingham, YA | 9 |
| Ackerman, LL | 1 |
| Snider, AA | 1 |
| Ye, J | 1 |
| Abdallah, Z | 1 |
| Staibano, P | 1 |
| Zhou, K | 2 |
| Khalife, S | 1 |
| Nguyen, TBV | 1 |
| Sommer, DD | 1 |
| Yalamanchili, S | 1 |
| Talei, B | 1 |
| Azizzadeh, B | 1 |
| Auersvald, A | 1 |
| Frankel, AS | 1 |
| Fijany, AJ | 1 |
| Givechian, KB | 1 |
| Zago, I | 1 |
| Olsson, SE | 1 |
| Boctor, MJ | 1 |
| Gandhi, RR | 1 |
| Pekarev, M | 1 |
| Shen, L | 1 |
| Xu, W | 3 |
| Sipos, K | 1 |
| Kämäräinen, S | 1 |
| Kauhanen, S | 1 |
| Shen, M | 1 |
| Bosilah, AH | 2 |
| Eldesouky, E | 2 |
| Alghazaly, MM | 1 |
| Farag, E | 2 |
| Sultan, EEK | 1 |
| Alazazy, H | 1 |
| Mohamed, A | 2 |
| Ali, SMS | 1 |
| Elsror, AGA | 2 |
| Mahmoud, M | 1 |
| Abd Elhalim, AEM | 1 |
| Kamel, MA | 2 |
| Abd-ElGawad, M | 2 |
| Sayed, FM | 1 |
| Bakry, MS | 1 |
| Cheema, HA | 1 |
| Ahmad, AB | 1 |
| Ehsan, M | 1 |
| Shahid, A | 3 |
| Ayyan, M | 1 |
| Azeem, S | 1 |
| Hussain, A | 1 |
| Nashwan, AJ | 1 |
| Mikuš, M | 1 |
| Laganà, AS | 1 |
| Tsan, SEH | 1 |
| Viknaswaran, NL | 1 |
| Cheah, S | 1 |
| Ng, KT | 2 |
| Mong, SXY | 1 |
| Gopal Subramaniam, A | 1 |
| Hau, R | 1 |
| Lin, PS | 1 |
| Tian, LJ | 1 |
| Jiang, JJ | 1 |
| Yu, YP | 1 |
| Perka, C | 2 |
| Kaufner, L | 1 |
| Treskatsch, S | 1 |
| Ye, S | 1 |
| Chen, M | 2 |
| Zhao, C | 3 |
| Lin, YH | 1 |
| Lee, KC | 1 |
| Hsu, CC | 1 |
| Chen, KT | 1 |
| Imanishi, K | 1 |
| Kobayashi, N | 1 |
| Kamono, E | 1 |
| Yukizawa, Y | 1 |
| Takagawa, S | 1 |
| Choe, H | 1 |
| Kumagai, K | 1 |
| Inaba, Y | 1 |
| Stejskal, P | 1 |
| Trnka, Š | 1 |
| Hrabálek, L | 1 |
| Wanek, T | 1 |
| Jablonský, J | 1 |
| Novák, V | 1 |
| 't Hart, JWH | 1 |
| Noordman, BJ | 1 |
| Wijnand, JMA | 1 |
| Biter, LU | 1 |
| Verbrugge, SJC | 1 |
| Birnie, E | 1 |
| Dunkelgrun, M | 1 |
| Huisbrink, J | 1 |
| Apers, JA | 1 |
| Yusufu, A | 1 |
| Haibier, A | 1 |
| Ren, Z | 6 |
| Qin, Q | 1 |
| Ran, J | 2 |
| de Abreu de Vasconcellos, SJ | 1 |
| Souza Dos Santos Marques, R | 1 |
| Gomes Magalhães de Melo, E | 1 |
| Silva de Almeida, C | 1 |
| de Almeida Góes Silva, JV | 1 |
| de Almeida Souza, LM | 1 |
| Martins-Filho, PR | 1 |
| Foster, D | 1 |
| Sebro, R | 1 |
| Garner, H | 1 |
| Stanborough, R | 1 |
| Goulding, K | 1 |
| Houdek, M | 1 |
| Wilke, B | 1 |
| Ogah, CO | 1 |
| Anikwe, CC | 1 |
| Ikeoha, CC | 1 |
| Dimejesi, OB | 1 |
| Okorochukwu, BC | 1 |
| Esike, CO | 1 |
| Salamah, MA | 1 |
| Al Bialy, HA | 1 |
| Khairy, MA | 1 |
| Ali, AG | 1 |
| Li, F | 3 |
| Shi, W | 1 |
| Abdou, AM | 1 |
| Mohammed, A | 1 |
| Abdelaziz, DFM | 1 |
| Shaaban, A | 1 |
| Ellaban, M | 1 |
| Elhalim, AEMA | 1 |
| Marai, AAE | 1 |
| Abdel-Hakam, F | 1 |
| Elrashedy, AA | 1 |
| Abdelmonem, H | 1 |
| Afiffi, IK | 1 |
| Elsayed, HGA | 1 |
| Abdelhamed, SA | 1 |
| Marie, H | 1 |
| Ikeda, K | 1 |
| Nollet, KE | 1 |
| Kenmegne, GR | 1 |
| Zou, C | 1 |
| Yin, Y | 1 |
| Huang, S | 1 |
| Banneyake, EL | 1 |
| Gunasekera, IS | 1 |
| Fang, Y | 4 |
| AlQahtani, FA | 1 |
| Kuriadom, ST | 1 |
| Varma, S | 1 |
| AlAnzy, H | 1 |
| AlOtaibi, S | 1 |
| Yang, YZ | 1 |
| Cheng, QH | 1 |
| Zhang, AR | 1 |
| Zhang, ZZ | 1 |
| Guo, HZ | 1 |
| Vanderbruggen, W | 1 |
| Brits, T | 1 |
| Tilborghs, S | 1 |
| Derickx, K | 1 |
| De Wachter, S | 1 |
| Albasha, A | 1 |
| Salman, LA | 1 |
| Elramadi, A | 1 |
| Abudalou, A | 1 |
| Mustafa, A | 1 |
| Hejleh, HAA | 1 |
| Ahmed, G | 1 |
| Dawoud, M | 1 |
| Al-Husseiny, M | 1 |
| Helal, O | 1 |
| Elsherbini, M | 1 |
| Abdel-Rasheed, M | 1 |
| Sediek, M | 1 |
| Chen, K | 2 |
| Gao, Q | 1 |
| Masood, U | 1 |
| Zeng, Z | 1 |
| Song, Y | 4 |
| Yu, H | 2 |
| Jin, H | 1 |
| Zhao, L | 2 |
| Yu, Z | 4 |
| Guo, JJ | 1 |
| Bao, W | 1 |
| Zhou, J | 1 |
| Chu, M | 2 |
| Setliff, J | 1 |
| Dalton, J | 1 |
| Sadhwani, S | 1 |
| Tang, MY | 1 |
| Mirvish, A | 1 |
| Adida, S | 1 |
| Wawrose, R | 1 |
| Fourman, MS | 1 |
| Shaw, JD | 1 |
| Izima, C | 1 |
| Sampath, SG | 1 |
| Tang, AJ | 1 |
| Ambati, VS | 1 |
| Chou, D | 1 |
| Chan, AK | 1 |
| Dong, H | 1 |
| Ye, C | 1 |
| Zou, Z | 1 |
| Wan, W | 1 |
| Nejat, MH | 1 |
| Khayami, A | 1 |
| Daliri, M | 1 |
| Ebrahimzadeh, MH | 1 |
| Sadeghi, M | 1 |
| Moradi, A | 1 |
| Wiktor, Ł | 1 |
| Osadnik, B | 1 |
| Damps, M | 1 |
| Albouq, B | 1 |
| Ghazi, A | 1 |
| Khadawardi, K | 1 |
| Bukhari, IA | 1 |
| Alyousef, A | 1 |
| Abdulmalik, NA | 1 |
| Alblewi, H | 1 |
| Alsehaimi, SO | 1 |
| Albadawi, MI | 1 |
| Abuzaid, M | 1 |
| Alomar, O | 1 |
| Salem, H | 1 |
| Eisinger, EC | 1 |
| Forsythe, L | 1 |
| Joergensen, S | 1 |
| Murali, S | 1 |
| Cannon, JW | 1 |
| Reilly, PM | 1 |
| Kim, PK | 1 |
| Kaufman, EJ | 1 |
| Zhou, D | 2 |
| Sessler, DI | 1 |
| Sermet, M | 1 |
| Ozsoy, MS | 1 |
| Kwak, SG | 1 |
| Kwon, JB | 1 |
| Bae, JW | 1 |
| Bae, DJ | 1 |
| Kim, DK | 1 |
| Zhang, ZF | 1 |
| Guo, FJ | 1 |
| Lan, Y | 1 |
| Mei, Z | 1 |
| Tao, Q | 1 |
| Ji, X | 1 |
| Shi, L | 5 |
| Tian, F | 1 |
| Al-Dardery, NM | 1 |
| Abdelwahab, OA | 1 |
| Abouzid, M | 1 |
| Albakri, K | 1 |
| Elkhadragy, A | 1 |
| Katamesh, BE | 1 |
| Hamamreh, R | 1 |
| Mohd, AB | 1 |
| Abdelaziz, A | 1 |
| Khaity, A | 1 |
| Liang, B | 3 |
| Guo, Y | 1 |
| Park, JG | 1 |
| Han, SB | 1 |
| Park, JH | 2 |
| Moon, SJ | 1 |
| Jang, WY | 1 |
| Chen, S | 3 |
| Luo, F | 1 |
| Yu, G | 1 |
| Luo, J | 1 |
| Beynon, C | 1 |
| Olivares, A | 1 |
| Gumbinger, C | 1 |
| Younsi, A | 1 |
| Zweckberger, K | 1 |
| Unterberg, AW | 1 |
| Zhao, M | 1 |
| Geng, X | 1 |
| Wang, C | 6 |
| Zeng, L | 2 |
| Tian, H | 1 |
| Cui, D | 2 |
| Zhou, XD | 2 |
| Jiang, LF | 1 |
| Zhang, JJ | 1 |
| Wu, LD | 3 |
| Xu, NW | 1 |
| Hariharan, D | 1 |
| Mammi, M | 1 |
| Daniels, K | 1 |
| Lamba, N | 1 |
| Petrucci, K | 1 |
| Cerecedo-Lopez, CD | 1 |
| Doucette, J | 1 |
| Hulsbergen, AFC | 1 |
| Papatheodorou, S | 1 |
| Aglio, LS | 1 |
| Smith, TR | 1 |
| Mekary, RA | 1 |
| Zaidi, H | 1 |
| Xin, WQ | 1 |
| Gao, YL | 1 |
| Yang, XY | 1 |
| Lin, H | 2 |
| Xu, P | 2 |
| Lei, Z | 1 |
| Taam, J | 1 |
| Yang, QJ | 1 |
| Pang, KS | 1 |
| Karanicolas, P | 1 |
| Choi, S | 1 |
| Wasowicz, M | 3 |
| Jerath, A | 3 |
| Yao, RZ | 1 |
| Gao, WQ | 1 |
| Wang, BW | 1 |
| Wang, GL | 1 |
| Wu, CX | 1 |
| A-Mu, YD | 1 |
| Yin, C | 1 |
| Er, Z | 1 |
| Hood, M | 2 |
| Dilley, JE | 1 |
| Ziemba-Davis, M | 4 |
| Meneghini, RM | 5 |
| Bai, J | 2 |
| Zhang, P | 5 |
| Liang, Y | 6 |
| Zhao, X | 3 |
| Yang, Z | 3 |
| King, L | 1 |
| Randle, R | 1 |
| Dare, W | 1 |
| Bernaitis, N | 1 |
| Bradley, KE | 1 |
| Ryan, SP | 2 |
| Penrose, CT | 1 |
| Grant, SA | 1 |
| Wellman, SS | 3 |
| Attarian, DE | 2 |
| Green, CL | 5 |
| Risoli, T | 1 |
| Bolognesi, MP | 4 |
| Huang, ZY | 1 |
| Zeng, HJ | 1 |
| Zhou, ZK | 10 |
| Pei, FX | 12 |
| Salomon, O | 2 |
| Budnik, I | 1 |
| Avishai, E | 1 |
| Tamarin, I | 2 |
| Bashari, D | 1 |
| Dardik, R | 1 |
| Livnat, T | 2 |
| Couto, RA | 1 |
| Charafeddine, A | 1 |
| Nayak, LM | 2 |
| Pathan, S | 1 |
| Cruz, JE | 1 |
| Curtin, P | 1 |
| Lonner, BS | 4 |
| Ren, Y | 2 |
| Asghar, J | 1 |
| Shah, SA | 3 |
| Samdani, AF | 1 |
| Newton, PO | 3 |
| White, LJ | 1 |
| Osagiede, O | 1 |
| Robards, CB | 1 |
| Gerstein, NS | 2 |
| Cushnyr, BW | 1 |
| Petersen, TR | 1 |
| Siegel, D | 1 |
| Alaifan, T | 1 |
| Alenazy, A | 1 |
| Xiang Wang, D | 1 |
| Fernando, SM | 1 |
| Fox-Robichaud, A | 1 |
| Ainswoth, C | 1 |
| Karachi, T | 1 |
| Kyeremanteng, K | 1 |
| Zarychanski, R | 5 |
| Whitlock, R | 1 |
| Pan, DQ | 1 |
| Chen, LL | 1 |
| Sun, B | 1 |
| Ge, JB | 1 |
| Miao, MF | 1 |
| Dong, Z | 1 |
| Han, L | 1 |
| Qi, J | 2 |
| Lostak, J | 5 |
| Gallo, J | 5 |
| Slavik, L | 1 |
| Zapletalova, J | 3 |
| Balaz, L | 3 |
| Qiu, J | 1 |
| Ke, X | 1 |
| Yang, G | 2 |
| Abdul, IF | 1 |
| Amadu, MB | 1 |
| Adesina, KT | 1 |
| Olarinoye, AO | 1 |
| Omokanye, LO | 1 |
| Monaco, F | 1 |
| Nardelli, P | 1 |
| Pasin, L | 1 |
| Barucco, G | 1 |
| Mattioli, C | 1 |
| Di Tomasso, N | 1 |
| Dalessandro, G | 1 |
| Giardina, G | 1 |
| Chiesa, R | 1 |
| Zangrillo, A | 2 |
| Barzilai, M | 1 |
| Kirgner, I | 1 |
| Steimatzky, A | 1 |
| Salzer Gotler, D | 1 |
| Belnick, Y | 1 |
| Shacham-Abulafia, A | 1 |
| Avivi, I | 1 |
| Raanani, P | 1 |
| Yahalom, V | 1 |
| Nakav, S | 1 |
| Varon, D | 1 |
| Yussim, E | 1 |
| Bachar, GN | 1 |
| Spectre, G | 1 |
| Visagie, M | 1 |
| Qin, CX | 1 |
| Cho, BC | 1 |
| Merkel, KR | 1 |
| Kajstura, TJ | 1 |
| Amin, RM | 1 |
| Purvis, TE | 1 |
| Kebaish, KM | 1 |
| Frank, SM | 3 |
| Wang, HY | 8 |
| Luo, ZY | 6 |
| Mukherjee, S | 1 |
| Maiti, R | 1 |
| Nayak, C | 1 |
| Samal, BP | 1 |
| Rao, B | 1 |
| Panda, A | 1 |
| Richards, JE | 1 |
| Samet, RE | 1 |
| Koerner, AK | 1 |
| Grissom, TE | 1 |
| Jia, J | 1 |
| Siegel, MG | 1 |
| Ackerman, RS | 1 |
| Hirschi, M | 1 |
| Trona, N | 1 |
| Joyce, DM | 1 |
| Evans, T | 2 |
| Patel, SY | 1 |
| Das, A | 1 |
| Mitra, S | 1 |
| Ghosh, D | 1 |
| Sengupta, A | 1 |
| Yazdi, H | 1 |
| Klement, MR | 2 |
| Hammad, M | 1 |
| Inoue, D | 1 |
| Xu, C | 4 |
| Goswami, K | 1 |
| Parvizi, J | 4 |
| Xu, Y | 1 |
| Sun, S | 1 |
| Feng, Q | 1 |
| Zhang, G | 2 |
| Dong, B | 1 |
| Guo, M | 1 |
| Cai, J | 1 |
| Ribkoff, J | 1 |
| Olson, S | 1 |
| Raghunathan, V | 1 |
| Al-Samkari, H | 1 |
| DeLoughery, TG | 1 |
| Shatzel, JJ | 1 |
| Charette, RS | 1 |
| Bernstein, JA | 1 |
| Sloan, M | 1 |
| Nchako, CM | 1 |
| Kamath, AF | 1 |
| Nelson, CL | 1 |
| Bosch, P | 1 |
| Kenkre, TS | 1 |
| Soliman, D | 1 |
| Londino, JA | 1 |
| Novak, NE | 1 |
| Thakur, A | 1 |
| Gupta, S | 1 |
| Thakur, JS | 1 |
| Minhas, RS | 1 |
| Azad, RK | 1 |
| Vasanthalakshmi, MS | 1 |
| Sharma, DR | 1 |
| Mohindroo, NK | 1 |
| Chambers, S | 1 |
| Tidwell, L | 1 |
| Kerkhof, A | 1 |
| Smith, R | 1 |
| Mihalko, WM | 2 |
| Mousavinejad, M | 1 |
| Mozafari, J | 1 |
| Ilkhchi, RB | 1 |
| Hanafi, MG | 1 |
| Ebrahimi, P | 1 |
| Meng, B | 1 |
| Du, C | 1 |
| Taunton, MJ | 2 |
| Jia, Y | 3 |
| Wang, R | 1 |
| Zhao, Y | 2 |
| Hua, Z | 2 |
| Yan, J | 2 |
| Yan, F | 2 |
| Helito, CP | 1 |
| Bonadio, MB | 1 |
| Sobrado, MF | 1 |
| Giglio, PN | 1 |
| Pécora, JR | 1 |
| Camanho, GL | 1 |
| Demange, MK | 1 |
| Grecula, MJ | 1 |
| Kimura, OS | 1 |
| Freitas, EH | 1 |
| Duarte, ME | 1 |
| Cavalcanti, AS | 1 |
| Fernandes, MB | 1 |
| Xu, X | 3 |
| Jiang, J | 2 |
| Li, X | 1 |
| Eikebrokk, TA | 1 |
| Vassmyr, BS | 1 |
| Hu, M | 1 |
| Liu, ZB | 1 |
| Bi, G | 1 |
| Fishman, J | 1 |
| Hussain, M | 1 |
| Fisher, E | 1 |
| Zakhari, A | 1 |
| Sanders, AP | 1 |
| Solnik, MJ | 1 |
| Lei, YT | 1 |
| Xie, JW | 1 |
| Yeersheng, R | 2 |
| Li, DH | 2 |
| Yang, ZY | 1 |
| Wu, KT | 1 |
| Siu, KK | 1 |
| Ko, JY | 1 |
| Chou, WY | 1 |
| Kuo, SJ | 1 |
| Hsu, YH | 1 |
| Yu, X | 4 |
| Xie, L | 2 |
| Zheng, W | 1 |
| Georgiadis, AG | 2 |
| Muh, SJ | 2 |
| Silverton, CD | 4 |
| Weir, RM | 4 |
| Laker, MW | 4 |
| Xing, F | 1 |
| Long, C | 1 |
| Huang, F | 2 |
| Xiang, Z | 3 |
| Fatima, N | 1 |
| Barra, ME | 1 |
| Roberts, RJ | 1 |
| Massaad, E | 1 |
| Hadzipasic, M | 1 |
| Shankar, GM | 1 |
| Shin, JH | 1 |
| Chen, SH | 1 |
| Chen, JY | 5 |
| Wong, TH | 1 |
| Buechel, F | 1 |
| Wu, MH | 1 |
| Ye, W | 2 |
| Liu, WF | 2 |
| Li, XL | 2 |
| Fei, Y | 1 |
| Gao, X | 2 |
| Yang, Y | 7 |
| Jin, Q | 2 |
| Clarius, M | 1 |
| Clarius, LM | 1 |
| Houston, BL | 3 |
| Uminski, K | 1 |
| Mutter, T | 1 |
| Rimmer, E | 3 |
| Houston, DS | 3 |
| Menard, CE | 1 |
| Garland, A | 3 |
| Ariano, R | 2 |
| Tinmouth, A | 8 |
| Abou-Setta, AM | 1 |
| Rabbani, R | 1 |
| Neilson, C | 1 |
| Turgeon, AF | 3 |
| Falk, J | 3 |
| Breau, RH | 7 |
| Fergusson, DA | 9 |
| Zhou, A | 1 |
| Meshram, P | 2 |
| Palanisamy, JV | 2 |
| Seo, JY | 2 |
| Lee, JG | 2 |
| Kim, TK | 3 |
| Ongun, EA | 1 |
| Dursun, O | 1 |
| Kazan, MS | 1 |
| Lins, LAB | 1 |
| Miller, PE | 1 |
| Samineni, A | 1 |
| Watkins, CJ | 1 |
| Matheney, TH | 1 |
| Snyder, BD | 1 |
| Shore, BJ | 1 |
| Qin, JZ | 1 |
| Wang, SJ | 1 |
| Zheng, XP | 1 |
| Zhao, HH | 1 |
| Xia, C | 1 |
| Tsukada, S | 2 |
| Kurosaka, K | 1 |
| Nishino, M | 1 |
| Maeda, T | 2 |
| Hirasawa, N | 1 |
| Matsue, Y | 1 |
| Wu, XD | 2 |
| Wu, D | 2 |
| Das, S | 3 |
| Sun, H | 3 |
| Pan, W | 1 |
| Wurtz, JW | 2 |
| Wurtz, LD | 2 |
| Deckard, ER | 2 |
| Bloom, B | 1 |
| Nan, L | 1 |
| Feng, X | 2 |
| Tao, Y | 1 |
| Cheng, X | 1 |
| Vles, GF | 1 |
| Corten, K | 1 |
| Driesen, R | 1 |
| van Elst, C | 1 |
| Ghijselings, SG | 1 |
| van der Merwe, JM | 1 |
| Mastel, MS | 1 |
| Tandogan, RN | 1 |
| Polat, M | 2 |
| Beyzadeoglu, T | 1 |
| Karabulut, E | 1 |
| Yildirim, K | 1 |
| Kayaalp, A | 1 |
| Cohen, JC | 1 |
| Glasgold, RA | 1 |
| Alloju, LM | 1 |
| Glasgold, MJ | 1 |
| Luo, X | 1 |
| Huang, H | 3 |
| Xu, D | 8 |
| Zhuang, Q | 6 |
| Morales Santias, M | 2 |
| Mas Martinez, J | 2 |
| Sanz-Reig, J | 2 |
| Martínez Gimenez, E | 2 |
| Verdu Román, C | 2 |
| Bustamante Suarez de Puga, D | 2 |
| Drain, NP | 1 |
| Gobao, VC | 1 |
| Bertolini, DM | 1 |
| Smith, C | 1 |
| Shah, NB | 1 |
| Rothenberger, SD | 1 |
| Dombrowski, ME | 1 |
| O'Malley, MJ | 1 |
| Klatt, BA | 1 |
| Hamlin, BR | 2 |
| Urish, KL | 1 |
| Xiong, Z | 2 |
| Yi, P | 2 |
| Tan, M | 2 |
| Sidelmann, JJ | 2 |
| Gram, JB | 1 |
| Godtfredsen, ACM | 1 |
| Thorn, JJ | 3 |
| Ingerslev, J | 3 |
| Pinholt, EM | 3 |
| Heyns, M | 1 |
| Knight, P | 1 |
| Steve, AK | 1 |
| Yeung, JK | 1 |
| Opoku-Anane, J | 1 |
| Vargas, MV | 1 |
| Marfori, CQ | 2 |
| Moawad, G | 1 |
| Maasen, MS | 1 |
| Robinson, JK | 1 |
| Tzatzairis, T | 1 |
| McMahon, S | 1 |
| Shilpa, J | 1 |
| Maizen, C | 1 |
| Çevik, HB | 2 |
| Eceviz, E | 1 |
| Çilingir Kaya, ÖT | 1 |
| Ercan, F | 1 |
| Çeçen, GS | 1 |
| Teoh, WY | 1 |
| Tan, TG | 1 |
| Ong, KX | 1 |
| Chan, XL | 1 |
| Hung Tsan, SE | 1 |
| Ma, H | 1 |
| Yao, H | 2 |
| Zhang, T | 1 |
| Wan, C | 1 |
| Bukhari, SS | 1 |
| Shamim, MS | 1 |
| Shao, K | 1 |
| Hurley, ET | 2 |
| Lim Fat, D | 1 |
| Pauzenberger, L | 3 |
| Mullett, H | 1 |
| Ince, ME | 1 |
| Ozkan, G | 1 |
| Ors, N | 1 |
| Yildirim, V | 1 |
| Franchini, M | 4 |
| Mannucci, PM | 4 |
| Locke, M | 1 |
| Longstaff, C | 1 |
| Myers, SP | 1 |
| Neal, MD | 1 |
| Balogh, ZJ | 1 |
| King, KL | 1 |
| Zhu, X | 2 |
| Shi, Q | 1 |
| Li, D | 2 |
| Guo, K | 3 |
| Zheng, X | 1 |
| Gómez-Aparicio, MDS | 1 |
| Gómez-Barbero, P | 1 |
| Blas-Dobón, JA | 1 |
| Villar-Blanco, A | 1 |
| Morales-Suárez-Varela, M | 1 |
| Rodrigo-Pérez, JL | 1 |
| Şahin, İG | 1 |
| Otuzbir, A | 1 |
| Özkan, Y | 1 |
| Palija, S | 1 |
| Bijeljac, S | 1 |
| Manojlovic, S | 1 |
| Jovicic, Z | 1 |
| Jovanovic, M | 1 |
| Cvijic, P | 1 |
| Dragicevic-Cvjetkovic, D | 1 |
| Kirksey, MA | 1 |
| Wilson, LA | 2 |
| Fiasconaro, M | 1 |
| Poeran, J | 4 |
| Rush, AJ | 1 |
| Goldstein, JP | 1 |
| Sheu, JI | 1 |
| Hernandez-Irizarry, RC | 1 |
| Quinnan, SM | 1 |
| Escher, PJ | 2 |
| Tu, AD | 1 |
| Kearney, SL | 1 |
| Linabery, AM | 1 |
| Petronio, JA | 1 |
| Kebriaei, MA | 1 |
| Chinnadurai, S | 2 |
| Tibesar, RJ | 2 |
| He, F | 2 |
| Cai, P | 1 |
| Luo, K | 1 |
| Ding, J | 1 |
| Yoon, JY | 1 |
| Kim, YS | 1 |
| Shin, SJ | 1 |
| Yoo, JC | 2 |
| Oh, JH | 1 |
| Morse, KW | 1 |
| Heinz, NK | 1 |
| Abolade, JM | 1 |
| Wright-Chisem, JI | 1 |
| Mirza, SZ | 1 |
| Orange, DE | 1 |
| Figgie, MP | 2 |
| Goodman, SM | 1 |
| Abdallah, AA | 1 |
| Sallam, AA | 1 |
| Arafa, MS | 1 |
| Henawy, AT | 1 |
| Ma, QM | 1 |
| Han, GS | 1 |
| Li, BW | 1 |
| Li, XJ | 1 |
| Jiang, T | 1 |
| Vestermark, GL | 2 |
| Rowe, TM | 2 |
| Martin, JR | 2 |
| Odum, SM | 2 |
| Springer, BD | 2 |
| Fehring, TK | 2 |
| Zalba Marcos, S | 1 |
| Plaja Martí, I | 1 |
| Antelo Caamaño, ML | 1 |
| Martínez de Morentin Garraza, J | 1 |
| Abinzano Guillén, ML | 1 |
| Martín Rodríguez, E | 1 |
| Aranguren Azparren, A | 1 |
| Torres López, A | 1 |
| Galbete Jiménez, A | 1 |
| García Erce, JA | 1 |
| Jeong, JH | 1 |
| Chang, MJ | 1 |
| Kang, SB | 1 |
| Park, HJ | 1 |
| Lee, KH | 1 |
| Chang, CB | 2 |
| Sharma, H | 1 |
| Arora, S | 1 |
| Bhatia, N | 1 |
| Rattan, V | 1 |
| Sethi, S | 1 |
| Lloyd, TD | 1 |
| Neal-Smith, G | 1 |
| Fennelly, J | 1 |
| Claireaux, H | 1 |
| Bretherton, C | 1 |
| Carr, AJ | 1 |
| Kendrick, BJ | 1 |
| Palmer, AJR | 1 |
| Song, F | 1 |
| de Faria, JL | 1 |
| da Silva Brito, J | 1 |
| Costa E Silva, LT | 1 |
| Kilesse, CTSM | 1 |
| de Souza, NB | 1 |
| Pereira, CU | 1 |
| Figueiredo, EG | 1 |
| Rabelo, NN | 1 |
| Aggarwal, AK | 2 |
| Jindal, K | 1 |
| Feng, D | 2 |
| Zhang, F | 3 |
| Han, P | 1 |
| Wei, W | 3 |
| Belay, ES | 1 |
| O'Donnell, J | 1 |
| Flamant, E | 1 |
| Hinton, Z | 1 |
| Klifto, CS | 1 |
| Anakwenze, O | 1 |
| Meara, JG | 2 |
| Proctor, MR | 2 |
| Tumolo, M | 1 |
| Cangemi, G | 1 |
| Disma, N | 1 |
| Jaffer, AA | 2 |
| Davis, LE | 1 |
| Behman, R | 1 |
| Hanna, SS | 1 |
| Law, CH | 2 |
| Coburn, NG | 2 |
| Lemke, M | 1 |
| Beyfuss, KA | 1 |
| Hallet, J | 3 |
| Kochuba, AL | 1 |
| Steinmetz, RG | 1 |
| Luick, L | 1 |
| Tkach, S | 1 |
| Falcon, S | 1 |
| Stoner, J | 1 |
| Hollabaugh, K | 1 |
| Ringus, V | 1 |
| Haleem, AM | 1 |
| Deng, Z | 3 |
| Sheng, P | 2 |
| He, A | 2 |
| Liao, W | 2 |
| Kang, Y | 4 |
| Liu, D | 2 |
| Xiao, X | 1 |
| Guan, T | 1 |
| Yue, H | 1 |
| Jiao, G | 1 |
| Wu, W | 1 |
| Liu, H | 2 |
| Meng, C | 1 |
| Sun, Z | 3 |
| Cuff, DJ | 1 |
| Simon, P | 1 |
| Gorman, RA | 1 |
| Ni, J | 2 |
| Dang, X | 1 |
| Shi, Z | 2 |
| Wright, GP | 1 |
| Wolf, AM | 1 |
| Waldherr, TL | 1 |
| Ritz-Holland, D | 1 |
| Laney, ED | 1 |
| Chapman, HA | 1 |
| Lane, BR | 1 |
| Assifi, MM | 1 |
| Chung, MH | 1 |
| Grzelecki, D | 1 |
| Dudek, P | 1 |
| Okoń, T | 1 |
| Marczak, D | 1 |
| Kordasiewicz, B | 1 |
| Sibiński, M | 1 |
| Kowalczewski, J | 1 |
| Ashkenazi, I | 3 |
| Schermann, H | 2 |
| Gold, A | 2 |
| Lin, R | 1 |
| Pardo, I | 1 |
| Steinberg, E | 1 |
| Sternheim, A | 1 |
| Snir, N | 3 |
| Carbone, A | 1 |
| Zubizarreta, N | 2 |
| Chan, J | 1 |
| Mazumdar, M | 3 |
| Parsons, BO | 1 |
| Galatz, LM | 2 |
| Cagle, PJ | 2 |
| Bai, T | 1 |
| Kang, BX | 3 |
| Gao, CX | 3 |
| Zhong, S | 3 |
| Sun, ST | 3 |
| Ma, YH | 3 |
| Zhai, WT | 3 |
| Xiao, LB | 3 |
| Golz, AG | 1 |
| Yee, HK | 1 |
| Davis, BJ | 1 |
| Adams, WH | 1 |
| Brown, NM | 1 |
| Kinsey, KE | 1 |
| Ganz, E | 1 |
| Khalil, S | 1 |
| Brustman, L | 1 |
| Ma, D | 2 |
| Wen, L | 2 |
| Pan, J | 2 |
| Yuan, MC | 1 |
| Xia, P | 1 |
| Zou, X | 1 |
| Wu, C | 2 |
| Tan, C | 1 |
| Levack, AE | 1 |
| McLawhorn, AS | 1 |
| Dodwell, E | 1 |
| Nguyen, J | 1 |
| Sink, E | 1 |
| Park, JY | 1 |
| Lee, DY | 1 |
| Ro, DH | 1 |
| Han, HS | 1 |
| Lee, MC | 1 |
| Weissmann, KA | 1 |
| Lafage, V | 4 |
| Barrios Pitaque, C | 1 |
| Lafage, R | 1 |
| Descazeaux, FM | 1 |
| Tan, JC | 1 |
| Yapa, S | 1 |
| Lockwood, C | 1 |
| Deng, ZF | 1 |
| Zhang, ZJ | 1 |
| Sheng, PY | 1 |
| Xu, DL | 1 |
| He, AS | 1 |
| Liao, WM | 1 |
| Fenger-Eriksen, C | 3 |
| Rasmussen, M | 2 |
| Juul, N | 2 |
| Mei, L | 1 |
| Zhu, W | 1 |
| Mao, X | 1 |
| Yang, L | 5 |
| Jia, X | 1 |
| Kang, J | 1 |
| Balkanlı, B | 1 |
| Çopuroğlu, C | 1 |
| Çopuroğlu, E | 1 |
| Levent, A | 2 |
| Köse, Ö | 2 |
| Linke, P | 2 |
| Gehrke, T | 3 |
| Çıtak, M | 3 |
| Turan, S | 1 |
| Bingöl, O | 1 |
| Kuint, R | 1 |
| Levy, L | 1 |
| Cohen Goichman, P | 1 |
| Huszti, E | 1 |
| Abu Rmeileh, A | 1 |
| Shriki, O | 1 |
| Abutbul, A | 1 |
| Fridlender, ZG | 1 |
| Berkman, N | 1 |
| Shao, J | 1 |
| Khiabani, K | 1 |
| Ahmadfar, M | 1 |
| Labafchi, A | 1 |
| Gosheh, MR | 1 |
| Samieirad, S | 1 |
| Gurel, R | 1 |
| Chechik, O | 1 |
| Warschawski, Y | 2 |
| Schwarzkopf, R | 7 |
| Shang, JJ | 1 |
| Zhang, ZD | 1 |
| Luo, DZ | 1 |
| Cheng, H | 1 |
| Wang, LN | 1 |
| Liu, LM | 1 |
| Xiu, P | 1 |
| Zhou, ZJ | 1 |
| Song, YM | 1 |
| Hamed, RA | 1 |
| Hamed, EM | 1 |
| Torky, H | 1 |
| El-Desouky, ES | 1 |
| Abo-Elmagd, I | 1 |
| Abdalhamid, A | 1 |
| El-Shahat, A | 1 |
| Ahmed Sileem, S | 1 |
| Tawfick, MM | 1 |
| Abo-Louz, A | 1 |
| Hussein, A | 1 |
| Jae Ho Lee, J | 1 |
| Da Jung Nam, D | 1 |
| Hyunkyung Cho, H | 1 |
| Shichman, I | 1 |
| Shaked, O | 1 |
| Hong, GJ | 1 |
| Danforth, RM | 1 |
| Cook, JA | 1 |
| Bennett, WE | 1 |
| Tholpady, SS | 1 |
| Gerety, PA | 1 |
| Mills, ES | 1 |
| Ellman, MB | 1 |
| Foran, JRH | 1 |
| Sershon, RA | 2 |
| Malkani, AL | 6 |
| Padgett, DE | 2 |
| Vail, TP | 1 |
| Nam, D | 2 |
| Nahhas, C | 1 |
| Culvern, C | 2 |
| Della Valle, CJ | 7 |
| Scrimshire, AB | 2 |
| Fairhurst, C | 2 |
| McDaid, C | 2 |
| Torgerson, DJ | 2 |
| An, S | 1 |
| Feng, M | 1 |
| Gao, G | 1 |
| Jiao, X | 1 |
| Ding, L | 1 |
| Song, L | 1 |
| Lang, B | 1 |
| Zhao, G | 1 |
| Mishu, M | 1 |
| Cushner, FD | 2 |
| Fu, J | 1 |
| Guan, H | 1 |
| Ni, M | 1 |
| Chai, W | 1 |
| Hao, L | 1 |
| Naeiji, Z | 1 |
| Delshadiyan, N | 1 |
| Saleh, S | 1 |
| Moridi, A | 1 |
| Rahmati, N | 1 |
| Fathi, M | 1 |
| Gilde, AK | 1 |
| Downes, KL | 1 |
| Leverett, S | 1 |
| Miranda, MA | 1 |
| Liu, R | 2 |
| Rai, S | 1 |
| Ze, R | 1 |
| Hong, P | 1 |
| Qian, XJ | 1 |
| Dong, YP | 1 |
| Ji, WF | 1 |
| Wu, XF | 1 |
| Yin, ZF | 1 |
| Sun, BF | 1 |
| Dong, F | 1 |
| Qian, PK | 1 |
| Zhang, JB | 1 |
| Xu, F | 1 |
| Bartlett, E | 1 |
| Urman, RD | 1 |
| Urits, I | 1 |
| Kaye, AD | 1 |
| Viswanath, O | 1 |
| Li, YL | 1 |
| Xu, XR | 2 |
| Hu, XX | 1 |
| Zufferey, PJ | 4 |
| Lanoiselée, J | 3 |
| Graouch, B | 1 |
| Vieille, B | 1 |
| Delavenne, X | 3 |
| Ollier, E | 2 |
| Yuan, M | 1 |
| Ding, Z | 2 |
| Touzopoulos, P | 1 |
| Arvanitidis, K | 1 |
| Filidou, E | 1 |
| Tilkeridis, K | 1 |
| Karanikas, M | 1 |
| Kolios, G | 1 |
| Ververidis, A | 1 |
| Miller, TM | 1 |
| Hagar, A | 1 |
| Anderson, M | 1 |
| Gad, B | 1 |
| Talmo, CT | 2 |
| Stronach, BM | 1 |
| Jones, RE | 1 |
| Balík, M | 1 |
| Košina, J | 1 |
| Hušek, P | 1 |
| Broďák, M | 1 |
| Čečka, F | 1 |
| Owen, A | 1 |
| Wellings, EP | 1 |
| Wyles, CC | 1 |
| Yuan, BJ | 1 |
| Rose, PS | 1 |
| Houdek, MT | 2 |
| Montroy, J | 2 |
| Hutton, B | 3 |
| Lavallée, LT | 3 |
| Cagiannos, I | 4 |
| Morash, C | 4 |
| Flaman, A | 1 |
| Franz, ND | 1 |
| Machado-Aranda, D | 1 |
| Miller, JT | 1 |
| Farina, N | 1 |
| Asserson, DB | 1 |
| Sahar, DE | 1 |
| Molinar, VE | 1 |
| Johns, WL | 1 |
| Walley, KC | 1 |
| Jackson, B | 1 |
| Gonzalez, TA | 1 |
| Cunningham, G | 1 |
| Hughes, J | 1 |
| Borner, B | 1 |
| Mattern, O | 1 |
| Taha, ME | 1 |
| Smith, MM | 1 |
| Young, AA | 1 |
| Cass, B | 1 |
| Demirel, M | 1 |
| Büget, Mİ | 1 |
| Edipoğlu, İS | 2 |
| Atalar, AC | 1 |
| Erşen, A | 1 |
| Shrestha, IK | 1 |
| Ruan, TY | 1 |
| Na, XQ | 1 |
| Qu, QC | 1 |
| Chen, JC | 1 |
| Si, YY | 1 |
| Tao, JP | 1 |
| Lasocki, S | 1 |
| Loupec, T | 1 |
| Parot-Schinkel, E | 1 |
| Vielle, B | 1 |
| Danguy des Déserts, M | 2 |
| Roquilly, A | 1 |
| Lahlou-Casulli, M | 1 |
| Collange, V | 1 |
| Desebbe, O | 1 |
| Duchalais, A | 1 |
| Drugeon, B | 1 |
| Bouzat, P | 1 |
| Garrigue, D | 1 |
| Mounet, B | 1 |
| Hamard, F | 1 |
| David, JS | 1 |
| Leger, M | 1 |
| Rineau, E | 1 |
| Abdelaziz, H | 1 |
| Chaabene, A | 1 |
| Schulmeyer, J | 1 |
| Haasper, C | 1 |
| Hawi, N | 1 |
| Lu, F | 1 |
| Guo, W | 2 |
| De Falco, L | 1 |
| Troiano, E | 1 |
| Cesar, M | 1 |
| Aiuto, P | 1 |
| Peri, G | 1 |
| Nuvoli, N | 1 |
| Fortina, M | 1 |
| Mondanelli, N | 1 |
| Giannotti, S | 1 |
| Wu, K | 2 |
| Leng, D | 1 |
| Yen, SH | 3 |
| Lin, PC | 5 |
| Wu, CT | 1 |
| Wang, JW | 5 |
| Yi, Z | 1 |
| Yan, L | 1 |
| Haibo, S | 1 |
| Yuangang, W | 1 |
| Mingyang, L | 1 |
| Yuan, L | 3 |
| Bin, S | 1 |
| El-Ozairy, HSE | 1 |
| Mady, OM | 1 |
| Tawfik, GM | 1 |
| Elhennawy, AM | 1 |
| Teaima, AA | 1 |
| Ebied, A | 1 |
| Huy, NT | 1 |
| Kanthasamy, S | 1 |
| Guhan, B | 1 |
| Chakravarty, D | 1 |
| Parker, MJ | 1 |
| Ayan, NRS | 1 |
| Güler, BO | 1 |
| Othman, Y | 1 |
| Melebeck, F | 1 |
| Daubresse, F | 1 |
| Sussman, MS | 1 |
| Urrechaga, EM | 1 |
| Cioci, AC | 1 |
| Iyengar, RS | 1 |
| Herrington, TJ | 1 |
| Ryon, EL | 1 |
| Namias, N | 1 |
| Galbut, DL | 1 |
| Salerno, TA | 1 |
| Proctor, KG | 1 |
| Krupka, E | 2 |
| Blankstein, A | 1 |
| Perelman, I | 5 |
| McIsaac, DI | 2 |
| Balshaw, R | 2 |
| Jacobsohn, E | 2 |
| Bohm, E | 1 |
| Sah, AP | 5 |
| Xi, C | 1 |
| Pekrul, I | 1 |
| Schachtner, T | 1 |
| Zwißler, B | 1 |
| Möhnle, P | 1 |
| Pempe, C | 1 |
| Werdehausen, R | 1 |
| Pieroh, P | 1 |
| Federbusch, M | 1 |
| Petros, S | 1 |
| Henschler, R | 1 |
| Roth, A | 1 |
| Pfrepper, C | 1 |
| Batagello, CA | 1 |
| Vicentini, FC | 1 |
| Monga, M | 1 |
| Miller, AW | 1 |
| Marchini, GS | 1 |
| Torricelli, FCM | 1 |
| Danilovic, A | 1 |
| Coelho, RF | 1 |
| Srougi, M | 1 |
| Nahas, WC | 1 |
| Mazzucchi, E | 1 |
| Yang, K | 1 |
| He, J | 7 |
| Jin, Y | 1 |
| Ding, D | 1 |
| Gümüştaş, SA | 1 |
| Çelen, ZE | 1 |
| Onay, T | 1 |
| Abul, MS | 1 |
| Floros, T | 2 |
| Chronopoulos, E | 2 |
| Skertsou, M | 2 |
| Babis, GC | 3 |
| Gundtoft, PH | 1 |
| Schønnemann, JO | 1 |
| Pedersen, L | 1 |
| Andersen, LR | 1 |
| Titlestad, K | 1 |
| Madsen, CF | 1 |
| Clemmensen, SB | 1 |
| Halekoh, U | 1 |
| Lauritsen, J | 1 |
| Overgaard, S | 1 |
| Li, N | 1 |
| Qin, LW | 1 |
| Jiang, HJ | 1 |
| Chen, B | 3 |
| Shao, Y | 1 |
| Yin, H | 1 |
| Adams, JD | 1 |
| Marshall, WA | 1 |
| Kizilkurt, T | 1 |
| Bayram, S | 1 |
| Ayik, Ö | 1 |
| Ergin, ÖN | 1 |
| Öztürk, İ | 1 |
| Hunstad, J | 1 |
| Alsubaie, S | 1 |
| Deutsch, MA | 2 |
| von Dossow, V | 2 |
| Gummert, JF | 2 |
| Echanique, KA | 1 |
| Kerr, R | 1 |
| Kim, I | 1 |
| Keller, G | 1 |
| Nabili, V | 1 |
| Halpern, LM | 1 |
| Bronson, WE | 1 |
| Kogan, CJ | 1 |
| Chu, P | 1 |
| Xue, Q | 2 |
| Masrouha, KZ | 1 |
| Shabin, ZM | 1 |
| Bhutada, K | 1 |
| Sala, DA | 1 |
| Godfried, DH | 1 |
| Karamitopoulos, MS | 1 |
| George, S | 1 |
| Ramchandran, S | 1 |
| Mihas, A | 1 |
| George, K | 1 |
| Mansour, A | 1 |
| Errico, T | 3 |
| Hasan, MS | 1 |
| Yunus, SN | 1 |
| Ng, CC | 1 |
| Chan, CYW | 1 |
| Chiu, CK | 1 |
| Kwan, MK | 1 |
| Wadhwa, H | 1 |
| Tigchelaar, SS | 1 |
| Chen, MJ | 1 |
| Koltsov, JCB | 1 |
| Bellino, MJ | 1 |
| Bishop, JA | 1 |
| Gardner, MJ | 1 |
| Yuan, C | 1 |
| Jia, HD | 1 |
| Tong, XM | 1 |
| Liu, JW | 1 |
| Leow, L | 1 |
| Ng, J | 1 |
| Luo, HD | 1 |
| Choong, AMTL | 1 |
| Mithiran, H | 1 |
| Kofidis, T | 1 |
| Tam, JKC | 1 |
| Ariano, RE | 1 |
| Shi, P | 1 |
| Cai, T | 1 |
| Chen, D | 1 |
| Gao, XJ | 1 |
| Cui, H | 1 |
| Yu, S | 1 |
| Ruan, J | 1 |
| Fan, C | 1 |
| Zak, SG | 1 |
| Tang, A | 1 |
| Sharan, M | 1 |
| Waren, D | 1 |
| Rozell, JC | 1 |
| Wong, J | 5 |
| George, RB | 1 |
| Hanley, CM | 1 |
| Saliba, C | 1 |
| Yee, DA | 1 |
| Wang, N | 2 |
| Gong, D | 1 |
| Bonfield, CM | 1 |
| Deenadayalan, PS | 1 |
| Le, CH | 1 |
| Xu, M | 2 |
| Sobey, JH | 1 |
| Reddy, SK | 2 |
| Shi, H | 2 |
| Zhou, ZM | 1 |
| Xu, ZY | 1 |
| Zhu, L | 1 |
| Jiang, ZL | 1 |
| Chen, L | 3 |
| Wu, XT | 1 |
| Colquhoun, DA | 1 |
| Hallstrom, BR | 1 |
| Kheterpal, S | 1 |
| Allen, G | 1 |
| McClatchy, SG | 1 |
| Cline, JT | 1 |
| Rider, CM | 1 |
| Pharr, ZK | 1 |
| Toy, PC | 1 |
| Bemelmans, Y | 1 |
| Van Haaren, E | 1 |
| Boonen, B | 1 |
| Hendrickx, R | 1 |
| Schotanus, M | 1 |
| Zhou, P | 1 |
| Do, HT | 1 |
| Krell, EC | 1 |
| Valle, AGD | 1 |
| Hui, S | 3 |
| Tao, L | 2 |
| Du, Y | 2 |
| Hovgesen, NT | 1 |
| Larsen, JB | 1 |
| Hansen, AK | 1 |
| AlSumadi, M | 1 |
| Mahmood, A | 2 |
| Whittam, D | 1 |
| Kharma, L | 1 |
| Ashour, R | 1 |
| Banim, R | 1 |
| Yu, CC | 3 |
| Fidai, M | 1 |
| Washington, T | 1 |
| Bartol, S | 2 |
| Graziano, G | 2 |
| Pereira, EG | 1 |
| Carvalho, MM | 1 |
| Oliveira, T | 1 |
| Sacramento, T | 1 |
| Cruz, H | 1 |
| Viegas, R | 1 |
| Fontes, AP | 1 |
| Marreiros, A | 1 |
| Sousa, JP | 1 |
| Sofulu, O | 1 |
| Ozturk, O | 1 |
| Buyuktopcu, O | 1 |
| Kesimer, MD | 1 |
| Erol, B | 1 |
| Fathimani, K | 1 |
| Perenack, J | 1 |
| Christensen, BJ | 1 |
| González Osuna, A | 1 |
| Rojas, LF | 1 |
| Lamas, C | 1 |
| Aguilera Roig, X | 1 |
| Pla-Junca, F | 1 |
| Videla, S | 2 |
| Martínez-Zapata, MJ | 3 |
| Valle, M | 1 |
| Guo, T | 1 |
| Xuan, W | 1 |
| Feng, H | 1 |
| Hazrati, E | 1 |
| Haki, BK | 1 |
| Masnour-Ghanaei, A | 1 |
| Soleimanlo, A | 1 |
| Rafiei, M | 1 |
| Perskin, CR | 1 |
| Littlefield, CP | 1 |
| Umeh, U | 1 |
| Egol, KA | 1 |
| Tumber, S | 1 |
| Bacon, A | 1 |
| Stondell, C | 1 |
| Tafoya, S | 1 |
| Taylor, SL | 1 |
| Javidan, Y | 1 |
| Klineberg, E | 1 |
| Roberto, R | 1 |
| Mokhtari, MR | 1 |
| Farshid, S | 1 |
| Modresi, P | 1 |
| Abedi, F | 1 |
| Chen, Q | 1 |
| Zhou, Q | 1 |
| Feng, J | 1 |
| Wei, P | 1 |
| Lin, JA | 1 |
| Cui, HD | 1 |
| Hong, Y | 1 |
| Lyu, SJ | 1 |
| B H, PP | 1 |
| Diskina, D | 1 |
| Lin, HM | 1 |
| Vulcano, E | 1 |
| Lai, YH | 1 |
| Al Sheikh, K | 1 |
| AlHandi, A | 1 |
| Bin Dohaim, A | 1 |
| Ateeq, K | 1 |
| AlAqeely, K | 1 |
| Rodríguez-García, FA | 1 |
| Sánchez-Peña, MA | 1 |
| de Andrea, GT | 1 |
| Villarreal-Salgado, JL | 1 |
| Álvarez-Trejo, HJ | 1 |
| Medina-Quintana, VM | 1 |
| García-Valenzuela, SE | 1 |
| Morfin-Meza, KE | 1 |
| Fierro-Rodríguez, DA | 1 |
| Dorado-Hernández, E | 1 |
| Bonilla-Catalán, PV | 1 |
| Ramos-Maciel, J | 1 |
| Romero-Algara, E | 1 |
| Jiménez-Pavón, KE | 1 |
| Torres-Salazar, QL | 1 |
| Dong, Y | 2 |
| Tong, B | 1 |
| Zhao, H | 5 |
| Kim, KI | 3 |
| Bae, JK | 1 |
| Kim, JH | 2 |
| Gwak, HG | 1 |
| Lee, SH | 2 |
| Witmer, D | 1 |
| Solomito, MJ | 1 |
| Kumar, M | 1 |
| Shearier, E | 1 |
| Davis, S | 1 |
| Costain, D | 1 |
| Elder, G | 1 |
| Fraser, B | 1 |
| Slagel, B | 1 |
| Kelly, A | 1 |
| Cheong, Y | 1 |
| Fera, L | 1 |
| Burbul, M | 1 |
| Tomaszewski, D | 1 |
| Rogalska, A | 1 |
| Gawroński, K | 1 |
| Literacki, S | 1 |
| Waśko, M | 1 |
| Bian, J | 1 |
| Deng, B | 1 |
| Lin, YK | 1 |
| Tsai, SW | 1 |
| Wu, PK | 1 |
| Yang, JC | 1 |
| Chen, CF | 1 |
| Chen, WM | 1 |
| Changjun, C | 1 |
| Xin, Z | 1 |
| Yue, L | 1 |
| Chengcheng, Z | 1 |
| Qiuru, W | 1 |
| Qianhao, L | 1 |
| Pengde, K | 1 |
| Oseni, RO | 1 |
| Zakari, M | 1 |
| Adamou, N | 1 |
| Umar, UA | 1 |
| Chen, Z | 2 |
| D'Amore, T | 1 |
| Lonner, JH | 1 |
| Wei, H | 1 |
| Xiao, Q | 1 |
| Xian, S | 1 |
| Xia, M | 1 |
| Arantes, GC | 1 |
| Pereira, RMR | 1 |
| de Melo, DB | 1 |
| Alonso, N | 1 |
| Duarte, MDCMB | 1 |
| Hu, Q | 5 |
| Chiem, J | 1 |
| Ivanova, I | 1 |
| Parker, A | 1 |
| Krengel, W | 1 |
| Jimenez, N | 1 |
| Evangelista, PJ | 1 |
| Aversano, MW | 1 |
| Koli, E | 1 |
| Hutzler, L | 1 |
| Inneh, I | 1 |
| Bosco, J | 2 |
| Iorio, R | 1 |
| Sun, G | 1 |
| Cornell, CN | 1 |
| Watterson, C | 1 |
| Beacher, N | 1 |
| Demos, HA | 1 |
| Lin, ZX | 1 |
| Barfield, WR | 3 |
| Wilson, SH | 1 |
| Robertson, DC | 1 |
| Pellegrini, VD | 1 |
| Fergusson, NA | 1 |
| Cnossen, S | 2 |
| Lopez-Picado, A | 4 |
| Albinarrate, A | 2 |
| Barrachina, B | 4 |
| Mi, B | 2 |
| Zhou, W | 1 |
| Lv, H | 3 |
| Zha, K | 2 |
| Wu, Q | 3 |
| Moskal, JT | 4 |
| Capps, SG | 2 |
| Fleischman, M | 1 |
| Leighton, RK | 1 |
| Ghavimi, MA | 1 |
| Taheri Talesh, K | 1 |
| Ghoreishizadeh, A | 1 |
| Chavoshzadeh, MA | 1 |
| Zarandi, A | 1 |
| Yang, T | 3 |
| Cao, F | 2 |
| Yang, C | 3 |
| Eachempati, KK | 2 |
| Gurava Reddy, AV | 2 |
| Apsingi, S | 1 |
| Sankineani, SR | 1 |
| Shaheed, J | 1 |
| Dannana, C | 1 |
| Dawes, TJ | 1 |
| Price, S | 1 |
| Milojevic, M | 1 |
| Kappetein, AP | 1 |
| Head, SJ | 1 |
| Painter, T | 1 |
| Jimenez-Rivera, JJ | 1 |
| Iribarren-Sarrías, JL | 1 |
| Martínez-Sanz, R | 1 |
| Wang, DS | 2 |
| Orser, BA | 1 |
| Prieto, HA | 1 |
| Vincent, HK | 1 |
| Deen, JT | 1 |
| Iams, DA | 1 |
| Parvataneni, HK | 1 |
| Cybulska, P | 1 |
| Goss, C | 1 |
| Tew, WP | 1 |
| Parameswaran, R | 1 |
| Sonoda, Y | 1 |
| He, G | 1 |
| Xu, B | 4 |
| Chen, P | 4 |
| Sun, CX | 1 |
| Mi, LD | 1 |
| Du, GY | 1 |
| Sun, XG | 1 |
| He, SW | 1 |
| Kurnik, NM | 2 |
| Pflibsen, LR | 2 |
| Bristol, RE | 1 |
| Singh, DJ | 2 |
| Lin, X | 1 |
| Peng Zhang, MM | 1 |
| Jifeng Li, MM | 1 |
| Xiao Wang, MM | 1 |
| Watts, CD | 2 |
| Sems, SA | 1 |
| Cross, WW | 1 |
| Liu, WB | 1 |
| Huang, YT | 1 |
| Kearns, SM | 1 |
| Kuhar, HN | 1 |
| Bohl, DD | 1 |
| Levine, BR | 2 |
| Zhang, JW | 1 |
| Wang, BH | 1 |
| Stowers, MDJ | 1 |
| Aoina, J | 1 |
| Vane, A | 1 |
| Poutawera, V | 1 |
| Hill, AG | 2 |
| Nagabhushan, RM | 1 |
| Shetty, AP | 1 |
| Dumpa, SR | 1 |
| Subramanian, B | 1 |
| Kanna, RM | 1 |
| Shanmuganathan, R | 1 |
| Sridharan, K | 1 |
| Sivaramakrishnan, G | 1 |
| Desborough, MJ | 1 |
| Oakland, K | 1 |
| Brierley, C | 1 |
| Bennett, S | 1 |
| Doree, C | 1 |
| Trivella, M | 1 |
| Hopewell, S | 1 |
| Stanworth, SJ | 1 |
| Estcourt, LJ | 1 |
| Chapelle, C | 1 |
| Borisov, DB | 1 |
| Bien, JY | 1 |
| Lambert, P | 1 |
| Philippot, R | 1 |
| Molliex, S | 2 |
| Kim, KT | 1 |
| Kim, CK | 1 |
| Kim, YC | 1 |
| Juh, HS | 1 |
| Kim, HS | 1 |
| Hong, SJ | 1 |
| Hey, HWD | 1 |
| Du, S | 1 |
| Sun, Y | 2 |
| Zhang, LK | 2 |
| Ma, JX | 3 |
| Kuang, MJ | 2 |
| Zhao, J | 2 |
| Lu, B | 2 |
| Perreault, RE | 1 |
| Fournier, CA | 1 |
| Mattingly, DA | 1 |
| Junghans, RP | 1 |
| Lacko, M | 1 |
| Cellar, R | 1 |
| Schreierova, D | 1 |
| Vasko, G | 1 |
| Domej, MA | 1 |
| Heuberer, PR | 1 |
| Hexel, M | 1 |
| Grieb, A | 1 |
| Laky, B | 1 |
| Blasl, J | 1 |
| Anderl, W | 1 |
| Peres-Da-Silva, A | 1 |
| Nickel, BT | 1 |
| Seyler, TM | 3 |
| Jeon, Y | 1 |
| Lee, WI | 1 |
| Kang, SY | 1 |
| Kim, MH | 1 |
| Schnettler, T | 1 |
| Papillon, N | 1 |
| Rees, H | 1 |
| Yu, BF | 1 |
| Yang, GJ | 1 |
| Liu, LL | 1 |
| Centeno, A | 1 |
| Rojas, S | 1 |
| Arias, B | 1 |
| Miquel, I | 1 |
| Sánchez, P | 1 |
| Ureta, C | 1 |
| Rincón, E | 1 |
| López, R | 1 |
| Murat, J | 1 |
| Piolanti, N | 1 |
| Del Chiaro, A | 1 |
| Matassi, F | 1 |
| Graceffa, A | 1 |
| Nistri, L | 1 |
| Dai, WL | 1 |
| Zhou, AG | 1 |
| Kirsch, JM | 1 |
| Bedi, A | 1 |
| Horner, N | 1 |
| Wiater, JM | 2 |
| Koueiter, DM | 2 |
| Miller, BS | 1 |
| Bhandari, M | 1 |
| Khan, M | 1 |
| Wang, XE | 1 |
| Yuan, GH | 1 |
| Zhang, LH | 1 |
| Yozawa, S | 1 |
| Ogawa, H | 1 |
| Matsumoto, K | 1 |
| Akiyama, H | 1 |
| Večeřa, M | 1 |
| Špička, J | 2 |
| Langová, K | 2 |
| Cornell, C | 1 |
| Gausden, EB | 2 |
| Qudsi, R | 1 |
| Boone, MD | 1 |
| OʼGara, B | 1 |
| Ruzbarsky, JJ | 1 |
| Lorich, DG | 2 |
| Amer, KM | 1 |
| Rehman, S | 1 |
| Amer, K | 1 |
| Haydel, C | 1 |
| Lack, WD | 1 |
| Crist, BD | 1 |
| Seymour, RB | 1 |
| Harvin, W | 1 |
| Karunakar, MA | 1 |
| Rohrich, RJ | 2 |
| Cho, MJ | 2 |
| Hobbs, JC | 1 |
| Welsby, IJ | 1 |
| Dhakal, IB | 1 |
| Boese, CK | 1 |
| Centeno, L | 1 |
| Walters, RW | 1 |
| Gortemoller, MA | 1 |
| Allen, B | 1 |
| Forsyth, R | 1 |
| Theiss, K | 1 |
| Cunningham, K | 1 |
| Tucker, C | 1 |
| Baskaran, D | 1 |
| Rahman, S | 1 |
| Salmasi, Y | 1 |
| Froghi, S | 1 |
| Berber, O | 1 |
| George, M | 1 |
| Jiang, C | 1 |
| Shen, X | 1 |
| Sheng, L | 3 |
| Jiang, P | 1 |
| Compton, F | 1 |
| Wahed, A | 1 |
| Gregoric, I | 1 |
| Kar, B | 1 |
| Dasgupta, A | 1 |
| Tint, H | 1 |
| Jendoubi, A | 1 |
| Malouch, A | 1 |
| Bouzouita, A | 1 |
| Riahi, Y | 1 |
| Necib, H | 1 |
| Ghedira, S | 1 |
| Houissa, M | 1 |
| Fan, ZR | 1 |
| Park, C | 1 |
| Wormald, J | 1 |
| Miranda, BH | 1 |
| Ong, J | 1 |
| Hare, A | 1 |
| Eccles, S | 1 |
| Dai, Z | 1 |
| Chu, H | 1 |
| Liu, JL | 1 |
| Zeng, WN | 5 |
| Wang, FY | 1 |
| Gong, XY | 1 |
| Tan, ZJ | 1 |
| Jia, XL | 1 |
| Johnson, DJ | 1 |
| Johnson, CC | 1 |
| Nami, N | 1 |
| Wetzler, JA | 1 |
| Apipan, B | 3 |
| Rummasak, D | 2 |
| Narainthonsaenee, T | 1 |
| Ishihara, T | 1 |
| Miyata, S | 1 |
| Yamashita, K | 1 |
| Sasaki, H | 1 |
| Kobayashi, J | 2 |
| Ohnishi, Y | 2 |
| Nishimura, K | 1 |
| Shintani, A | 1 |
| Iso, H | 1 |
| Carabini, LM | 1 |
| Moreland, NC | 1 |
| Vealey, RJ | 1 |
| Bebawy, JF | 1 |
| Koski, TR | 1 |
| Koht, A | 1 |
| Gupta, DK | 1 |
| Avram, MJ | 1 |
| Duan, K | 1 |
| Ma, M | 1 |
| Liu, T | 2 |
| Hao, D | 1 |
| Hodin, S | 1 |
| Do, A | 1 |
| Bristol, R | 1 |
| Levy, JH | 3 |
| Quinones, QJ | 1 |
| Milling, TJ | 1 |
| Key, NS | 1 |
| Bini, SA | 5 |
| Darbinian, JA | 1 |
| Brox, WT | 1 |
| Khatod, M | 1 |
| Secher, JJ | 1 |
| Goldstein, M | 1 |
| Feldmann, C | 1 |
| Wulf, H | 1 |
| Wiesmann, T | 1 |
| Xie, X | 1 |
| Kraus, VB | 1 |
| Rueckl, K | 1 |
| Ni, JR | 1 |
| Wang, LX | 1 |
| Chen, XJ | 1 |
| Ji, JJ | 1 |
| Zhao, YL | 1 |
| Tan, L | 1 |
| Deriy, L | 1 |
| Ou, Y | 3 |
| Wei, J | 2 |
| Qiu, D | 2 |
| Wei, M | 1 |
| Mu, X | 2 |
| Altun, G | 1 |
| Hemşinli, D | 1 |
| Pulathan, Z | 1 |
| Civelek, A | 1 |
| Mengoli, C | 2 |
| Marietta, M | 1 |
| Marano, G | 2 |
| Vaglio, S | 2 |
| Pupella, S | 2 |
| Liumbruno, GM | 3 |
| George, J | 1 |
| Subramanyam, KN | 2 |
| Clark, N | 1 |
| Morris, S | 1 |
| Sargant, N | 2 |
| Nathan, N | 1 |
| Waskowski, J | 1 |
| Schefold, JC | 1 |
| Stueber, F | 1 |
| Brignardello-Petersen, R | 1 |
| Yu, J | 2 |
| Zhu, J | 2 |
| Zhu, Y | 4 |
| Lei, P | 1 |
| Su, W | 1 |
| Liao, L | 1 |
| Tang, Q | 1 |
| Chen, YY | 1 |
| Wang, WC | 1 |
| Huang, CC | 2 |
| Tian, S | 1 |
| Shen, Z | 1 |
| Peng, A | 1 |
| Bullmann, V | 1 |
| Granitzka, M | 1 |
| Khanchandani, P | 1 |
| Tulajaprasad, PV | 1 |
| Jaipuria, J | 1 |
| Mundargi, AV | 1 |
| Mufarrih, SH | 1 |
| Malik, AT | 1 |
| Qureshi, NQ | 1 |
| Lakdawala, RH | 2 |
| Rabbani, MU | 1 |
| Ali, A | 2 |
| Noordin, S | 2 |
| Kuo, LT | 1 |
| Hsu, WH | 1 |
| Chi, CC | 1 |
| Bouthors, AS | 1 |
| Hennart, B | 2 |
| Jeanpierre, E | 2 |
| Baptiste, AS | 2 |
| Saidi, I | 2 |
| Simon, E | 2 |
| Lannoy, D | 2 |
| Duhamel, A | 2 |
| Allorge, D | 2 |
| Susen, S | 2 |
| Ducloy-Bouthors, AS | 1 |
| Xiang, M | 1 |
| López-Hualda, Á | 1 |
| Dauder-Gallego, C | 1 |
| Ferreño-Márquez, D | 1 |
| Martínez-Martín, J | 1 |
| Zhao, MW | 1 |
| Dorweiler, MA | 1 |
| Boin, MA | 1 |
| Froehle, AW | 1 |
| Lawless, MW | 2 |
| May, JH | 2 |
| Zhu, H | 1 |
| Meng, WK | 4 |
| Junejo, F | 1 |
| Akhtar, MI | 1 |
| Hamid, M | 1 |
| Ahmed, SS | 1 |
| Minai, F | 1 |
| Amanullah, M | 1 |
| Arora, M | 1 |
| Singh, S | 1 |
| Gupta, V | 1 |
| Dongre, A | 1 |
| Shetty, V | 1 |
| Gu, LJ | 1 |
| Zhang, HM | 1 |
| Zhao, TJ | 1 |
| Shan, PC | 1 |
| He, MJ | 1 |
| Ramkumar, DB | 5 |
| Ramkumar, N | 1 |
| Tapp, SJ | 1 |
| Moschetti, WE | 1 |
| Zirk, M | 1 |
| Zinser, M | 1 |
| Buller, J | 1 |
| Bilinsky, V | 1 |
| Dreiseidler, T | 1 |
| Zöller, JE | 1 |
| Kreppel, M | 1 |
| Luo, Z | 1 |
| Cerit, L | 1 |
| Sun, RX | 1 |
| Jiang, H | 1 |
| Wakui, M | 1 |
| Cansancao, AL | 1 |
| Condé-Green, A | 1 |
| David, JA | 1 |
| Cansancao, B | 1 |
| Vidigal, RA | 1 |
| Jevsevar, DS | 4 |
| Yates, AJ | 4 |
| Shores, P | 4 |
| Mullen, K | 4 |
| Clarke, HD | 4 |
| Schemitsch, E | 4 |
| Johnson, RL | 4 |
| Sayeed, SA | 4 |
| Pong, RP | 1 |
| Leveque, JA | 1 |
| Edwards, A | 1 |
| Yanamadala, V | 1 |
| Wright, AK | 1 |
| Herodes, M | 1 |
| Sethi, RK | 1 |
| Witiuk, K | 1 |
| Momoli, F | 2 |
| Bryson, G | 1 |
| Kanji, S | 1 |
| Turgeon, A | 1 |
| Mallick, R | 1 |
| Knoll, G | 2 |
| Guo, P | 1 |
| Gao, F | 1 |
| Sun, W | 1 |
| Cheng, L | 1 |
| Liu, Q | 2 |
| Geng, P | 1 |
| Wang, P | 2 |
| Longo, MA | 1 |
| Cavalheiro, BT | 1 |
| de Oliveira Filho, GR | 1 |
| White, CC | 1 |
| Eichinger, JK | 1 |
| Friedman, RJ | 2 |
| Gianakos, AL | 1 |
| Haring, RS | 1 |
| Yoon, RS | 1 |
| Liporace, FA | 1 |
| Cruciani, M | 1 |
| Bergamini, V | 1 |
| Presti, F | 1 |
| Masiello, F | 1 |
| Veropalumbo, E | 1 |
| Piccinini, V | 1 |
| Pati, I | 1 |
| Stoicea, N | 1 |
| Moran, K | 1 |
| Mahmoud, AR | 1 |
| Glassman, A | 1 |
| Ellis, T | 1 |
| Ryan, J | 1 |
| Granger, J | 1 |
| Joseph, N | 1 |
| Salon, N | 1 |
| Ackermann, W | 1 |
| Rogers, B | 1 |
| Niermeyer, W | 1 |
| Bergese, SD | 1 |
| Mu, P | 1 |
| El Beheiry, H | 2 |
| Lubberdink, A | 1 |
| Clements, N | 1 |
| Dihllon, K | 1 |
| Sharma, V | 2 |
| Dabash, S | 1 |
| Barksdale, LC | 2 |
| McNamara, CA | 2 |
| Patel, PD | 2 |
| Suarez, JC | 2 |
| Polanco-García, M | 1 |
| Capielo, AM | 1 |
| Miret, X | 1 |
| Chamero, A | 1 |
| Sainz, J | 1 |
| Revilla, E | 1 |
| Guinjoan, A | 1 |
| Arranz, T | 1 |
| Mariani, P | 1 |
| Buttaro, MA | 2 |
| Slullitel, PA | 2 |
| Comba, FM | 1 |
| Zanotti, G | 1 |
| Ali, P | 1 |
| Piccaluga, F | 1 |
| Dang, S | 1 |
| Duan, D | 1 |
| Wei, L | 1 |
| Numkanisorn, S | 1 |
| Pornrattanamaneewong, C | 2 |
| Kildow, BJ | 2 |
| Howell, EP | 2 |
| Karas, V | 2 |
| Baumgartner, WT | 1 |
| Cunningham, DJ | 2 |
| Grant, AL | 1 |
| Trousdale, RT | 2 |
| Sierra, RJ | 7 |
| Lee, YY | 1 |
| Su, EP | 1 |
| Haas, SB | 1 |
| Mayman, DJ | 1 |
| Hu, KJ | 1 |
| Sun, YY | 1 |
| Linkov, G | 1 |
| Tabrizi, R | 2 |
| Kim, YT | 1 |
| Kang, MW | 1 |
| Lee, JK | 1 |
| Lee, YM | 1 |
| Kim, JI | 1 |
| Mohammadi Sichani, M | 1 |
| Kazemi, R | 1 |
| Nouri-Mahdavi, K | 1 |
| Gholipour, F | 1 |
| Fraval, A | 2 |
| Duncan, S | 1 |
| Murray, T | 1 |
| Duggan, J | 1 |
| Tirosh, O | 1 |
| Tran, P | 2 |
| Feng, C | 1 |
| Akman, B | 1 |
| Şaylı, U | 1 |
| Güven, M | 1 |
| Altıntaş, F | 1 |
| Hill, J | 1 |
| Eggleton, A | 1 |
| Murphy, L | 1 |
| Adams, C | 1 |
| Agus, A | 1 |
| Phair, G | 1 |
| Molloy, D | 1 |
| Mockford, B | 1 |
| O'Hagan, S | 1 |
| de Vasconcellos, SJA | 1 |
| do Nascimento-Júnior, EM | 1 |
| de Aguiar Menezes, MV | 1 |
| Tavares Mendes, ML | 1 |
| de Souza Dantas, R | 1 |
| Martins-Filho, PRS | 1 |
| Goel, R | 1 |
| Buckley, P | 1 |
| Sterbis, E | 1 |
| Peck, J | 1 |
| Kepecs, DM | 1 |
| Mei, B | 1 |
| Safir, OA | 1 |
| Backstein, D | 1 |
| Gross, AE | 1 |
| Kuzyk, PR | 1 |
| Nodzo, SR | 1 |
| Pavlesen, S | 1 |
| Ritter, C | 1 |
| Boyle, KK | 1 |
| Xiong, H | 1 |
| Han, YH | 1 |
| Huang, HT | 2 |
| Pan, JK | 1 |
| Zeng, LF | 1 |
| Liang, GH | 1 |
| Liang, HD | 1 |
| Yang, WY | 1 |
| Guo, D | 1 |
| Zhao, KC | 1 |
| Zhao, MM | 1 |
| Zhao, DX | 1 |
| Pérez-Jimeno, N | 1 |
| Muñoz, M | 2 |
| Mateo, J | 1 |
| Mayoral, AP | 1 |
| Herrera, A | 1 |
| Cao, C | 1 |
| Li, LL | 1 |
| Karampinas, PK | 1 |
| Megaloikonomos, PD | 1 |
| Lampropoulou-Adamidou, K | 1 |
| Papadelis, EG | 1 |
| Mavrogenis, AF | 1 |
| Vlamis, JA | 1 |
| Pneumaticos, SG | 1 |
| Kim, YH | 1 |
| Pandey, K | 1 |
| Park, JW | 1 |
| Kim, JS | 2 |
| Zhang, HJ | 2 |
| Kim, GB | 1 |
| Bae, SH | 1 |
| Zhou, KD | 1 |
| Liu, ZH | 1 |
| He, C | 2 |
| Feng, JM | 1 |
| Arslan, A | 1 |
| Görmeli, G | 1 |
| Lévy, Y | 1 |
| Azar, M | 1 |
| Tran, L | 1 |
| Boileau, P | 1 |
| Bronsard, N | 1 |
| Trojani, C | 1 |
| Bao, X | 1 |
| Zhong, J | 2 |
| Gong, M | 1 |
| Chen, R | 1 |
| Rahe, C | 1 |
| Cybulski, KA | 1 |
| Yoon, BH | 1 |
| Kim, TY | 1 |
| Ko, YS | 1 |
| Lee, YK | 1 |
| Ha, YC | 1 |
| Koo, KH | 2 |
| Fusca, L | 1 |
| Fergusson, D | 5 |
| Boutet, M | 1 |
| Chen, I | 1 |
| Lu, VM | 1 |
| Goyal, A | 1 |
| Daniels, DJ | 1 |
| Wu, YG | 2 |
| Hu, QS | 1 |
| Bao, XC | 1 |
| Xiong, HZ | 1 |
| Bai, L | 1 |
| Fang, Z | 1 |
| Abbas, AM | 1 |
| Shady, NW | 1 |
| Sallam, HF | 1 |
| Li, G | 1 |
| Deng, J | 3 |
| Yu, ZP | 1 |
| Liu, LX | 1 |
| Yu, QP | 1 |
| Chung, E | 1 |
| Karlberg, HI | 1 |
| Huerfano, E | 1 |
| Huerfano, M | 1 |
| Shanaghan, KA | 1 |
| Zhou, L | 1 |
| Bao, J | 1 |
| Free, MD | 1 |
| Owen, DH | 1 |
| Pascoe, E | 1 |
| Allen, P | 1 |
| Harvie, P | 1 |
| Sagiv, O | 1 |
| Rosenfeld, E | 1 |
| Kalderon, E | 1 |
| Barazani, TB | 2 |
| Zloto, O | 1 |
| Martinowitz, U | 2 |
| Ben Simon, GJ | 1 |
| Zilinsky, I | 2 |
| Han, X | 1 |
| Gong, G | 1 |
| Han, N | 1 |
| Zurakowski, D | 5 |
| Glotzbecker, MP | 1 |
| McCann, ME | 1 |
| Hedequist, D | 1 |
| Brustowicz, RM | 2 |
| Sethna, NF | 4 |
| Karlin, LI | 1 |
| Emans, JB | 2 |
| Hresko, MT | 1 |
| Yates, J | 2 |
| Khair, S | 2 |
| Taylor, J | 3 |
| Lampron, J | 2 |
| Saidenberg, E | 2 |
| Jordan, M | 2 |
| Aguilera, X | 3 |
| González, JC | 2 |
| Castillón, P | 1 |
| Salomó, M | 1 |
| Hernández, JA | 1 |
| Ruiz, L | 1 |
| Mora, JM | 1 |
| Camacho-Carrasco, P | 1 |
| Prat-Fabregat, S | 1 |
| Bosch, A | 1 |
| Rodriguez-Arias, A | 2 |
| Kadri, O | 1 |
| Kadado, A | 1 |
| Buraimoh, M | 1 |
| Pawloski, J | 1 |
| Xue, P | 1 |
| Qiao, F | 1 |
| Halawi, MJ | 1 |
| Plourde, JM | 1 |
| Cote, MP | 1 |
| Wei, BG | 1 |
| Zhang, XS | 1 |
| Torsha, TT | 1 |
| Xiao, J | 2 |
| Shi, ZJ | 1 |
| Luo, GG | 1 |
| Lin, ZQ | 1 |
| Xie, HF | 1 |
| Yao, JC | 1 |
| Zhang, HZ | 1 |
| Reichel, F | 1 |
| Peter, C | 1 |
| Ewerbeck, V | 1 |
| Egermann, M | 1 |
| Kim, DH | 2 |
| Kang, H | 1 |
| Jin, HJ | 1 |
| Hwang, SH | 1 |
| McGuire, C | 1 |
| Nurmsoo, S | 1 |
| Samargandi, OA | 1 |
| Bezuhly, M | 1 |
| Zhao, Z | 3 |
| Wolfson, TS | 1 |
| Novikov, D | 1 |
| Chen, KK | 1 |
| Kim, KY | 1 |
| Anoushiravani, AA | 1 |
| Deshmukh, AJ | 1 |
| Lajam, CM | 1 |
| Aytuluk, HG | 1 |
| Yaka, HO | 1 |
| Larson, E | 1 |
| Long, J | 1 |
| Gannon, E | 1 |
| Lyden, E | 1 |
| Cornett, C | 1 |
| Visentin, D | 1 |
| Ahuja, K | 1 |
| Haik, J | 1 |
| Yaghmour, KM | 1 |
| Atkinson, S | 1 |
| Chisari, E | 1 |
| McDonnell, SM | 1 |
| Khan, W | 1 |
| Sahu, J | 1 |
| Mishra, N | 1 |
| Deng, L | 1 |
| Ning, X | 2 |
| Dibiasi, C | 1 |
| Wiegele, M | 1 |
| Gratz, J | 1 |
| Lemoine, A | 1 |
| Lambaudie, E | 1 |
| Bonnet, F | 1 |
| Leblanc, E | 1 |
| Sun, Q | 3 |
| Liu, C | 1 |
| Clavé, A | 1 |
| Gérard, R | 1 |
| Lacroix, J | 1 |
| Baynat, C | 1 |
| Gatineau, F | 1 |
| Mottier, D | 1 |
| Sandri, A | 1 |
| Mimor, BF | 1 |
| Ditta, A | 1 |
| Finocchio, E | 1 |
| Danzi, V | 1 |
| Piccoli, P | 1 |
| Regis, D | 1 |
| Magnan, B | 1 |
| Concina, C | 1 |
| Crucil, M | 1 |
| Fabbro, S | 1 |
| Gherlinzoni, F | 1 |
| Meftah, M | 1 |
| White, PB | 1 |
| Siddiqi, A | 1 |
| Siddappa, VH | 1 |
| Kirschenbaum, I | 1 |
| Wu, F | 1 |
| Shang, X | 1 |
| Mahmood, F | 1 |
| Laoruengthana, A | 2 |
| Rattanaprichavej, P | 2 |
| Rasamimongkol, S | 1 |
| Galassi, M | 2 |
| Weerakul, S | 1 |
| Pongpirul, K | 2 |
| Zhang, YM | 1 |
| Yang, B | 1 |
| Sun, XD | 1 |
| Slattery, C | 1 |
| Kark, J | 1 |
| Wagner, T | 2 |
| Verma, K | 4 |
| Siotou, K | 1 |
| Siotos, C | 1 |
| Azizi, A | 1 |
| Cheah, MA | 1 |
| Seal, SM | 1 |
| Redett, RJ | 1 |
| Rosson, GD | 1 |
| Yuan, Y | 1 |
| Luo, H | 1 |
| Saracoglu, A | 1 |
| Ezelsoy, M | 1 |
| Saracoglu, KT | 1 |
| Ma, C | 1 |
| Cao, JG | 2 |
| Chen, A | 1 |
| Pi, B | 1 |
| McIlroy, D | 1 |
| Gombár, C | 1 |
| Gálity, H | 1 |
| Bácsi, M | 1 |
| Sisák, K | 1 |
| Shang, L | 1 |
| Mei, A | 1 |
| Qiu, L | 1 |
| Wen, Y | 1 |
| Kashyap, S | 1 |
| Mahajan, S | 1 |
| Lal, M | 1 |
| Habbab, LM | 1 |
| Hussain, S | 1 |
| Power, P | 1 |
| Bashir, S | 1 |
| Gao, P | 1 |
| Semelhago, L | 1 |
| Parry, D | 1 |
| Chu, V | 1 |
| Legnani, C | 1 |
| Oriani, G | 1 |
| Parente, F | 1 |
| Ventura, A | 1 |
| Chen, F | 2 |
| Grass, F | 1 |
| Braafladt, S | 1 |
| Alabbad, J | 1 |
| Lovely, JK | 1 |
| Kelley, SR | 1 |
| Mathis, KL | 1 |
| Huebner, M | 1 |
| Larson, DW | 1 |
| Buell, TJ | 1 |
| Taylor, DG | 1 |
| Dunn, LK | 1 |
| Mullin, JP | 1 |
| Mazur, MD | 1 |
| Yen, CP | 1 |
| Shaffrey, ME | 1 |
| Shaffrey, CI | 2 |
| Smith, JS | 2 |
| Naik, BI | 1 |
| Spitler, CA | 1 |
| Row, ER | 1 |
| Gardner, WE | 1 |
| Swafford, RE | 1 |
| Hankins, MJ | 1 |
| Nowotarski, PJ | 1 |
| Kiner, DW | 1 |
| D'Amore Lindholm, A | 1 |
| Nørholt, SE | 1 |
| von Oettingen, G | 1 |
| Tarpgaard, M | 1 |
| Krogh, L | 1 |
| Gulabi, D | 1 |
| Yuce, Y | 1 |
| Erkal, KH | 1 |
| Saglam, N | 1 |
| Camur, S | 1 |
| Anthony, SG | 1 |
| Patterson, DC | 1 |
| Remón, M | 2 |
| Errea, M | 1 |
| Ping, WD | 1 |
| Zhao, QM | 1 |
| Sun, HF | 1 |
| Lu, HS | 1 |
| Klebanoff, JS | 1 |
| Ingraham, CF | 1 |
| Wu, CZ | 1 |
| Moawad, GN | 1 |
| Xiong, X | 1 |
| Xu, L | 1 |
| Ji, M | 1 |
| Chen, H | 3 |
| Mannová, J | 1 |
| Kubát, P | 1 |
| Pospíchal, M | 1 |
| Longin, P | 1 |
| Zheng, F | 1 |
| Kwak, DK | 1 |
| Jang, CY | 1 |
| Rhyu, SH | 1 |
| Hwang, JH | 1 |
| Yoo, JH | 1 |
| Chaibhuddanugul, N | 1 |
| Varakornpipat, P | 1 |
| Hines, JT | 1 |
| Hernandez, NM | 1 |
| Amundson, AW | 1 |
| Tu, A | 1 |
| Kearney, S | 1 |
| Wheelwright, M | 1 |
| Petronio, J | 1 |
| Kebriaei, M | 1 |
| Perez-Roman, RJ | 1 |
| Lugo-Pico, JG | 1 |
| Burks, JD | 1 |
| Madhavan, K | 1 |
| Sheinberg, D | 1 |
| Green, BA | 1 |
| Gjolaj, JP | 1 |
| Wanderman, N | 1 |
| Robinson, W | 1 |
| Carlson, B | 1 |
| Bydon, M | 1 |
| Currier, B | 1 |
| Huddleston, P | 1 |
| Nassr, A | 1 |
| Freedman, B | 1 |
| Cao, K | 1 |
| Wang, B | 2 |
| Lin, N | 1 |
| Herndon, CL | 1 |
| Grosso, MJ | 1 |
| Shah, RP | 1 |
| Geller, JA | 1 |
| Cooper, HJ | 1 |
| Damade, C | 1 |
| Tesson, G | 1 |
| Gilard, V | 1 |
| Vigny, S | 1 |
| Foulongne, E | 1 |
| Gauthé, R | 1 |
| Ould-Slimane, M | 1 |
| Raman, T | 1 |
| Varlotta, C | 1 |
| Vasquez-Montes, D | 1 |
| Buckland, AJ | 1 |
| Errico, TJ | 5 |
| Kaplan, A | 1 |
| Wisniewski, M | 1 |
| Waters, JH | 3 |
| Yazer, MH | 1 |
| Darrith, B | 1 |
| Calkins, TE | 1 |
| Bini, S | 1 |
| Abeysiri, S | 1 |
| Chau, M | 1 |
| Highton, D | 1 |
| Feng, S | 1 |
| Lv, Z | 1 |
| Qu, Z | 1 |
| Xue, C | 1 |
| Zhu, M | 2 |
| Wu, P | 1 |
| Alexander, PG | 1 |
| Riaz, O | 1 |
| Aqil, A | 1 |
| Asmar, S | 1 |
| Vanker, R | 1 |
| Hahnel, J | 1 |
| Brew, C | 1 |
| Grogan, R | 1 |
| Radcliffe, G | 1 |
| Tille, E | 1 |
| Mysliwietz, J | 1 |
| Beyer, F | 1 |
| Postler, A | 1 |
| Lützner, J | 1 |
| Shakur, H | 4 |
| Ker, K | 11 |
| Coats, T | 2 |
| Ji, H | 2 |
| Ren, F | 1 |
| Xue, Y | 1 |
| Faraday, N | 1 |
| Perel, P | 2 |
| Morales Uribe, CH | 1 |
| Fu, DJ | 1 |
| Guo, L | 1 |
| Wind, TC | 2 |
| Koh, IJ | 1 |
| Davis, A | 1 |
| Walsh, M | 1 |
| McCarthy, P | 1 |
| Brown, G | 1 |
| Roberts, S | 1 |
| Tran, H | 1 |
| Street, A | 1 |
| Fong, CY | 1 |
| Kemp, W | 1 |
| Abdel-Aleem, H | 1 |
| Alhusaini, TK | 1 |
| Abdel-Aleem, MA | 1 |
| Menoufy, M | 1 |
| Gülmezoglu, AM | 1 |
| Muñoz Gómez, M | 1 |
| Páramo Fernández, JA | 1 |
| Forget, P | 1 |
| Grosu, I | 1 |
| Thienpont, E | 2 |
| Tao, LJ | 1 |
| Vigna-Taglianti, F | 1 |
| Basso, L | 1 |
| Rolfo, P | 1 |
| Brambilla, R | 1 |
| Vaccari, F | 1 |
| Lanci, G | 1 |
| Russo, R | 1 |
| Tan, J | 1 |
| Gandhi, R | 1 |
| Evans, HM | 1 |
| Mahomed, SR | 1 |
| Mahomed, NN | 1 |
| Xing, D | 1 |
| Zhang, HF | 1 |
| Zang, JC | 1 |
| Ortmann, E | 1 |
| Besser, MW | 1 |
| Klein, AA | 1 |
| Iwai, T | 2 |
| Tsuji, S | 2 |
| Panteli, M | 1 |
| Papakostidis, C | 1 |
| Dahabreh, Z | 1 |
| Giannoudis, PV | 1 |
| Whiting, DR | 3 |
| Gillette, BP | 2 |
| Duncan, C | 1 |
| Smith, H | 1 |
| Khan, A | 1 |
| Prieto-Merino, D | 1 |
| Guerrero-Domínguez, R | 1 |
| Padilla-Morales, V | 1 |
| Montero-López, N | 1 |
| Marenco de la Fuente, ML | 1 |
| Beecher, D | 1 |
| Maradit Kremers, H | 1 |
| Smith, HM | 3 |
| Sigaut, S | 1 |
| Tremey, B | 1 |
| Ouattara, A | 3 |
| Couturier, R | 2 |
| Taberlet, C | 1 |
| Grassin-Delyle, S | 3 |
| Dreyfus, JF | 1 |
| Schlumberger, S | 1 |
| Fischler, M | 1 |
| Bruce-Brand, R | 1 |
| Dragomir, R | 1 |
| Baker, J | 1 |
| Harty, J | 1 |
| Schindler, E | 2 |
| Hertfelder, HJ | 1 |
| Strang, CM | 1 |
| Hachenberg, T | 1 |
| Smit, KM | 1 |
| Naudie, DD | 2 |
| Ralley, FE | 2 |
| Berta, DM | 1 |
| Howard, JL | 1 |
| Lee, YC | 1 |
| Park, SJ | 1 |
| Cho, CH | 1 |
| Jacobs, IG | 2 |
| Reade, MC | 2 |
| Chimento, GF | 1 |
| Huff, T | 1 |
| Ochsner, JL | 1 |
| Meyer, M | 1 |
| Brandner, L | 1 |
| Babin, S | 1 |
| Makhija, N | 1 |
| Sarupria, A | 1 |
| Kumar Choudhary, S | 1 |
| Lakshmy, R | 1 |
| Kiran, U | 1 |
| Remérand, F | 1 |
| Cotten, M | 1 |
| N'Guessan, YF | 1 |
| Couvret, C | 1 |
| Rosset, P | 1 |
| Favard, L | 1 |
| Laffon, M | 1 |
| Fusciardi, J | 1 |
| Karam, JA | 1 |
| Bloomfield, MR | 1 |
| DiIorio, TM | 1 |
| Irizarry, AM | 1 |
| Sharkey, PF | 1 |
| Ma, G | 1 |
| Yin, Z | 1 |
| Gilbody, J | 1 |
| Dhotar, HS | 1 |
| Perruccio, AV | 1 |
| Davey, JR | 1 |
| Alipour, M | 1 |
| Tabari, M | 1 |
| Keramati, M | 1 |
| Zarmehri, AM | 1 |
| Makhmalbaf, H | 1 |
| Sakallioğlu, Ö | 1 |
| Polat, C | 1 |
| Soylu, E | 1 |
| Düzer, S | 1 |
| Orhan, İ | 1 |
| Akyiğit, A | 1 |
| Flanagan, D | 1 |
| Alshryda, S | 3 |
| Mason, J | 2 |
| Vaghela, M | 2 |
| Sarda, P | 3 |
| Nargol, A | 3 |
| Maheswaran, S | 1 |
| Tulloch, C | 1 |
| Anand, S | 1 |
| Logishetty, R | 2 |
| Stothart, B | 1 |
| Hungin, AP | 2 |
| Cooke, N | 1 |
| Ahmad, H | 1 |
| McPartlin, L | 1 |
| Martin, JG | 1 |
| Cassatt, KB | 1 |
| Kincaid-Cinnamon, KA | 1 |
| Westendorf, DS | 1 |
| Garton, AS | 1 |
| Lemke, JH | 1 |
| Pundir, V | 1 |
| Pundir, J | 1 |
| Georgalas, C | 1 |
| Fokkens, WJ | 1 |
| Ritter, M | 1 |
| Michel, MS | 1 |
| Raveendran, R | 2 |
| Martin-Hirsch, PP | 2 |
| Bryant, A | 2 |
| Moráis, S | 1 |
| Ortega-Andreu, M | 3 |
| Rodríguez-Merchán, EC | 3 |
| Padilla-Eguiluz, NG | 3 |
| Pérez-Chrzanowska, H | 2 |
| Figueredo-Zalve, R | 2 |
| Gómez-Barrena, E | 3 |
| Zhao-Yu, C | 1 |
| Yan, G | 1 |
| Wei, C | 1 |
| Yuejv, L | 1 |
| Ying-Ze, Z | 2 |
| Charles, I | 1 |
| Górriz, R | 1 |
| López, M | 1 |
| Coderch, J | 1 |
| Rubatti, M | 1 |
| Credico, C | 1 |
| Louvain-Quintard, V | 1 |
| Anerkian, V | 1 |
| Doubine, S | 1 |
| Vasse, M | 1 |
| Lundin, ES | 1 |
| Johansson, T | 3 |
| Zachrisson, H | 1 |
| Leandersson, U | 1 |
| Bäckman, F | 1 |
| Falknäs, L | 1 |
| Kjølhede, P | 1 |
| Rasouli, MR | 1 |
| Gomes, LS | 1 |
| Parsley, B | 1 |
| Barsoum, W | 1 |
| Bezwada, H | 1 |
| Cashman, J | 1 |
| Garcia, J | 1 |
| Hamilton, W | 1 |
| Hume, E | 1 |
| Malhotra, R | 1 |
| Memtsoudis, S | 1 |
| Ong, A | 1 |
| Orozco, F | 1 |
| Padgett, D | 1 |
| Reina, R | 1 |
| Teloken, M | 1 |
| Rikhraj, IS | 1 |
| Tay, DK | 2 |
| Chin, PL | 3 |
| Chia, SL | 4 |
| Lo, NN | 4 |
| Yeo, SJ | 4 |
| Cacheux, C | 2 |
| Van Aelbrouck, C | 2 |
| Ickx, BE | 2 |
| Barvais, L | 1 |
| Ahn, KT | 1 |
| Yamanaka, K | 1 |
| Iwakura, A | 1 |
| Hirose, K | 2 |
| Nakatsuka, D | 1 |
| Kusuhara, T | 1 |
| Ikarashi, J | 1 |
| Halder, S | 1 |
| Samanta, B | 1 |
| Sardar, R | 1 |
| Chattopadhyay, S | 1 |
| Tuttle, JR | 1 |
| Ritterman, SA | 1 |
| Cassidy, DB | 1 |
| Anazonwu, WA | 1 |
| Froehlich, JA | 1 |
| Rubin, LE | 1 |
| Jarman, J | 1 |
| Brier, A | 1 |
| Geirsson, RT | 1 |
| Acharya, G | 1 |
| Sarzaeem, MM | 1 |
| Razi, M | 1 |
| Kazemian, G | 1 |
| Moghaddam, ME | 1 |
| Rasi, AM | 1 |
| Karimi, M | 1 |
| George, DA | 1 |
| Sarraf, KM | 1 |
| Nwaboku, H | 1 |
| Patel, JN | 1 |
| Spanyer, JM | 1 |
| Smith, LS | 2 |
| Huang, J | 1 |
| Yakkanti, MR | 1 |
| Christabel, A | 2 |
| Muthusekhar, MR | 2 |
| Narayanan, V | 2 |
| Ashok, Y | 1 |
| Soh, CL | 2 |
| Ilangovan, M | 1 |
| Krishnan, N | 1 |
| Robb, PJ | 1 |
| Thorning, G | 1 |
| Soni, A | 1 |
| Saini, R | 1 |
| Gulati, A | 1 |
| Paul, R | 1 |
| Bhatty, S | 1 |
| Rajoli, SR | 1 |
| Lv, YM | 1 |
| Ding, PJ | 1 |
| Walsh, K | 1 |
| Nikkhah, D | 1 |
| Dheansa, B | 1 |
| Diefenbach, C | 1 |
| Hoelscher, C | 2 |
| Peters, A | 2 |
| Dryer, J | 1 |
| Huncke, T | 2 |
| Boenigk, K | 1 |
| Phi, JH | 1 |
| Hong, KH | 1 |
| Dholakia, A | 1 |
| Smith, ER | 1 |
| Kokolo, MB | 1 |
| Punjani, N | 1 |
| Beck, A | 1 |
| Niznick, N | 1 |
| Buenaventura, C | 1 |
| Cowan, J | 1 |
| Ruzicka, M | 1 |
| Schachkina, S | 1 |
| Xie, HY | 1 |
| Espahbod, C | 1 |
| Veitz-Keenan, A | 1 |
| Cuellar, JM | 1 |
| Yoo, A | 1 |
| Tovar, N | 1 |
| Coelho, PG | 1 |
| Jimbo, R | 1 |
| Vandeweghe, S | 1 |
| Kirsch, T | 1 |
| Quirno, M | 1 |
| Haughom, BD | 1 |
| Belkin, MN | 1 |
| Goldstein, ZH | 1 |
| Samujh, C | 1 |
| Falls, TD | 1 |
| Wessel, R | 1 |
| Smith, L | 1 |
| Olmos Rodríguez, M | 1 |
| Ballester Hernández, JA | 1 |
| Arteta Bárcenas, MT | 1 |
| Rodríguez Cerezo, A | 1 |
| Vidarte Ortiz de Artiñano, MA | 1 |
| Veiga Alameda, C | 1 |
| Ahmed, MR | 2 |
| Sayed Ahmed, WA | 1 |
| Madny, EH | 1 |
| Arafa, AM | 1 |
| Said, MM | 1 |
| Krebs, V | 1 |
| Hozack, WJ | 1 |
| Callaghan, JJ | 2 |
| Bohannon Mason, J | 1 |
| Mont, M | 1 |
| Machin, JT | 1 |
| Batta, V | 1 |
| Soler, JA | 1 |
| Sivagaganam, K | 1 |
| Kalairajah, Y | 1 |
| Rasul, R | 1 |
| Suzuki, S | 2 |
| Danninger, T | 1 |
| Opperer, M | 1 |
| Jahanshahi, J | 1 |
| Hashemian, F | 1 |
| Pazira, S | 1 |
| Bakhshaei, MH | 1 |
| Farahani, F | 1 |
| Abasi, R | 1 |
| Poorolajal, J | 1 |
| Wei, B | 1 |
| Falana, O | 1 |
| Patel, G | 1 |
| Robertson, J | 1 |
| Koyfman, A | 1 |
| Slover, J | 1 |
| Oiartzabal, I | 1 |
| López-Ariznabarreta, C | 1 |
| Molano, J | 1 |
| Liu, WX | 1 |
| Zhang, HA | 1 |
| Liu, SL | 1 |
| Meng, T | 1 |
| Eftekharian, H | 1 |
| Vahedi, R | 1 |
| Karagah, T | 1 |
| Li, T | 1 |
| Si, Y | 1 |
| DiGioia, AM | 1 |
| Plakseychuk, AY | 1 |
| Levison, TJ | 1 |
| Badeaux, J | 1 |
| Hawley, D | 1 |
| Durga, P | 2 |
| Raavula, P | 1 |
| Gurajala, I | 1 |
| Gunnam, P | 1 |
| Veerabathula, P | 1 |
| Reddy, M | 1 |
| Upputuri, O | 1 |
| Ramachandran, G | 2 |
| Wang, K | 2 |
| Li, FN | 1 |
| Tang, YB | 1 |
| Shen, HX | 1 |
| Song, QX | 1 |
| Crantford, JC | 1 |
| Wood, BC | 1 |
| Claiborne, JR | 1 |
| Ririe, DG | 1 |
| Couture, DE | 1 |
| Thompson, JT | 1 |
| David, LR | 1 |
| Lin, SY | 1 |
| Chen, CH | 1 |
| Fu, YC | 1 |
| Huang, PJ | 1 |
| Chang, JK | 1 |
| Pinzón-Florez, CE | 1 |
| Vélez Cañas, KM | 1 |
| Díaz Quijano, DM | 1 |
| Dang, P | 1 |
| Luu, M | 1 |
| Mozaffar, T | 1 |
| Gupta, R | 1 |
| Kaplunov, OA | 1 |
| Mikhin, IV | 1 |
| Biriukov, SN | 1 |
| Cheriyan, T | 2 |
| Maier, SP | 1 |
| Bianco, K | 1 |
| Slobodyanyuk, K | 2 |
| Rattenni, RN | 1 |
| Schwab, FJ | 2 |
| Xie, S | 1 |
| Karaaslan, F | 1 |
| Karaoğlu, S | 1 |
| Mermerkaya, MU | 1 |
| Baktir, A | 1 |
| Nawabi, DH | 1 |
| Shen, PF | 1 |
| Hou, WL | 1 |
| Chen, JB | 1 |
| Qu, YX | 1 |
| Shemshaki, H | 1 |
| Nourian, SM | 1 |
| Nourian, N | 1 |
| Dehghani, M | 1 |
| Mokhtari, M | 1 |
| Mazoochian, F | 1 |
| Ali Shah, MU | 1 |
| Asghar, MI | 1 |
| Siddiqi, R | 1 |
| Chaudhri, MS | 1 |
| Janjua, AM | 1 |
| Iqbal, A | 1 |
| Ng, W | 1 |
| Berney, MJ | 1 |
| Dawson, PH | 1 |
| Phillips, M | 1 |
| Lui, DF | 1 |
| Connolly, P | 1 |
| Schwab, F | 1 |
| Carling, MS | 1 |
| Jeppsson, A | 1 |
| Eriksson, BI | 1 |
| Brisby, H | 1 |
| Coppola, A | 2 |
| Windyga, J | 1 |
| Tufano, A | 1 |
| Yeung, C | 1 |
| Di Minno, MN | 1 |
| Hinarejos, P | 1 |
| Leal, J | 1 |
| Monllau, JC | 1 |
| Celaya, F | 2 |
| Fernández, JA | 2 |
| Pelfort, X | 1 |
| Puig-Verdie, Ll | 1 |
| Coats, TJ | 1 |
| Yue, C | 3 |
| Yang, P | 3 |
| Wingerter, SA | 1 |
| Keith, AD | 1 |
| Schoenecker, PL | 1 |
| Baca, GR | 1 |
| Clohisy, JC | 1 |
| Hodgson, S | 1 |
| Larvin, JT | 1 |
| Dearman, C | 1 |
| Wei, Z | 1 |
| Wang, CG | 1 |
| Sun, ZH | 1 |
| Olsen, JJ | 1 |
| Skov, J | 1 |
| Engel, M | 1 |
| Bodem, JP | 1 |
| Busch, CJ | 1 |
| Horn, D | 1 |
| Mertens, C | 1 |
| Hoffmann, J | 1 |
| Freudlsperger, C | 1 |
| Ichikawa, J | 1 |
| Kodaka, M | 1 |
| Kitahara, T | 1 |
| Sato, N | 1 |
| Nishiyama, K | 1 |
| Nakano, K | 1 |
| Komori, M | 1 |
| Hsu, CH | 2 |
| Kuo, FC | 2 |
| Averbukh, VM | 1 |
| Dzhafarova, MZ | 1 |
| Bebchuk, GB | 1 |
| Avdeeva, KS | 1 |
| Digas, G | 1 |
| Koutsogiannis, I | 1 |
| Meletiadis, G | 1 |
| Antonopoulou, E | 1 |
| Karamoulas, V | 1 |
| Bikos, Ch | 1 |
| Conforti, A | 1 |
| Mollo, A | 1 |
| Alviggi, C | 1 |
| Tsimpanakos, I | 1 |
| Strina, I | 1 |
| Magos, A | 1 |
| De Placido, G | 1 |
| Lee, C | 1 |
| Freeman, R | 1 |
| Edmondson, M | 1 |
| Rogers, BA | 1 |
| Raksakietisak, M | 1 |
| Sathitkarnmanee, B | 1 |
| Srisaen, P | 1 |
| Duangrat, T | 1 |
| Chinachoti, T | 1 |
| Rushatamukayanunt, P | 1 |
| Sakulpacharoen, N | 1 |
| Hong, SK | 1 |
| Duan, Y | 1 |
| Yin, HM | 1 |
| Bagsby, DT | 1 |
| Samujh, CA | 1 |
| Vissing, JL | 1 |
| Empson, JA | 1 |
| Pomeroy, DL | 1 |
| Baker, JE | 1 |
| Pavenski, K | 1 |
| Pirani, RA | 1 |
| White, A | 1 |
| Kataoka, M | 1 |
| Waddell, JP | 1 |
| Ho, A | 1 |
| Schemitsch, EH | 1 |
| Lo, N | 1 |
| Bogoch, ER | 1 |
| Pronovost, A | 1 |
| Luke, K | 1 |
| Howell, A | 1 |
| Nassis, A | 1 |
| Tsui, AK | 1 |
| Tanzini, RM | 1 |
| Pulendrarajah, R | 1 |
| Freedman, J | 1 |
| Hare, GM | 1 |
| Anantanarayanan, P | 1 |
| Subash, P | 1 |
| Ramanathan, M | 1 |
| Helal, OM | 1 |
| Elsherbini, MM | 1 |
| Eid, MM | 1 |
| Elkomy, RO | 1 |
| Dahab, S | 1 |
| Elsissy, MH | 1 |
| Maruyama, M | 1 |
| Holt, JB | 1 |
| Miller, BJ | 1 |
| Clark, CR | 1 |
| Willenborg, MD | 1 |
| Noiseux, NO | 1 |
| Sizer, SC | 1 |
| Cherian, JJ | 1 |
| Elmallah, RD | 1 |
| Pierce, TP | 1 |
| Beaver, WB | 1 |
| Mont, MA | 2 |
| Formby, PM | 1 |
| Pickett, AM | 1 |
| Van Blarcum, GS | 1 |
| Mack, AW | 1 |
| Newman, MT | 1 |
| Bai, G | 1 |
| Qiu, Y | 1 |
| Wu, H | 1 |
| Fu, P | 1 |
| Gillespie, R | 1 |
| Shishani, Y | 1 |
| Joseph, S | 1 |
| Streit, JJ | 1 |
| Gobezie, R | 1 |
| Melvin, JS | 2 |
| Stryker, LS | 1 |
| Pitta, M | 1 |
| Zawadsky, M | 1 |
| Verstraete, R | 1 |
| Rubinstein, A | 1 |
| Çavuşoğlu, AT | 1 |
| Ayanoğlu, T | 1 |
| Esen, E | 1 |
| Atalar, H | 1 |
| Turanlı, S | 1 |
| Na, HS | 1 |
| Shin, HJ | 1 |
| Lee, YJ | 1 |
| Do, SH | 1 |
| Sa-ngasoongsong, P | 1 |
| Chanplakorn, P | 1 |
| Wongsak, S | 1 |
| Uthadorn, K | 1 |
| Panpikoon, T | 1 |
| Jittorntam, P | 1 |
| Aryurachai, K | 1 |
| Angchaisukisiri, P | 1 |
| Kawinwonggowit, V | 1 |
| Phan, DL | 1 |
| Ani, F | 1 |
| Khan, N | 1 |
| Troelsen, A | 4 |
| Husted, H | 6 |
| Wassilew, GI | 1 |
| Janz, V | 1 |
| Krämer, M | 1 |
| Renner, L | 1 |
| Gordon, E | 1 |
| Butler, RB | 1 |
| Mock, L | 1 |
| Dumas, B | 1 |
| Eftekharian, HR | 2 |
| Rajabzadeh, Z | 1 |
| North, WT | 2 |
| Mehran, N | 2 |
| Davis, JJ | 2 |
| van Galen, KP | 1 |
| Engelen, ET | 1 |
| Mauser-Bunschoten, EP | 1 |
| van Es, RJ | 1 |
| Schutgens, RE | 1 |
| Yew, AK | 1 |
| Shaaban, MM | 1 |
| Farhan, RE | 1 |
| Dardeer, HH | 1 |
| Moo, IH | 2 |
| Pang, HN | 2 |
| Ueno, M | 1 |
| Sonohata, M | 1 |
| Fukumori, N | 1 |
| Kawano, S | 1 |
| Kitajima, M | 1 |
| Mawatari, M | 1 |
| Pongcharoen, B | 1 |
| Ruetiwarangkoon, C | 1 |
| Prakash, J | 6 |
| Chand, S | 1 |
| Tió, MM | 1 |
| Sánchez-Etayo, G | 1 |
| Bergé, R | 1 |
| Salazar, F | 2 |
| Basora, M | 3 |
| Sala-Blanch, X | 1 |
| Pertlíček, J | 1 |
| Stehlík, J | 1 |
| Sadovský, P | 1 |
| Musil, D | 1 |
| Mezera, V | 1 |
| Goyal, N | 2 |
| Kaul, R | 1 |
| Harris, IA | 2 |
| Chen, DB | 2 |
| MacDessi, SJ | 2 |
| Kietpeerakool, C | 1 |
| Supoken, A | 1 |
| Laopaiboon, M | 1 |
| Lumbiganon, P | 1 |
| Jans, Ø | 2 |
| Grevstad, U | 1 |
| Mandøe, H | 1 |
| Kehlet, H | 1 |
| Johansson, PI | 1 |
| Topsoee, MF | 2 |
| Bergholt, T | 2 |
| Ravn, P | 1 |
| Schouenborg, L | 1 |
| Moeller, C | 1 |
| Ottesen, B | 2 |
| Settnes, A | 2 |
| Sassoon, A | 1 |
| Jackups, R | 1 |
| Johnson, SR | 1 |
| Nunley, RM | 1 |
| Barrack, RL | 1 |
| Liu, KL | 1 |
| Chen, IH | 1 |
| Wen, SH | 1 |
| Idialisoa, R | 1 |
| Jouffroy, R | 1 |
| Philippe, P | 1 |
| Lamhaut, L | 1 |
| Baud, F | 1 |
| Carli, P | 1 |
| Vivien, B | 1 |
| Kong, G | 1 |
| Appelmann, I | 1 |
| Kreher, S | 1 |
| Parmentier, S | 1 |
| Wolf, HH | 1 |
| Bisping, G | 1 |
| Kirschner, M | 1 |
| Bergmann, F | 1 |
| Schilling, K | 1 |
| Brümmendorf, TH | 1 |
| Petrides, PE | 1 |
| Tiede, A | 1 |
| Matzdorff, A | 1 |
| Griesshammer, M | 1 |
| Riess, H | 1 |
| Koschmieder, S | 1 |
| Singh, N | 1 |
| Sudesh, P | 1 |
| Sujata, N | 1 |
| Tobin, R | 1 |
| Kaur, R | 1 |
| Aneja, A | 1 |
| Khanna, M | 1 |
| Hanjoora, VM | 1 |
| Huang, GP | 1 |
| Jia, XF | 1 |
| Ji, Y | 1 |
| Wu, GY | 1 |
| Murphy, GR | 1 |
| Glass, GE | 1 |
| Jain, A | 1 |
| Ma, TK | 1 |
| Chow, KM | 1 |
| Kwan, BC | 1 |
| Leung, CB | 1 |
| Szeto, CC | 1 |
| Li, PK | 1 |
| Drakos, A | 1 |
| Raoulis, V | 1 |
| Karatzios, K | 1 |
| Doxariotis, N | 1 |
| Kontogeorgakos, V | 1 |
| Malizos, K | 1 |
| Varitimidis, SE | 1 |
| Fondarella, A | 1 |
| Iriarte, I | 1 |
| Bastida, R | 1 |
| Rodríguez-Gascón, A | 1 |
| Achaerandio, MA | 1 |
| Iturricastillo, MC | 1 |
| Aizpuru, F | 1 |
| Valero, CA | 1 |
| Tobalina, R | 1 |
| Hernanz, R | 1 |
| Heller, S | 1 |
| Secrist, E | 1 |
| Shahi, A | 1 |
| Chen, AF | 1 |
| Roy, A | 2 |
| Simpson, S | 1 |
| Chandrakumaran, K | 1 |
| Alves, S | 1 |
| Coakes, J | 1 |
| Knight, J | 1 |
| Wilson, P | 1 |
| Mohamed, F | 1 |
| Cecil, T | 1 |
| Moran, B | 1 |
| Stowers, MD | 1 |
| Gomez-Cardero, P | 2 |
| Martinez-Lloreda, Á | 1 |
| Calvo, C | 1 |
| Szubski, CR | 1 |
| Beton, O | 1 |
| Saricam, E | 1 |
| Kaya, H | 1 |
| Yucel, H | 1 |
| Dogdu, O | 1 |
| Turgut, OO | 1 |
| Berkan, O | 1 |
| Tandogan, I | 1 |
| Yilmaz, MB | 1 |
| Abildgaard, JT | 1 |
| McLemore, R | 1 |
| Hattrup, SJ | 1 |
| Adanu, RM | 1 |
| Sui, WY | 1 |
| Ye, F | 1 |
| Yang, JL | 1 |
| Yan, CH | 1 |
| Mehtani, A | 2 |
| Duymus, TM | 1 |
| Aydogmus, S | 1 |
| Anand, A | 1 |
| Uğurlu, M | 1 |
| Aksekili, MA | 1 |
| Çağlar, C | 1 |
| Yüksel, K | 1 |
| Şahin, E | 1 |
| Akyol, M | 1 |
| Cao, X | 1 |
| Zhu, Q | 1 |
| Yang, TM | 1 |
| Si, HB | 2 |
| Nielsen, CS | 1 |
| Ørsnes, T | 1 |
| Foss, NB | 2 |
| Romero-Garrido, JA | 1 |
| Tengberg, PT | 2 |
| Palm, H | 1 |
| Kallemose, T | 1 |
| Rieser, GR | 1 |
| Williams, CG | 1 |
| Markert, RJ | 1 |
| Bauman, RD | 1 |
| Dong, Q | 1 |
| Zhang, YG | 1 |
| Tzatzairis, TK | 1 |
| Drosos, GI | 1 |
| Kotsios, SE | 1 |
| Ververidis, AN | 1 |
| Vogiatzaki, TD | 1 |
| Kazakos, KI | 1 |
| Churchill, JL | 1 |
| Puca, KE | 1 |
| Meyer, ES | 1 |
| Carleton, MC | 1 |
| Truchan, SL | 1 |
| Anderson, MJ | 1 |
| Garner, MR | 1 |
| Warner, SJ | 1 |
| Levack, A | 1 |
| Nellestein, AM | 1 |
| Tedore, T | 1 |
| Flores, E | 1 |
| Prokopchuk-Gauk, O | 1 |
| Rosin, MW | 1 |
| Mycyk, TR | 1 |
| Lim, HJ | 1 |
| Brose, K | 1 |
| Soroceanu, A | 1 |
| Oren, JH | 1 |
| Hostin, R | 1 |
| Mundis, GM | 1 |
| Ames, CP | 1 |
| Burton, DC | 1 |
| Bess, S | 1 |
| Gupta, MC | 1 |
| Deviren, V | 1 |
| Shin, YS | 1 |
| Yoon, JR | 1 |
| Lee, HN | 1 |
| Park, SH | 2 |
| Lee, DH | 1 |
| Akgül, T | 1 |
| Büget, M | 1 |
| Salduz, A | 1 |
| Küçükay, S | 1 |
| Şen, C | 1 |
| Nie, X | 1 |
| Gong, J | 1 |
| Cai, M | 2 |
| Lee, QJ | 1 |
| Chang, WY | 1 |
| Wong, YC | 1 |
| Mayeux, J | 1 |
| Alwon, K | 1 |
| Collins, S | 1 |
| Hewer, I | 1 |
| Xiao, W | 1 |
| Wang, T | 1 |
| Martin, DT | 1 |
| Gries, H | 1 |
| Esmonde, N | 1 |
| Diggs, B | 1 |
| Koh, J | 1 |
| Selden, NR | 1 |
| Schreiber, M | 1 |
| Kuang, AA | 1 |
| Rowden, NJ | 1 |
| Kirsh, G | 1 |
| Jiang, X | 1 |
| Song, EK | 2 |
| Seon, JK | 2 |
| Seol, YJ | 1 |
| Park, YJ | 2 |
| Jin, C | 2 |
| Guild, GN | 1 |
| Runner, RP | 1 |
| Castilleja, GM | 1 |
| Smith, MJ | 1 |
| Vu, CL | 1 |
| Liu, F | 1 |
| Spanyer, J | 1 |
| Patel, J | 1 |
| Emberton, E | 1 |
| Hallstrom, B | 1 |
| Singal, B | 1 |
| Cowen, ME | 1 |
| Roberts, KC | 1 |
| Hughes, RE | 1 |
| Nascimento, B | 1 |
| Pawliszyn, J | 1 |
| McCluskey, SA | 3 |
| Fígar, A | 1 |
| Mc Loughlin, S | 1 |
| Scordo, W | 1 |
| An, Y | 1 |
| Shang, J | 1 |
| Zheng, B | 1 |
| Rui, M | 1 |
| R Baylis, J | 1 |
| Finkelstein-Kulka, A | 1 |
| Macias-Valle, L | 1 |
| Manji, J | 1 |
| Lee, M | 1 |
| Levchenko, E | 1 |
| Okpaleke, C | 1 |
| Al-Salihi, S | 1 |
| Javer, A | 1 |
| J Kastrup, C | 1 |
| Kushioka, J | 1 |
| Yamashita, T | 1 |
| Okuda, S | 1 |
| Maeno, T | 1 |
| Matsumoto, T | 2 |
| Yamasaki, R | 1 |
| Iwasaki, M | 1 |
| Ge, W | 1 |
| Maniar, RN | 2 |
| Singhi, T | 2 |
| Patil, A | 1 |
| Kumar, G | 3 |
| Maniar, P | 1 |
| Singh, J | 2 |
| Aziz, M | 1 |
| Mahmood, SB | 1 |
| Ahmad, T | 2 |
| Yuan, QM | 1 |
| Zhao, ZH | 1 |
| Xu, BS | 1 |
| Kasparek, MF | 1 |
| Faschingbauer, M | 1 |
| Waldstein, W | 1 |
| Boettner, CS | 1 |
| Zhang, XQ | 1 |
| Ge, WH | 1 |
| Amour, J | 2 |
| Garnier, M | 1 |
| Szymezak, J | 1 |
| Le Manach, Y | 1 |
| Helley, D | 1 |
| Bertil, S | 1 |
| Riou, B | 1 |
| Gaussem, P | 1 |
| Fu, Y | 1 |
| Han, B | 1 |
| Ye, Y | 1 |
| You, T | 1 |
| Jing, J | 1 |
| Delanois, RE | 1 |
| Gwam, C | 1 |
| Mistry, JB | 1 |
| Chughtai, M | 1 |
| Thomas, M | 1 |
| Mudaliar, PP | 1 |
| Khlopas, A | 1 |
| Tangri, V | 1 |
| Bansal, A | 1 |
| Arora, A | 1 |
| Lin, C | 1 |
| Qi, Y | 1 |
| Jie, L | 1 |
| Li, HB | 1 |
| Zhao, XC | 1 |
| Qin, L | 1 |
| Jiang, XQ | 1 |
| Zhang, ZH | 1 |
| Ma, L | 1 |
| Baruah, RK | 1 |
| Borah, PJ | 1 |
| Haque, R | 1 |
| Jiang, D | 1 |
| Quan, Z | 1 |
| Effeney, P | 1 |
| Fiddelaers, L | 1 |
| Smith, B | 1 |
| Towell, B | 1 |
| Chen, TP | 1 |
| Chen, YM | 1 |
| Jiao, JB | 1 |
| Wang, YF | 1 |
| Qian, LG | 1 |
| Guo, Z | 1 |
| Ma, Z | 1 |
| Han, CY | 1 |
| Shi, TH | 1 |
| Sawalha, S | 1 |
| Borbora, A | 1 |
| Peter, V | 1 |
| Hu, KZ | 1 |
| Sun, HY | 1 |
| Sui, C | 1 |
| Gao, WJ | 1 |
| Yang, JS | 1 |
| Gu, H | 1 |
| Md, MZ | 1 |
| Sun, K | 1 |
| Hao, DJ | 1 |
| Li, JF | 1 |
| Wu, HF | 1 |
| Vara, AD | 1 |
| Pinkas, DE | 1 |
| Gowda, A | 1 |
| Wiater, BP | 1 |
| Dasar, U | 1 |
| Satilmis, AB | 1 |
| Basaran, SH | 1 |
| Akkaya, M | 1 |
| Bozkurt, M | 1 |
| Badenoch, A | 1 |
| Sharma, A | 1 |
| Gower, S | 1 |
| Selzner, M | 1 |
| Srinivas, C | 1 |
| van Diepen, S | 1 |
| Merrill, PD | 1 |
| Carrier, M | 1 |
| Tardif, JC | 1 |
| Podgoreanu, M | 1 |
| Alexander, JH | 1 |
| Lopes, RD | 1 |
| Colomina, MJ | 3 |
| Koo, M | 2 |
| Pizones, J | 1 |
| Mora, L | 2 |
| Bagó, J | 3 |
| Cladis, FP | 1 |
| Glover, CD | 1 |
| Fernandez, AM | 1 |
| Tay, DKJ | 1 |
| Deloge, E | 1 |
| Scherrer, B | 1 |
| Kayupov, E | 1 |
| Okroj, K | 1 |
| Plummer, DR | 1 |
| Moric, M | 1 |
| Gerlinger, TL | 1 |
| Gertler, R | 3 |
| Gruber, M | 1 |
| Urien, S | 1 |
| Martin, K | 5 |
| Tassani-Prell, P | 1 |
| Braun, S | 2 |
| Burg, S | 1 |
| Wiesner, G | 5 |
| Takagi, H | 2 |
| Ando, T | 1 |
| Umemoto, T | 2 |
| Ohashi, N | 1 |
| Ohashi, M | 1 |
| Endo, N | 2 |
| Kohno, T | 1 |
| Hooda, B | 1 |
| Chouhan, RS | 1 |
| Rath, GP | 1 |
| Bithal, PK | 1 |
| Suri, A | 1 |
| Lamsal, R | 1 |
| Lindvall, G | 1 |
| Sartipy, U | 1 |
| Ivert, T | 1 |
| van der Linden, J | 1 |
| Taneja, R | 1 |
| Fernandes, P | 1 |
| Marwaha, G | 1 |
| Cheng, D | 1 |
| Bainbridge, D | 1 |
| Rosencher, N | 2 |
| Bellamy, L | 2 |
| Chabbouh, T | 1 |
| Arnaout, L | 1 |
| Ozier, Y | 1 |
| Dietrich, W | 1 |
| Spannagl, M | 2 |
| Boehm, J | 1 |
| Hauner, K | 1 |
| Schuster, T | 1 |
| Busley, R | 1 |
| Rampersaud, YR | 1 |
| Lewis, S | 1 |
| Ahn, H | 1 |
| De Silva, Y | 1 |
| Abrishami, A | 2 |
| Baig, N | 1 |
| McBroom, RJ | 1 |
| Chung, F | 2 |
| Harkness, M | 1 |
| Palmer, JB | 1 |
| Watson, D | 1 |
| Walsh, TS | 1 |
| Gill, JB | 2 |
| Chin, Y | 1 |
| Levin, A | 1 |
| Elwatidy, S | 1 |
| Jamjoom, Z | 1 |
| Elgamal, E | 1 |
| Zakaria, A | 1 |
| Turkistani, A | 1 |
| El-Dawlatly, A | 1 |
| Breuer, T | 2 |
| Wilhelm, M | 1 |
| Schreiber, C | 3 |
| Hess, J | 1 |
| Lange, R | 2 |
| Tassani, P | 4 |
| Henry, D | 1 |
| Carless, P | 1 |
| Laupacis, A | 3 |
| Choi, WS | 1 |
| Irwin, MG | 1 |
| Samman, N | 1 |
| Jonnavithula, N | 1 |
| Pochiraju, R | 1 |
| Anne, KK | 1 |
| Alkozai, EM | 1 |
| Lisman, T | 1 |
| Porte, RJ | 2 |
| Ranucci, M | 1 |
| Castelvecchio, S | 1 |
| Romitti, F | 1 |
| Isgrò, G | 1 |
| Ballotta, A | 1 |
| Conti, D | 1 |
| Schouten, ES | 1 |
| van de Pol, AC | 1 |
| Schouten, AN | 1 |
| Turner, NM | 1 |
| Jansen, NJ | 1 |
| Bollen, CW | 1 |
| Vidal, X | 1 |
| Pellisé, F | 1 |
| Tanaka, K | 1 |
| Lison, S | 1 |
| Heindl, B | 1 |
| Manabe, H | 1 |
| Kawai, N | 1 |
| Goto, SN | 1 |
| Fuentes García, D | 1 |
| Ramírez Muñoz, G | 1 |
| Rajesparan, K | 1 |
| Biant, LC | 1 |
| Ahmad, M | 1 |
| Field, RE | 1 |
| Gram, J | 1 |
| Koniari, I | 1 |
| Apostolakis, E | 1 |
| Mandellou, M | 1 |
| Martha, M | 1 |
| Mor, Y | 1 |
| Winckler, H | 1 |
| Horowitz, Z | 1 |
| Korianski, Y | 1 |
| Bar-Zakay, B | 1 |
| Seligsohn, U | 1 |
| Weber, CF | 1 |
| Schneider, AC | 1 |
| Kirschning, T | 1 |
| Hofstetter, C | 1 |
| Görlinger, K | 1 |
| Günaldi, M | 1 |
| Helvaci, A | 1 |
| Yildirim, ND | 1 |
| Kiskaç, M | 1 |
| Küçükkaya, RD | 1 |
| Fuentes, I | 1 |
| Gurusamy, KS | 2 |
| Sharma, D | 1 |
| Davidson, BR | 2 |
| Karkouti, K | 3 |
| Wijeysundera, DN | 1 |
| Yau, TM | 2 |
| Tait, G | 1 |
| Beattie, WS | 2 |
| Miquet, M | 1 |
| Quenet, S | 1 |
| Martin, P | 1 |
| Adam, P | 1 |
| Albaladejo, P | 1 |
| Mismetti, P | 1 |
| Murkin, JM | 2 |
| Falter, F | 1 |
| Granton, J | 1 |
| Young, B | 1 |
| Burt, C | 1 |
| Berta, D | 1 |
| Binns, V | 1 |
| Howard, J | 1 |
| Baldus, CR | 1 |
| Bridwell, KH | 1 |
| Okubadejo, GO | 1 |
| Eubanks, JD | 1 |
| Vaz, KM | 1 |
| Yilmaz, D | 1 |
| Akin, M | 1 |
| Ay, Y | 1 |
| Balkan, C | 1 |
| Celik, A | 1 |
| Ergün, O | 1 |
| Kavakli, K | 1 |
| Keep, SL | 1 |
| Waters, TS | 1 |
| Garbuz, DS | 1 |
| Duncan, CP | 1 |
| Masri, BA | 1 |
| Fox, MA | 1 |
| Sander, M | 1 |
| Spies, CD | 1 |
| Martiny, V | 1 |
| Rosenthal, C | 1 |
| Wernecke, KD | 1 |
| Photiadis, J | 1 |
| Sinzobahamvya, N | 1 |
| Döres, A | 1 |
| Asfour, B | 1 |
| Hraska, V | 1 |
| Sasanuma, H | 1 |
| Sekiya, H | 1 |
| Takatoku, K | 1 |
| Takada, H | 1 |
| Sugimoto, N | 1 |
| Hoshino, Y | 1 |
| Raghunathan, K | 1 |
| Connelly, NR | 1 |
| Kanter, GJ | 1 |
| Berman, M | 1 |
| Cardone, D | 1 |
| Sharples, L | 1 |
| Vuylsteke, A | 1 |
| Klein, A | 1 |
| Gerrard, C | 1 |
| Dunning, J | 1 |
| Tsui, S | 2 |
| Jenkins, D | 1 |
| Gungorduk, K | 1 |
| Yıldırım, G | 1 |
| Asıcıoğlu, O | 1 |
| Gungorduk, OC | 1 |
| Sudolmus, S | 1 |
| Ark, C | 1 |
| Liu, JM | 1 |
| Shen, JX | 1 |
| Qiu, GX | 1 |
| Vonk, AB | 2 |
| Meesters, MI | 1 |
| Schats, J | 1 |
| Romijn, JW | 1 |
| Jansen, EK | 1 |
| Boer, C | 1 |
| Adler Ma, SC | 1 |
| Brindle, W | 1 |
| Burton, G | 1 |
| Gallacher, S | 1 |
| Hong, FC | 1 |
| Manelius, I | 1 |
| Smith, A | 1 |
| Ho, W | 1 |
| Alston, RP | 1 |
| Bhattacharya, K | 1 |
| Bird, S | 1 |
| McGill, N | 1 |
| Ballal, MS | 1 |
| Mitchell, P | 1 |
| Denn, PG | 1 |
| Rahman, Z | 1 |
| Hoque, R | 1 |
| Rahman, M | 1 |
| Rahman, MS | 1 |
| Henry, DA | 3 |
| Carless, PA | 3 |
| Moxey, AJ | 3 |
| O'Connell, D | 2 |
| Stokes, BJ | 3 |
| Ishida, K | 1 |
| Tsumura, N | 1 |
| Kitagawa, A | 1 |
| Hamamura, S | 1 |
| Fukuda, K | 3 |
| Dogaki, Y | 1 |
| Kubo, S | 1 |
| Matsushita, T | 1 |
| Chin, T | 1 |
| Iguchi, T | 1 |
| Kurosaka, M | 1 |
| Kuroda, R | 1 |
| Anderson, L | 1 |
| Knorr, J | 1 |
| Macguill, M | 2 |
| Chen, WS | 1 |
| Tsutsumimoto, T | 1 |
| Shimogata, M | 1 |
| Ohta, H | 1 |
| Yui, M | 1 |
| Yoda, I | 1 |
| Misawa, H | 1 |
| Peitsidis, P | 1 |
| Kadir, RA | 2 |
| Wahba, A | 1 |
| Vonk, A | 1 |
| Bidstrup, B | 1 |
| Dadure, C | 1 |
| Sauter, M | 1 |
| Bringuier, S | 1 |
| Bigorre, M | 1 |
| Raux, O | 1 |
| Rochette, A | 1 |
| Canaud, N | 1 |
| Capdevila, X | 1 |
| Meier, PM | 1 |
| Pereira, LM | 1 |
| McGowan, FX | 2 |
| Prescilla, RP | 1 |
| Scharp, LA | 1 |
| Rogers, GF | 1 |
| Soriano, SG | 1 |
| Kaewpradub, P | 1 |
| Sterner, A | 1 |
| Hörer, J | 1 |
| Vogt, M | 1 |
| Sepah, YJ | 1 |
| Umer, M | 1 |
| Nasim, F | 1 |
| Chaudhry, MU | 1 |
| Umar, M | 1 |
| Tran, HT | 1 |
| Tjønnfjord, GE | 1 |
| Paus, A | 1 |
| Holme, PA | 1 |
| Bokesch, PM | 1 |
| Szabo, G | 1 |
| Wojdyga, R | 1 |
| Grocott, HP | 1 |
| Smith, PK | 1 |
| Vetticaden, S | 1 |
| Wheeler, A | 1 |
| McConnell, JS | 2 |
| Shewale, S | 2 |
| Munro, NA | 2 |
| Shah, K | 2 |
| Deakin, AH | 2 |
| Kinninmonth, AW | 2 |
| Farrokhi, MR | 1 |
| Kazemi, AP | 1 |
| Akbari, K | 1 |
| Movafegh, A | 1 |
| Eslamian, L | 1 |
| Dorabadi, A | 1 |
| Bharath, K | 1 |
| Bhagat, H | 1 |
| Mohindra, S | 1 |
| Wu, A | 1 |
| Shimizu, K | 1 |
| Toda, Y | 1 |
| Iwasaki, T | 1 |
| Takeuchi, M | 1 |
| Morimatsu, H | 1 |
| Egi, M | 1 |
| Suemori, T | 1 |
| Morita, K | 1 |
| Sano, S | 1 |
| Maugans, TA | 1 |
| Martin, D | 1 |
| Salisbury, S | 1 |
| Istaphanous, G | 1 |
| Tang, YM | 1 |
| Chapman, TW | 1 |
| Brooks, P | 1 |
| Crescenti, A | 1 |
| Borghi, G | 1 |
| Bignami, E | 1 |
| Bertarelli, G | 1 |
| Casiraghi, GM | 1 |
| Briganti, A | 1 |
| Montorsi, F | 1 |
| Rigatti, P | 1 |
| Ahn, SW | 1 |
| Shim, JK | 1 |
| Youn, YN | 1 |
| Song, JW | 1 |
| Yang, SY | 1 |
| Chung, SC | 1 |
| Kwak, YL | 1 |
| Dhawale, AA | 1 |
| Bastrom, T | 1 |
| Neiss, G | 1 |
| Yorgova, P | 1 |
| Yaszay, B | 1 |
| Abel, MF | 1 |
| Shufflebarger, H | 1 |
| Gabos, PG | 1 |
| Dabney, KW | 1 |
| Miller, F | 1 |
| Endres, S | 1 |
| Heinz, M | 1 |
| Wilke, A | 1 |
| Que, W | 1 |
| Graham, EM | 1 |
| Atz, AM | 1 |
| Gillis, J | 1 |
| Desantis, SM | 1 |
| Haney, AL | 1 |
| Deardorff, RL | 1 |
| Uber, WE | 1 |
| Reeves, ST | 1 |
| Bradley, SM | 1 |
| Spinale, FG | 1 |
| Neal, DE | 1 |
| Shah, NC | 1 |
| Gnanpragasam, VJ | 1 |
| Pati, V | 1 |
| Alimian, M | 1 |
| Mohseni, M | 1 |
| Pissanou, T | 1 |
| Pikhart, H | 1 |
| Vaughan, J | 1 |
| Burroughs, AK | 1 |
| Sukeik, M | 1 |
| Blenkinsopp, J | 1 |
| Mason, JM | 1 |
| Eschen, CT | 1 |
| Sankar, D | 1 |
| Krishnan, R | 1 |
| Veerabahu, M | 1 |
| Vikraman, B | 1 |
| Vergnaud, E | 1 |
| Vecchione, A | 1 |
| Blanot, S | 1 |
| di Rocco, F | 1 |
| Arnaud, E | 1 |
| Renier, D | 1 |
| Meyer, P | 1 |
| Khurana, A | 1 |
| Guha, A | 1 |
| Saxena, N | 1 |
| Pugh, S | 1 |
| Ahuja, S | 1 |
| Nayak, RM | 1 |
| Maniar, PR | 1 |
| Almenara, M | 1 |
| Gich, I | 1 |
| Willems, A | 1 |
| Melot, C | 2 |
| De Hert, S | 1 |
| Van der Linden, P | 1 |
| Edwards, P | 1 |
| Yang, ZG | 1 |
| Chen, WP | 1 |
| Imai, N | 1 |
| Dohmae, Y | 1 |
| Suda, K | 1 |
| Miyasaka, D | 1 |
| Ito, T | 1 |
| Brum, MR | 1 |
| Miura, MS | 1 |
| Castro, SF | 1 |
| Machado, GM | 1 |
| Lima, LH | 1 |
| Lubianca Neto, JF | 1 |
| Seo, JG | 1 |
| Moon, YW | 1 |
| Kim, SM | 1 |
| Ko, KR | 1 |
| Yagi, M | 1 |
| Hasegawa, J | 1 |
| Nagoshi, N | 1 |
| Iizuka, S | 1 |
| Kaneko, S | 1 |
| Takemitsu, M | 1 |
| Shioda, M | 1 |
| Machida, M | 1 |
| Chareancholvanich, K | 1 |
| Siriwattanasakul, P | 1 |
| Narkbunnam, R | 1 |
| Dell'Amore, A | 1 |
| Caroli, G | 1 |
| Nizar, A | 1 |
| Cassanelli, N | 1 |
| Luciano, G | 1 |
| Greco, D | 1 |
| Dolci, G | 1 |
| Bini, A | 1 |
| Stella, F | 1 |
| Irisson, E | 2 |
| Hémon, Y | 2 |
| Pauly, V | 1 |
| Parratte, S | 2 |
| Argenson, JN | 2 |
| Kerbaul, F | 2 |
| Bastrom, TP | 1 |
| Shufflebarger, HL | 1 |
| Sucato, DJ | 1 |
| Basta, MN | 1 |
| Taylor, JA | 1 |
| Joseph, L | 1 |
| Shapiro, S | 1 |
| Chan, CC | 1 |
| Chan, YY | 1 |
| Tanweer, F | 1 |
| de Jonge, T | 1 |
| Cho, KY | 1 |
| Khurana, S | 1 |
| Mahaffey, R | 1 |
| Hamilton, A | 1 |
| Phelan, R | 1 |
| Arellano, R | 2 |
| Beckerman, Z | 1 |
| Shopen, Y | 1 |
| Alon, H | 1 |
| Cohen, O | 1 |
| Nir, RR | 1 |
| Adler, Z | 1 |
| Bolotin, G | 1 |
| Randhawa, MS | 1 |
| Ganesamoni, R | 1 |
| Singh, SK | 1 |
| Riddell, RE | 1 |
| Buth, KJ | 2 |
| Sullivan, JA | 2 |
| Sentürk, MB | 1 |
| Cakmak, Y | 1 |
| Yildiz, G | 1 |
| Yildiz, P | 1 |
| Atik, OS | 1 |
| Song, G | 2 |
| Hu, J | 2 |
| Zhu, S | 2 |
| Panchmatia, JR | 1 |
| Chegini, S | 1 |
| Lobban, C | 1 |
| Shah, G | 1 |
| Stapleton, C | 1 |
| Smallman, JM | 1 |
| Kucheria, R | 1 |
| Luo, E | 1 |
| Feng, G | 1 |
| Tomita, T | 1 |
| Sugamoto, K | 1 |
| Hideki, Y | 1 |
| Hamada, M | 1 |
| Zabeeda, D | 1 |
| Medalion, B | 1 |
| Sverdlov, M | 1 |
| Ezra, S | 1 |
| Schachner, A | 1 |
| Ezri, T | 1 |
| Cohen, AJ | 1 |
| Veien, M | 2 |
| Sørensen, JV | 1 |
| Madsen, F | 1 |
| Juelsgaard, P | 2 |
| Vacharaksa, K | 1 |
| Prakanrattana, U | 1 |
| Suksompong, S | 1 |
| Chumpathong, S | 1 |
| Kajihara, A | 1 |
| Kurehara, H | 1 |
| Kitaguchi, K | 1 |
| Furuya, H | 1 |
| Morimoto, Y | 1 |
| Kirita, T | 1 |
| Takahashi, Y | 2 |
| Garcia-Darennes, F | 1 |
| Darennes, J | 1 |
| Freidel, M | 1 |
| Breton, P | 1 |
| Ait Houssa, M | 2 |
| Boulahya, A | 2 |
| Wahid, FA | 2 |
| Elbekkali, Y | 1 |
| Amahzoune, B | 2 |
| Selkane, C | 2 |
| Elkirat, A | 2 |
| Jabrani, K | 1 |
| Ibbat, D | 1 |
| Azendour, H | 2 |
| Mamoun, F | 1 |
| Arji, M | 1 |
| Jares, M | 2 |
| Vanek, T | 2 |
| Straka, Z | 2 |
| Brucek, P | 2 |
| Koh, MB | 1 |
| Øberg, BL | 1 |
| Lauritsen, AØ | 1 |
| Gravesen, HS | 1 |
| Erichsen, H | 1 |
| Ho, KM | 1 |
| Ismail, H | 1 |
| Durán de la Fuente, P | 1 |
| García-Fernández, J | 1 |
| Pérez-López, C | 1 |
| Carceller, F | 1 |
| Gilsanz Rodríguez, F | 1 |
| Hynes, M | 1 |
| Calder, P | 2 |
| Scott, G | 2 |
| Carter, G | 1 |
| Goss, A | 1 |
| Lloyd, J | 1 |
| Tocchetti, R | 1 |
| Lemay, E | 1 |
| Guay, J | 1 |
| Côté, C | 1 |
| Hekmat, K | 1 |
| Zimmermann, T | 1 |
| Kampe, S | 1 |
| Kasper, SM | 1 |
| Weber, HJ | 1 |
| Geissler, HJ | 1 |
| Mehlhorn, U | 1 |
| Gai, MY | 1 |
| Wu, LF | 1 |
| Su, QF | 1 |
| Tatsumoto, K | 1 |
| Blønd, L | 1 |
| Sonne-Holm, S | 1 |
| Holm, G | 1 |
| Jacobsen, TW | 1 |
| Gebuhr, P | 1 |
| Tobias, JD | 1 |
| Neilipovitz, DT | 2 |
| Zellin, G | 1 |
| Rasmusson, L | 1 |
| Pålsson, J | 1 |
| Kahnberg, KE | 1 |
| Garneti, N | 1 |
| Field, J | 1 |
| Casati, V | 4 |
| Della Valle, P | 1 |
| Benussi, S | 2 |
| Franco, A | 2 |
| Gerli, C | 2 |
| Baili, P | 1 |
| Alfieri, O | 3 |
| D'Angelo, A | 1 |
| Yamasaki, S | 2 |
| Masuhara, K | 2 |
| Fuji, T | 2 |
| Tenholder, M | 1 |
| Kafali, H | 1 |
| Roberts, HR | 1 |
| Escobar, M | 1 |
| Monroe, DM | 1 |
| Arora, RC | 1 |
| Légaré, JF | 1 |
| Hirsch, GM | 1 |
| Rannikko, A | 1 |
| Pétas, A | 1 |
| Taari, K | 1 |
| Zohar, E | 3 |
| Ellis, M | 2 |
| Ifrach, N | 2 |
| Stern, A | 3 |
| Sapir, O | 1 |
| Fredman, B | 3 |
| Diprose, P | 1 |
| Herbertson, MJ | 1 |
| O'Shaughnessy, D | 1 |
| Deakin, CD | 1 |
| Gill, RS | 1 |
| Bulutcu, FS | 1 |
| Ozbek, U | 1 |
| Polat, B | 1 |
| Yalçin, Y | 1 |
| Karaci, AR | 1 |
| Bayindir, O | 1 |
| De Bels, D | 1 |
| Demeere, JL | 1 |
| Dugauquier, J | 1 |
| Louis, P | 1 |
| Van der Vorst, E | 1 |
| Yasim, A | 1 |
| Aşik, R | 1 |
| Atahan, E | 1 |
| Bacsik, J | 1 |
| Sullivan, LJ | 1 |
| Shapiro, F | 2 |
| Hynes, MC | 1 |
| Rosenfeld, P | 1 |
| Shore-Lesserson, L | 1 |
| Bodian, C | 1 |
| Vela-Cantos, F | 1 |
| Silvay, G | 1 |
| Reich, DL | 1 |
| Fajt, R | 1 |
| Jirasek, K | 1 |
| Kolesar, M | 1 |
| Maly, M | 1 |
| Pettersson, LG | 1 |
| Lisander, B | 1 |
| Wu, CC | 1 |
| Ho, WM | 1 |
| Cheng, SB | 1 |
| Yeh, DC | 1 |
| Wen, MC | 1 |
| Liu, TJ | 1 |
| P'eng, FK | 1 |
| Mangano, DT | 1 |
| Tudor, IC | 1 |
| Dietzel, C | 1 |
| Niskanen, RO | 1 |
| Korkala, OL | 1 |
| Camarasa, MA | 1 |
| Ollé, G | 1 |
| Serra-Prat, M | 2 |
| Martín, A | 1 |
| Sánchez, M | 1 |
| Ricós, P | 1 |
| Pérez, A | 1 |
| Opisso, L | 1 |
| van der Linden, PJ | 1 |
| Wijns, W | 1 |
| de Pauw, L | 1 |
| Vandestadt, J | 1 |
| Hut, F | 1 |
| Pradier, O | 1 |
| Martínez Rodríguez, E | 1 |
| Mato, M | 1 |
| Otero, J | 1 |
| Ferri, JR | 1 |
| Gonzálvez, A | 1 |
| Torres, LM | 1 |
| Groenland, TH | 1 |
| Rada, RE | 1 |
| Rosenstein, A | 1 |
| Alberca, I | 1 |
| Asuero, MS | 1 |
| Bóveda, JL | 1 |
| Carpio, N | 1 |
| Contreras, E | 1 |
| Fernández-Mondéjar, E | 1 |
| Forteza, A | 1 |
| García-Erce, JA | 1 |
| García de Lorenzo, A | 1 |
| Gomar, C | 1 |
| Gómez, A | 1 |
| Llau, JV | 1 |
| López-Fernández, MF | 1 |
| Moral, V | 1 |
| Páramo, JA | 1 |
| Torrabadella, P | 1 |
| Quintana, M | 1 |
| Sánchez, C | 1 |
| Body, SC | 1 |
| Cravens, GT | 1 |
| Brown, MJ | 1 |
| Brown, DR | 1 |
| Wass, CT | 1 |
| Sarris, I | 1 |
| Arafa, A | 1 |
| Konaris, L | 1 |
| Bechstein, WO | 1 |
| Strey, C | 1 |
| Gunaydin, B | 1 |
| Ozkose, Z | 1 |
| Pezek, S | 1 |
| Simone, CD | 1 |
| Palmieri, NM | 1 |
| Coppola, D | 1 |
| Lanza, F | 1 |
| Ruosi, C | 1 |
| Amoriello, A | 1 |
| Di Minno, G | 1 |
| Molloy, DO | 1 |
| Archbold, HA | 1 |
| Ogonda, L | 1 |
| McConway, J | 1 |
| Wilson, RK | 1 |
| Beverland, DE | 1 |
| Varela Crespo, CA | 1 |
| Sanabria Carretero, P | 1 |
| Palomero Rodríguez, MA | 1 |
| Tormo las de Heras, C | 1 |
| Rodríguez Pérez, E | 1 |
| Goldman Tarlousky, L | 1 |
| Caglar, GS | 1 |
| Tasci, Y | 1 |
| Kayikcioglu, F | 1 |
| Haberal, A | 1 |
| Brown, JR | 1 |
| Birkmeyer, NJ | 1 |
| O'Connor, GT | 1 |
| Maddali, MM | 1 |
| Rajakumar, MC | 1 |
| Namazi, H | 1 |
| Mozaffarian, K | 1 |
| El Bekkali, Y | 1 |
| Moutaki Allah, Y | 1 |
| Ibat, D | 1 |
| Drissi, M | 1 |
| Alvarez, JC | 1 |
| Santiveri, FX | 1 |
| Ramos, I | 1 |
| Vela, E | 1 |
| Puig, L | 1 |
| Escolano, F | 1 |
| Chau, A | 1 |
| Ansermino, M | 1 |
| Tredwell, S | 1 |
| Purdy, R | 1 |
| Mouton, R | 1 |
| Finch, D | 1 |
| Davies, I | 1 |
| Binks, A | 1 |
| Shuhaiber, JH | 1 |
| Goldsmith, K | 1 |
| Large, SR | 1 |
| Lozano, M | 1 |
| Peidro, L | 1 |
| Merino, I | 1 |
| Segur, JM | 1 |
| Pereira, A | 1 |
| Cid, J | 1 |
| Lozano, L | 1 |
| Mazzara, R | 1 |
| Macule, F | 1 |
| Turturro, F | 1 |
| Rocca, B | 1 |
| Montanaro, A | 1 |
| Camarasa Godoy, MA | 1 |
| Palomera Fanegas, E | 1 |
| Trudell, J | 1 |
| McMurdy, N | 1 |
| Corbeau, JJ | 1 |
| Monrigal, JP | 1 |
| Jacob, JP | 1 |
| Cottineau, C | 1 |
| Moreau, X | 1 |
| Bukowski, JG | 1 |
| Subayi, JB | 1 |
| Delhumeau, A | 1 |
| Boughenou, F | 1 |
| Madi-Jebara, S | 1 |
| Massonnet-Castel, S | 1 |
| Benmosbah, L | 1 |
| Carpentier, A | 1 |
| Cousin, MT | 1 |
| Guenther, CR | 1 |
| Fremes, SE | 1 |
| Wong, BI | 1 |
| Lee, E | 1 |
| Mai, R | 1 |
| Christakis, GT | 1 |
| McLean, RF | 1 |
| Goldman, BS | 1 |
| Naylor, CD | 1 |
| Blauhut, B | 1 |
| Harringer, W | 1 |
| Bettelheim, P | 1 |
| Doran, JE | 1 |
| Späth, P | 1 |
| Lundsgaard-Hansen, P | 1 |
| Hardy, JF | 2 |
| Bélisle, S | 2 |
| Speekenbrink, RG | 1 |
| Wildevuur, CR | 1 |
| Eijsman, L | 1 |
| Royston, D | 2 |
| Pugh, SC | 1 |
| Wielogorski, AK | 1 |
| Benoni, G | 3 |
| Carlsson, A | 1 |
| Petersson, C | 1 |
| Fredin, H | 2 |
| Karski, JM | 3 |
| Teasdale, SJ | 4 |
| Norman, P | 1 |
| Carroll, J | 2 |
| VanKessel, K | 1 |
| Wong, P | 1 |
| Glynn, MF | 5 |
| Penta de Peppo, A | 1 |
| Pierri, MD | 1 |
| Scafuri, A | 1 |
| De Paulis, R | 1 |
| Colantuono, G | 1 |
| Caprara, E | 1 |
| Tomai, F | 1 |
| Chiariello, L | 1 |
| Couto, WJ | 1 |
| Gregori Júnior, F | 1 |
| Cordeiro, CO | 1 |
| Silva, SS | 1 |
| Ketzer, JL | 1 |
| Silva, L | 1 |
| Rosa, V | 1 |
| Freitas, M | 1 |
| Wanderley, WR | 1 |
| Hiippala, S | 1 |
| Strid, L | 1 |
| Wennerstrand, M | 1 |
| Arvela, V | 1 |
| Mäntylä, S | 1 |
| Ylinen, J | 1 |
| Niemelä, H | 1 |
| Horrow, JC | 1 |
| Van Riper, DF | 1 |
| Strong, MD | 1 |
| Grunewald, KE | 1 |
| Parmet, JL | 1 |
| Rousou, JA | 1 |
| Engelman, RM | 1 |
| Flack, JE | 1 |
| Deaton, DW | 1 |
| Owen, SG | 1 |
| Norman, PH | 1 |
| Carroll, JA | 1 |
| Weisel, RD | 2 |
| Borea, G | 1 |
| Montebugnoli, L | 1 |
| Capuzzi, P | 1 |
| Magelli, C | 1 |
| Rubens, F | 1 |
| Wells, P | 1 |
| Harmon, DE | 1 |
| Zonis, Z | 1 |
| Seear, M | 1 |
| Reichert, C | 1 |
| Sett, S | 1 |
| Allen, C | 1 |
| Menichetti, A | 1 |
| Tritapepe, L | 1 |
| Ruvolo, G | 1 |
| Speziale, G | 1 |
| Cogliati, A | 1 |
| Di Giovanni, C | 1 |
| Pacilli, M | 1 |
| Criniti, A | 1 |
| Boylan, JF | 1 |
| Klinck, JR | 1 |
| Sandler, AN | 1 |
| Greig, PD | 1 |
| Nierenberg, H | 1 |
| Roger, SL | 1 |
| Howes, JP | 1 |
| Cohen, AT | 1 |
| As, AK | 1 |
| Hagen, P | 1 |
| Webb, JB | 1 |
| Hiippala, ST | 1 |
| Strid, LJ | 1 |
| Wennerstrand, MI | 1 |
| Arvela, JV | 1 |
| Niemelä, HM | 1 |
| Mäntylä, SK | 1 |
| Kuisma, RP | 1 |
| Ylinen, JE | 1 |
| Katoh, J | 1 |
| Tsuchiya, K | 1 |
| Sato, W | 1 |
| Nakajima, M | 2 |
| Iida, Y | 1 |
| van der Staak, FH | 1 |
| de Haan, AF | 1 |
| Geven, WB | 1 |
| Festen, C | 1 |
| Reid, RW | 1 |
| Zimmerman, AA | 1 |
| Laussen, PC | 1 |
| Mayer, JE | 1 |
| Gorlin, JB | 1 |
| Burrows, FA | 1 |
| Dryden, PJ | 2 |
| O'Connor, JP | 2 |
| Jamieson, WR | 2 |
| Reid, I | 1 |
| Ansley, D | 1 |
| Sadeghi, H | 2 |
| Burr, LH | 1 |
| Munro, AI | 1 |
| Merrick, PM | 2 |
| Brown, RS | 1 |
| Thwaites, BK | 1 |
| Mongan, PD | 1 |
| Ansley, DM | 1 |
| Dupont, C | 1 |
| Harel, F | 1 |
| Robitaille, D | 1 |
| Roy, M | 1 |
| Gagnon, L | 1 |
| Lambert, W | 1 |
| Brisebois, FJ | 1 |
| Wharton, TJ | 1 |
| Carrier, RC | 1 |
| Boyle, D | 1 |
| Rowe, BH | 1 |
| Bernardoni-Socorro, C | 1 |
| Arteaga-Vizcaino, M | 1 |
| Villamizar, Y | 1 |
| Diez-Ewald, M | 1 |
| Vizcaíno-Salazar, G | 1 |
| Torres-Guerra, E | 1 |
| Quintero, J | 1 |
| Okuyama, K | 1 |
| Matsukawa, T | 1 |
| Abe, F | 1 |
| Kumazawa, T | 1 |
| Shimamura, Y | 1 |
| Hirayama, T | 1 |
| Misumi, H | 1 |
| Shimokawa, T | 1 |
| Uesugi, H | 1 |
| Uemura, K | 1 |
| Misfeld, M | 1 |
| Dubbert, S | 1 |
| Eleftheriadis, S | 1 |
| Siemens, HJ | 1 |
| Sievers, HH | 1 |
| Dowd, NP | 1 |
| Joiner, R | 1 |
| Peniston, C | 1 |
| Bailey, K | 1 |
| Cheng, DC | 1 |
| Bach, KF | 1 |
| Kjoergaard, J | 1 |
| Christensen, HR | 1 |
| Bevan, DH | 1 |
| Luban, I | 1 |
| Jedeikin, R | 2 |
| Guzzon, D | 2 |
| Oppizzi, M | 2 |
| Cossolini, M | 2 |
| Torri, G | 2 |
| Calori, G | 3 |
| Levi, M | 1 |
| Cromheecke, ME | 1 |
| de Jonge, E | 1 |
| Prins, MH | 1 |
| de Mol, BJ | 1 |
| Briët, E | 1 |
| Büller, HR | 1 |
| Jansen, AJ | 1 |
| Andreica, S | 1 |
| Claeys, M | 1 |
| D'Haese, J | 1 |
| Camu, F | 1 |
| Jochmans, K | 1 |
| De Bonis, M | 1 |
| Cavaliere, F | 1 |
| Alessandrini, F | 1 |
| Lapenna, E | 1 |
| Santarelli, F | 1 |
| Moscato, U | 1 |
| Schiavello, R | 1 |
| Possati, GF | 1 |
| Nuttall, GA | 2 |
| Oliver, WC | 2 |
| Ereth, MH | 2 |
| Santrach, PJ | 1 |
| Bryant, SC | 1 |
| Orszulak, TA | 1 |
| Schaff, HV | 1 |
| Cvachovec, K | 1 |
| Horácek, M | 1 |
| Vislocký, I | 1 |
| Martin-Hirsch, PL | 1 |
| Kitchener, H | 1 |
| Coker, N | 1 |
| Higgins, DJ | 1 |
| Dalmau, A | 1 |
| Sabaté, A | 1 |
| Acosta, F | 1 |
| Garcia-Huete, L | 1 |
| Sansano, T | 1 |
| Rafecas, A | 1 |
| Figueras, J | 1 |
| Jaurrieta, E | 1 |
| Parrilla, P | 1 |
| Cattaneo, M | 1 |
| Innerhofer, P | 1 |
| Kühbacher, G | 1 |
| Schobersberger, W | 1 |
| Bellotti, F | 1 |
| Ido, K | 1 |
| Neo, M | 1 |
| Asada, Y | 1 |
| Kondo, K | 1 |
| Morita, T | 1 |
| Sakamoto, T | 1 |
| Hayashi, R | 1 |
| Kuriyama, S | 1 |
| Tagariello, G | 1 |
| De Biasi, E | 1 |
| Gajo, GB | 1 |
| Risato, R | 1 |
| Radossi, P | 1 |
| Davoli, PG | 1 |
| Traldi, A | 1 |
| Ekbäck, G | 1 |
| Axelsson, K | 1 |
| Ryttberg, L | 1 |
| Edlund, B | 1 |
| Kjellberg, J | 1 |
| Weckström, J | 1 |
| Carlsson, O | 1 |
| Schött, U | 1 |
| Miyashita, T | 1 |
| Kamibayashi, T | 1 |
| Kuro, M | 1 |
| Nitu-Whalley, IC | 1 |
| Griffioen, A | 1 |
| Harrington, C | 1 |
| Lee, CA | 1 |
| Fiechtner, BK | 1 |
| Johnson, ME | 1 |
| Sujirattanawimol, N | 1 |
| Sarpal, RS | 1 |
| Oyen, LJ | 1 |
| Armellin, G | 1 |
| Casella, S | 1 |
| Guzzinati, S | 1 |
| Pasini, L | 1 |
| Marcassa, A | 1 |
| Giron, G | 1 |
| Murto, K | 1 |
| Hall, L | 1 |
| Barrowman, NJ | 1 |
| Splinter, WM | 1 |
| Uozaki, Y | 1 |
| Watanabe, G | 1 |
| Kotou, K | 1 |
| Ueyama, K | 1 |
| Doi, Y | 1 |
| Misaki, T | 1 |
| Tanaka, N | 1 |
| Sakahashi, H | 1 |
| Sato, E | 1 |
| Ishima, T | 1 |
| Ishii, S | 1 |
| Ellis, MH | 1 |
| Santagostino, E | 1 |
| Morfini, M | 1 |
| Rocino, A | 1 |
| Baudo, F | 1 |
| Scaraggi, FA | 1 |
| Gringeri, A | 1 |
| Katz, E | 1 |
| Gaitini, L | 1 |
| Samri, M | 1 |
| Egoz, N | 1 |
| Nielsen, RE | 1 |
| Ozal, E | 1 |
| Kuralay, E | 1 |
| Bingöl, H | 1 |
| Cingöz, F | 1 |
| Ceylan, S | 1 |
| Tatar, H | 1 |
| Sandrelli, L | 1 |
| Speziali, G | 1 |
| Grasso, MA | 1 |
| Spagnolo, S | 1 |
| Carson, S | 1 |
| Ivanov, J | 1 |
| Yu, R | 1 |
| Tanaka, T | 1 |
| Nakajima, N | 1 |
| Yoshioka, A | 1 |
| Fukui, H | 1 |
| Miyauchi, Y | 1 |
| Mii, Y | 1 |
| Tamai, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Tranexamic Acid in Debridement Surgery of Burns on the Volume of Bleeding in Transfusion Requirements at Centro Medico de Occidente'[NCT05855590] | Phase 3 | 20 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | ||
| PeriOperative ISchemic Evaluation-3 Trial[NCT03505723] | Phase 3 | 9,535 participants (Actual) | Interventional | 2018-06-27 | Completed | ||
| A Randomized, Parallel-group, Placebo Control, Non-inferiority Trial to Investigate the Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection[NCT04595786] | 600 participants (Actual) | Interventional | 2020-10-30 | Active, not recruiting | |||
| The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial: Tranexamic Acid (TXA) Versus Placebo to Reduce Perioperative Blood Transfusion in Patients Undergoing Liver Resection: A Randomized Controlled Trial[NCT02261415] | Phase 3 | 1,386 participants (Actual) | Interventional | 2014-11-30 | Active, not recruiting | ||
| Disorders of the Acute Phase Response Accelerated by Plasmin Activation Following Trauma and Invasive Surgery: A Prospective Study[NCT03741023] | 320 participants (Anticipated) | Interventional | 2019-12-12 | Enrolling by invitation | |||
| The Value of Tranxemic Acid to Reduce Intraoperative Blood Loss During Elective Cesarean Sections in High Risk Women: A Randomized Controlled Trial[NCT03820206] | 160 participants (Actual) | Interventional | 2019-01-31 | Completed | |||
| Low Versus High Dose Tranexamic Acid in Adult Spinal Deformity Surgery: A Randomized, Blinded, Controlled Trial[NCT02053363] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19[NCT04401423] | Phase 2 | 22 participants (Actual) | Interventional | 2021-02-10 | Completed | ||
| Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): A Pilot and Feasibility Study[NCT02840097] | Phase 2 | 31 participants (Actual) | Interventional | 2019-03-04 | Completed | ||
| Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass (the OPTIMAL Study)[NCT03782350] | Phase 4 | 3,079 participants (Actual) | Interventional | 2018-12-26 | Completed | ||
| Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery[NCT04754230] | Phase 4 | 40 participants (Actual) | Interventional | 2021-06-17 | Completed | ||
| Comparative Use of Tranexamic Acid Intravenous and Topical Application in the Treatment of Intertrochanteric Fractures With Proximate Femoral Nail[NCT04696224] | 90 participants (Anticipated) | Interventional | 2020-12-18 | Recruiting | |||
| Efficacy of Tranexamic Acid in Femoral Shaft Fractures Osteosynthesis; A Double Blind Randomized Controlled Trial[NCT04803591] | Phase 4 | 0 participants (Actual) | Interventional | 2021-08-01 | Withdrawn (stopped due to Not approved by Ethics Commettee) | ||
| Use of Tranexamic Acid in Liposculpture: A Double-blind, Multicenter, Randomized Trial[NCT04430777] | Phase 2/Phase 3 | 141 participants (Actual) | Interventional | 2019-01-17 | Completed | ||
| Efficacy of Postoperative Pain Control Between Transarticular VS Periartiucular Multimodal Drug Infiltration in Total Hip Arthroplasty: Double-blinded Randomized Control Trial[NCT05325671] | 120 participants (Anticipated) | Interventional | 2022-04-05 | Not yet recruiting | |||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Tranexamic Acid in Major Vascular Surgery. A Randomized Placebo-controlled Trial.[NCT02335359] | Phase 4 | 100 participants (Actual) | Interventional | 2015-03-04 | Completed | ||
| Extended Postoperative Tranexamic Acid Use in Primary Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial[NCT05099276] | Phase 4 | 46 participants (Actual) | Interventional | 2021-12-07 | Active, not recruiting | ||
| Efficacy of Local Hemostatic Management in Implant Surgery in Anticoagulated Patients on Warfarin: a Randomized Clinical Study[NCT04846114] | 71 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding[NCT05345613] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
| Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty - Randomized Prospective Study[NCT02152917] | Phase 4 | 45 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER: A RANDOMIZED CONTROLLED TRIAL[NCT03019198] | Phase 4 | 256 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Randomized Study on the Topical Application of Tranexamic Acid to Wound Bed for Hemostasis in the Setting Granulating Wounds Following Mohs Micrographic Surgery[NCT04541303] | Early Phase 1 | 62 participants (Anticipated) | Interventional | 2020-10-08 | Recruiting | ||
| Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer[NCT04360629] | 151 participants (Actual) | Interventional | 2020-06-03 | Completed | |||
| Efficacy of Tranexamic Acid (TXA) in Humerus ORIF[NCT05802238] | Phase 2 | 130 participants (Anticipated) | Interventional | 2023-04-12 | Recruiting | ||
| TOPICAL AND INTRAVENOUS ADMINISTRATION OF TRANEXAMIC ACID ARE EQUALLY EFFECTIVE IN DIRECT ANTERIOR TOTAL HIP ARTHROPLASTY - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL[NCT01940692] | Phase 2 | 120 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial[NCT04863339] | Phase 2 | 0 participants (Actual) | Interventional | 2022-03-31 | Withdrawn (stopped due to Challenges in recruitment) | ||
| Effect of Intravenous Tranexamic Acid Plus Intramyometrial Desmopressin on Blood Loss During Laparoscopic Myomectomy: Randomized, Double-blind, Placebo-controlled Trial[NCT05517590] | 100 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | |||
| The Efficacy and Population Pharmacokinetics/ Pharmacogenomics of a Reduced Dose of Tranexamic Acid for Craniosynostosis Surgery[NCT02188576] | Phase 4 | 66 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Does Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Reduce Blood Loss and Transfusion Requirements? A Double-blinded Randomized Controlled Trial[NCT05024253] | Phase 3 | 48 participants (Anticipated) | Interventional | 2021-08-02 | Recruiting | ||
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
| Prospective, Multicenter, Randomized, Parallel Groups Study Comparing the Safety and the Efficacy of the Administration of One Intra-articular Injection of 4.8 ml (HO-1) or Three Intra-articular Injections of 2.2 ml (HS-3) of Pandora Gel to One Intra-arti[NCT05978180] | 252 participants (Anticipated) | Interventional | 2023-10-18 | Recruiting | |||
| Prospective, Multicenter, Open Study Evaluating the Short-term Safety of Use of Pandora Administered in the Form of 1 Intra-articular Injection of Happyone or 3 Intra-articular Injections of Happysoft in Patients Suffering From Gonarthrosis[NCT05414617] | 20 participants (Actual) | Interventional | 2022-06-08 | Completed | |||
| Is Serum Gentamicin Concentration Modified With Autologous Cell-saved Blood Transfusion After Total Knee Arthroplasty Using Tranexamic Acid: A Randomized Control Trial[NCT04505748] | 40 participants (Actual) | Interventional | 2020-01-01 | Completed | |||
| Can the Prophylactic Administration of Tranexamic Acid Reduce Blood Loss After Robotic-assisted Radical Prostatectomy? The RARPEX (Robotic Assisted Radical Prostatectomy With TranEXamic Acid) Study.[NCT04319614] | Phase 4 | 200 participants (Actual) | Interventional | 2020-02-24 | Completed | ||
| Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy: a Randomized, Double-blind, Placebo-controlled Trial[NCT05816668] | Phase 3 | 122 participants (Anticipated) | Interventional | 2023-04-30 | Not yet recruiting | ||
| The Effect of Use of Tranexamic Acid in Percutaneous Nephrolithotomy on Blood Loss and Surgical Visual Clarity[NCT05947435] | 75 participants (Actual) | Interventional | 2022-01-01 | Completed | |||
| Effects of the Application of a New Pharmacological Protocol for Shoulder Arthroscopy in Beach Chair Position[NCT05397652] | Phase 4 | 104 participants (Actual) | Interventional | 2021-05-24 | Completed | ||
| HiFIT Study: Interest of Intravenous Iron and Tranexamic Acid to Reduce Transfusion in Hip Fracture Patients[NCT02972294] | Phase 3 | 419 participants (Actual) | Interventional | 2017-03-31 | Terminated (stopped due to 1year inclusion hold due to PV new fact (Monofer hold for risk revaluation) DSMB Interim analysis : 1treatment with important transfusion risk reduction/inclusions issues (COVID)/sites change of practice if study continue=>stop inclusions) | ||
| Comparison of Topical Tranexamic Acid and Floseal® on Blood Loss After Total Knee Arthroplasty in Patients With a Thromboembolic Risk[NCT02865174] | Phase 4 | 90 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | ||
| Impact of Tranexamic Acid Use in Transfusion Rate in Patients With Complex Kidney Stone Undergoing Percutaneous Nephrolithotomy: Randomised, Double-blind, Placebo Controlled Trial[NCT02966236] | Phase 4 | 192 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Comparison Between the Effect of Topical Tranexamic Acid Versus Hydrogen Peroxide on Perioperative Blood Loss in Elective Spine Surgeries[NCT05152186] | Phase 3 | 120 participants (Actual) | Interventional | 2021-06-01 | Active, not recruiting | ||
| Topical Tranexamic Acid (TXA) in Hip Fractures, A Double-Blind, Randomized Controlled Trial[NCT02993341] | Phase 3 | 65 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial[NCT04947514] | Phase 4 | 98 participants (Actual) | Interventional | 2021-10-29 | Completed | ||
| The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery Based on Rotational Thromboelastometry (ROTEM®).[NCT03897621] | 50 participants (Actual) | Interventional | 2019-05-20 | Completed | |||
| The Use of Tranexamic Acid in Chinese Elderly Patients Undergoing Femoral Nailing for Intertrochanteric Fracture: A Randomized Controlled Trial[NCT04290884] | Phase 4 | 120 participants (Anticipated) | Interventional | 2018-05-23 | Active, not recruiting | ||
| Postoperative Drainage in Total Knee Arthroplasty in the Presence of Tranexamic Acid: a Clinical Trial[NCT03915756] | 42 participants (Anticipated) | Interventional | 2019-08-22 | Recruiting | |||
| Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial[NCT02278263] | Phase 4 | 150 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| The Effectiveness Of Intravenous Tranexamic Acid (TXA) on Reducing Perioperative Blood Loss For Patients Undergoing Periacetabular Osteotomy (PAO): A Randomized Double Blind Placebo Controlled Trial[NCT03823417] | Phase 4 | 0 participants (Actual) | Interventional | 2019-07-31 | Withdrawn (stopped due to Investigators decided not to begin the study.) | ||
| A Randomised, Prospective Evaluation on the Effectiveness of Tranexamic Acid in Reducing Postoperative Swelling and Haematoma Formation After the Latarjet Procedure.[NCT03458468] | 100 participants (Actual) | Interventional | 2018-03-01 | Completed | |||
| Intravenous Administration of Tranexamic Acid Significantly Improved Clarity of Visual Field in Arthroscopic Shoulder Surgery. A Prospective, Double-blind and Randomized Controlled Trial[NCT04025736] | 72 participants (Actual) | Interventional | 2017-06-07 | Completed | |||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Role of Tranexamic Acid (TXA) in the Reduction of Post-operative Hematoma and Seroma in Patients Undergoing Panniculectomy or Abdominoplasty, a Pilot Study.[NCT04902950] | Phase 4 | 9 participants (Actual) | Interventional | 2020-08-17 | Terminated (stopped due to Logistics) | ||
| Comparative Study of the Efficiency of Oral Tranexamic Tcid vs. Oral Tminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. A Prospective, Randomized, Double Blinded Controlled Clinical Trial.[NCT03365999] | Phase 2 | 92 participants (Actual) | Interventional | 2017-10-15 | Completed | ||
| The Effects of the Timing of Tranexamic Acid Administration on Blood Loss in Hip Fractures.[NCT04488367] | Early Phase 1 | 120 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial[NCT04187014] | Phase 2 | 90 participants (Actual) | Interventional | 2020-02-06 | Completed | ||
| Effect of no Drainage Tube on Blood Loss and Recovery After High Tibial Osteotomy[NCT03954860] | 80 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| Blood-saving Effect of Kaolin-based Hemostatic Gauze Combined With Intravenous Tranexamic Acid in Total Knee Arthroplasty[NCT05504577] | Phase 4 | 120 participants (Anticipated) | Interventional | 2022-03-16 | Recruiting | ||
| Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk[NCT02797119] | Phase 4 | 225 participants (Actual) | Interventional | 2016-03-15 | Terminated (stopped due to Study will be stopped due to the impossibility of reaching the objective of inclusions within a reasonable time frame and taking into account the recommendations of the international WOMAN study) | ||
| Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery[NCT03856164] | Phase 2/Phase 3 | 110 participants (Actual) | Interventional | 2019-06-17 | Completed | ||
| Evaluation of Tranexamic Acid Prior to Surgery in the Geriatric Hip Fracture Population for the Reduction of Post-Operative Blood Transfusion[NCT03923959] | Phase 3 | 400 participants (Anticipated) | Interventional | 2020-02-01 | Active, not recruiting | ||
| Tranexamic Acid During Cystectomy Trial (TACT)[NCT01869413] | Phase 2/Phase 3 | 354 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events[NCT05313620] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis[NCT05774717] | Phase 1 | 60 participants (Anticipated) | Interventional | 2023-04-01 | Recruiting | ||
| Efficacy of Tranexamic Acid in Reducing Requirement of Blood Transfusion in Lower Limb Trauma Surgery: A Prospective Randomized Controlled Study[NCT04986813] | Phase 4 | 100 participants (Actual) | Interventional | 2017-04-01 | Completed | ||
| Study of the Noninferiority of an Oral vs Intravenous Administration of Tranexamic Acid in Total Hip Arthroplasty[NCT04691362] | Phase 4 | 230 participants (Actual) | Interventional | 2021-01-01 | Completed | ||
| Local Injection of Tranexamic Acid May Reduce Bleeding, Injection Pain, and Other Post-op Complications During Mohs Micrographic Surgery[NCT04630886] | Early Phase 1 | 200 participants (Anticipated) | Interventional | 2021-06-16 | Enrolling by invitation | ||
| Intravenous Versus Topical Use of Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries (TARGETS) : A Prospective, Randomized, Double Blind, Head-to-head Comparison Study[NCT03011866] | 176 participants (Anticipated) | Interventional | 2017-02-28 | Not yet recruiting | |||
| Topical Application Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery[NCT05708690] | Phase 4 | 132 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314] | Phase 3 | 3,242 participants (Actual) | Interventional | 2019-09-17 | Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.) | ||
| Tranexamic Acid to Prevent Bleeding After Endoscopic Resection of Large Colorectal Polyps: A Pilot Project[NCT04559880] | Phase 4 | 25 participants (Actual) | Interventional | 2020-09-10 | Active, not recruiting | ||
| Effects of Antifibrinolytics on Bleeding and Transfusion Outcomes in Patients Receiving Coronary Artery Bypass Surgery With Preoperative Clopidogrel Exposure[NCT01060163] | 552 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Prophylactic Use of Tranexamic Acid for Preventing Postpartum Hemorrhage: A Randomized, Double-blinded, Placebo-controlled Pilot Trial[NCT03069859] | Phase 2 | 31 participants (Actual) | Interventional | 2018-03-06 | Active, not recruiting | ||
| Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939] | Phase 4 | 52 participants (Actual) | Interventional | 2015-04-21 | Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.) | ||
| Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty[NCT03328832] | Phase 4 | 70 participants (Actual) | Interventional | 2017-09-12 | Completed | ||
| Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma: Controlled Clinical Trial[NCT02650856] | Phase 3 | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Randomized Control Trial Evaluating the Use of Topical Tranexamic Acid in Bilateral Breast Reduction Surgery to Prevent Bleeding Complications[NCT04918576] | Phase 3 | 106 participants (Anticipated) | Interventional | 2022-08-31 | Not yet recruiting | ||
| Effects of Tranexamic Acid for Alloplastic Breast Reconstruction: A Randomized Control Trial[NCT04918589] | Phase 3 | 106 participants (Anticipated) | Interventional | 2022-08-31 | Not yet recruiting | ||
| Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty[NCT02453802] | Phase 4 | 90 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037] | Phase 4 | 1,089 participants (Actual) | Interventional | 2016-07-07 | Completed | ||
| Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study (TAPPAS): A Randomized, Placebo-controlled Double Blind Trial[NCT02806024] | Phase 4 | 14 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| The Use of Tranexamic Acid in Irrigation Fluid to Improve Arthroscopic Visualization in Shoulder Surgery: A Randomized Controlled Trial[NCT04594408] | Phase 4 | 128 participants (Actual) | Interventional | 2020-09-01 | Active, not recruiting | ||
| Range of Motion and Function Following Primary Repair of Traumatic Zone 1 or Zone 2 Digit Flexor Tendon Injuries - Impact of Tranexamic Acid Use - A Prospective Study[NCT04178655] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2019-11-30 | Not yet recruiting | ||
| Investigation of the Blood Sparing Properties of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty[NCT02569658] | 110 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.[NCT02319915] | Early Phase 1 | 14 participants (Actual) | Interventional | 2015-02-18 | Completed | ||
| Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.[NCT02579941] | 40 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087] | Phase 3 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty: A Prospective, Double-Blind Randomized, Controlled Trial[NCT03074994] | Phase 2 | 108 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| [NCT02644473] | Phase 4 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Study did not receive IRB approval, so did not start) | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| Comparative Study For Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section: A Randomised Controlled Trial[NCT02739815] | Phase 4 | 200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section[NCT02780245] | Phase 4 | 100 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Precise Application of Topical Tranexamic Acid to Enhance Endoscopic Hemostasis for Peptic Ulcer Bleeding: A Randomized Controlled Study[NCT05248321] | 60 participants (Actual) | Interventional | 2022-03-24 | Completed | |||
| A Multi-centre Randomised, Double-blinded, Placebo-controlled Trial of Pre-hospital Treatment With Tranexamic Acid for Severely Injured Patients at Risk of Acute Traumatic Coagulopathy.[NCT02187120] | Phase 3 | 1,310 participants (Actual) | Interventional | 2014-07-28 | Completed | ||
| The Effect of Intravenous E-Aminocaproic Acid (EACA) on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy (VRO)[NCT02257580] | Phase 4 | 28 participants (Actual) | Interventional | 2015-04-01 | Completed | ||
| Tranexamic Acid Comparison in Hip Replacement (TeACH-R) Trial: Comparative Efficacy of Intravenous Versus Topical Tranexamic Acid for Reducing Blood Loss in Elective Primary Total Hip Arthroplasty.[NCT02056444] | 149 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Tranexamic Acid (TXA) During Pediatric Cardiac Surgery: A Prospective Randomised Study Comparing Two Dosing Regimens[NCT01141127] | Phase 2 | 18 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Blood Transfusion Applications in Hip Replacements: A Retrospective Study[NCT05627544] | 560 participants (Actual) | Observational | 2022-11-01 | Completed | |||
| The Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin / Hematocrit in Isolated Operative Posterior Wall Acetabular Fractures: a Prospective, Randomized, Double-blinded, Multicenter Study[NCT05357079] | Early Phase 1 | 98 participants (Anticipated) | Interventional | 2017-08-25 | Recruiting | ||
| A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss[NCT03793153] | 99 participants (Actual) | Interventional | 2018-12-19 | Completed | |||
| The Use of Tranexamic Acid to Reduce the Need for Transfusion 1 Week Post-operatively for Hemiarthroplasty or Intramedullary Nailing Needed to Correct Acute Hip Fractures[NCT02947529] | Phase 4 | 113 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty[NCT03359525] | Phase 4 | 114 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT02753816] | 25 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Study enrollment and goals unable to be reached.) | |||
| Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients: A Randomized Controlled Study[NCT03109652] | Phase 4 | 144 participants (Anticipated) | Interventional | 2017-07-10 | Recruiting | ||
| Evaluation of the Use of Tranexamic Acid in Tibial Osteotomies: a Randomised Controlled Clinical Trial.[NCT04785651] | 84 participants (Anticipated) | Interventional | 2021-02-22 | Recruiting | |||
| Efficacy of Topical Tranexamic Acid Versus Intravenous Administration to Reduce Blood Transfusion Rate in Total Knee Arthroplasty Surgery: Phase III, Unicentric, Controlled,Double Blind, Randomized Non Inferiority Clinical Trial.[NCT01881568] | Phase 3 | 79 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| By Reza Abbasi and Isfahan University of Medical Sciences[NCT02493894] | Phase 1/Phase 2 | 105 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department[NCT02930941] | Phase 4 | 35 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Terminate due to slow enrollment rate.) | ||
| Blood-saving Effect of Combined Intravenous Tranexamic Acid With Topical Floseal® Application, a Comparison With Intravenous Tranexamic Acid Only in Total Hip Arthroplasty[NCT03623789] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-08-15 | Recruiting | ||
| Prevention of Postpartum Hemorrhage With Tranexamic Acid (TXA)[NCT03326596] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2018-04-20 | Recruiting | ||
| Analgesic Efficacy of Adductor Canal Block (ACB) Before and After Primary Total Knee Arthroplasty (TKA): A Prospective Randomized Trial to Compare Postoperative Clinical Outcomes[NCT02908711] | Phase 4 | 50 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Analgesic Efficacy of Quadaratus Lumborum Block (QLB) for Laparoscopic Colectomy Surgery: A Prospective Observational Case Control Trial to Evaluate Clinical Outcomes[NCT03017638] | 14 participants (Actual) | Observational | 2017-02-27 | Completed | |||
| Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial[NCT02829346] | Phase 2 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Comparison of the Effect of Two Common Regimens of Administration of Tranexamic Acid on Hemostasis and Clinical Outcome of Patients Undergoing Total Knee Arthroplasty[NCT04443920] | Phase 4 | 86 participants (Actual) | Interventional | 2019-10-29 | Completed | ||
| An Ideal End-tidal Carbon Dioxide Level to Control Intraoperative Bleeding and Improve the Quality of Surgical Field Vision in Septorhinoplasty Operations Under General Anesthesia: a Prospective Clinical Study[NCT05497375] | 70 participants (Actual) | Interventional | 2022-08-20 | Completed | |||
| The Effect of Intraoperative Low Dose Adrenaline on Bleeding in Total Hip Arthroplasty - a Randomized Placebo-controlled Trial[NCT01708642] | Phase 3 | 106 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Does Tranexamic Acid Significantly Reduce Total Blood Loss During Proximal Femoral Nailing for the Intertrochanteric Femoral Fracture in the Elderly?[NCT05359172] | 100 participants (Actual) | Observational | 2021-04-01 | Completed | |||
| Evaluation of Efficacy and Safety of Perioperative Tranexamic Acid During Primary Total Knee Arthroplasty: A Randomized, Clinical Trial[NCT05919615] | 100 participants (Actual) | Interventional | 2021-07-15 | Completed | |||
| Do Peri-operative High Doses of Intravenous Glucocorticoids Improve Short-term Functional Outcome After Direct Anterior Total Hip Arthroplasty? A Randomized, Single Surgeon, Placebo Controlled, Double Blind Study[NCT04317872] | 70 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | |||
| The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures: A Prospective, Double-Blind, Randomized Controlled Trial[NCT01940536] | Phase 4 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn (stopped due to Possible change in study protocol) | ||
| Open Label, Non-Randomized, Study to Evaluate the Pharmacokinetics of Tranexamic Acid in Patients Undergoing Major Liver Resection[NCT01651182] | Phase 3 | 24 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Randomized Control Trial Investigating for Prophylactic Tranexamic Acid Use at Time of Minimally Invasive Myomectomies[NCT04311073] | Phase 3 | 50 participants (Anticipated) | Interventional | 2020-06-20 | Recruiting | ||
| Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery[NCT01136590] | Phase 4 | 96 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal[NCT03558516] | Phase 3 | 80 participants (Actual) | Interventional | 2018-08-01 | Completed | ||
| The Influence of High-Dose Aprotinin and Tranexamic Acid on Bleeding Tendency and Allogeneic Blood Transfusion in Patients Undergoing Primary Aortic Valve Replacement or Coronary Artery Revascularization[NCT00396760] | Phase 3 | 220 participants | Interventional | 2005-01-31 | Active, not recruiting | ||
| Topical Application of Tranexamic Acid to Reduce Postoperative Blood Loss in Posterior Approach Spinal Surgery[NCT02063035] | Phase 4 | 29 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery[NCT01728636] | Phase 2 | 61 participants (Actual) | Interventional | 2013-01-15 | Completed | ||
| Role of Topical Tranexamic Acid in Total Hip Arthroplasty[NCT01866943] | Phase 2 | 41 participants (Actual) | Interventional | 2011-11-30 | Terminated | ||
| Role of Tranexamic Acid for Reducing Blood Loss in Patients Undergoing Major Gastro-intestinal Surgery[NCT01655641] | Phase 2/Phase 3 | 118 participants (Anticipated) | Interventional | 2012-07-31 | Active, not recruiting | ||
| The PRICE Trial: Phlebotomy Resulting in Controlled Hypovolemia to Prevent Blood Loss in Major Hepatic Resections[NCT02548910] | 62 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection[NCT03323359] | 98 participants (Anticipated) | Interventional | 2017-03-17 | Recruiting | |||
| PRICE 2: A Phase 3 Randomized Controlled Trial of Phlebotomy Resulting in Controlled Hypovolemia to Prevent Blood Loss in Major Hepatic Resections[NCT03651154] | 440 participants (Anticipated) | Interventional | 2018-09-28 | Active, not recruiting | |||
| Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery[NCT01519245] | Phase 3 | 44 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Efficacy of Tranexamic Acid on Perioperative Blood Loss During Hip Fracture Surgery.[NCT00327106] | Phase 3 | 110 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid Administration of Trauma Patients: A Randomized, Double-blind Controlled Clinical Trial[NCT03846973] | Phase 3 | 220 participants (Actual) | Interventional | 2018-12-02 | Completed | ||
| The Effect of Preoperative Tranexamic Acid on Blood Loss and Transfusion Rates in Intertrochanteric and Subtrochanteric Femur Fractures.[NCT02580227] | Phase 4 | 100 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Use of Combined Tranexamic Acid and Intravenous Iron for Hip Fracture Surgery in Elderly[NCT02428868] | 150 participants (Anticipated) | Interventional | 2015-04-30 | Not yet recruiting | |||
| Seizures After Cardiac Surgery -- A Prospective Study With Continuous EEG Monitoring[NCT01291992] | 100 participants (Actual) | Observational | 2010-09-30 | Completed | |||
| Single Dose Tranexamic Acid for Dacryocystorhinostomy[NCT01221909] | 80 participants (Anticipated) | Interventional | 2010-12-31 | Not yet recruiting | |||
| Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty, a Randomized-clinical Trial.[NCT01651806] | Phase 2/Phase 3 | 65 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Indication and Treatment of Adult Kyphoscoliosis[NCT04536909] | 300 participants (Anticipated) | Observational [Patient Registry] | 2020-01-01 | Recruiting | |||
| A Prospective, Randomized, Double-blinded Single-site Control Study Comparing Blood Loss Prevention of Tranexamic Acid (TXA) to Epsilon Aminocaproic Acid (EACA) for Corrective Spinal Surgery[NCT00958581] | Phase 4 | 177 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement; A Prospective Triple-blinded Randomized Controlled Trial.[NCT01850394] | 152 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial[NCT02302456] | Phase 3 | 4,079 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| The Efficacy of Intravenous Tranexamic Acid in Decreasing Blood Loss in Pediatric Idiopathic Scoliosis Surgery?[NCT01813058] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Peroperative Tranexamic Acid as Prophylaxis of Haemorrhage in Benign Hysterectomy - a Randomized, Placebo-controlled Trial[NCT01940419] | Phase 4 | 332 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Efficacy of ε-Aminocaproic Acid (EACA) in Children Undergoing Craniofacial Reconstruction Surgery[NCT02229968] | Phase 2 | 22 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| CONSERV - 2 (Clinical Outcomes and Safety Trial to Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume) - A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery a[NCT00888940] | Phase 2 | 243 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Prospective Randomised Trial Comparing Intraoperative Topical Quixil and Intravenous Tranexamic Acid, in Reduction of Blood Loss Following Primary Hip & Knee Joint Replacement Surgery.[NCT00378872] | 132 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| Tranexamic Acid Reduces Blood Loss in Pediatric Cardiac Surgery[NCT00994994] | 160 participants (Actual) | Interventional | 2006-01-31 | Completed | |||
| The Effect of Tranexamic Acid on Blood Loss and Transfusion Rates in Major Oncologic Surgery[NCT01980355] | 76 participants (Actual) | Interventional | 2012-06-12 | Completed | |||
| Efficacy of Tranexamic Acid in Reducing Perioperative Bleeding in Patients Undergoing Radical Prostatectomy. A Randomized Controlled Double-blind Study.[NCT00670345] | Phase 4 | 0 participants | Interventional | 2008-04-30 | Completed | ||
| Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty[NCT02043132] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis Using an in Vitro Experimental Model of Fibrinolysis.[NCT02352675] | 40 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| A Randomized Comparison of Two Doses of Tranexamic Acid in Open-Heart Surgery[NCT04996368] | 120 participants (Actual) | Interventional | 2022-02-01 | Completed | |||
| The Effect of Tranexamic Acid (TXA) on Blood Loss in Burn Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT03113253] | Phase 4 | 121 participants (Actual) | Interventional | 2016-09-22 | Active, not recruiting | ||
| The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty During the Early Perioperative Period[NCT02553122] | Phase 3 | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to Data has been published on this study (this would have been a duplicate study)) | ||
| Effects on Bleeding in Knee Arthroplasty After Ischemic Preconditioning With Sevoflurane[NCT03379103] | 30 participants (Actual) | Interventional | 2018-02-02 | Completed | |||
| Use of Tranexamic Acid for Bleeding Reduction in Adenotonsillectomy in Children[NCT01228136] | Phase 4 | 95 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.[NCT01449552] | 240 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients: a Randomized Placebo-controlled Trial[NCT01895101] | Phase 4 | 750 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Efficacy and Safety of Erythropoietin And/Or Intravenous Iron Sucrose For Treatment of Anemia In Hip and Knee Arthroplasty: A Single-center Retrospective Study[NCT03917394] | 780 participants (Anticipated) | Observational | 2019-04-24 | Recruiting | |||
| Prevention of Bleeding and Edema in Bimaxillary Orthognathic Surgery; the Effectiveness of Tranexamic Acid on Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery.[NCT02229292] | Phase 4 | 104 participants (Actual) | Interventional | 2014-08-19 | Completed | ||
| Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery: A Double Blind Randomized Controlled Trial[NCT01111669] | 28 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty[NCT00375440] | 0 participants (Actual) | Interventional | 2005-02-28 | Withdrawn (stopped due to Study halted prematurely as investigator left the institution.) | |||
| Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116] | Phase 4 | 100 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Prospective, Randomized, Single-blinded, Non-inferiority Study to Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer Compared to the Unipolar Electrocautery in Primary Unilateral Total Knee Arthroplasty[NCT03952546] | 211 participants (Actual) | Interventional | 2019-05-07 | Completed | |||
| Tranexamic Acid for the Reduction of Allogeneic Blood Exposure in Infants and Children Having Craniofacial Surgery[NCT00722436] | Phase 4 | 20 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Study dose changed based on recent publications) | ||
| Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery - The InCreAS Trial[NCT02598271] | 200 participants (Actual) | Observational | 2016-10-31 | Completed | |||
| Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis[NCT04855110] | 114 participants (Anticipated) | Interventional | 2021-04-19 | Recruiting | |||
| Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery[NCT04058665] | 300 participants (Actual) | Observational | 2019-06-18 | Completed | |||
| The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery: A Randomized, Prospective, Double-Blinded Study[NCT00671281] | 74 participants (Anticipated) | Interventional | 2008-10-31 | Withdrawn (stopped due to Study was cancelled) | |||
| Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section[NCT02350179] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | ||
| The Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty[NCT01815918] | Phase 4 | 60 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To compare the estimated blood loss in patients undergoing complex, reconstructive, spinal fusion surgeries receiving one of two dosing protocols for the anti-fibrinolytic, TXA.~Estimated blood loss was calculated by suction canister volume minus intraoperative irrigation fluid plus blood content in sponges as estimated by weight for all cases." (NCT02053363)
Timeframe: This outcome is measured during surgery, from exposure to wound closure, approximately 8 hours.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 2046 |
| Standard of Care/Control | 1596 |
To compare the rates of intraoperative complications and 90 day complications observed in the two groups. (NCT02053363)
Timeframe: Perioperative complications were defined as complications occurring within 90 days of surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| High Dose/Study Group | 2 |
| Standard of Care/Control | 3 |
To compare the mean volume (mL) of packed red blood cell (PRBC) transfusions given to the two groups. Volumes of RBC vary from bag to bag and real volumes will be recorded as provided by the blood bank. (NCT02053363)
Timeframe: Participants will be followed for the duration of their hospital stay measured from day of surgery to day of discharge from the hospital, approximately 7 days.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 1259 |
| Standard of Care/Control | 935 |
Calculated from baseline (at enrollment) to end of study (NCT04401423)
Timeframe: Day 1 and Day 10
| Intervention | mg/dL (Mean) |
|---|---|
| TXA127 | 0.92 |
| Placebo | 0.70 |
(NCT04401423)
Timeframe: Day 1 to Day 10
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA127 | 1 |
| Placebo | 0 |
(NCT04401423)
Timeframe: Up to Day 10
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA127 | 3 |
| Placebo | 1 |
(NCT04401423)
Timeframe: Up to Day 10
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA127 | 0 |
| Placebo | 0 |
(NCT04401423)
Timeframe: From Day 1 to Day 10
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA127 | 3 |
| Placebo | 2 |
(NCT04401423)
Timeframe: Day 1 and Day 10
| Intervention | percent change of oxygen (Mean) |
|---|---|
| TXA127 | 0.71 |
| Placebo | 0.91 |
(NCT04401423)
Timeframe: Day 5
| Intervention | pg/ml (Median) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interferon-γ | IL-1β | IL-1Ra | IL-2 | IL-4 | IL-5 | IL-6 | IL-8 | TNF-α | IL-10 | IL-12p40 | IL-12p70 | IL-13 | MCP-1 | |
| Placebo | 0.78 | 50.6 | 7.38 | 0.91 | 0.74 | 0.99 | 1.34 | 14.3 | 42.1 | 4.19 | 29.8 | 1.21 | 11.4 | 237 |
| TXA127 | 0.88 | 14.4 | 17.77 | 0.20 | 0.09 | 3.36 | 12.88 | 24.5 | 31.1 | 2.46 | 45.40 | 1.28 | 10.71 | 218 |
(NCT04401423)
Timeframe: Day 1
| Intervention | pg/ml (Median) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interferon-γ | IL-1β | IL-1Ra | IL-2 | IL-4 | IL-5 | IL-6 | IL-8 | TNF-α | IL-10 | IL-12p40 | IL-12p70 | IL-13 | MCP-1 | |
| Placebo | 1.0 | 30.6 | 7.6 | 0.37 | 0.21 | 1.21 | 3.35 | 16.2 | 45.9 | 10.8 | 28.9 | 0.63 | 8.5 | 283 |
| TXA127 | 1.44 | 20.7 | 15.9 | 0.52 | 0.41 | 1.72 | 9.63 | 24.4 | 68.4 | 12.3 | 32.4 | 1.74 | 9.9 | 345 |
(NCT04401423)
Timeframe: Day 1 to Day 10
| Intervention | days (Median) | |
|---|---|---|
| Length of Hospital Stay | Days of Drug/placebo administration | |
| Placebo | 7 | 5 |
| TXA127 | 11 | 4 |
Total volume of packed red blood cells, platelets, fresh frozen plasma, and cryoprecipitate (NCT02840097)
Timeframe: First 48 hours after randomization
| Intervention | ml (Mean) |
|---|---|
| Tranexamic Acid Dose A | 367.4 |
| Tranexamic Acid Dose B | 150.4 |
| Placebo | 303.6 |
Intracranial hemorrhage progression on cranial computed tomography (CT) imaging; hemorrhage will be measured using the ABC/2 volume estimation and relative to the total brain volume (calculated by the XYZ/2 volume estimation); more intracranial hemorrhage progression represents a worse outcome. Change is calculated as the difference between the baseline and repeat cranial CT imaging. The repeat CT is conducted 24 hours (±6 hours) after the baseline CT. (NCT02840097)
Timeframe: 24 hours (±6 hours)
| Intervention | Proportional change (Mean) |
|---|---|
| Tranexamic Acid Dose A | 0.003 |
| Tranexamic Acid Dose B | 0.001 |
| Placebo | 0.003 |
Any non-cerebral venous or arterial thrombosis on standard diagnostic imaging post-randomization (NCT02840097)
Timeframe: Day 7 of hospitalization or hospital discharge (whichever comes first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Dose A | 0 |
| Tranexamic Acid Dose B | 0 |
| Placebo | 0 |
Clinical or electroencephalogram-documented (NCT02840097)
Timeframe: 24 hours after receiving drug
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Dose A | 0 |
| Tranexamic Acid Dose B | 0 |
| Placebo | 1 |
Neurocognitive functioning and quality-of-life measures; range from 0 to 100 quality of life units with higher scores representing better outcomes. Measurements occur at 1 week, 1 month, 3 months, and 6 months to generate an area under the curve of quality of life units. (NCT02840097)
Timeframe: 6 months
| Intervention | Quality of life units * months (Mean) |
|---|---|
| Tranexamic Acid Dose A | 64.9 |
| Tranexamic Acid Dose B | 60.2 |
| Placebo | 67.2 |
Test of working memory; higher scores represent a better outcome, range from 0 to infinity (NCT02840097)
Timeframe: 1 week, 1 month, 3 months, and 6 months
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total forward digit span, 1 week | Total backward digit span, 1 week | Total forward digit span, 1 month | Total backward digit span, 1 month | Total forward digit span, 3 months | Total backward digit span, 3 months | Total forward digit span, 6 months | Total backward digit span, 6 months | |
| Placebo | 8.8 | 7.3 | 7.5 | 5.3 | 8.6 | 6.5 | 8.4 | 5.8 |
| Tranexamic Acid Dose A | 8.4 | 6.0 | 7.2 | 6.2 | 9.1 | 8.7 | 11.7 | 10.4 |
| Tranexamic Acid Dose B | 8.4 | 6.0 | 7.9 | 6.2 | 10.4 | 7.8 | 10.0 | 6.0 |
Global functioning; range is 1 to 8 with higher scores representing better outcomes; 1=death, 2=vegetative state, 3=lower severe disability, 4=upper severe disability, 5=lower moderate disability, 6=upper moderate disability, 7=lower good recovery, 8=upper good recovery (NCT02840097)
Timeframe: 1 week, 1 month, 3 months, and 6 months
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| 1 week | 1 month | 3 months | 6 months | |
| Placebo | 5.3 | 4.5 | 4.2 | 4.3 |
| Tranexamic Acid Dose A | 4.6 | 4.9 | 3.8 | 3.7 |
| Tranexamic Acid Dose B | 5.2 | 5.1 | 4.6 | 2.9 |
Neurocognitive functioning and quality-of-life measures; range from 0 to 100 with higher scores representing better outcomes (NCT02840097)
Timeframe: 1 week, 1 month, 3 months, and 6 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 1 week | 1 month | 3 months | 6 months | |
| Placebo | 57.9 | 60.5 | 68.9 | 68.9 |
| Tranexamic Acid Dose A | 43.7 | 57.0 | 77.3 | 81.6 |
| Tranexamic Acid Dose B | 52.4 | 61.5 | 77.5 | 84.3 |
Patient-reported Visual Analog Scale - Bleeding Score Day 1. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 1 (assessed within first 24 hours following surgery)
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 5.03 |
| 1,000mg IV Tranexamic Acid | 4.82 |
Patient-reported Visual Analog Scale - Bleeding Score Day 2. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 4.47 |
| 1,000mg IV Tranexamic Acid | 3.89 |
Patient-reported Visual Analog Scale - Bleeding Score Day 3. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 3
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.93 |
| 1,000mg IV Tranexamic Acid | 2.29 |
Patient-reported Visual Analog Scale - Bleeding Score Day 4. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 4
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.12 |
| 1,000mg IV Tranexamic Acid | 1.44 |
Patient-reported Visual Analog Scale - Bleeding Score Day 5. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 5
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.32 |
| 1,000mg IV Tranexamic Acid | 1.15 |
Patient-reported Visual Analog Scale - Bleeding Score Day 6. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 6
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.36 |
| 1,000mg IV Tranexamic Acid | 0.76 |
Patient-reported Visual Analog Scale - Bleeding Score Day 7. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 7
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 0.97 |
| 1,000mg IV Tranexamic Acid | 0.72 |
Number of patients in each arm requiring evaluation by the resident service for bleeding concerns expressed by the recovery nurse (in PACU), had any follow-up visit or phone call outside of regularly scheduled follow-up (NCT04754230)
Timeframe: Day of surgery through 1 week
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PACU | Follow-up visit | Follow-up phone call | |
| 1,000mg IV Tranexamic Acid | 0 | 1 | 2 |
| Normal Saline | 0 | 0 | 2 |
Patient-reported Visual Analog Scale - Guaze Saturation Score through Postoperative Day 7. Score range: 0 (not at all) to 10 (dripping blood). (NCT04754230)
Timeframe: Postoperative Day 2 through Postoperative Day 7
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | Postoperative day 5 | Postoperative day 6 | Postoperative day 7 | |
| 1,000mg IV Tranexamic Acid | 4.56 | 2.09 | 0.76 | 0.40 | 0.29 | 0.28 |
| Normal Saline | 5.16 | 3.03 | 1.74 | 1.11 | 0.99 | 0.80 |
Determine the efficacy ( as measured by blood loss and blood transfusion) of TXA in infants and children undergoing open craniofacial surgery with this lower dosage scheme. (NCT02188576)
Timeframe: perioperatively from the intraoperative period to 24 hours postoperatively
| Intervention | mL/kg (Mean) |
|---|---|
| High Dose TXA | 23.6 |
| Low Dose TXA | 21.3 |
Determine the plasma levels (in micrograms/mL) of TXA in infants and children undergoing open craniofacial surgery with this dosage scheme (NCT02188576)
Timeframe: up to 24h postoperatively
| Intervention | ug/mL (Mean) |
|---|---|
| High Dose TXA | 50.2 |
| Low Dose TXA | 29.6 |
The number of breasts with clinically significant hematoma (collection of blood under the skin) requiring either conservative management or operative washout was determined. (NCT04947514)
Timeframe: Up to 30 days
| Intervention | breasts (Number) |
|---|---|
| Treatment Side (Right or Left) | 2 |
| Placebo Side (Right or Left) | 1 |
The number of participants requiring blood transfusion was based on the postoperative decline in hematocrit level (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Incidence of clinically significant deep vein thrombosis or pulmonary embolism detected on imaging (ultrasound or CT scan) (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
"The loss of haemoglobin (Hb) was then estimated according to the formula:~Hb(loss) = Blood volume (BV) x (Hbi-Hbe) x 0.001+Hbt~where Hb (loss) (g) is the amount of Hb lost, Hbi (g/L) the Hb concentration before surgery, Hbe (g/L) is the Hbe concentration on the third day after surgery, and Hbt (g) is the total amount of allogeneic Hb transfused. A unit of banked blood is considered to contain a minimum of 40g Hb (Blood component data sheet, New Zealand Blood Services [NZBS]). All units of blood are processed and stored in a nationally standardised manner. The blood loss (ml) was related to the patient's preoperative Hb value (g/L):~Blood loss =1000 x Hb(loss) /Hbi" (NCT02278263)
Timeframe: Post operative day 3
| Intervention | mls (Mean) |
|---|---|
| Control | 1090 |
| Intraarticular | 716 |
| Systemic | 746 |
Day of surgery is counted as Day 0. (NCT02278263)
Timeframe: Average length of stay is expected to be 3 to 5 days
| Intervention | days (Median) |
|---|---|
| Control | 4 |
| Topical | 4 |
| Systemic | 4 |
"Those patients receiving blood products. Standardised protocol is as follows:~The criterion for transfusion of blood products will be a haemoglobin < 80g/L or a haemoglobin <100g/L in a patient with ischaemic heart disease or with significant symptomatology" (NCT02278263)
Timeframe: Participants will be followed for the duration of their hospital stay expected to be an average of 3-5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 2 |
| Topical | 1 |
| Systemic | 0 |
Intravenous fluid (excluding blood transfusion) given during and first 24 hours after surgery (NCT02278263)
Timeframe: Day 1
| Intervention | mls (Mean) |
|---|---|
| Control | 1765 |
| Topical | 1613 |
| Systemic | 1807 |
Rates of deep vein thrombosis (DVT) and pulmonary embolus (PE) in each group recorded as a percentage (NCT02278263)
Timeframe: Postoperatively within 30 days after surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| DVT | PE | |
| Control | 0 | 0 |
| Systemic | 0 | 1 |
| Topical | 0 | 2 |
Range of motion measured in degrees on postoperative days 1-3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 57 | 71 | 75 |
| Systemic | 58 | 72 | 78 |
| Topical | 65 | 75 | 82 |
Range of motion measured in degrees for postoperative days 1 to 3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 65 | 76 | 82 |
| Systemic | 68 | 80 | 87 |
| Topical | 74 | 81 | 87 |
The number of days that the post surgical drains remain in place after the surgery. When less than 30 cc per drain in a 24-hour period, the participants are to call and schedule drain removal. (NCT04902950)
Timeframe: Up to 56 days post operatively.
| Intervention | Days (Mean) |
|---|---|
| Group 1 | 16 |
| Group 2 | 22 |
Return to the operating room for evacuation post surgical operative hematoma or seroma assessed by clinical evaluation to include palpation for ballotable fluid collection and assessment of skin for a shiny/tight appearance suggestive of an underlying fluid collection. (NCT04902950)
Timeframe: Up to 8 weeks postoperatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Group 1 | 0 |
| Group 2 | 0 |
Patients will be monitored clinically at each post-operative visit for signs of post-operative hematoma or seroma. Each patient will be evaluated one week, three weeks, and eight weeks following their procedure to assess overall wound healing. (NCT04902950)
Timeframe: Up to 8 weeks postoperatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Group 1 | 0 |
| Group 2 | 1 |
Total blood volume loss will be calculated in milliliters. (NCT03856164)
Timeframe: 24 hours postpartum.
| Intervention | milliliters (Mean) |
|---|---|
| Tranexamic Acid | 2274 |
| Placebo | 2407 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | µg/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 4.0 | 3.8 | 4.3 |
| Tranexamic Acid | 2.9 | 2.4 | 2.1 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 550.7 | 484.9 | 525.4 |
| Tranexamic Acid | 563.5 | 499.6 | 527.4 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | IU/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 61.7 | 63.3 | 22.1 |
| Tranexamic Acid | 81.8 | 67.0 | 20.7 |
Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter). (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| Before Surgery INTEM Clotting Time | After Delivery INTEM Clotting Time | P.O.D. 1 INTEM Clotting Time | Before Surgery EXTEM Clotting Time | After Delivery EXTEM Clotting Time | P.O.D. 1 EXTEM Clotting Time | |
| Placebo | 150.5 | 140.7 | 141.2 | 56.1 | 56.3 | 50.2 |
| Tranexamic Acid | 149.7 | 137.4 | 145.1 | 54.0 | 54.9 | 49.3 |
Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter). (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | millimeter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Before Surgery INTEM Maximum Clot Firmness | After Delivery INTEM Maximum Clot Firmness | P.O.D. 1 INTEM Maximum Clot Firmness | Before Surgery EXTEM Maximum Clot Firmness | After Delivery EXTEM Maximum Clot Firmness | P.O.D. 1 EXTEM Maximum Clot Firmness | Before Surgery FIBTEM Maximum Clot Firmness | After Delivery FIBTEM Maximum Clot Firmness | P.O.D. 1 FIBTEM Maximum Clot Firmness | |
| Placebo | 69.4 | 68.4 | 68.8 | 71.2 | 69.6 | 70.4 | 23.9 | 22.0 | 25.0 |
| Tranexamic Acid | 69.3 | 68.9 | 68.8 | 70.8 | 69.8 | 70.5 | 24.2 | 22.5 | 25.8 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 8.2 | 9.6 | 7.4 |
| Tranexamic Acid | 8.1 | 9.0 | 7.5 |
Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge
| Intervention | Days (Mean) |
|---|---|
| Intravenous Tranexamic Acid | 3 |
| Intravenous Placebo | 3 |
| Intravenous Tranexamic Acid Followed by Intravenous Placebo | 3 |
We will record the event of blood transfusion, and calculate the incidence of transfusion (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 1 |
| Topical TXA Alone | 0 |
The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents (NCT03328832)
Timeframe: within 30 days of the operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 0 |
| Topical TXA Alone | 0 |
Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | ml (Mean) |
|---|---|
| Combined Topical TXA and Floseal | 678 |
| Topical TXA Alone | 733 |
The blood quantification will be taken at 6am every day. (NCT02650856)
Timeframe: up to 2nd day post operative (24 and 48 hrs)
| Intervention | mL (Mean) | |
|---|---|---|
| 24 hours | 48 hours | |
| Group 1 Tranexamic Acid | 246.4 | 120.8 |
| Group 2 Platelet Rich Plasma | 263.2 | 140.2 |
The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)
| Intervention | percentage of Hematocrite (Mean) | |||
|---|---|---|---|---|
| Baseline | 24 hours | 48 hours | 72 hours | |
| Group 1 Tranexamic Acid | 41.7 | 31.6 | 29.1 | 28.6 |
| Group 2 Platelet Rich Plasma | 41.5 | 29.8 | 27.7 | 27.3 |
The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | 24 hours | 48 hours | 72 hours | |
| Group 1 Tranexamic Acid | 13.6 | 10.3 | 9.5 | 9.3 |
| Group 2 Platelet Rich Plasma | 13.6 | 9.9 | 9.2 | 9.1 |
Total number of units of blood transfused (whole blood, platelets, cryoprecipitate, and fresh frozen plasma) intra-operatively is a secondary outcome. (NCT02806024)
Timeframe: Pulled from operative note, completed by the time of discharge.
| Intervention | units (Mean) |
|---|---|
| Treatment Arm (Tranexamic Acid, or TXA) | 5.2 |
| Placebo Arm | 17.6 |
EBL is estimated by the surgeon and anesthesia team at the completion of the surgery (cesarean delivery &/or cesarean hysterectomy). (NCT02806024)
Timeframe: 1-3 hours (will be determined at the completion of the surgery).
| Intervention | cc (Mean) |
|---|---|
| Treatment Arm (Tranexamic Acid, or TXA) | 3116 |
| Placebo Arm | 9420 |
Must be diagnosed via ultrasound duplex (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 1 |
Must be diagnosed via CT chest or V/Q lung scan (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Must be diagnosed via CT scan or MRI (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Patients who received a post-op transfusion of pack red blood cells (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Units of pack red blood cells that the patients recieved (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | Units of PRBCs (Number) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Equated based on the patient's predicted blood volume and change in hemoglobin from the pre-operative level to the lowest post-operative level. (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | mL (Mean) |
|---|---|
| Tranexamic Acid Group | 152.2 |
| Placebo Group | 178.0 |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Incidence of VTE (symptomatic of DVT or PE), infection (superficial, deep), hematoma, seroma, reoperation, and death, measured in person-years ( x cases per 100,000 person years) (NCT02257580)
Timeframe: an expected average of 1 week (post-surgery), Follow-up at 6 weeks
| Intervention | cases per 100,000 person years (Number) |
|---|---|
| E-Aminocaproic Acid (EACA) | 0 |
| Placebo | 0 |
Determined by estimated blood volume, calculated using difference in preoperative and postoperative hemoglobin and applied to the Nadler equation for estimating blood volume while adjusting for transfused hemoglobin to produce a single metric of calculated intraoperative blood loss. (NCT02257580)
Timeframe: Intraoperative (3-6 hours)
| Intervention | mL (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 535.7 |
| Placebo | 628.0 |
Number of participants requiring 1 unit of intraoperative cell saver transfusion. Patients either received or did not receive intraoperative cell saver transfusion. The maximum number of intraoperative units transfused in this study was 1 unit. The count of participants in the data table refers to the number of patients who received this transfusion. (NCT02257580)
Timeframe: Intraoperative, 1 day
| Intervention | Participants (Count of Participants) |
|---|---|
| E-Aminocaproic Acid (EACA) | 7 |
| Placebo | 7 |
postoperative day of discharge after surgery- day of intake. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week
| Intervention | days (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 5.5 |
| Placebo | 5.1 |
24 hour drain output (mL) (NCT02257580)
Timeframe: Post-Surgery, 24 hours
| Intervention | mL (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 72.5 |
| Placebo | 103.3 |
The number of participants that required 1 unit of blood transfused post-operatively. Patients received blood if necessary post operatively, and the maximum number of units a patient received was 1. The count of participants refers to the number of patients who received this transfusion unit. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| E-Aminocaproic Acid (EACA) | 4 |
| Placebo | 3 |
To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries. (NCT02753816)
Timeframe: First burn surgery to hospital discharge
| Intervention | Patients with 1 or more transfusions (Number) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 3 |
To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival. (NCT02753816)
Timeframe: Hospital admission to hospital discharge
| Intervention | Days (Median) |
|---|---|
| Tranexamic Acid | 23 |
| Placebo | 9 |
To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries. (NCT02753816)
Timeframe: Intraoperative, average 122 minutes
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 100 |
| Placebo | 325 |
Length of stay was defined as time from enrollment in study to discharge from the emergency department (NCT02930941)
Timeframe: During emergency department (ED) visit
| Intervention | minutes (Median) |
|---|---|
| TXA Group | 268 |
| NS Group | 346 |
The number of participants with re-bleeding at 24 Hours was evaluated during follow up phone call (NCT02930941)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 3 |
| NS Group | 9 |
The number of participants with re-bleeding at one week was evaluated during the follow-up phone call (NCT02930941)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 2 |
| NS Group | 6 |
Patient reported thromboembolic events during follow-up phone calls at 24 hours and at one week (NCT02930941)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 0 |
| NS Group | 0 |
Time to control of bleeding was defined as the time from the start of enrollment and direct pressure and administration of study drug to the resolution of bleeding (NCT02930941)
Timeframe: During emergency department (ED) visit
| Intervention | minutes (Median) |
|---|---|
| TXA Group | 64 |
| NS Group | 42 |
Patient-reported drug-related adverse events during ED visit (NCT02930941)
Timeframe: during emergency department (ED) visit
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Nasal burning | Nasal irritation | Unpleasant taste | |
| NS Group | 0 | 0 | 0 |
| TXA Group | 2 | 0 | 1 |
Amount of cis-atracurium usage during surgery (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | mg/kg/hr (Mean) |
|---|---|
| Group NSS | 0.08 |
| Group Mg | 0.08 |
Amount of fentanyl usage during surgery (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | mcg/kg/hr (Mean) |
|---|---|
| Group NSS | 0.65 |
| Group Mg | 0.6 |
We measure the amount of blood loss in the operative room in suction box, gauze and plastic bag. The unit measure is millimeter. (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | ml (Median) |
|---|---|
| Group NSS | 510 |
| Group Mg | 500 |
The amount of blood transfusion in patient who required PRC transfusion intraoperatively. (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | unit of packed red cell (Median) |
|---|---|
| Group NSS | 2 |
| Group Mg | 1 |
Number of patients who required Intraoperative PRC transfusion (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group NSS | 10 |
| Group Mg | 7 |
"MOCA or Montreal Cognitive Assessment is a screening instrument used to facilitate the assessment of cognitive impairment.~MOCA scores range between 0-30, do higher values represent a better outcome. A score of 26 or over is considered to be normal. We measure Montreal assessment score for assess cognitive function after operation at postoperative day 3-7." (NCT03558516)
Timeframe: Postoperative day 3-7
| Intervention | score on the MOCA scale (Median) |
|---|---|
| Group NSS | 23 |
| Group Mg | 25 |
Amount of sevoflurane agents usage during surgery. The unit of measurement of volatile agent is minimum alveolar concentration (MAC). 1 MAC-hour was defined as 2% of sevoflurane for 1 hour duration. (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | average minimum alveolar concentration (Mean) |
|---|---|
| Group NSS | 0.65 |
| Group Mg | 0.66 |
Blood loss following surgery was defined as the total amount of fluid collected from the drain in the wound site during the hospital stay. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 5 days
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 534 |
| Placebo | 530 |
Blood loss was calculated from the difference between the level of hemoglobin at the preoperative appointment and the lowest level during the postoperative hospitalization period. Reported here is the change in hemoglobin level after surgery. A negative number indicates a reduction in hemoglobin level. (NCT02063035)
Timeframe: From preoperative appointment approximately one week before surgery to end of hospital stay up to approximately 5 days after surgery
| Intervention | grams per deciliter (g/dL) (Median) |
|---|---|
| Tranexamic Acid | -3.2 |
| Placebo | -4.6 |
The number of days the participants stayed in the hospital after surgery was recorded. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 2 weeks
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 5 |
| Placebo | 6 |
All units of blood transfused during the hospital stay after surgery were recorded. One red blood cell unit contains 300 to 360 mL of whole blood. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 5 days
| Intervention | units of blood (Median) |
|---|---|
| Tranexamic Acid | 0 |
| Placebo | 0 |
Total additional blood products (fresh frozen plasma, cryoprecipitate, and platelets) transfused in the perioperative period measured in units. (NCT01728636)
Timeframe: 24 hours after skin incision
| Intervention | Units (Mean) |
|---|---|
| Tranexamic Acid | 1 |
| Placebo | 2 |
Estimated Intraoperative blood loss in milliliters (mLs) (NCT01728636)
Timeframe: Incision to skin closure (approximately 10 hours)
| Intervention | Milliliters (Mean) |
|---|---|
| Tranexamic Acid | 1550 |
| Placebo | 1600 |
Number of participants who experienced arterial or venous thromboembolism, neurologic complications (including stroke, seizure,and delirium), infections, and pulmonary renal or cardiac adverse outcomes (demand ischemia, myocardial infarction or new arrhythmia) before another operative procedure or hospital discharge. (NCT01728636)
Timeframe: Time of surgery to date of discharge from hospital (average 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 9 |
| Placebo | 9 |
Total operating room time from incision to closure of incision in minutes. (NCT01728636)
Timeframe: Minutes
| Intervention | Minutes (Median) |
|---|---|
| Tranexamic Acid | 602 |
| Placebo | 576 |
Total red blood cells transfused in the intraoperative period in (mL). Total RBC equal packed red blood cells and cell saver infusion. (NCT01728636)
Timeframe: Intraoperative period (approximately 12 hours)
| Intervention | milliliters (Median) |
|---|---|
| Tranexamic Acid | 1140 |
| Placebo | 1460 |
Total milligrams of intravenous tranexamic acid administered during the surgical procedure. (NCT01728636)
Timeframe: Intraoperative period
| Intervention | milligrams (Median) |
|---|---|
| Tranexamic Acid | 1408 |
| Placebo | 0 |
Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb. (NCT01866943)
Timeframe: Pre Op, Post Op Day 2
| Intervention | Hemoglobin (grams/deciliter) (Mean) |
|---|---|
| Baseline Population | 2.93 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 2 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 65.76 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 81.77 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: Preoperative
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 58.34 |
Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur. No data recorded at 2 weeks or 6 weeks for this study population. (NCT01866943)
Timeframe: Pre Op
| Intervention | centimeters (Mean) |
|---|---|
| Baseline Population | 52.99 |
Trial accrual (NCT02548910)
Timeframe: through study completion, an average of 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Participant Accrual | 62 |
(NCT02548910)
Timeframe: Will be measured in the operating room and in the first postoperative week
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Intraoperative | Postoperative | Total | |
| Control | 1 | 3 | 4 |
| Phlebotomy | 1 | 5 | 5 |
(NCT02548910)
Timeframe: Will be measured in the operating room
| Intervention | I per min per m2 (Median) | |
|---|---|---|
| Before transection | transection | |
| Control | 4.2 | 3.9 |
| Phlebotomy | 3.5 | 3.5 |
(NCT02548910)
Timeframe: Will be measured in the operating room
| Intervention | cmH2O (Median) | |
|---|---|---|
| before transection | transection | |
| Control | 7 | 7.5 |
| Phlebotomy | 8 | 8 |
(NCT02548910)
Timeframe: Postoperative setting up to 30 days following surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| postoperative complications | Major complication | |
| Control | 15 | 3 |
| Phlebotomy | 10 | 2 |
Intraoperative blood loss is notoriously difficult to measure. It is suggested that calculation of blood loss using preoperative and postoperative hemoglobin levels in most consistently accurate. In order to minimize the risk of bias associated with any one method of intraoperative measurement of blood loss, three methods will be used independently. In the operating room, all blood and fluid aspirated from the abdomen will be measured accurately using graduated suction containers. As well, the amount of irrigation fluid will be carefully monitored and recorded. Finally, the weight of all surgical sponges will be measured. This information will be used by the surgeon and anesthesiologist to independently visually estimate blood loss, as is commonly done in clinical practice. In parallel, intraoperative blood loss will also be calculated based on an equation. (NCT02548910)
Timeframe: 1 week prior to surgery (hemoglobin level), and day two of post-op (hemoglobin again).
| Intervention | mL (Median) | ||
|---|---|---|---|
| Anaesthetist Estimate | Surgeon Estimate | Calculated EBL | |
| Control | 872 | 872 | 1249 |
| Phlebotomy | 862 | 761 | 1116 |
Research participants were to receive a blood transfusion in the Intensive Care Unit (ICU) post-operatively if hemoglobin reached a nadir of 80g/L, or at the discretion of the intensivist or cardiac surgeon according to patient clinical status. Transfusion was quantified based on the number of units of PRBC received. (1 unit = 1 bag of blood, as prepared by Canadian Blood Services). Clinical status of research participants was followed throughout their duration in the ICU only. Participation in this study ended upon transfer out of the ICU, to the Cardiology Ward. (NCT01519245)
Timeframe: From ICU admission to transfer to the Cardiology Ward (placebo group = 24.4 hours; trial group = 24.7 hours)
| Intervention | Unit(s) of PRBC (Number) |
|---|---|
| Trial Drug | 0 |
| Placebo | 0 |
According to standard practice, research participants were be transferred to the intensive care unit (ICU) for post-operative monitoring. Measurement of chest tube output began immediately on arrival to the ICU. Hourly measurements were recorded. Data collection ended upon chest tube removal, or return to the operating room for exploratory surgery due to massive blood loss. As per ICU protocol, chest tubes were be removed when blood loss was recorded to be less than 200mL after six consecutive hours. (NCT01519245)
Timeframe: From ICU admission post-operatively to mediastinal chest tube removal (placebo group = 20.6 hours; trial group = 19.8 hours)
| Intervention | mL (Mean) |
|---|---|
| Trial Drug | 632 |
| Placebo | 789 |
Volume of chest tube loss at 12 hours (assuming the total volume of loss is blood). (NCT01519245)
Timeframe: 12 hours following admission to the Intensive Care Unit
| Intervention | mL (Mean) |
|---|---|
| Trial Drug | 464 |
| Placebo | 570 |
Volume of chest tube loss at 6 hours (assuming the total volume of loss is blood). (NCT01519245)
Timeframe: 6 hours following admission to the Intensive Care Unit
| Intervention | mL (Mean) |
|---|---|
| Trial Drug | 342 |
| Placebo | 417 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 21 |
| Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
| Intervention | mL (Mean) |
|---|---|
| Tranexamic | 727.6 |
| Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 1 |
| Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
| Intervention | Units of packed red blood cells (Mean) |
|---|---|
| Tranexamic | 2.65 |
| Placebo | 2.36 |
"DVT = Deep Venous thrombosis~Patients were assessed every 12 hours for development of pain within the lower extremity. Any reported muscle pain was evaluate with a bedside venous ultrasound by an ultrasound technician." (NCT01651806)
Timeframe: 1 year
| Intervention | Events (Number) |
|---|---|
| Female Uniform Single Dose TA Patient | 1 |
| Female Weighted Dose TA Patient | 1 |
| Control | 0 |
| Male Uniform Single Dose TA | 0 |
| Male Weighted Dose TA | 0 |
Record intra-operative blood loss through drain output (NCT01651806)
Timeframe: Intra-operative, an average of 3 hours
| Intervention | mL (Mean) |
|---|---|
| Female Uniform Single Dose TA Patient | 100.00 |
| Female Weighted Dose TA Patient | 65.00 |
| Control | 142.80 |
| Male Uniform Single Dose TA | 100.00 |
| Male Weighted Dose TA Patient | 65.00 |
(NCT00958581)
Timeframe: 1 Week
| Intervention | ml (Mean) |
|---|---|
| Epsilon Aminocaproic Acid | 1775 |
| Normal Saline | 2116 |
| Tranexamic Acid | 1531 |
(NCT01850394)
Timeframe: postoperative period (5 days after surgery)
| Intervention | participants (Number) |
|---|---|
| Control Group | 10 |
| TXA-250 Group | 6 |
| TXA-500 Group | 0 |
Total hemoglobin loos measured by difference between hemoglobin preoperatively and the fourth postoperative day (NCT01850394)
Timeframe: 5 days after surgery
| Intervention | g/dL (Mean) |
|---|---|
| Control Group | 2.9 |
| TXA-250 Group | 2.2 |
| TXA-500 Group | 2.2 |
"Knee function score was measured with 2 methods, and were evaluated preoperatively and then postoperatively at 3-month, 6-month, and 1-year period.~Knee Society Knee Score using for rating knee function measurement and subdivided into two parts; knee score and function score 1.1. Knee score : calculated from pain, presence of deformity, total range of flexion, alignment, and stability. Total score is 100 (0-100), more score means better.~1.2. Function score : calculated from patient's ability to walk and climb stairs. The score ranges from 0-100, more score means better.~Western Ontario and McMaster Universities Arthritis Index or WOMAC score : a widely used, standardized questionnaires for evaluating the condition of patients with knee osteoarthritis, including pain (score = 0-20), stiffness (0-8), and functional limitation (0-68). Total score ranges from 0-68, lower score means better." (NCT01850394)
Timeframe: 1 year after surgery
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knee Society Knee score at 1 year | WOMAC score at 1 year | |
| Control Group | 148.9 | 15.5 |
| TXA-250 Group | 151.2 | 15.1 |
| TXA-500 Group | 150.9 | 14.5 |
"Postoperative complications were measured as an incidence of the following complications;~wound hematoma~surgical site infection~systemic infection~deep vein thrombosis~pulmonary embolism~knee stiffness requiring manipulation~medical complication such as myocardial infarction, congestive hear failure" (NCT01850394)
Timeframe: postoperative 1-year period
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Re-clamp incidence | Re-dressing incidence | Venous thromboembolic complication | Congestive heart failure | |
| Control Group | 6 | 3 | 4 | 0 |
| TXA-250 Group | 1 | 0 | 1 | 1 |
| TXA-500 Group | 0 | 0 | 2 | 0 |
"Drainage blood loss measured by accumulating total drainage volume postoperatively~Calculated total blood loss measured by using specific formula and difference between hematocrit preoperatively and the fourth postoperative day" (NCT01850394)
Timeframe: 5 days after surgery
| Intervention | ml (Median) | |
|---|---|---|
| Drainage blood loss | Calculated total blood loss | |
| Control Group | 546.9 | 329.2 |
| TXA-250 Group | 475.0 | 239.7 |
| TXA-500 Group | 430.2 | 217.2 |
Perioperative blood loss (during operation and for entire hospital admission) (NCT01813058)
Timeframe: perioperarively - during entire hospital admission
| Intervention | mL (Mean) |
|---|---|
| Placebo | 1031 |
| Tranexamic Acid | 836 |
(NCT00888940)
Timeframe: 12 hours after the end of surgery
| Intervention | mL (Mean) |
|---|---|
| Ecallantide | 1223.2 |
| Cyklokapron(R) | 623.5 |
(NCT00888940)
Timeframe: Over the duration of the study.
| Intervention | events (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| At Least 1 TEAE | At Least 1 Related TEAE | At Least 1 Severe TEAE | At Least 1 Serious TEAE | At Least 1 Related & Serious TEAE | Premature Study Drug Discontinuations Due to TEAE | Related TEAE Resulting in Discontinuation of Drug | TEAE Resulting in Death | Related TEAE Resulting in Death | |
| Cyklokapron(R) | 94 | 5 | 17 | 28 | 1 | 2 | 0 | 4 | 0 |
| Ecallantide | 100 | 5 | 38 | 45 | 4 | 2 | 0 | 13 | 0 |
Surgical blood loss estimation (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 450 |
| Placebo | 365 |
To determine the impact of perioperative administration of tranexamic acid on blood loss and transfusion rates in major oncologic surgery (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 8 |
| Placebo | 5 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Deep venous thrombosis" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Hematoma" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Infection" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Myocardial infarction" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 1 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Pulmonary Embolism" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
Total Blood Loss as calculated according to method as described by Good et al. Total Blood Loss (mL) = 1000 X Hb(loss)/Hb(initial) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | Total Blood Loss (mL) (Mean) |
|---|---|
| Tranexamic Acid | 1122.4 |
| Normal Saline | 1472 |
Total Drain Output as measured postoperatively 0-48 hours (NCT02043132)
Timeframe: 0-48 hours postoperatively
| Intervention | mL (Mean) |
|---|---|
| Tranexamic Acid | 221 |
| Normal Saline | 372 |
Total hemoglobin loss estimated using the formula for total blood volume described by Nadler et al Hb(loss) = blood volume (L) x [Hb(initial)(g/L) - Hb(final)(g/L)] + Hb(transfused) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | g (Mean) |
|---|---|
| Tranexamic Acid | 154.6 |
| Normal Saline | 200.1 |
the secondary objective of this study is to determine whether pericardial lavage with saline gives an improvement in haemostasis, compared with no pericardial lavage, resulting in a reduction of surgical re-explorations and post-operative 12-hour blood loss. The choice for a surgical re-exploration will be decided according to the ICU protocol. (NCT01895101)
Timeframe: participants will be followed for the duration of ICU stay, an expected average of 2 days
| Intervention | participants (Number) |
|---|---|
| Pericardial Lavage With 200 ml Normothermic Saline Solution | 10 |
| No Pericardial Lavage | 9 |
| 2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline | 12 |
The primary study parameter is 12 hours postoperative blood loss and is assessed by postoperative chest tube production. Postoperative chest tube production 12 hours after surgical procedure (NCT01895101)
Timeframe: 12 hours postoperative
| Intervention | ml (Median) |
|---|---|
| Pericardial Lavage With 200 ml Normothermic Saline Solution | 290 |
| No Pericardial Lavage | 300 |
| 2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline | 290 |
The amount of red blood cell transfusions the patient receive pre, peri and postoperatively during their stay in the hospital. (NCT01895101)
Timeframe: participants will be followed for the duration of ICU stay, an expected average of 2 days/ And participants will be followed for the duration of hospital stay, an expected average of 3 weeks
| Intervention | IU (Mean) |
|---|---|
| Pericardial Lavage With 200 ml Normothermic Saline Solution | 0.7 |
| No Pericardial Lavage | 1.1 |
| 2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline | 0.7 |
Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Median) |
|---|---|
| The Placebo Group | 2 |
| The Tranexamic Acid Group | 2 |
Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | participants (Number) |
|---|---|
| Tranexamic Group | 15 |
| Placebo Group | 22 |
Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Group | 2 |
| Placebo Group | 5 |
Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Number) |
|---|---|
| Tranexamic Group | 38 |
| Placebo Group | 53 |
Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | milliliter (Median) |
|---|---|
| Tranexamic Group | 520 |
| Placebo Group | 730 |
"Functional outcomes measured by the 2011 Knee Society Score. The Functional Activities section consists of 4 sub-sections with a total score ranging from 0-100 points. The higher the numerical value the better the outcome. The sub-sections consist of: (1)Walking and Standing 0-30 points (2)Standard Activities 0-30 points (3)Advanced Activities 0-25 points (4)Discretionary Knee Activities 0-15 points." (NCT03952546)
Timeframe: 8 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm | 56.45 |
| Control Arm | 61.79 |
Postoperative day 1 estimated blood loss as calculated by the Gross' Formula (NCT03952546)
Timeframe: Postoperative day 1
| Intervention | milliliters (Mean) |
|---|---|
| Treatment Arm | 924 |
| Control Arm | 1062 |
Participants were assessed for any wound infection within 90 days of surgery. (NCT03952546)
Timeframe: 90 days postoperatively
| Intervention | Number of events (Number) |
|---|---|
| Saline-Coupled Bipolar Sealer | 1 |
| Unipolar Electrocautery | 3 |
(NCT00722436)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
This is the blood administered during surgery. The blood comes form the blood bank. It is not cell salvage blood. The volume was normalized by weight. (NCT00722436)
Timeframe: intraoperative and postoperative (24 hr)
| Intervention | ml/kg (Mean) |
|---|---|
| Tranexamic Acid | 16.1 |
| Placebo | 17.1 |
(NCT00722436)
Timeframe: (baseline, after osteotomies, and immediately after procedure)
| Intervention | seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| PT -baseline | PT-after osteotomies | PT-immediately after surgery | PTT -baseline | PTT-after osteotomies | PTT-immediately after surgery | |
| Placebo | 13.8 | 16.1 | 17 | 32.9 | 34.6 | 34.8 |
| Tranexamic Acid | 15.1 | 18.5 | 17.7 | 34.6 | 37.2 | 33.3 |
(NCT00722436)
Timeframe: baseline, after osteotomies, immediately after surgery
| Intervention | 10^9 platelets/L (Mean) | ||
|---|---|---|---|
| platelets-baseline | platelets-after osteotomies | platelets-immediately after surgery | |
| Placebo | 364 | 300 | 231 |
| Tranexamic Acid | 301 | 253 | 223 |
Study patients received 100 mg of intravenous hydrocortisone 2 h prior to surgery, and controls received normal saline. Blood samples, drawn pre-incision and at 4 h post tourniquet release, were assayed for PF1.2 and PAP (NCT01815918)
Timeframe: Baseline and up to 4 hours following surgery
| Intervention | ug/L (Mean) | |
|---|---|---|
| Baseline | 4 hs | |
| Placebo | 623.3 | 1086.8 |
| Treatment | 808.4 | 1638.6 |
Study patients received 100 mg of intravenous hydrocortisone 2 h prior to surgery, and controls received normal saline. Blood samples, drawn pre-incision and at 4 h post tourniquet release, were assayed for PF1.2 and PAP (NCT01815918)
Timeframe: Baseline and up to 4 hours following surgery
| Intervention | pMol/L (Mean) | |
|---|---|---|
| Baseline | 4s | |
| Placebo | 263.6 | 935.8 |
| Treatment | 266.5 | 615.9 |
363 reviews available for tranexamic acid and Blood Loss, Surgical
| Article | Year |
|---|---|
A Systematic Review and Meta-Analysis Evaluating the Impact of Tranexamic Acid Administration in Aesthetic Plastic Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Female; Hematoma; Humans; Surgery, Plasti | 2022 |
The efficacy of Tranexamic Acid Administration in Patients Undergoing Tonsillectomy: An Updated Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Hemorrhage; Tonsillectomy; Tran | 2022 |
The Efficacy and Safety of Tranexamic Acid in the Management of Perioperative Bleeding After Percutaneous Nephrolithotomy: A Systematic Review and Meta-Analysis of Comparative Studies.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Nephrolithotomy, Percutaneous; Postoperative | 2022 |
Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
Topics: Aminocaproic Acid; Anaphylaxis; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Su | 2022 |
Blood Loss and Transfusion in a Pediatric Scoliosis Surgery Cohort in the Antifibrinolytic Era.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Humans; Retrosp | 2022 |
Tranexamic Acid Administration in Arthroscopic Surgery Is a Safe Adjunct to Decrease Postoperative Pain and Swelling: A Systematic Review and Meta-analysis.
Topics: Adult; Anterior Cruciate Ligament Reconstruction; Arthroscopy; Blood Loss, Surgical; Female; Hemarth | 2022 |
Tranexamic acid in head and neck procedures: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemoglobins; Humans; Postoperative Hemorrhage; Random | 2022 |
Efficacy and safety of tranexamic acid in hip fracture surgery. How does dosage affect outcomes: A meta-analysis of randomized controlled trials.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Randomized Controlled Tr | 2022 |
Tranexamic acid in sinus and nasal surgery: an up-to-date meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Nasal Surgical Procedures; Paranasal Sinuses; | 2022 |
Tranexamic acid usage in hip fracture surgery: a meta-analysis and meta-regression analysis of current practice.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2022 |
Association of tranexamic acid with decreased blood loss in patients undergoing laminectomy and fusion with posterior instrumentation: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Laminectomy; Tranexamic Ac | 2022 |
Safety and Efficacy of Tranexamic Acid to Minimise Perioperative Bleeding in Hepatic Surgery: A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Liver; Tranexamic Acid | 2022 |
Tranexamic Acid versus Epsilon-Aminocaproic Acid in Total Knee Arthroplasty: A Meta-Analysis.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; H | 2021 |
Efficacy and safety of aprotinin in paediatric cardiac surgery: A systematic review and meta-analysis.
Topics: Adolescent; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; C | 2022 |
Effect of Tranexamic Acid on Bleeding Outcomes After Percutaneous Nephrolithotomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Nephrolithotomy, Percutaneous; Ra | 2022 |
Tranexamic Acid: When is It Indicated in Orthopaedic Surgery?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Blood Transfusion; Humans; | 2023 |
Commentary on: A Systematic Review and Meta-Analysis Evaluating the Impact of Tranexamic Acid Administration in Aesthetic Plastic Surgery.
Topics: Blood Loss, Surgical; Humans; Plastic Surgery Procedures; Surgery, Plastic; Tranexamic Acid | 2022 |
The administration of tranexamic acid for corrective surgery involving eight or more spinal levels: A systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Humans; Spine; Trane | 2022 |
Role of tranexamic acid in craniosynostosis surgery: Systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; Prospective Studies; | 2022 |
Use of Tranexamic Acid for Elective Resection of Intracranial Neoplasms: A Systematic Review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Brain Neoplasms; Humans; Prospective Studies; Retrosp | 2022 |
Topics: Blood Loss, Surgical; Humans; Nephrolithotomy, Percutaneous; Randomized Controlled Trials as Topic; | 2022 |
Impact of tourniquet during total knee arthroplasty when tranexamic acid was used: a meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Intraoperati | 2022 |
Tranexamic Acid Use for Hemorrhagic Events Prevention in Percutaneous Nephrolithotomy: Systematic Review and Meta-Analysis.
Topics: Blood Loss, Surgical; Blood Transfusion; Humans; Kidney Calculi; Lithotripsy; Nephrolithotomy, Percu | 2022 |
Safety and Efficacy of Local Tranexamic Acid for the Prevention of Surgical Bleeding in Soft-Tissue Surgery: A Review of the Literature and Recommendations for Plastic Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Plastic Surgery Procedures; Tranexamic Acid; | 2022 |
Tranexamic acid reduces postoperative blood loss in Chinese pediatric patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Component Transfusion; Blood Loss, Surgical; Cardiac Surgical Procedu | 2022 |
Tranexamic acid-associated fatal status epilepticus in a paediatric non-cardiac surgery: A case report and literature review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Humans; Male; Propofol; Seiz | 2022 |
The effect of antifibrinolytic agents in periacetabular osteotomy: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Osteotomy; Tranexamic Acid | 2022 |
The use of tranexamic acid reduces blood loss in osteotomy at knee level: a systematic review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemoglobins; Humans; Osteotomy; Postoperative Hemorrh | 2022 |
The efficacy and safety of tranexamic acid in lumbar surgery: A meta-analysis of randomized-controlled trials.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; R | 2022 |
Intra-articular versus intravenous administration of tranexamic acid in lower limb total arthroplasty: a systematic review and meta-analysis of randomised clinical trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
Impact on blood loss and transfusion rates following administration of tranexamic acid in major oncological abdominal and pelvic surgery: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Pelvic Neoplasms; Tranexamic Acid; Venous Thr | 2022 |
[Hemostatic efficacy of tranexamic acid and ε-aminocaproic acid in hip and knee arthroplasty:a Meta-analysis].
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2022 |
Tranexamic Acid and Its Potential Anti-Inflammatory Effect: A Systematic Review.
Topics: Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surg | 2022 |
Intravenous tranexamic acid and thromboembolic events in hip fracture surgery: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemoglobins; Hip Frac | 2023 |
Tranexamic Acid Was Not Associated with Increased Complications in High-Risk Patients with Intertrochanteric Fracture.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2022 |
The efficacy and safety of combined administration of intravenous and intra-articular tranexamic acid in total knee arthroplasty: An update meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2022 |
Prophylactic tranexamic acid during myomectomy: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Randomized Controlled Trials as Topic | 2022 |
Tranexamic acid dosage for spinal surgery: a meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Human | 2022 |
Is Tranexamic Acid Beneficial in Open Spine Surgery? and its Effects Vary by Dosage, Age, Sites, and Locations: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Randomized Controlled Trials as Topic; Spinal | 2022 |
Optimal administration strategies of tranexamic acid to minimize blood loss during spinal surgery: results of a Bayesian network meta-analysis.
Topics: Antifibrinolytic Agents; Bayes Theorem; Blood Loss, Surgical; Humans; Network Meta-Analysis; Tranexa | 2022 |
The effect of tranexamic acid in open reduction and internal fixation of pelvic and acetabular fracture: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, Internal; Hip Fractures; Humans; P | 2022 |
Optimizing Blood Loss and Management in Craniosynostosis Surgery: A Systematic Review of Outcomes Over the Last 40 Years.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Humans; Tranexam | 2023 |
Effect of Tranexamic Acid on Blood Management during a High Tibial Osteotomy: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemoglobins; Humans; Male; Osteotomy; Tranexa | 2022 |
The effect of tranexamic acid on myocardial injury in cardiac surgical patients: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Human | 2022 |
Update on Applications and Limitations of Perioperative Tranexamic Acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Child; Humans; Periopera | 2022 |
Update on Applications and Limitations of Perioperative Tranexamic Acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Child; Humans; Periopera | 2022 |
Update on Applications and Limitations of Perioperative Tranexamic Acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Child; Humans; Periopera | 2022 |
Update on Applications and Limitations of Perioperative Tranexamic Acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Child; Humans; Periopera | 2022 |
Tranexamic Acid Utilization in Foot and Ankle Surgery: A Meta-analysis.
Topics: Administration, Intravenous; Ankle; Antifibrinolytic Agents; Blood Loss, Surgical; Hemoglobins; Huma | 2022 |
The Safety and Effectiveness of Tranexamic Acid in Lumbar Interbody Fusion Surgery: An Updated Meta-analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemoglobins; Humans; Randomized Controlled Trials as | 2022 |
Update on the efficacy and safety of intravenous tranexamic acid in hip fracture surgery: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; P | 2023 |
Patient blood management and patient safety.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Patient Safety; Tranexamic Acid | 2022 |
Comparison between peri-articular injection and intra-articular injection of tranexamic acid during total knee arthroplasty: A meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Injections, | 2022 |
Efficacy and safety of tranexamic acid in unicompartmental knee arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
Efficacy and safety of tranexamic acid in unicompartmental knee arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
Efficacy and safety of tranexamic acid in unicompartmental knee arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
Efficacy and safety of tranexamic acid in unicompartmental knee arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
Efficacy and safety of tranexamic acid in unicompartmental knee arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
Efficacy and safety of tranexamic acid in unicompartmental knee arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
Efficacy and safety of tranexamic acid in unicompartmental knee arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
Efficacy and safety of tranexamic acid in unicompartmental knee arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
Efficacy and safety of tranexamic acid in unicompartmental knee arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
The Use of Tranexamic Acid in Hip Fracture Surgery-A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2022 |
The Use of Tranexamic Acid in Hip Fracture Surgery-A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2022 |
The Use of Tranexamic Acid in Hip Fracture Surgery-A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2022 |
The Use of Tranexamic Acid in Hip Fracture Surgery-A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2022 |
The Use of Tranexamic Acid in Hip Fracture Surgery-A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2022 |
The Use of Tranexamic Acid in Hip Fracture Surgery-A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2022 |
The Use of Tranexamic Acid in Hip Fracture Surgery-A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2022 |
The Use of Tranexamic Acid in Hip Fracture Surgery-A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2022 |
The Use of Tranexamic Acid in Hip Fracture Surgery-A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2022 |
Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiar | 2023 |
Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiar | 2023 |
Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiar | 2023 |
Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiar | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
Efficacy of prophylactic pre-operative desmopressin administration during functional endoscopic sinus surgery for chronic rhinosinusitis: A systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Blood Loss, Surgical; Deamino Arginine Vasopressin; Hemostatics; Humans; Randomized Controlled Trial | 2023 |
The role of tranexamic acid in reducing post-operative bleeding and seroma formation in breast surgery: A meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Seroma; T | 2023 |
Efficacy and safety of tranexamic acid in posterior lumbar interbody fusion: a meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Randomized Controlled Trials as Topic; System | 2023 |
A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Meningeal Neoplasms; Meningioma; Middl | 2023 |
Is tranexamic acid associated with decreased need for blood transfusion in percutaneous nephrolithotomy: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Nephrolithotomy, Percutane | 2023 |
Tranexamic Acid Use in Breast Surgery: A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Mastectom | 2023 |
Efficacy of high dose tranexamic acid (TXA) for hemorrhage: A systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemorrhage; Humans; Randomi | 2023 |
Surgeon-Specific Treatment Selection Bias and Heterogeneous Perioperative Practices in an Observational Spine Surgery Study. A Statistical Tutorial with Implications for Analysis of Observational Studies of Perioperative Interventions.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Retrospective Studies; Selection Bias; | 2023 |
Tranexamic acid use in meningioma surgery - A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Meningeal Neoplasms; Meningioma; Tranexamic A | 2023 |
Local Application of Tranexamic Acid in Plastic Surgery Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Humans; Randomized Controlled Trials as T | 2023 |
The Efficacy of Tranexamic Acid for the Treatment of Traumatic Hip Fractures: A Network Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Network Meta-Analysis; Randomi | 2023 |
CONTEMPORARY RECOMMENDATIONS ON PATIENT BLOOD MANAGEMENT IN JOINT ARTHROPLASTY.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2022 |
Tranexamic acid-associated intrathecal toxicity during spinal anaesthesia: A narrative review of 22 recent reports.
Topics: Anesthesia, Spinal; Anesthetics, Local; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemor | 2023 |
The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon-Aminocaproic Acid to Reduce Bleeding in TKA: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
Role of Tranexamic Acid (TXA) in Preventing Bleeding Following Sleeve Gastrectomy: a Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Gastrectomy; Humans; | 2023 |
The Effects of Tranexamic Acid in Breast Surgery: A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Postopera | 2023 |
A systematic review on the efficacy of tranexamic acid in head and neck surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Hemorrhage; Tonsillectom | 2023 |
Modern use of tranexamic acid in facial plastic surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Plastic Surgery Procedures; Rhinoplasty; Surg | 2023 |
Tranexamic acid in endoscopic sinus and skull base surgery: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Paranasal Sinuses; Skull Base; Tranexamic Aci | 2023 |
Tranexamic acid in burn surgery: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Burns; Humans; Tranexamic Acid; Venous Thromboembolis | 2023 |
Effect of preoperative prophylactic intravenous tranexamic acid on perioperative blood loss control in patients undergoing cesarean delivery: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female | 2023 |
Tranexamic acid for the prevention of blood loss after cesarean section: an updated systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Postpartum Hemorrha | 2023 |
Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Thr | 2023 |
Effects of combined dexamethasone and tranexamic acid in lower limb total arthroplasty: a systematic review and meta-analysis of randomized clinical trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2023 |
Efficacy and safety of intravenous tranexamic acid in urologic surgery: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Randomized Controlled Trials as Topic; Thromb | 2023 |
Tranexamic acid administration for the prevention of periprosthetic joint infection and surgical site infection: a systematic review and meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthritis, Infectious; Arthroplasty, Replacement, | 2023 |
Intravenous application of tranexamic acid in intramedullary nailing for the treatment of geriatric intertrochanteric fractures: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, | 2023 |
Effectiveness of tranexamic acid in orthognathic surgery: A systematic review of systematic reviews.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Orthognathic Surgery; Systematic Reviews as T | 2023 |
Efficacy and safety of single- and double-dose intravenous tranexamic acid in hip and knee arthroplasty: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2023 |
Tranexamic acid can reduce blood loss in adolescent scoliosis surgery: a systematic review and meta-analysis.
Topics: Adolescent; Blood Loss, Surgical; Exsanguination; Humans; Orthopedic Procedures; Scoliosis; Tranexam | 2023 |
Systematic review and meta-analysis of topical tranexamic acid in spine surgery.
Topics: Blood Loss, Surgical; Case-Control Studies; Cross-Sectional Studies; Hemoglobins; Humans; Postoperat | 2023 |
Does tranexamic acid diminish hemorrhage and pain in open elbow arthrolysis? a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Elbow; Humans; Pain; Postoperative Hemorrhage; Tranex | 2023 |
Tranexamic acid versus misoprostol for management of postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemostatics; Humans; Misoprostol; Postpartum | 2023 |
Effects of intraoperative or postoperative administration of intravenous iron supplements on hemoglobin recovery in patients with total knee arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
Efficacy and safety of tranexamic acid in prevention of postpartum hemorrhage: a systematic review and meta-analysis of 18,649 patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemoglobins; Humans; Nausea; Postpartum Hemor | 2023 |
Comparison of efficacy between tranexamic acid and epsilon-aminocaproic acid for total knee arthroplasty: A meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The Safety and Efficacy of Tranexamic Acid in Adult Spinal Deformity Surgery: A Systematic Review and Meta-Analysis.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Spinal Curvatures; Tranexamic Acid | 2019 |
Intravenous tranexamic acid reduces blood transfusions in revision total hip arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2019 |
Current Evidence and Future Directions of Tranexamic Acid Use, Efficacy, and Dosing for Major Surgical Procedures.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Cardi | 2020 |
Efficacy and Safety of Tranexamic Acid in Reducing Blood Loss of Lower Extremity Osteotomy in Peri-acetabulum and High Tibia: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Lower Extremity; Osteotomy | 2019 |
Efficacy and safety of tranexamic acid usage in patients undergoing posterior lumbar fusion: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Humans; Intervertebra | 2019 |
Hemostatic techniques to reduce blood transfusion after primary TKA: a meta-analysis and systematic review.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2019 |
Reducing blood loss in pediatric craniosynostosis surgery by use of tranexamic acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2019 |
Tranexamic Acid in the Perioperative Period: Yes, No, Maybe?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Dose-Response Relationship, Drug; Humans; Postoperati | 2019 |
Incidence of Thromboembolic Events in Oncology Patients Receiving Intraoperative Tranexamic Acid During Orthopedic Surgery: A Retrospective Review at a Comprehensive Cancer Center.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Incidence; Intraoperativ | 2020 |
The efficiency and safety of oral tranexamic acid in total hip arthroplasty: A meta-analysis.
Topics: Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; | 2019 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
Topical Tranexamic Acid Is Effective in Cementless Total Knee Arthroplasty.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2020 |
Efficacy and Safety of Tranexamic Acid Combined with Rivaroxaban in Primary Total Knee Arthroplasty: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Randomized C | 2021 |
Efficacy and safety of tranexamic acid in orthopaedic trauma surgery: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Orthopedic Procedures; Tra | 2019 |
Tranexamic acid in gynecologic surgery.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Femal | 2020 |
The efficacy and safety of tranexamic acid in the treatment of intertrochanteric fracture: an updated meta-analysis of 11 randomized controlled trials.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Fracture Fixation; Hip Fractures; Human | 2020 |
Postoperative outcomes of tranexamic acid use in geriatric trauma patients treated with proximal femoral intramedullary nails: A systematic review and meta-analysis.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, Intramedullary; Hip Fracture | 2020 |
Advances in surgical hemostasis: a comprehensive review and meta-analysis on topical tranexamic acid in spinal deformity surgery.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Hemostatic Techniques; Human | 2021 |
Comparison of efficacy and safety between oral and intravenous administration of tranexamic acid for primary total knee/hip replacement: a meta-analysis of randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2020 |
[Fast-track arthroplasty-intra- and post-operative management].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; I | 2020 |
Efficacy and Safety of Tranexamic Acid in Major Non-Cardiac Surgeries at High Risk for Transfusion: A Systematic Review and Meta-Analysis.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Humans; Male; Risk | 2020 |
Controversial Topics in Total Knee Arthroplasty: A Five-Year Update (Part 2).
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Aspirin; Blood Loss, Surgi | 2020 |
Efficacy and safety of tranexamic acid for reducing blood loss in elderly patients with intertrochanteric fracture treated with intramedullary fixation surgery: A meta-analysis of randomized controlled trials.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, Intramedullary; Hip Fracture | 2020 |
Comparison of Intravenous versus Topical Tranexamic Acid in Nondeformity Spine Surgery: A Meta-Analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Datab | 2020 |
A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Preoperative Care; Tranexamic Acid | 2021 |
A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Preoperative Care; Tranexamic Acid | 2021 |
A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Preoperative Care; Tranexamic Acid | 2021 |
A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Preoperative Care; Tranexamic Acid | 2021 |
Prophylactic Topical Tranexamic Acid Versus Placebo in Surgical Patients: A Systematic Review and Meta-analysis∗.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Hemorr | 2021 |
Utility of Tranexamic acid to minimize blood loss in brain tumour surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Brain Neoplasms; Humans; Neurosurgical Procedures; Tr | 2020 |
Acute Myocardial Infarction After Tranexamic Acid: Review of Published Case Reports.
Topics: Adult; Aged; Blood Loss, Surgical; Female; Humans; Male; Middle Aged; Myocardial Infarction; Risk Fa | 2020 |
The never ending success story of tranexamic acid in acquired bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Thromboembolism; Tranexami | 2020 |
Effectiveness and safety of the use of antifibrinolytic agents in total-knee arthroplasty: A meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2020 |
Tranexamic acid in Neurosurgery: a controversy indication-review.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Brain Injuries, Traumatic; | 2021 |
Efficacy and safety of the tranexamic acid in reducing blood loss and transfusion requirements during percutaneous nephrolithotomy: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Nephrolithotomy, Percutane | 2020 |
The effect of tranexamic acid on the values of activated clotting time in patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Humans; Postoperative He | 2020 |
The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Hemostatic effect of tourniquet combined with tranexamic acid in total knee arthroplasty: a network meta-analysis.
Topics: Administration, Topical; Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control S | 2020 |
Intra-articular vs. intravenous administration: a meta-analysis of tranexamic acid in primary total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Intra-articular vs. intravenous administration: a meta-analysis of tranexamic acid in primary total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Intra-articular vs. intravenous administration: a meta-analysis of tranexamic acid in primary total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Intra-articular vs. intravenous administration: a meta-analysis of tranexamic acid in primary total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Exposure-Response Relationship of Tranexamic Acid in Cardiac Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Dose-Response Relationsh | 2021 |
Tranexamic Acid in Foot and Ankle Surgery: A Topical Review and Value Analysis.
Topics: Ankle; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Trane | 2022 |
The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis.
Topics: Adolescent; Blood Loss, Surgical; Female; Humans; Infusions, Intravenous; Intraoperative Complicatio | 2021 |
What is the ideal route of administration of tranexamic acid in total knee arthroplasty? A meta-analysis based on randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Randomized C | 2021 |
Different Dose Regimens of Intravenous Tranexamic Acid in Adolescent Spinal Deformity Surgery: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood | 2020 |
Role of tranexamic acid in blood loss control and blood transfusion management of patients undergoing multilevel spine surgery: A meta-analysis.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Case-Cont | 2021 |
[Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?]
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Hemorrhage; Humans; Orth | 2021 |
Comparative efficacy and safety of topical hemostatic agents in primary total knee arthroplasty: A network meta-analysis of randomized controlled trials.
Topics: Administration, Topical; Adult; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2021 |
The Use of Tranexamic Acid in Hip and Pelvic Fracture Surgeries.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Tranexamic | 2021 |
Assessment of Tranexamic Acid in Reducing Intraoperative Blood Loss During Rhytidectomy.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Practice Guidelines as Topic; Rhytidoplasty; | 2022 |
Safety and efficacy of tranexamic acid in minimizing perioperative bleeding in extrahepatic abdominal surgery: meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Perioperative Care; Randomized Controlled Tri | 2021 |
Antifibrinolytics reduces blood loss in thoracic surgery: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Humans; Thoracic Surgery; Tranexamic Acid | 2021 |
Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemorrhage; Humans; Obstetrics; Tr | 2021 |
A Meta-Analysis of Complications of Tranexamic Acid Use in Lower-Limb Orthopedic Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Orthopedic Procedures; Orthopedics; Tranexami | 2021 |
Blood Management in Outpatient Total Hip Arthroplasty.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip | 2021 |
The efficacy and safety of tranexamic acid in high tibial osteotomy: a systematic review and meta-analysis.
Topics: Blood Loss, Surgical; Female; Hemoglobins; Humans; Male; Osteotomy; Postoperative Complications; Saf | 2021 |
Tranexamic acid given into wound reduces postoperative drainage, blood loss, and hospital stay in spinal surgeries: a meta-analysis.
Topics: Administration, Topical; Blood Loss, Surgical; Clinical Trials as Topic; Drainage; Humans; Length of | 2021 |
Efficacy and Safety of Antifibrinolytic Drugs in Pediatric Surgery: A Systematic Review.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Humans; Pharmaceutical Prep | 2021 |
The Efficacy and Safety of Topical Tranexamic Acid for Spinal Surgery.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; T | 2021 |
Comparison of intravenous versus topical tranexamic acid in primary total hip and knee arthroplasty: An updated meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
A comparison of combined intravenous and topical administration of tranexamic acid with intravenous tranexamic acid alone for blood loss reduction after total hip arthroplasty: A meta-analysis.
Topics: Administration, Cutaneous; Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Repla | 2017 |
Preventing perioperative bleeding in patients with inherited bleeding disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Hemophilia A; Humans; Postoperativ | 2017 |
The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis.
Topics: Adult; Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Erythrocyte Transfusion; Humans; | 2017 |
Intra-articular versus intravenous tranexamic acid application in total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2017 |
Intra-articular Tranexamic Acid in Primary Total Knee Arthroplasty: Meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2018 |
Is combined use of intravenous and intraarticular tranexamic acid superior to intravenous or intraarticular tranexamic acid alone in total knee arthroplasty? A meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2017 |
Tranexamic acid reduces blood loss and transfusion requirements in primary simultaneous bilateral total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; Humans; Middle Aged; | 2017 |
Indications for and complications of transfusion and the management of gynecologic malignancies.
Topics: Acute Lung Injury; Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Erythrocyte Transfusion; F | 2017 |
Is combined topical and intravenous tranexamic acid superior to intravenous tranexamic acid alone for controlling blood loss after total hip arthroplasty?: A meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: A meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Fractures; Humans; Orthopedic | 2017 |
Efficiency and safety of tranexamic acid in reducing blood loss in total shoulder arthroplasty: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, Surgical; Blood Transfusio | 2017 |
The efficiency and safety of tranexamic acid for reducing blood loss in open myomectomy: A meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Randomized Controlled Trials as Topic | 2017 |
Combined versus single application of tranexamic acid in total knee and hip arthroplasty: A meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2017 |
Tranexamic acid plus diluted-epinephrine versus tranexamic acid alone for blood loss in total joint arthroplasty: A meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Drug Therapy, Combination; | 2017 |
The efficacy and safety of tranexamic acid in revision total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Length of St | 2017 |
Efficacy of tranexamic acid plus drain-clamping to reduce blood loss in total knee arthroplasty: A meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Clinical Studies as | 2017 |
Tranexamic Acid in Total Knee Arthroplasty: Mixed Treatment Comparisons and Recursive Cumulative Meta-Analysis of Randomized, Controlled Trials and Cohort Studies.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Antifibrinolytic Agents; | 2018 |
Desmopressin use for minimising perioperative blood transfusion.
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Deamin | 2017 |
Is combined topical and intravenous tranexamic acid superior to single use of tranexamic acid in total joint arthroplasty?: A meta-analysis from randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2017 |
Comparison of oral versus intravenous application of tranexamic acid in total knee and hip arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2017 |
Tranexamic acid decreases blood loss in shoulder arthroplasty: A meta-analysis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, Surgical; Blood Tran | 2017 |
Most Effective Regimen of Tranexamic Acid for Reducing Bleeding and Transfusions in Primary Total Knee Arthroplasty: A Meta-Analysis of Randomized Controlled Trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2018 |
Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2017 |
Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2017 |
Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2017 |
Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2017 |
Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2017 |
Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2017 |
Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2017 |
Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2017 |
Tranexamic Acid in Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2017 |
The efficacy of tranexamic acid in reducing blood loss in total shoulder arthroplasty: A meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, Surgical; Humans; Tranexam | 2017 |
Tranexamic Acid in Orthopaedic Trauma Surgery: A Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Case-Control Studies; Female; Humans; Male; Orthopedi | 2017 |
Efficacy and Safety of Tranexamic Acid in Orthopaedic Fracture Surgery: A Meta-Analysis and Systematic Literature Review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Fracture Fixation; Fractur | 2017 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedure | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
A systematic review and meta-analysis comparing combined intravenous and topical tranexamic acid with intravenous administration alone in THA.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
The efficacy of combined intra-articular and intravenous tranexamic acid for blood loss in primary total knee arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
The efficacy of tranexamic acid using oral administration in total knee arthroplasty: a systematic review and meta-analysis.
Topics: Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical | 2017 |
The effect of tranexamic acid to reduce blood loss and transfusion on off-pump coronary artery bypass surgery: A systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass, Off-Pump; | 2018 |
Antifibrinolytic Therapy and Perioperative Considerations.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Fibrinolysis; Humans; Pe | 2018 |
Can tranexamic acid conserve blood and save operative time in spinal surgeries? A meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Neurosurgical Pr | 2018 |
Tranexamic Acid Prophylaxis in Hip and Knee Joint Replacement.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2017 |
[Research progress on tranexamic acid application strategy in total knee arthroplasty].
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2016 |
Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials.
Topics: Administration, Intravenous; Blood Loss, Surgical; Female; Humans; Male; Orthopedic Procedures; Rand | 2018 |
[Prophylactic use of tranexamic acid in noncardiac surgery : Update 2017].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Intraoperative Care; Male; Tranexamic | 2019 |
Tranexamic acid reduces blood loss in intertrochanteric fractures: A meta-analysis from randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, Internal; Hip Fractures; Humans; R | 2017 |
Efficacy and safety of tranexamic acid in total hip replacement: A PRISMA-compliant meta-analysis of 25 randomized controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
Tranexamic acid plus drain-clamping can reduce blood loss in total knee arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2018 |
[Blood management in complex reconstructive spine surgery in ASD patients : Do effective measures to reduce bleeding exist?]
Topics: Blood Loss, Surgical; Drainage; Hemostatics; Humans; Male; Spine; Tranexamic Acid | 2018 |
Tranexamic acid in total shoulder arthroplasty and reverse shoulder arthroplasty: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, Surgical; Blood Transfusio | 2018 |
The efficacy and safety of topical administration of tranexamic acid in spine surgery: a meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Length of Stay; Rand | 2018 |
The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Thromboembolism; T | 2018 |
The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Thromboembolism; T | 2018 |
The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Thromboembolism; T | 2018 |
The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Thromboembolism; T | 2018 |
Efficacy and safety of oral tranexamic acid in total knee arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical | 2018 |
Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: A systematic review and meta-analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Systematic review and meta-analyses of tranexamic acid use for bleeding reduction in prostate surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Incidence; Male; Prostatec | 2018 |
Reduction of Blood Loss by Tranexamic Acid Following Total Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2018 |
Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: an updated systematic review and meta-analysis.
Topics: Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; PubMed; Randomized Controlled Tri | 2018 |
The Efficacy of Tranexamic Acid in Total Knee Arthroplasty: A Network Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans; Netw | 2018 |
The Efficacy of Tranexamic Acid in Total Hip Arthroplasty: A Network Meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2018 |
The Efficacy of Tranexamic Acid on Blood Loss from Lumbar Spinal Fusion Surgery: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Databases, Bibliographic; Female; Humans; Male; Rando | 2018 |
Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration Schedule; Ecchymosis; Edema; Eyel | 2018 |
The efficacy and safety of combined administration of intravenous and topical tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2018 |
Is the combined application of both drain-clamping and tranexamic acid superior to the single use of either application in patients with total-knee arthroplasty?: A meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Combined Modality Th | 2018 |
The efficacy of oral versus intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthritis; Arthroplasty, | 2018 |
A systematic review of tranexamic acid usage in patients undergoing femoral fracture surgery.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; | 2018 |
Comparative effectiveness and safety of tranexamic acid plus diluted epinephrine to control blood loss during total hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Co | 2018 |
The Efficacy and Safety of Intravenous Tranexamic Acid in Reducing Surgical Blood Loss in Posterior Lumbar Interbody Fusion for the Adult: A Systematic Review and a Meta-Analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Human | 2019 |
Use of antifibrinolytics in pediatric cardiac surgery: Where are we now?
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2019 |
Optimal use of tranexamic acid for total hip arthroplasty: A network meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Network Meta- | 2018 |
The Effectiveness of Tranexamic Acid at Reducing Blood Loss and Transfusion Requirement for Women Undergoing Myomectomy: A Systematic Review and Meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Humans; Leiomyoma; | 2019 |
Tranexamic Acid Decreases Blood Transfusion Burden in Open Craniosynostosis Surgery Without Operative Compromise.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Erythrocyte Transfusion; Humans; In | 2019 |
Tranexamic Acid Plus Low-dose Epinephrine Reduces Blood Loss in Total Knee Arthroplasty: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; D | 2018 |
Oral tranexamic acid reduces blood loss in total-knee arthroplasty: A meta-analysis.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Su | 2018 |
Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2018 |
Exclusion criteria and adverse events in perioperative trials of tranexamic acid: a systematic review and meta-analysis.
Topics: Blood Loss, Surgical; Blood Transfusion; Drug Hypersensitivity; Humans; Randomized Controlled Trials | 2019 |
Efficacy of tranexamic acid on operative bleeding in endoscopic sinus surgery: A meta-analysis and systematic review.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Endoscopy; Female; Humans; Incidence; Male; Mi | 2019 |
Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Edema; Humans; Postoperative Complication | 2019 |
Comparative efficacy and safety of different hemostatic methods in total hip arthroplasty: a network meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemostatic Techniques | 2019 |
Is intravenous tranexamic acid effective and safe during hip fracture surgery? An updated meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Fract | 2019 |
Effectiveness and safety of tranexamic acid in total joint arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2019 |
[Perioperative care of epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF a
Topics: Analgesia, Patient-Controlled; Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Carcinoma, Ova | 2019 |
Comparison of intravenous, topical or combined routes of tranexamic acid administration in patients undergoing total knee and hip arthroplasty: a meta-analysis of randomised controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Anemia; Antifibrinolytic Agents; Arthroplasty, | 2019 |
The Use of Tranexamic Acid to Reduce Surgical Blood Loss: A Review Basic Science, Subspecialty Studies, and The Evolution of Use in Spine Deformity Surgery.
Topics: Arthroplasty; Blood Loss, Surgical; Dose-Response Relationship, Drug; Humans; Spine; Tranexamic Acid | 2019 |
The Role of Antifibrinolytics in Reducing Blood Loss During Craniofacial or Orthognathic Surgical Procedures: A Meta-Analysis.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Denmark; Humans; Ort | 2019 |
Comprehensive assessment of tranexamic acid during orthognathic surgery: A systematic review and meta-analysis of randomized, controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Orthognathic Surgery; Rand | 2019 |
Comparison between oral and intravenous application of tranexamic acid for total hip arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2019 |
Does Tranexamic Acid Improve Bleeding, Transfusion, and Hemoglobin Level in Patients Undergoing Multilevel Spine Surgery? A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Humans; Postoperative | 2019 |
Tranexamic acid can reduce blood loss in patients undergoing intertrochanteric fracture surgery: A meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hematoma; Hemoglobins; Hip Fractur | 2019 |
Tranexamic acid and perioperative bleeding in children: what do we still need to know?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Dose-Response Relationship, | 2019 |
The efficacy of tranexamic acid for orthognathic surgery: a meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Orthognathic Surgery; Randomized Controlled T | 2019 |
Role of tranexamic acid in nasal surgery: A systemic review and meta-analysis of randomized control trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Edema; Eyelid Diseases; Humans; Nasal Sur | 2019 |
Role of tranexamic acid in nasal surgery: A systemic review and meta-analysis of randomized control trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Edema; Eyelid Diseases; Humans; Nasal Sur | 2019 |
Role of tranexamic acid in nasal surgery: A systemic review and meta-analysis of randomized control trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Edema; Eyelid Diseases; Humans; Nasal Sur | 2019 |
Role of tranexamic acid in nasal surgery: A systemic review and meta-analysis of randomized control trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Edema; Eyelid Diseases; Humans; Nasal Sur | 2019 |
Applications of Tranexamic acid in benign gynecology.
Topics: Administration, Oral; Blood Loss, Surgical; Female; Gynecologic Surgical Procedures; Humans; Infusio | 2019 |
Transfusions and cost-benefit of oral versus intravenous tranexamic acid in primary total hip arthroplasty: A meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2019 |
Oral vs intravenous tranexamic acid in total-knee arthroplasty and total hip arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic | 2019 |
Exclusion criteria and adverse events in perioperative trials of tranexamic acid in cardiac surgery: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Eligi | 2019 |
The Perioperative Efficacy and Safety of Tranexamic Acid in Adolescent Idiopathic Scoliosis.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Scoliosis; Spinal F | 2019 |
Prophylactic use of tranexamic acid reduces blood loss and transfusion requirements in patients undergoing cesarean section: A meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cesarean Section; Female; Humans; | 2019 |
Management of the patient presenting with anaemia in the preoperative setting.
Topics: Anemia; Blood Loss, Surgical; Erythrocyte Transfusion; Humans; Operative Blood Salvage; Preoperative | 2019 |
Epsilon-aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta-analysis study.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; B | 2019 |
Antifibrinolytic drugs for acute traumatic injury.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemo | 2012 |
Tranexamic acid for reducing mortality in emergency and urgent surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Emergencies; Humans; Random | 2013 |
Tranexamic acid for reducing mortality in emergency and urgent surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Emergencies; Humans; Random | 2013 |
Tranexamic acid for reducing mortality in emergency and urgent surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Emergencies; Humans; Random | 2013 |
Tranexamic acid for reducing mortality in emergency and urgent surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Emergencies; Humans; Random | 2013 |
Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2013 |
Practical issues for the use of tranexamic acid in total knee arthroplasty: a systematic review.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Dose-Response Relati | 2014 |
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative | 2013 |
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative | 2013 |
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative | 2013 |
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Randomized Controlled Trials as T | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Dose-Response Relationship, Drug; Humans; Rand | 2013 |
[Perioperative management of type 2B Von Willebrand's disease in a patient undergoing urgent abdominal surgery].
Topics: Abdomen, Acute; Blood Loss, Surgical; Emergencies; Factor VIII; Female; Heparin, Low-Molecular-Weigh | 2014 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
[Hemostasis and antifibrinolytic therapy in major pediatric surgery].
Topics: Adolescent; Age Factors; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical | 2013 |
[Current strategies to minimize of blood loss during radical prostatectomy].
Topics: Adult; Aged; Anesthesia, Epidural; Antifibrinolytic Agents; Blood Loss, Surgical; Fibrinolysis; Flui | 2013 |
The use of tranexamic acid to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis.
Topics: Anti-Arrhythmia Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Humans; Orthopedic Pr | 2014 |
Role of tranexamic acid in endoscopic sinus surgery - a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Endoscopy; Humans; Paranasal Sinuses; Tranexamic Acid | 2013 |
Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia.
Topics: Blood Loss, Surgical; Female; Ferric Compounds; Hemostasis, Surgical; Hemostatics; Humans; Inositol; | 2013 |
Reduced blood loss after intra-articular tranexamic acid injection during total knee arthroplasty: a meta-analysis of the literature.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2014 |
The effects of lysine analogs during pelvic surgery: a systematic review and meta-analysis.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Gynecologic Surgical Procedures; Hemorrh | 2014 |
Safety and efficacy of intra-articular injection of tranexamic acid in total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2014 |
Is tranexamic acid clinically effective and safe to prevent blood loss in total knee arthroplasty? A meta-analysis of 34 randomized controlled trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
A systematic review of the effectiveness of intravenous tranexamic acid administration in managing perioperative blood loss in patients undergoing spine surgery.
Topics: Blood Loss, Surgical; Humans; Infusions, Intravenous; Orthopedic Procedures; Spine; Tranexamic Acid | 2014 |
Effectiveness of tranexamic acid in reducing blood loss in spinal surgery: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Neurosurgical Procedures; Randomized Controll | 2014 |
Efficiency of tranexamic acid in perioperative blood loss in hip arthroplasty: a systematic literature review and meta-analysis.
Topics: Adolescent; Adult; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Female; | 2015 |
Efficacy of tranexamic acid on surgical bleeding in spine surgery: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Orthopedic Procedures; Spine; Tranexamic Acid | 2015 |
One step closer to sparing total blood loss and transfusion rate in total knee arthroplasty: a meta-analysis of different methods of tranexamic acid administration.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2015 |
Tranexamic acid: a clinical review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; General Surgery; Humans; Tranexamic Acid | 2015 |
Tranexamic acid: a clinical review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; General Surgery; Humans; Tranexamic Acid | 2015 |
Tranexamic acid: a clinical review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; General Surgery; Humans; Tranexamic Acid | 2015 |
Tranexamic acid: a clinical review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; General Surgery; Humans; Tranexamic Acid | 2015 |
Tranexamic acid: a clinical review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; General Surgery; Humans; Tranexamic Acid | 2015 |
Tranexamic acid: a clinical review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; General Surgery; Humans; Tranexamic Acid | 2015 |
Tranexamic acid: a clinical review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; General Surgery; Humans; Tranexamic Acid | 2015 |
Tranexamic acid: a clinical review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; General Surgery; Humans; Tranexamic Acid | 2015 |
Tranexamic acid: a clinical review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; General Surgery; Humans; Tranexamic Acid | 2015 |
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor VIIa; Hemophilia A; Hemophi | 2015 |
Antifibrinolytic drugs for acute traumatic injury.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemo | 2015 |
Effect of Topical Tranexamic Acid in Reducing Bleeding and Transfusions in TKA.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2015 |
What dose of tranexamic acid is most effective and safe for adult patients undergoing cardiac surgery?
Topics: Adult; Angina, Unstable; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Dose | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
Prevention of Bleeding in Orthognathic Surgery--A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Blood Loss, Surgical; Hematocrit; Hemoglobins; Hemostatics; Humans; Operative Time; Orthognathic Sur | 2016 |
[The possibility of using tranexamic acid for the treatment of bleeding in otorhinolaryngology].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Otorhinolaryngologic Surgical Procedures; Pos | 2015 |
Techniques to reduce blood loss during open myomectomy: a qualitative review of literature.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Gonadotropin-Releasing Hormone; Hemostasis, S | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Exploring redundant research into the effect of tranexamic acid on surgical bleeding: further analysis of a systematic review of randomised controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Randomized Controlled Trials as Topic; Resear | 2015 |
Predicting Blood Loss in Total Knee and Hip Arthroplasty.
Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bl | 2015 |
Safety and Efficacy of Tranexamic Acid in Total Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; D | 2015 |
[PERIOPERATIVE BLOOD MANAGEMENT STRATEGIES FOR JOINT ARTHROPLASTY].
Topics: Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Blood Transfusion; Blood Transfusion, A | 2015 |
Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2015 |
Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2015 |
Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2015 |
Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2015 |
Blood Loss and Transfusion After Topical Tranexamic Acid Administration in Primary Total Knee Arthroplasty.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2015 |
Prevention of post-operative anaemia in hip and knee arthroplasty--a systematic review.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, K | 2015 |
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor IX; Factor VIII; Hemophilia | 2015 |
Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cytoreduction Surgical Proc | 2016 |
The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis
Topics: Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Blood Loss, Surgical; Blood Transf | 2016 |
The Efficacy and Safety of Tranexamic Acid in Cranio-Maxillofacial and Plastic Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Face; Facial Bones; Humans; Micros | 2016 |
Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Blood Loss, Surgic | 2017 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Intravenous versus topical tranexamic acid in primary total hip replacement: A systemic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Comparison of efficacy and safety of topical versus intravenous tranexamic acid in total hip arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Efficiency and Safety of Intravenous Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Systematic Review and Meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2016 |
Topical versus intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2017 |
Combined intravenous and topical tranexamic acid versus intravenous use alone in primary total knee and hip arthroplasty: A meta-analysis of randomized controlled trials.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2016 |
Efficacy and safety of tranexamic acid in reducing blood loss in scoliosis surgery: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemoglobins; Humans; Postoperative Hemorrhage; Scolio | 2017 |
Combined use of intravenous and topical versus intravenous tranexamic acid in primary total joint arthroplasty: A meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
Intravenous versus topical tranexamic acid in primary total hip replacement: A meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Comparing efficacy and safety of 2 methods of tranexamic acid administration in reducing blood loss following total knee arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
A systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cesarean Section; Female; Gynecolo | 2017 |
Comparison of the effectiveness and safety of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
Combined use of intravenous and topical versus intravenous tranexamic acid in primary total knee and hip arthroplasty: a meta-analysis of randomised controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
Combined application versus topical and intravenous application of tranexamic acid following primary total hip arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2017 |
Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and non-randomized studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac S | 2017 |
[Blood conservation approaches in orthopedic surgery].
Topics: Anemia; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Blood Transfusion, Autologous; Drug Admi | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery | 2009 |
The effect of aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in major pediatric surgery: a meta-analysis.
Topics: Aminocaproates; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Child; Hemostatics; Humans; Plac | 2009 |
Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Trans | 2009 |
Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Trans | 2009 |
Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Trans | 2009 |
Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Trans | 2009 |
Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Trans | 2009 |
Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Trans | 2009 |
Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Trans | 2009 |
Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Trans | 2009 |
Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Trans | 2009 |
[Hemostatic management for cardiac surgical patients in the post-aprotinin era].
Topics: Aminocaproates; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass | 2009 |
Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Proced | 2009 |
[Therapeutic options for perioperatively acquired platelet dysfunctions].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Platelet Disorders; Deamino Arginine Vasopressi | 2009 |
Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resection.
Topics: Antithrombin III; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Deamino Arginine Vasopressin; | 2009 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia.
Topics: Blood Loss, Surgical; Female; Ferric Compounds; Hemostasis, Surgical; Hemostatics; Humans; Randomize | 2010 |
[A meta-analysis of the effectiveness and safety of using tranexamic acid in spine surgery].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Child; Child, Preschool; Female; H | 2010 |
Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass, Off-Pump; | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Antifibrinolytic drugs for acute traumatic injury.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemorrhage; Humans; Ran | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2012 |
The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2012 |
The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2012 |
The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2012 |
Methods to decrease blood loss and transfusion requirements for liver transplantation.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Factor VIIa; Hemostatic | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Child | 2012 |
Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Child | 2012 |
Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Child | 2012 |
Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Child | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
A systematic review of the use of antifibrinolytic agents in pediatric surgery and implications for craniofacial use.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Card | 2012 |
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2012 |
Systematic review and meta-analysis of the use of tranexamic acid in tonsillectomy.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Hemorrhage; Tonsillectomy; Tran | 2013 |
Minimising blood loss and transfusion in contemporary hip and knee arthroplasty.
Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bl | 2012 |
The effect of tranexamic acid on blood loss in orthognathic surgery: a meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Hematocrit; Hemoglobins; | 2013 |
Tranexamic Acid reducing blood transfusion in children undergoing craniosynostosis surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Craniosynostoses; Humans; In | 2013 |
The management of perioperative bleeding.
Topics: Aprotinin; Blood Coagulation Disorders; Blood Loss, Surgical; Deamino Arginine Vasopressin; Factor V | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2003 |
Antifibrinolytics.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemo | 2003 |
Strategies for minimizing blood loss in orthopedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surg | 2004 |
Tranexamic acid for major spinal surgery.
Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Humans; Scolios | 2004 |
Intraoperative blood management in joint replacement surgery.
Topics: Antifibrinolytic Agents; Aprotinin; Arthroplasty, Replacement; Blood Loss, Surgical; Blood Transfusi | 2004 |
[Reducing blood loss in total knee arthroplasty].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drainage; Humans; Pe | 2004 |
Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Bayes Theorem; Blood Loss, Surgical; Blood Tr | 2005 |
Antifibrinolytics in liver transplantation.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Humans; Liver Transplan | 2006 |
The use of antifibrinolytic agents in total hip arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Aprotinin; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Tran | 2006 |
[Local and systemic hemostasis in surgery].
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Factor VIIa; Fibrin Tissue Adhesive; Hemos | 2007 |
Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Humans; Intra | 2007 |
Current antifibrinolytic therapy for coronary artery revascularization.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Coro | 2008 |
Pro: tranexamic acid is better than aprotinin in decreasing bleeding after cardiac surgery.
Topics: Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Hemostatics; H | 1994 |
Con: tranexamic acid is not better than aprotinin in decreasing bleeding after cardiac surgery.
Topics: Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Hemostatics; H | 1994 |
Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Coronary Artery Byp | 1994 |
Natural and synthetic antifibrinolytics in adult cardiac surgery: efficacy, effectiveness and efficiency.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusio | 1994 |
Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Graft Occlusion, Va | 1995 |
Clinical use of synthetic antifibrinolytic agents during liver transplantation.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Clini | 1993 |
Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; | 1997 |
Hemostatic drugs.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surgica | 1998 |
Cardiac bypass haemostasis: putting blood through the mill.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion, Autologous; Coronary Ar | 1999 |
[Tranexamic acid reduces the blood loss in knee arthroplasty--if it's administered at the right time].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Volume; Guidel | 1999 |
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac | 1999 |
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac | 1999 |
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac | 1999 |
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac | 1999 |
Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia.
Topics: Blood Loss, Surgical; Female; Ferric Compounds; Hemostasis, Surgical; Hemostatics; Humans; Sulfates; | 2000 |
Current status of non-transfusional haemostatic agents.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surg | 1999 |
Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.
Topics: Anesthesia, Obstetrical; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Deamino Ar | 2001 |
[Tranexamic acid reduces blood loss and the need of blood transfusion after knee arthroplasty].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2002 |
478 trials available for tranexamic acid and Blood Loss, Surgical
| Article | Year |
|---|---|
The effect of tranexamic acid on blood loss in orthognathic surgery: a randomized, placebo-controlled, equivalence study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Orthognathic Surgery; Or | 2022 |
Multimodal Peri-articular Injection with Tranexamic Acid can reduce postoperative blood loss versus Intravenous Tranexamic Acid in Total Knee Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2021 |
Comparison of single versus double tranexamic acid dose regimens in reducing post-operative blood loss following intramedullary nailing of femoral fracture nonunions.
Topics: Adult; Blood Loss, Surgical; Femoral Fractures; Fracture Fixation, Intramedullary; Humans; Prospecti | 2022 |
Re-Evaluating the Effect of Preoperative Tranexamic Acid on Blood Loss and Field Quality During Rhinoplasty: A Randomized Double-Blinded Controlled Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Rhinoplasty; Tranexamic | 2022 |
Oral tranexamic acid for an additional 24 hours postoperatively versus a single preoperative intravenous dose for reducing blood loss in total knee arthroplasty: results of a randomized controlled trial (TRAC-24).
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antif | 2021 |
Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial.
Topics: Adrenochrome; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemosta | 2022 |
Use of a Multifunctional Cocktail for Postoperative Bleeding and Pain Control in Spinal Fusion: A Randomized, Double-blind, Controlled Trial.
Topics: Analgesics, Opioid; Blood Loss, Surgical; Double-Blind Method; Hemoglobins; Humans; Pain; Pain Manag | 2022 |
Characterisation of Plasma Mitochondrial DNA, MMP-9 and Neutrophil Elastase in Patients Undergoing Coronary Artery Bypass Grafting: Effects of Tranexamic Acid and Postoperative Pneumonia.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; DNA, Mitochondrial; Humans; L | 2022 |
The efficacy, safety, and cost-effectives of combined administration of Intravenous and Local Tranexamic Acid in the management of Patients Undergoing Primary Total Hip Arthroplasty: A prospective, blinded and randomized clinical study.
Topics: Administration, Intravenous; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; B | 2021 |
Synergistic Effect of a Prolonged Combination Course of Tranexamic Acid and Dexamethasone Involving High Initial Doses in Total Knee Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
Adjunctive Topical Tranexamic Acid for Blood Salvage Does Not Reduce Postoperative Blood Loss Compared with Placebo in Patients Who Undergo Palliative Decompressive Spinal Metastasis Surgery: A Randomized Controlled Trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Hemorr | 2022 |
Topical administration of tranexamic acid in elderly patients undergoing short femoral nailing for intertrochanteric fracture: A randomised controlled trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, Int | 2022 |
Study protocol: haemostatic efficacy and safety of preemptive antifibrinolysis with multidose intravenous tranexamic acid in elderly hip fracture patients: design of a prospective randomised controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Hemostatics; Hip F | 2021 |
Tranexamic acid administration for arthroscopic rotator cuff repair: A prospective, double-blind, randomized controlled trial.
Topics: Arthroscopy; Blood Loss, Surgical; Humans; Prospective Studies; Rotator Cuff; Rotator Cuff Injuries; | 2023 |
Effect of single dose intravenous tranexamic acid on blood loss in tangential excision of burn wounds - A double blind randomised controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Burns; Double-Blind Method; Hemoglobins; Humans; Pros | 2022 |
Pre-Emptive Antifibrinolysis: Its Role and Efficacy in Hip Fracture Patients Undergoing Total Hip Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hip Fractures; | 2022 |
Invited Discussion on: Re-evaluating the Effect of Preoperative Tranexamic Acid on Blood Loss and Field Quality During Rhinoplasty: A Randomized double-blinded controlled Trial.
Topics: Blood Loss, Surgical; Double-Blind Method; Humans; Postoperative Hemorrhage; Rhinoplasty; Tranexamic | 2022 |
Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Hypotension; Perioperative Care; Tranexamic A | 2022 |
Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Meningeal Neoplasms; Men | 2022 |
Safety and efficacy of aprotinin versus tranexamic acid for reducing absolute blood loss and transfusion in pediatric patients undergoing craniosynostosis surgery: a randomized, double-blind, three-arm controlled trial.
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Child; Craniosyn | 2022 |
Tranexamic acid combined with compression dressing reduces blood loss in gluteal muscle contracture surgery.
Topics: Antifibrinolytic Agents; Bandages; Blood Loss, Surgical; Contracture; Humans; Muscles; Postoperative | 2022 |
Should tranexamic acid be used for 3 days after total knee replacement? A randomized study in 250 patients.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Hemoglobins; Humans; | 2021 |
Tranexamic acid versus placebo to reduce perioperative blood transfusion in patients undergoing liver resection: protocol for the haemorrhage during liver resection tranexamic acid (HeLiX) randomised controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Liver; Prospective Studies | 2022 |
Safety and efficacy of preoperative tranexamic acid in reducing intraoperative and postoperative blood loss in high-risk women undergoing cesarean delivery: a randomized controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Electiv | 2022 |
The Effect of Topical Tranexamic Acid in Endoscopic Sinus Surgery: A Triple Blind Randomized Clinical Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Endoscopy; Humans; Sinusitis; Tr | 2023 |
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2022 |
Is intravenous tranexamic acid effective in reduction of blood loss during pelvic and acetabular surgery?
Topics: Acetabulum; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Prospective Studies; Tranexamic A | 2022 |
Comparison of the therapeutic efficacy of topical tranexamic acid, epinephrine, and lidocaine in stopping bleeding in non-traumatic epistaxis: a prospective, randomized, double-blind study.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Me | 2022 |
Omission of tranexamic acid does not increase the amount of perioperative blood transfusions in patients undergoing one-level spinal fusion surgery: a retrospective propensity score-matched noninferiority study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Propensity Score; Retrospe | 2023 |
Randomized, controlled trial of two tranexamic acid dosing protocols in adult spinal deformity surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Prospective Studies; Seizures; Tranexa | 2022 |
Use of Tranexamic Acid in Liposculpture: A Double-Blind, Multicenter, Randomized Clinical Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Female; Hemoglobins; Humans; Lys | 2022 |
A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19.
Topics: Angiotensin I; Antifibrinolytic Agents; Blood Loss, Surgical; COVID-19; Double-Blind Method; Humans; | 2022 |
Value of Tranexamic Acid and Progressive Nursing in Accelerating Postoperative Rehabilitation After Total Knee Arthroplasty.
Topics: Activities of Daily Living; Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Kne | 2023 |
The addition of oral Tranexamic acid to knee arthroplasty patients does not further improve blood loss: a double blinded randomized control trial.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2022 |
Safety and efficacy of perioperative tranexamic acid infusion in acetabular fracture fixation: A randomized placebo-controlled double-blind prospective study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, Internal; Hemoglobins; Hip Fractur | 2022 |
Comparison of Intravenous and Topical Tranexamic Acid in Total Joint Arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2022 |
A randomized control trial on the role of tranexamic acid in preventing intraoperative bleeding during external dacryocystorhinostomy.
Topics: Blood Loss, Surgical; Dacryocystorhinostomy; Double-Blind Method; Female; Humans; Lacrimal Duct Obst | 2022 |
Tranexamic acid effects in postoperative bleeding outcomes in laparoscopic sleeve gastrectomy: a controlled study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Blood Loss, Surgical; Gastrectomy; | 2022 |
A single dose of tranexamic acid infusion is safe and effective to reduce total blood loss during proximal femoral nailing for intertrochanteric fractures: A prospective randomized study.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, Intramedullary; Hip Fracture | 2022 |
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Pancreaticoduoden | 2023 |
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Pancreaticoduoden | 2023 |
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Pancreaticoduoden | 2023 |
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Pancreaticoduoden | 2023 |
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Pancreaticoduoden | 2023 |
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Pancreaticoduoden | 2023 |
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Pancreaticoduoden | 2023 |
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Pancreaticoduoden | 2023 |
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Pancreaticoduoden | 2023 |
Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2023 |
Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2023 |
Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2023 |
Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2023 |
Topics: Aged; Antifibrinolytic Agents; Arthrodesis; Blood Loss, Surgical; Bone Screws; Fracture Fixation, In | 2022 |
Topics: Aged; Antifibrinolytic Agents; Arthrodesis; Blood Loss, Surgical; Bone Screws; Fracture Fixation, In | 2022 |
Topics: Aged; Antifibrinolytic Agents; Arthrodesis; Blood Loss, Surgical; Bone Screws; Fracture Fixation, In | 2022 |
Topics: Aged; Antifibrinolytic Agents; Arthrodesis; Blood Loss, Surgical; Bone Screws; Fracture Fixation, In | 2022 |
Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Dalt | 2023 |
Tranexamic acid does not significantly lower postoperative bleeding after endoscopic sinus and nasal surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Epistaxis; Humans; Nasal Surgica | 2023 |
Topical Tranexamic Acid in Breast Reconstruction: A Double-Blind Randomized Controlled Trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Breast Ne | 2023 |
Efficacy of intravenous tranexamic acid administration in medial opening-wedge distal tibial tuberosity osteotomy (MOWDTO) for varus knee osteoarthritis: a randomized control trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Osteoarthritis, | 2023 |
The effect of intravenous unit-dose tranexamic acid on visible and hidden blood loss in posterior lumbar interbody fusion: a randomized clinical trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; C-Reactive Protein; Hemostatics; Humans; Postoperativ | 2023 |
Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical | 2023 |
Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cesarean Section; Chemoprevention; | 2023 |
Single Dose of Tranexamic Acid Effectively Reduces Blood Loss in Patients Undergoing Spine Surgery: A Prospective Randomized Controlled Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Prospective Studies; Spine; Tranexamic Acid | 2023 |
Tourniquets can further reduce perioperative blood loss in patients on dexamethasone and tranexamic acid during cemented total knee arthritis: a single-center, double-blind, randomized controlled trial.
Topics: Albumins; Antifibrinolytic Agents; Arthritis; Blood Loss, Surgical; Dexamethasone; Humans; Inflammat | 2023 |
Medullary cavity application of tranexamic acid to reduce blood loss in tibial intramedullary nailing procedures-a randomized controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Exsanguination; Fracture Fixation, Intramedullary; Hu | 2023 |
Topical use of tranexamic acid can reduce opioid consumption compared with intravenous use for patients undergoing primary total hip arthroplasty: a prospective randomized controlled trial.
Topics: Administration, Intravenous; Administration, Topical; Analgesics, Opioid; Antifibrinolytic Agents; A | 2023 |
Comparative study between oxytocin and combination of tranexamic acid and ethamsylate in reducing intra-operative bleeding during emergency and elective cesarean section after 38 weeks of normal pregnancy.
Topics: Blood Loss, Surgical; Cesarean Section; Ethamsylate; Female; Humans; Oxytocin; Pregnancy; Pregnancy | 2023 |
Comparative study of carbazochrome sodium sulfonate and tranexamic acid in reducing blood loss and inflammatory response following direct anterior total hip arthroplasty: a prospective randomized controlled trial.
Topics: Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgi | 2023 |
Tranexamic acid administration for the prevention of periprosthetic joint infection and surgical site infection: a systematic review and meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthritis, Infectious; Arthroplasty, Replacement, | 2023 |
[Effects of Tranexamic Acid on Perioperative Blood Loss and Wound Hematoma Development in Lumbar Spine Surgery: a Prospective Randomized Study].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hematoma; Humans; Postoperative Hemorrhage; Prospecti | 2023 |
Peroperative administration of tranexamic acid in sleeve gastrectomy to reduce hemorrhage: a double-blind randomized controlled trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Hum | 2023 |
Risk of bleeding in anticoagulated patients undergoing dental extraction treated with topical tranexamic acid compared to collagen-gelatin sponge: Randomized clinical trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Collagen; Gelatin; Humans; P | 2023 |
A randomised controlled trial of tranexamic acid versus misoprostol in reducing blood loss during caesarean section.
Topics: Blood Loss, Surgical; Cesarean Section; Female; Humans; Misoprostol; Oxytocics; Oxytocin; Pregnancy; | 2022 |
Topical combined tranexamic acid and epinephrine versus topical epinephrine in control of intraoperative bleeding of external dacryocystorhinostomy.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Dacryocystorhinostomy; Epine | 2023 |
Efficacy of perioperative cryotherapy combined with intra-articular injection of tranexamic acid in total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Injections, | 2023 |
Oxytocin versus a combination of tranexamic acid and ethamsylate in reducing intraoperative bleeding during abdominal myomectomy: a randomized clinical trial.
Topics: Blood Loss, Surgical; Ethamsylate; Female; Humans; Leiomyoma; Oxytocin; Saline Solution; Tranexamic | 2023 |
The effect of tranexamic acid on perioperative blood loss in transurethral resection of the prostate: A double-blind, randomized controlled trial.
Topics: Blood Loss, Surgical; Hemoglobins; Humans; Male; Prospective Studies; Prostate; Tranexamic Acid; Tra | 2023 |
Intravenous tranexamic acid vs. sublingual misoprostol in high-risk women for postpartum haemorrhage following cesarean delivery; a randomised clinical trial.
Topics: Blood Loss, Surgical; Cesarean Section; Female; Humans; Misoprostol; Oxytocin; Postoperative Hemorrh | 2023 |
The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial.
Topics: Blood Loss, Surgical; Brain; Humans; Meningeal Neoplasms; Meningioma; Randomized Controlled Trials a | 2023 |
Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study.
Topics: Administration, Intravenous; Adult; Anticoagulants; Antifibrinolytic Agents; Arthritis; Arthroplasty | 2023 |
[Efficacy and safety of multiple-dose intravenous tranexamic acid for reducing blood loss in complex tibial plateau fractures: A prospective randomized controlled trial].
Topics: Blood Loss, Surgical; Humans; Interleukin-6; Prospective Studies; Thrombosis; Tibial Fractures; Tibi | 2023 |
Clinical utilization of methylprednisolone in conjunction with tranexamic acid for accelerated rehabilitation in total hip arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Methylprednis | 2023 |
Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Meningeal Neoplasms; Men | 2024 |
Effect of Tranexamic Acid on Postoperative Bleeding in Sleeve Gastrectomy: a Randomized Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Obesity, Morbid; Postoperative Hemorrhage; Tr | 2023 |
Blood-conserving and therapeutic efficacy of intravenous tranexamic acid at different time points after primary total knee arthroplasty with tourniquet application: a randomised controlled trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The efficacy of temperature intervention combined with tranexamic acid in reducing blood loss and accelerating recovery during spinal fusion.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemoglobins; Humans; Postoperative Hemorrhage; Pulmon | 2023 |
Effect of intravenous low-dose norepinephrine on blood loss in non-tourniquet total knee arthroplasty under general anesthesia: a randomized, double-blind, controlled, single-center trial.
Topics: Anesthesia, General; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; | 2023 |
[Efficacy and safety of a loading high-dose tranexamic acid followed by postoperative five doses in total hip arthroplasty: A randomized controlled trial].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2019 |
Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single-Blind Randomized Controlled Trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; | 2019 |
Perioperative combined administration of tranexamic acid and dexamethasone in total knee arthroplasty-benefit versus harm?
Topics: Aged; Analgesics; Anti-Inflammatory Agents; Antiemetics; Antifibrinolytic Agents; Arthroplasty, Repl | 2019 |
Hemostatic and Anti-Inflammatory Effects of Carbazochrome Sodium Sulfonate in Patients Undergoing Total Knee Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Topical; Adrenochrome; Anti-Inflammatory Agents; Antifi | 2020 |
Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A | 2019 |
Tranexamic acid or epsilon-aminocaproic acid in total joint arthroplasty? A randomized controlled trial.
Topics: Administration, Intravenous; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replace | 2019 |
[Effect of tranexamic acid combined flexion position of hip and knee on perioperative bleeding following unilateral total knee arthroplasty].
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2019 |
Monitoring of fibrinolytic system activity with plasminogen, D-dimers and FDP in primary total knee arthroplasty (TKA) after topical, intravenous or combined administration of tranexamic acid.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2020 |
Effect of topical tranexamic acid in total hip arthroplasty patients who receive continuous aspirin for prevention of cardiovascular or cerebrovascular events: A prospective randomized study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2019 |
Adjunctive use of tranexamic acid to tourniquet in reducing haemorrhage during abdominal myomectomy - A randomized controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Female; Humans; Leiomyoma | 2019 |
Tranexamic acid in open aortic aneurysm surgery: a randomised clinical trial.
Topics: Aged; Antifibrinolytic Agents; Aortic Aneurysm; Blood Loss, Surgical; Blood Transfusion; Cardiac Sur | 2020 |
Tranexamic acid in open aortic aneurysm surgery: a randomised clinical trial.
Topics: Aged; Antifibrinolytic Agents; Aortic Aneurysm; Blood Loss, Surgical; Blood Transfusion; Cardiac Sur | 2020 |
Tranexamic acid in open aortic aneurysm surgery: a randomised clinical trial.
Topics: Aged; Antifibrinolytic Agents; Aortic Aneurysm; Blood Loss, Surgical; Blood Transfusion; Cardiac Sur | 2020 |
Tranexamic acid in open aortic aneurysm surgery: a randomised clinical trial.
Topics: Aged; Antifibrinolytic Agents; Aortic Aneurysm; Blood Loss, Surgical; Blood Transfusion; Cardiac Sur | 2020 |
Intravenous and subsequent long-term oral tranexamic acid in enhanced-recovery primary total knee arthroplasty without the application of a tourniquet: a randomized placebo-controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2019 |
Combined use of intravenous and topical tranexamic acid in patients aged over 70 years old undergoing total hip arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agen | 2019 |
Does tranexamic acid improve intra-operative visualisation in endoscopic ear surgery? A double-blind, randomised, controlled trial.
Topics: Adolescent; Adult; Anatomic Landmarks; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind M | 2019 |
Tranexamic acid has no advantage in head and neck surgical procedures: a randomised, double-blind, controlled clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Female; Humans; Male; Mid | 2019 |
Intravenous Tranexamic Acid for Brain Contusion with Intraparenchymal Hemorrhage: Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Brain Contusion; Brain Hemorrhage, Traum | 2020 |
Safety and efficacy of tranexamic acid in paediatric cardiac surgery: study protocol for a double-blind randomised controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Cardi | 2019 |
Comparison of Floseal® and Tranexamic Acid for Bleeding Control after Total Knee Arthroplasty: a Prospective Randomized Study.
Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control Studies; Female; Follow-Up Studi | 2019 |
Tranexamic acid use in high-risk blood transfusion patients undergoing total hip replacement: a randomised controlled trial.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2021 |
Application of thromboelastography to evaluate the effect of different routes administration of tranexamic acid on coagulation function in total hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2019 |
Tranexamic acid in ENT.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Brain Injuries, Traumatic; Humans; Otolaryngology; Pl | 2019 |
The antifibrinolytic and anti-inflammatory effects of a high initial-dose tranexamic acid in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, | 2020 |
A new improvement: subperiosteal cocktail application to effectively reduce pain and blood loss after total knee arthroplasty.
Topics: Aged; Anesthetics, Local; Anti-Inflammatory Agents; Arthroplasty, Replacement, Knee; Blood Loss, Sur | 2020 |
Comparison of hemocoagulase atrox versus tranexamic acid used in primary total knee arthroplasty: A randomized controlled trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Batroxobin; B | 2020 |
Intraoperative Intravenous and Intra-Articular Plus Postoperative Intravenous Tranexamic Acid in Total Knee Arthroplasty: A Placebo-Controlled Randomized Controlled Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2020 |
Outcome impact of different tranexamic acid regimens in cardiac surgery with cardiopulmonary bypass (OPTIMAL): Rationale, design, and study protocol of a multicenter randomized controlled trial.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; | 2020 |
Hidden blood loss in direct anterior total hip arthroplasty: a prospective, double blind, randomized controlled trial on topical versus intravenous tranexamic acid.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2021 |
Topical co-delivery of platelet rich fibrin and tranexamic acid does not decrease blood loss in primary total knee arthroplasty compared to the standard of care: a prospective, randomized, controlled trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2021 |
Effects of Intravenous Tranexamic Acid During Rhytidectomy: A Randomized, Controlled, Double-Blind Pilot Study.
Topics: Blood Loss, Surgical; Double-Blind Method; Humans; Pilot Projects; Postoperative Hemorrhage; Prospec | 2021 |
Tranexamic acid reduce hidden blood loss in posterior lumbar interbody fusion (PLIF) surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Lumbar Vertebrae; Male; Middle Aged; | 2020 |
Topical tranexamic acid in cemented primary total knee arthroplasty without tourniquet: a prospective randomized study.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2020 |
Orthognathic Surgery-Induced Fibrinolytic Shutdown Is Amplified by Tranexamic Acid.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Double-Blind Method; | 2020 |
Intraoperative tranexamic acid to decrease blood loss during myomectomy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Female; Humans; Injection | 2020 |
Additional benefits of multiple-dose tranexamic acid to anti-fibrinolysis and anti-inflammation in total knee arthroplasty: a randomized controlled trial.
Topics: Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surg | 2020 |
Tranexamic acid for the Latarjet procedure: a randomized controlled trial.
Topics: Administration, Intravenous; Adult; Analgesics, Opioid; Antifibrinolytic Agents; Blood Loss, Surgica | 2020 |
Two Doses of Tranexamic Acid Reduce Blood Loss in Primary Posterior Lumbar Fusion Surgery: A Randomized-controlled Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Lumbosacral Region; Tranex | 2020 |
Results after the application of tranexamic acid intravenous or intra-articular in the control of postsurgical bleeding after total hip arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2020 |
Tranexamic acid in total knee replacement which protocol? which application form? A prospective randomised study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2019 |
Effectiveness of different doses and routes of administration of tranexamic acid for total hip replacement.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2021 |
Tranexamic acid safely reduces hidden blood loss in patients undergoing intertrochanteric fracture surgery: a randomized controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Meta-Analysis as Topic; Tranex | 2022 |
Effect of topical tranexamic acid on post-traumatic elbow stiffness in patients treated with open arthrolysis: a prospective comparative study.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Drainage; Elbow; Elbow Joint; Female; Humans; | 2020 |
Effect of tranexamic acid on blood loss after reverse total shoulder arthroplasty according to the administration method: a prospective, multicenter, randomized, controlled study.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthritis; Arth | 2020 |
Topical Tranexamic Acid in Total Knee Arthroplasty: Does It Augment the Effect of the Intravenous Administration in Patients with Moderate-to-High Risk of Bleeding? A Randomized Clinical Trial.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2021 |
Tranexamic Acid Is Associated With Improved Operative Field in Orthognathic Surgery.
Topics: Adolescent; Adult; Blood Loss, Surgical; Child; Dexmedetomidine; Double-Blind Method; Female; Humans | 2020 |
Intravenous versus topical tranexamic acid in lumbar interbody fusion: A protocol of randomized controlled trial.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; | 2020 |
High-dose versus low-dose tranexamic acid for paediatric craniosynostosis surgery: a double-blind randomised controlled non-inferiority trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child, Preschool; Craniosynostoses; Dose-Response Rel | 2020 |
Effectiveness of preemptive antifibrinolysis with tranexamic acid in rheumatoid arthritis patients undergoing total knee arthroplasty: a study protocol for a randomized controlled trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replaceme | 2020 |
Combined use of tranexamic acid and rivaroxaban in posterior lumbar interbody fusion safely reduces blood loss and transfusion rates without increasing the risk of thrombosis-a prospective, stratified, randomized, controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Prospective Studies; Rivar | 2020 |
Randomized prospective evaluation of the use of tranexamic acid and effects on blood loss for proximal humeral fracture surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2020 |
Tranexamic acid is beneficial for blood management of high tibial osteotomy: a randomized controlled study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Middle Aged; Osteotomy; Postoperative Hemorrh | 2021 |
Preoperative tranexamic acid does not reduce transfusion rates in major oncologic surgery: Results of a randomized, double-blind, and placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; Follo | 2020 |
Combined use of intravenous and topical tranexamic acid efficiently reduces blood loss in patients aged over 60 operated with a 2-level lumbar fusion.
Topics: Administration, Topical; Age Factors; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2020 |
Multiple-dose tranexamic acid for perioperative blood loss in total knee arthroplasty in patients with rheumatoid arthritis：a single-blinded, randomised, parallel-controlled study protocol in China.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Rep | 2020 |
Better Treatment Values in Local Application of Tranexamic Acid (TXA) than Intravenous Application with the Same Dose in Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative | 2020 |
The efficacy and safety of intravenous tranexamic acid in anterior cruciate ligament reconstruction: A randomized controlled trial protocol.
Topics: Anterior Cruciate Ligament Reconstruction; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tran | 2020 |
Intravenous tranexamic acid reduces blood loss and transfusion requirements after periacetabular osteotomy.
Topics: Acetabulum; Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Sur | 2020 |
Optimal dose of topical tranexamic acid considering efficacy and safety in total knee arthroplasty: a randomized controlled study.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2021 |
Effect of tranexamic acid on markers of inflammation in children undergoing craniofacial surgery.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Child; Double-Blind Method; Humans; Infla | 2021 |
Tranexamic acid reduces blood cost in long-segment spinal fusion surgery: A randomized controlled study protocol.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; Human | 2020 |
Prophylactic use of tranexamic acid for prevention of bleeding during transbronchial lung biopsies - A randomized, double-blind, placebo-controlled trial.
Topics: Aged; Antifibrinolytic Agents; Biopsy; Blood Loss, Surgical; Bronchi; Double-Blind Method; Female; H | 2020 |
Is Preoperative Administration of Tranexamic Acid Effective on Blood Loss Reduction in Mandibular Fracture Surgeries? A Triple-Blind Randomized Clinical Trial.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Chicago; Female; | 2021 |
The effect of multiple-dose oral versus intravenous tranexamic acid in reducing postoperative blood loss and transfusion rate after adolescent scoliosis surgery: a randomized controlled trial.
Topics: Administration, Intravenous; Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Post | 2021 |
Combined and intravenous administration of TXA reduces blood loss more than topical administration in primary total knee arthroplasty: A randomized clinical trial.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2022 |
Topical use of tranexamic acid versus epinephrine to optimise surgical field during exploratory tympanotomy.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epinephrine; Humans; Tranexa | 2020 |
Pre-operative tranexemic acid vs. etamsylate in reducing blood loss during elective cesarean section: randomized controlled trial.
Topics: Adult; Blood Loss, Surgical; Blood Transfusion; Cesarean Section; Double-Blind Method; Elective Surg | 2021 |
Tranexamic ACid during PancereaticoDuodenectomy (TAC-PD): study protocol for a multicentre randomised, blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Japan; Multicenter Studi | 2020 |
The Optimal Dosing Regimen for Tranexamic Acid in Revision Total Hip Arthroplasty: A Multicenter Randomized Clinical Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2020 |
Prophylactic use of tranexamic acid for decreasing the blood loss in elective cesarean section: A placebo-controlled randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cesarean Section; Double-Bl | 2021 |
The influence of topical use of tranexamic acid in reducing blood loss on early operation for thoracolumbar burst fracture: a randomized double-blinded controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Hemorr | 2021 |
Effect of Multiple Doses of Intravenous Tranexamic Acid on Perioperative Blood Loss in Total Knee Arthroplasty: A Randomized Controlled Study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2021 |
Is serum gentamicin concentration modified with autologous cell-saved blood transfusion after total knee arthroplasty using tranexamic acid? A randomised control trial.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; B | 2021 |
Effects of Different Applications of Tranexamic Acid on Perioperative Blood Transfusion Rate and Postoperative Pain in Unilateral Total Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2021 |
Safety and Efficacy of Using Tranexamic Acid at the Beginning of Robotic-Assisted Radical Prostatectomy in a Double-Blind Prospective Randomized Pilot Study.
Topics: Adult; Aged; Blood Loss, Surgical; Double-Blind Method; Fibrinolytic Agents; Humans; Male; Middle Ag | 2020 |
Safety and Efficacy of Using Tranexamic Acid at the Beginning of Robotic-Assisted Radical Prostatectomy in a Double-Blind Prospective Randomized Pilot Study.
Topics: Adult; Aged; Blood Loss, Surgical; Double-Blind Method; Fibrinolytic Agents; Humans; Male; Middle Ag | 2020 |
Safety and Efficacy of Using Tranexamic Acid at the Beginning of Robotic-Assisted Radical Prostatectomy in a Double-Blind Prospective Randomized Pilot Study.
Topics: Adult; Aged; Blood Loss, Surgical; Double-Blind Method; Fibrinolytic Agents; Humans; Male; Middle Ag | 2020 |
Safety and Efficacy of Using Tranexamic Acid at the Beginning of Robotic-Assisted Radical Prostatectomy in a Double-Blind Prospective Randomized Pilot Study.
Topics: Adult; Aged; Blood Loss, Surgical; Double-Blind Method; Fibrinolytic Agents; Humans; Male; Middle Ag | 2020 |
Optimal Route for Tranexamic Acid in Diabetics and Obese Patients Undergoing Primary Total Knee Arthroplasty - a Data from Randomized Study.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2020 |
A single dose of tranexamic acid reduces blood loss after reverse and anatomic shoulder arthroplasty: a randomized controlled trial.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, Surgical; Blood Transfusio | 2021 |
The effect of intravenous tranexamic acid on visual clarity during arthroscopic rotator cuff repair: A randomized, double-blinded, placebo-controlled pilot study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty; Arthroscopy; Blood Loss, Surgica | 2020 |
The effect of intravenous tranexamic acid on visual clarity during arthroscopic rotator cuff repair: A randomized, double-blinded, placebo-controlled pilot study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty; Arthroscopy; Blood Loss, Surgica | 2020 |
The effect of intravenous tranexamic acid on visual clarity during arthroscopic rotator cuff repair: A randomized, double-blinded, placebo-controlled pilot study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty; Arthroscopy; Blood Loss, Surgica | 2020 |
The effect of intravenous tranexamic acid on visual clarity during arthroscopic rotator cuff repair: A randomized, double-blinded, placebo-controlled pilot study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty; Arthroscopy; Blood Loss, Surgica | 2020 |
Study protocol for a multicentre, 2×2 factorial, randomised, controlled trial evaluating the interest of intravenous iron and tranexamic acid to reduce blood transfusion in hip fracture patients (the HiFIT study).
Topics: Administration, Intravenous; Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusio | 2021 |
Comparison of Effects of a Thrombin-Based Hemostatic Agent and Topical Tranexamic Acid on Blood Loss in Patients with Preexisting Thromboembolic Risk Undergoing a Minimally Invasive Total Knee Arthroplasty. A Prospective Randomized Controlled Trial.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2021 |
Effects of tourniquet use on clinical outcomes and cement penetration in TKA when tranexamic acid administrated: a randomized controlled trial.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Bone Cements; Humans | 2021 |
Outcomes of combined use of topical and intravenous tranexamic acid on surgical field quality during functional endoscopic sinus surgery: Randomized controlled trial.
Topics: Administration, Intravenous; Blood Loss, Surgical; Endoscopy; Humans; Prospective Studies; Tranexami | 2021 |
Tranexamic acid in joint replacement : a randomized trial comparing intravenous oral and topical routes.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Aged, 80 and over; | 2020 |
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol | 2022 |
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol | 2022 |
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol | 2022 |
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol | 2022 |
Prospective, randomised, controlled study on the efficacy and safety of different strategies of tranexamic acid with total blood loss, blood transfusion rate and thrombogenic biomarkers in total knee arthroplasty: study protocol.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2021 |
Infographic: Single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial.
Topics: Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Bl | 2021 |
Single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; F | 2021 |
[Clinical effects of tranexamic acid in arthroscope for femoroacetabular impingement].
Topics: Adult; Aged; Arthroscopes; Arthroscopy; Blood Loss, Surgical; Female; Femoracetabular Impingement; H | 2021 |
Are The Applications of Tranexamic Acid in Reverse Hybrid Total Knee Arthroplasty (TKA) The Same as Those in Fully Cemented TKA?: A Randomized Controlled Trial.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2021 |
Tranexamic Acid in Pediatric Scoliosis Surgery: A Prospective Randomized Trial Comparing High-dose and Low-dose Tranexamic Acid in Adolescent Idiopathic Scoliosis Undergoing Posterior Spinal Fusion Surgery.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Humans; Prospective Studies | 2021 |
Multiple intravenous tranexamic acid doses in total knee arthroplasty in patients with rheumatoid arthritis: a randomized controlled study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Rep | 2021 |
Intravenous tranexamic acid reduce postoperative drainage and pain after open elbow arthrolysis: a randomized controlled trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Drainage; Elbow; Humans; | 2021 |
[Efficacy and safety of intravenous combined with topical administration of tranexamic acid in reducing blood loss after intramedullary fixation of intertrochanteric femoral fractures].
Topics: Administration, Intravenous; Administration, Topical; Blood Loss, Surgical; Bone Nails; Femoral Frac | 2021 |
Oral tranexamic acid for an additional 24 hours postoperatively versus a single preoperative intravenous dose for reducing blood loss in total hip arthroplasty: results of a randomized controlled trial (TRAC-24).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthropla | 2021 |
Oral Is as Effective as Intravenous Tranexamic Acid at Reducing Blood Loss in Thoracolumbar Spinal Fusions: A Prospective Randomized Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Ma | 2022 |
Evaluation of local tranexamic acid on septoplastic surgery quality.
Topics: Administration, Topical; Antifibrinolytic Agents; Arterial Pressure; Attitude of Health Personnel; B | 2021 |
The Effects of Tranexamic Acid on Bleeding Control During and after Percutaneous Nephrolithotomy (PCNL): A Randomized Clinical Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Humans; Nephr | 2021 |
Use of tranexamic acid does not influence perioperative outcomes in ambulatory foot and ankle surgery-a prospective triple blinded randomized controlled trial.
Topics: Ankle; Antifibrinolytic Agents; Blood Loss, Surgical; Foot; Humans; Prospective Studies; Tranexamic | 2021 |
Efficacy and Safety of Tranexamic Acid for the Control of Surgical Bleeding in Patients Under Liposuction.
Topics: Blood Loss, Surgical; Humans; Lipectomy; Prospective Studies; Tranexamic Acid; Treatment Outcome | 2022 |
Combined topical and intravenous administration of tranexamic acid further reduces postoperative blood loss in adolescent idiopathic scoliosis patients undergoing spinal fusion surgery: a randomized controlled trial.
Topics: Administration, Intravenous; Administration, Topical; Adolescent; Antifibrinolytic Agents; Blood Los | 2021 |
Tranexamic acid in a periarticular multimodal cocktail injection for blood management in total knee arthroplasty: a prospective randomized study.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2021 |
Topical tranexamic acid in hip fractures: a randomized, placebo-controlled double-blinded study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2021 |
Tranexamic acid attenuates early post-operative systemic inflammatory response and nutritional loss and avoids reduction of fibrinogen in total hip arthroplasty within an enhanced recovery after surgery pathway.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Enhanced Recovery Aft | 2021 |
Effectiveness of preoperative tranexamic acid in reducing blood loss during caesarean section at Aminu Kano Teaching Hospital, Kano: a randomized controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2021 |
Cost-Benefit Analysis of Using A Single Dose of Tranexamic Acid in Degenerative Lumbar Scoliosis Patients Undergoing Long-Segment Spinal Fusion Surgery: A Retrospective Study.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Decision-Making; Combined Modality The | 2021 |
Effectiveness of tranexamic acid for reducing intraoperative bleeding in palatoplasties: A randomized clinical trial.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Cleft Palate; Do | 2017 |
Determination of Perioperative Blood Loss: Accuracy or Approximation?
Topics: Algorithms; Anthropometry; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surg | 2017 |
Efficacy of tranexamic acid on side effects of rhinoplasty: A randomized double-blind study.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Ecchymosis; Edema; Female | 2017 |
Tranexamic Acid Reduces Occult Blood Loss, Blood Transfusion, and Improves Recovery of Knee Function after Total Knee Arthroplasty: A Comparative Study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; F | 2018 |
A comparative analysis of the role of Tranexamic acid as an independent variable in reducing intraoperative blood loss in patients undergoing conventional total knee arthroplasty versus computer-assisted total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Hemogl | 2017 |
Tranexamic Acid Safely Reduced Blood Loss in Hemi- and Total Hip Arthroplasty for Acute Femoral Neck Fracture: A Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2017 |
Tranexamic Acid in Knee Surgery Study-A Multicentered, Randomized, Controlled Trial.
Topics: Aged; Anesthetics; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; C | 2017 |
Effectiveness and Safety of Batroxobin, Tranexamic Acid and a Combination in Reduction of Blood Loss in Lumbar Spinal Fusion Surgery.
Topics: Adult; Aged; Antifibrinolytic Agents; Batroxobin; Blood Loss, Surgical; Blood Transfusion; Double-Bl | 2018 |
Intravenous Tranexamic Acid Bolus plus Infusion Is Not More Effective than a Single Bolus in Primary Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2017 |
Intra-articular Application is More Effective Than Intravenous Application of Tranexamic Acid in Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.
Topics: Administration, Intravenous; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; | 2017 |
The effectiveness of low-dose and high-dose tranexamic acid in posterior lumbar interbody fusion: a double-blinded, placebo-controlled randomized study.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Middle Aged; Postoperative Hemorrhage; | 2017 |
Comparison of intravenous and intra-articular tranexamic acid in reducing blood loss in primary total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2017 |
The effect of intravenous tranexamic acid on blood loss and early post-operative pain in total shoulder arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
Clinical and instrumental evaluation of two different regimens of tranexamic acid in total hip arthroplasty: a single-centre, prospective, randomized study with 80 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Volume; F | 2018 |
Effect of Tranexamic Acid on Transfusion: A Randomized Clinical Trial in Acetabular Fracture Surgery.
Topics: Acetabulum; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; F | 2017 |
Blood Conservation Using Tranexamic Acid Is Not Superior to Epsilon-Aminocaproic Acid After Total Knee Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2017 |
[Safety and efficacy of intravenous tranexamic acid in endoscopic transurethral resections in urology: Prospective randomized trial].
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cystectomy; Double-Bl | 2017 |
Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhanced-recovery primary total hip arthroplasty: a randomised clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Biomarkers; | 2017 |
Oral vs Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Study.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A | 2018 |
Oral vs Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Study.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A | 2018 |
Oral vs Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Study.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A | 2018 |
Oral vs Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Study.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A | 2018 |
Effects of low-dose epinephrine on perioperative hemostasis and inflammatory reaction in major surgical operations: a randomized clinical trial.
Topics: Adrenergic Agonists; Adult; Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, R | 2018 |
A randomized controlled trial on the effects of collagen sponge and topical tranexamic acid in posterior spinal fusion surgeries.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusi | 2017 |
The effect of different dosage regimens of tranexamic acid on blood loss in bimaxillary osteotomy: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Blood Component Transfusion; Blood Loss, Surgical; Doubl | 2018 |
A Randomized Controlled Trial of Low-Dose Tranexamic Acid versus Placebo to Reduce Red Blood Cell Transfusion During Complex Multilevel Spine Fusion Surgery.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Erythrocyte Transfusion; F | 2018 |
Tranexamic Acid Decreases Visible and Hidden Blood Loss Without Affecting Prethrombotic State Molecular Markers in Transforaminal Thoracic Interbody Fusion for Treatment of Thoracolumbar Fracture-Dislocation.
Topics: Adult; Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Double-Blind Method; Female; Fract | 2018 |
Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokinetic-pharmacodynamic study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Computer Simula | 2018 |
The Effect of Tranexamic Acid and Gender on Intraoperative Bleeding in Orthognathic Surgery-A Randomized Controlled Trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Denmark; Double-Blind Method; Female; Humans; | 2018 |
Intravenous and Topical Tranexamic Acid Alone Are Superior to Tourniquet Use for Primary Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial.
Topics: Administration, Topical; Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; China; Combine | 2017 |
[Comparison of different modes of using tranexamic acid administration on reducing hidden blood loss in total hip arthroplasty].
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2016 |
Emergency coronary bypass surgery in patients under the influence of dualantiplatelet therapy: effects of tranexamic acid and desmopressin acetate
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Deamino Ar | 2017 |
The comparative efficacy and safety of topical and intravenous tranexamic acid for reducing perioperative blood loss in Total knee arthroplasty- A randomized controlled non-inferiority trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2018 |
Synergistic effects of intravenous and intra-articular tranexamic acid on reducing hemoglobin loss in revision total knee arthroplasty: a prospective, randomized, controlled study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2018 |
Topical Tranexamic Acid Reduces Blood Loss in Minimally Invasive Total Knee Arthroplasty Receiving Rivaroxaban.
Topics: Administration, Topical; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2017 |
The effect of tranexamic acid on hidden bleeding in older intertrochanteric fracture patients treated with PFNA.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Fracture Fixation, Intramedullary; Hip | 2018 |
Efficacy and safety of intra-articular versus intravenous tranexamic acid in reducing perioperative blood loss in total knee arthroplasty: a prospective randomized double-blind equivalence trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans | 2018 |
The effect of oral versus intravenous tranexamic acid in reducing blood loss after primary total hip arthroplasty: A randomized clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Arthroplasty, Replacement, Hip; Blood Loss, Surgi | 2018 |
Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
Efficacy of oral tranexamic acid on blood loss in primary total hip arthroplasty using a direct anterior approach: a prospective randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl | 2018 |
Efficacy and safety of topical tranexamic acid in knee arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2018 |
Comparison of oral versus intra-articular tranexamic acid in enhanced-recovery primary total knee arthroplasty without tourniquet application: a randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Su | 2018 |
Comparison between Intravenous Boluses versus Infusion of Tranexamic Acid (TXA) to Reduce Bleeding in Paediatric Cyanotic Congenital Heart Disease (CHD) Surgeries.
Topics: Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cardi | 2018 |
Comparing the efficacy of intravenous or intra-articular tranexamic acid in reducing blood loss in simultaneous bilateral knee replacement surgery without the use of tourniquet.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2018 |
The efficacy and safety of multiple-dose oral tranexamic acid on blood loss following total hip arthroplasty: a randomized controlled trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2019 |
Use of Tranexamic Acid to Reduce Blood Loss in Liposuction.
Topics: Adult; Blood Loss, Surgical; Double-Blind Method; Female; Hematocrit; Humans; Injections, Intravenou | 2018 |
Tranexamic Acid versus Placebo to Prevent Blood Transfusion during Radical Cystectomy for Bladder Cancer (TACT): Study Protocol for a Randomized Controlled Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Canada; Cystectomy; Double-Blind M | 2018 |
Multiple-Dose Intravenous Tranexamic Acid Further Reduces Hidden Blood Loss After Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2018 |
Tranexamic acid use during total hip arthroplasty: A single center retrospective analysis.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2018 |
Comparison of intravenous and topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2018 |
Intravenous Versus Topical Tranexamic Acid in Total Knee Arthroplasty: Both Effective in a Randomized Clinical Trial of 640 Patients.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2018 |
Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy: a randomized clinical trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Humans; Infus | 2019 |
OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Doubl | 2019 |
Blood-conserving efficacy of multiple doses of oral tranexamic acid associated with an enhanced-recovery programme in primary total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Su | 2018 |
Assessment of the effect of addition of 24 hours of oral tranexamic acid post-operatively to a single intraoperative intravenous dose of tranexamic acid on calculated blood loss following primary hip and knee arthroplasty (TRAC-24): a study protocol for a
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthropla | 2018 |
Efficacy of topical tranexamic acid within a blood-saving programme for primary total hip arthroplasty: a pragmatic, open-label randomised study.
Topics: Administration, Topical; Aged; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; | 2018 |
Tranexamic acid in primary total knee arthroplasty without tourniquet: a randomized, controlled trial of oral versus intravenous versus topical administration.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthritis, Rheumat | 2018 |
Similar thromboprophylaxis with rivaroxaban and low molecular weight heparin but fewer hemorrhagic complications with combined intra-articular and intravenous tranexamic acid in total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgica | 2019 |
Comparative Efficacy of Intravenous With Intra-articular Versus Intravenous Only Administration of Tranexamic Acid to Reduce Blood Loss in Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2018 |
Is topical or intravenous tranexamic acid preferred in total hip arthroplasty? A randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2018 |
Using intra-articular tranexamic acid in total knee replacement surgery with and without bleeding control: a prospective randomized double blind study.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2018 |
Blood loss and cost-effectiveness of oral vs intravenous tranexamic acid in primary total hip arthroplasty: A randomized clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl | 2018 |
Intravenous Administration of Tranexamic Acid Significantly Reduces Visible and Hidden Blood Loss Compared with Its Topical Administration for Double-Segment Posterior Lumbar Interbody Fusion: A Single-Center, Placebo-Controlled, Randomized Trial.
Topics: Administration, Intravenous; Administration, Topical; Adult; Antifibrinolytic Agents; Blood Loss, Su | 2019 |
Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean delivery for placenta previa: a randomized double-blind controlled trial.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2019 |
[Comparison of combined intravenous and topical use of tranexamic acid with different dosage in primary total knee arthroplasty].
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2018 |
The antifibrinolytic and anti-inflammatory effects of multiple doses of oral tranexamic acid in total knee arthroplasty patients: a randomized controlled trial.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replace | 2018 |
Subcutaneous tranexamic acid in upper eyelid blepharoplasty: a prospective randomized pilot study.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blepharoplasty; Blood Loss, Surgical; Chalazion; D | 2018 |
Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery: A Randomized Placebo-Controlled Trial.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; F | 2018 |
Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery: A Randomized Placebo-Controlled Trial.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; F | 2018 |
Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery: A Randomized Placebo-Controlled Trial.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; F | 2018 |
Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery: A Randomized Placebo-Controlled Trial.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; F | 2018 |
Prevention of postoperative bleeding in hip fractures treated with prosthetic replacement: efficacy and safety of fibrin sealant and tranexamic acid. A randomised controlled clinical trial (TRANEXFER study).
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2019 |
Intravenous and Oral Tranexamic Acid Are Equivalent at Reducing Blood Loss in Thoracolumbar Spinal Fusion: A Prospective Randomized Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Blood Loss, Surgic | 2019 |
Effect of Multiple Doses of Oral Tranexamic Acid on Haemostasis and Inflammatory Reaction in Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Oral; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2019 |
Subcutaneous Injection of Tranexamic Acid to Reduce Bleeding During Dermatologic Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dermatologic Surgical Proced | 2019 |
A randomized, double-blind, placebo-controlled trial on the efficacy of tranexamic acid combined with rivaroxaban thromboprophylaxis in reducing blood loss after primary cementless total hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2019 |
Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries (TARGETS): study protocol for a prospective, randomized, double-blind, non-inferiority trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Data Interpretation, Statistical; | 2019 |
Intra-Articular Tranexamic Acid Mitigates Blood Loss and Morphine Use After Total Knee Arthroplasty. A Randomized Controlled Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2019 |
Combined intravenous and intra-articular tranexamic acid administration in total knee arthroplasty for preventing blood loss and hyperfibrinolysis: A randomized controlled trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2019 |
The efficacy and safety of multiple doses of oral tranexamic acid on blood loss, inflammatory and fibrinolysis response following total knee arthroplasty: A randomized controlled trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Double-Blind M | 2019 |
Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) study: Results of a pilot study.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aortic Valve; Blood Loss, Surgical; Cardiac | 2019 |
Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) study: Results of a pilot study.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aortic Valve; Blood Loss, Surgical; Cardiac | 2019 |
Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) study: Results of a pilot study.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aortic Valve; Blood Loss, Surgical; Cardiac | 2019 |
Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) study: Results of a pilot study.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Aortic Valve; Blood Loss, Surgical; Cardiac | 2019 |
Efficacy and safety of perioperative tranexamic acid in elderly patients undergoing trochanteric fracture surgery: a randomised controlled trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; | 2019 |
Tranexamic Acid Use in Open Reduction and Internal Fixation of Fractures of the Pelvis, Acetabulum, and Proximal Femur: A Randomized Controlled Trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Femoral Fractures; | 2019 |
Reduced perioperative blood loss in children undergoing craniosynostosis surgery using prolonged tranexamic acid infusion: a randomised trial.
Topics: Anesthesia, General; Antifibrinolytic Agents; Blood Loss, Surgical; Child, Preschool; Craniosynostos | 2019 |
The combined administration of systemic and topical tranexamic acid for total hip arthroplasty: Is it better than systemic?
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2019 |
Cost-benefit analysis of the use of tranexamic acid in total replacement hip surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2019 |
Blood loss reduction: effect of different knee prosthesis designs and use of tranexamic acid-a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2019 |
2019 Mark Coventry Award: A multicentre randomized clinical trial of tranexamic acid in revision total knee arthroplasty: does the dosing regimen matter?.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administration | 2019 |
Intra-Articular Injection of Tranexamic Acid on Perioperative Blood Loss During Unicompartmental Knee Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2019 |
Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial.
Topics: Age Factors; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; B | 2019 |
Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Clopidogr | 2013 |
Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study.
Topics: Adult; Aged; Biopsy; Blood Coagulation Factors; Blood Loss, Surgical; Demography; Endoscopy; Female; | 2013 |
Effectiveness of tranexamic acid on blood loss in patients undergoing elective cesarean section: randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Elective Surgical Procedures | 2013 |
Tranexamic acid in decreasing blood loss during and after caesarean section.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Tranexamic acid in decreasing blood loss during and after caesarean section.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Tranexamic acid in decreasing blood loss during and after caesarean section.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Tranexamic acid in decreasing blood loss during and after caesarean section.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Tranexamic acid in decreasing blood loss during and after caesarean section.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Tranexamic acid in decreasing blood loss during and after caesarean section.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Tranexamic acid in decreasing blood loss during and after caesarean section.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Tranexamic acid in decreasing blood loss during and after caesarean section.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Tranexamic acid in decreasing blood loss during and after caesarean section.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Comparison of two doses of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Platelets; Blood Transfusion; Cardiac Sur | 2014 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Effect of tranexamic acid on reducing postoperative blood loss in combined hypotensive epidural anesthesia and general anesthesia for total hip replacement.
Topics: Adult; Anesthesia, Epidural; Anesthesia, General; Antifibrinolytic Agents; Arthroplasty, Replacement | 2013 |
Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aorta, Thoracic; Blood Loss, Surgical; Blood Tran | 2013 |
Effectiveness of oral Tranexamic acid administration on blood loss after knee artroplasty: a randomized clinical trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Su | 2013 |
The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty.
Topics: Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration | 2015 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H).
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2013 |
Topical administration of tranexamic acid in primary total hip and total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty | 2014 |
Continuous or discontinuous tranexamic acid effectively inhibits fibrinolysis in children undergoing cardiac surgery with cardiopulmonary bypass.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; | 2014 |
Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2014 |
Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2014 |
Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2014 |
Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2014 |
Effect of two doses of tranexamic acid on fibrinolysis evaluated by thromboelastography during cardiac surgery: a randomised, controlled study.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiopulmonary Bypass; Dose | 2014 |
Tranexamic acid used before caesarean section reduces blood loss based on pre- and postoperative haemoglobin level: a case-control study.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Case-Control Studies; Cesarean Section; Female | 2013 |
Comparing efficacy of three methods of tranexamic acid administration in reducing hemoglobin drop following total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2014 |
Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2014 |
Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2014 |
Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2014 |
Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2014 |
Effectiveness of tranexamic acid on intraoperative blood loss in isolated Le Fort I osteotomies--a prospective, triple blinded randomized clinical trial.
Topics: Adolescent; Adult; Anesthesia, General; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemat | 2014 |
Comparison between intravenous and intra-articular regimens of tranexamic acid in reducing blood loss during total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2014 |
The reduction in blood loss with intra-articular injection of tranexamic acid in unilateral total knee arthroplasty without operative drains: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 2015 |
The relative efficacy of antifibrinolytics in adolescent idiopathic scoliosis: a prospective randomized trial.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Dou | 2014 |
Weighted versus uniform dose of tranexamic acid in patients undergoing primary, elective knee arthroplasty: a prospective randomized controlled trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood T | 2014 |
Weighted versus uniform dose of tranexamic acid in patients undergoing primary, elective knee arthroplasty: a prospective randomized controlled trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood T | 2014 |
Weighted versus uniform dose of tranexamic acid in patients undergoing primary, elective knee arthroplasty: a prospective randomized controlled trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood T | 2014 |
Weighted versus uniform dose of tranexamic acid in patients undergoing primary, elective knee arthroplasty: a prospective randomized controlled trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood T | 2014 |
[Effect of priming solution and ultrafiltration on post-operative bleeding and blood transfusion in cardiac surgery. Randomized controlled trial].
Topics: Aged; Aged, 80 and over; Albumins; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusion; | 2015 |
Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; P | 2015 |
Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; P | 2015 |
Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; P | 2015 |
Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; P | 2015 |
Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; P | 2015 |
Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; P | 2015 |
Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; P | 2015 |
Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; P | 2015 |
Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Pregnancy; P | 2015 |
Effect of topical tranexamic acid on bleeding and quality of surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: a triple blind randomized clinical trial.
Topics: Administration, Topical; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Chronic D | 2014 |
Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2014 |
Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2014 |
Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2014 |
Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2014 |
Effect of tranexamic acid irrigation on perioperative blood loss during orthognathic surgery: a double-blind, randomized controlled clinical trial.
Topics: Administration, Topical; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Bl | 2015 |
Preliminary investigation of high-dose tranexamic acid for controlling intraoperative blood loss in patients undergoing spine correction surgery.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Female; Humans; Male; Middl | 2015 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Evaluation of the Efficacy of Tranexamic Acid on the Surgical Field in Primary Cleft Palate Surgery on Children-A Prospective, Randomized Clinical Study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child, Preschool; Cleft Palate; Double-Blind Method; | 2015 |
The efficacy of combined use of intraarticular and intravenous tranexamic acid on reducing blood loss and transfusion rate in total knee arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agen | 2015 |
Reducing blood loss in simultaneous bilateral total knee arthroplasty: combined intravenous-intra-articular tranexamic acid administration. A prospective randomized controlled trial.
Topics: Aged; Analgesics; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Do | 2015 |
Effectiveness and safety of tranexamic acid for total knee arthroplasty: a prospective randomized controlled trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control Studies; Demography; Femal | 2015 |
Topical application of tranexamic acid reduces postoperative bleeding in open-heart surgery: myth or fact?
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgica | 2015 |
Antifibrinolytics reduce blood loss in adult spinal deformity surgery: a prospective, randomized controlled trial.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vo | 2015 |
Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replaceme | 2015 |
Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replaceme | 2015 |
Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replaceme | 2015 |
Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replaceme | 2015 |
Safety and efficacy of intra-articular tranexamic acid injection without drainage on blood loss in total knee arthroplasty: A randomized clinical trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2015 |
A regime of two intravenous injections of tranexamic acid reduces blood loss in minimally invasive total hip arthroplasty: a prospective randomised double-blind study.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2015 |
Intra-articular injection of tranexamic acid reduce blood loss in cemented total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2015 |
Two Doses of Tranexamic Acid Reduce Blood Transfusion in Complex Spine Surgery: A Prospective Randomized Study.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2015 |
Comparison of pterygomaxillary dysjunction with tuberosity separation in isolated Le Fort I osteotomies: a prospective, multi-centre, triple-blind, randomized controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Maxillofacial Abnormalit | 2016 |
A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2015 |
A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2015 |
A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2015 |
A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2015 |
A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2015 |
A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2015 |
A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2015 |
A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2015 |
A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2015 |
[A PROSPECTIVE RANDOMIZED SELF-CONTROLLED STUDY ON EFFECT OF TRANEXAMIC ACID IN REDUCING BLOOD LOSS IN TOTAL KNEE ARTHROPLASTY].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2015 |
Neer Award 2015: A randomized, prospective evaluation on the effectiveness of tranexamic acid in reducing blood loss after total shoulder arthroplasty.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2015 |
[Is intraarticular administration of tranexamic acid efficient and safe as systemic administration in total knee arthroplasty? Single center, randomized, controlled trial].
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2015 |
The effect of tranexamic acid on blood coagulation in total hip replacement arthroplasty: rotational thromboelastographic (ROTEM®) analysis.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagu | 2016 |
The effect of tranexamic acid on blood coagulation in total hip replacement arthroplasty: rotational thromboelastographic (ROTEM®) analysis.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagu | 2016 |
The effect of tranexamic acid on blood coagulation in total hip replacement arthroplasty: rotational thromboelastographic (ROTEM®) analysis.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagu | 2016 |
The effect of tranexamic acid on blood coagulation in total hip replacement arthroplasty: rotational thromboelastographic (ROTEM®) analysis.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagu | 2016 |
The Efficacy of Preoperative Oral Tranexamic Acid on Intraoperative Bleeding During Rhinoplasty.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Me | 2016 |
Topical vs Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Double-Blind, Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2016 |
Topical vs Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Double-Blind, Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2016 |
Topical vs Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Double-Blind, Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2016 |
Topical vs Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Double-Blind, Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2016 |
Efficacy of Tranexamic Acid on Myomectomy-Associated Blood Loss in Patients With Multiple Myomas: A Randomized Controlled Clinical Trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Leiomyoma; Prospective Studies | 2016 |
Intravenous versus intra-articular tranexamic acid in total knee arthroplasty: A double-blinded randomised controlled noninferiority trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
[The Effect of Tranexamic Acid on Blood Loss after Primary Unilateral Total Knee Arthroplasty. Prospective Single-Centre Study].
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2015 |
A randomized trial of the effect of low dose epinephrine infusion in addition to tranexamic acid on blood loss during total hip arthroplasty.
Topics: Adrenergic alpha-Agonists; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coag | 2016 |
Anti-hemorrhagic effect of prophylactic tranexamic acid in benign hysterectomy-a double-blinded randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2016 |
Anti-hemorrhagic effect of prophylactic tranexamic acid in benign hysterectomy-a double-blinded randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2016 |
Anti-hemorrhagic effect of prophylactic tranexamic acid in benign hysterectomy-a double-blinded randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2016 |
Anti-hemorrhagic effect of prophylactic tranexamic acid in benign hysterectomy-a double-blinded randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2016 |
Topical vs Intravenous Tranexamic Acid in Reducing Blood Loss After Bilateral Total Knee Arthroplasty: A Prospective Study.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Tranexamic Acid Reduces Hidden Blood Loss in Patients Undergoing Total Knee Arthroplasty: A Comparative Study and Meta-Analysis.
Topics: Aged; Arthroplasty, Replacement, Knee; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; B | 2016 |
Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2016 |
Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2016 |
Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2016 |
Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2016 |
Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2016 |
Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2016 |
Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2016 |
Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2016 |
Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Dou | 2016 |
Tranexamic Acid Compared with Placebo for Reducing Total Blood Loss in Hip Replacement Surgery: A Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
Single-dose tranexamic acid for reducing bleeding and transfusions in total hip arthroplasty: A double-blind, randomized controlled trial of different doses.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood | 2016 |
Closed Suction Drainage Has No Benefits in Anterior Hip Arthroplasty: A Prospective, Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Bl | 2016 |
Effect of Topical and Intravenously Applied Tranexamic Acid Compared to Control Group on Bleeding in Primary Unilateral Total Knee Arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2017 |
What is the optimal approach for tranexamic acid application in patients with unilateral total hip arthroplasty?
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Dose-Response | 2016 |
Effectiveness and Safety of Fixed-Dose Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Randomized Double-Blind Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
The Efficacy and Safety of Combination of Intravenous and Topical Tranexamic Acid in Revision Hip Arthroplasty: A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Animals; Antifibrinolytic Agents; Arthro | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; Double-Blind Method | 2016 |
The Assessment of Blood Loss During Total Knee Arthroplasty When Comparing Intravenous vs Intracapsular Administration of Tranexamic Acid.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2016 |
Multiple Boluses of Intravenous Tranexamic Acid to Reduce Hidden Blood Loss After Primary Total Knee Arthroplasty Without Tourniquet: A Randomized Clinical Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomark | 2016 |
Intravenous vs Topical Tranexamic Acid in Total Knee Arthroplasty Without Tourniquet Application: A Randomized Controlled Study.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2016 |
Dual-route tranexamic acid to reduce blood loss in coronary artery bypass graft surgery: a randomized controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Critical Care; Double-B | 2016 |
Efficacy of preoperative administration of single high dose intravenous tranexamic acid in reducing blood loss in total knee arthroplasty: A prospective clinical study.
Topics: Administration, Intravenous; Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Tran | 2016 |
Intravenous vs Intra-Articular Tranexamic Acid in Total Knee Arthroplasty: A Randomized, Double-Blind Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
Combined Administration of IV and Topical Tranexamic Acid is Not Superior to Either Individually in Primary Navigated TKA.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2017 |
Efficacy of Hybrid Plasma Scalpel in Reducing Blood Loss and Transfusions in Direct Anterior Total Hip Arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2017 |
The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2017 |
Major liver resection, systemic fibrinolytic activity, and the impact of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Drug Monitoring; Female; Fibrinolys | 2016 |
Efficacy of a Single Dose and an Additional Dose of Tranexamic Acid in Reduction of Blood Loss in Total Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
Optimizing effectivity of tranexamic acid in bilateral knee arthroplasty - A prospective randomized controlled study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2017 |
A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female | 2017 |
Use of tranexamic acid in dynamic hip screw plate fixation for trochanteric fractures.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Bone Plates; Bone Scr | 2016 |
Tranexamic acid reduces perioperative blood loss of posterior lumbar surgery for stenosis or spondylolisthesis: A randomized trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Decompression, Surgical; Double-Blind Me | 2017 |
OBTAIN A: Outcome Benefits of Tranexamic Acid in Hip Arthroplasty. A Randomized Double-Blinded Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2017 |
Intravenous Combined with Topical Administration of Tranexamic Acid in Primary Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthro | 2017 |
Effects of five treatment regimens on blood loss and blood transfusion in total knee arthroplasty: a preliminary study in China
.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Blood Lo | 2017 |
Intravenous tranexamic acid reduces total blood loss in reverse total shoulder arthroplasty: a prospective, double-blinded, randomized, controlled trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, Surgical; Blood Tran | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
Intraoperative tranexamic acid use in major spine surgery in adults: a multicentre, randomized, placebo-controlled trial†.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Bl | 2017 |
Clamping drainage is unnecessary after minimally invasive total knee arthroplasty in patients with tranexamic acid: A randomized, controlled trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Constriction; | 2017 |
Aprotinin vs. tranexamic acid in isolated coronary artery bypass surgery: A multicentre observational study.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery Bypass; Female; Hemo | 2017 |
A randomized control trial to evaluate the effectiveness of intravenous, intra-articular and topical wash regimes of tranexamic acid in primary total knee arthroplasty.
Topics: Accidental Falls; Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl | 2017 |
Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl | 2017 |
Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl | 2017 |
Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl | 2017 |
Pharmacokinetics of tranexamic acid in neonates and infants undergoing cardiac surgery.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedu | 2017 |
Administration of tranexamic acid to patients undergoing surgery for adolescent idiopathic scoliosis evokes pain and increases the infusion rate of remifentanil during the surgery.
Topics: Adolescent; Animals; Blood Loss, Surgical; Female; Humans; Male; Nociception; Pain; Rats; Scoliosis; | 2017 |
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica | 2017 |
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica | 2017 |
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica | 2017 |
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica | 2017 |
Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Bloo | 2008 |
Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Bloo | 2008 |
Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Bloo | 2008 |
Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Bloo | 2008 |
Tranexamic Acid reduces perioperative blood loss in adult patients having spinal fusion surgery.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2008 |
The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Component Transfusion; Blood Loss, Surgical; Drug Administ | 2009 |
The effect of tranexamic acid on blood loss during orthognathic surgery: a randomized controlled trial.
Topics: Adult; Analysis of Variance; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Fem | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
A prospective, randomized, double-blinded single-site control study comparing blood loss prevention of tranexamic acid (TXA) to epsilon aminocaproic acid (EACA) for corrective spinal surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, | 2010 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antifibrinolytic Agents; Apgar Score; Birth Weight; Blood Loss, Surgical; Blood Transfusion; | 2011 |
Effects of tranexamic acid on blood loss during total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2010 |
Blood conservation strategies for reducing peri-operative blood loss in open heart surgery.
Topics: Adult; Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Female; Huma | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Does tranexamic acid save blood in minimally invasive total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; H | 2011 |
Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cervical Vertebrae; F | 2011 |
Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cervical Vertebrae; F | 2011 |
Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cervical Vertebrae; F | 2011 |
Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cervical Vertebrae; F | 2011 |
Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschoo | 2011 |
Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschoo | 2011 |
Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschoo | 2011 |
Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschoo | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Does tranexamic acid in an irrigating fluid reduce intraoperative blood loss in orthognathic surgery? A double-blind, randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Female; Humans; Male; Max | 2011 |
A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial).
Topics: Aged; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Double-Blind Method | 2012 |
Reducing blood loss in primary knee arthroplasty: a prospective randomised controlled trial of tranexamic acid and fibrin spray.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Fibrin; Fibrinogen; | 2012 |
Efficacy of prophylactic low dose of tranexamic acid in spinal fixation surgery: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Intravenous; Antifibrinolytic Agents; Blood Cell Count; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Which is more effective in adolescent idiopathic scoliosis surgery: batroxobin, tranexamic acid or a combination?
Topics: Adolescent; Antifibrinolytic Agents; Batroxobin; Blood Loss, Surgical; Blood Transfusion; Drainage; | 2012 |
Effect of tranexamic acid on blood loss in pediatric cardiac surgery: a randomized trial.
Topics: Adolescent; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child; Child, | 2011 |
Effect of tranexamic acid on blood loss in pediatric cardiac surgery: a randomized trial.
Topics: Adolescent; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child; Child, | 2011 |
Effect of tranexamic acid on blood loss in pediatric cardiac surgery: a randomized trial.
Topics: Adolescent; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child; Child, | 2011 |
Effect of tranexamic acid on blood loss in pediatric cardiac surgery: a randomized trial.
Topics: Adolescent; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child; Child, | 2011 |
Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Follow | 2011 |
Effect of tranexamic acid on transfusion requirement in dual antiplatelet-treated anemic patients undergoing off-pump coronary artery bypass graft surgery.
Topics: Aged; Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Comorbidity; Coronar | 2012 |
The effect of intravenous tranexamic acid on blood loss and surgical field quality during endoscopic sinus surgery: a placebo-controlled clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Endoscopy; Female; Hospit | 2011 |
Evaluation of the efficacy of tranexamic acid on blood loss in orthognathic surgery. A prospective, randomized clinical study.
Topics: Adolescent; Adult; Anesthesia, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2012 |
Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2012 |
Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2012 |
Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2012 |
Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2012 |
Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2012 |
Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2012 |
Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2012 |
Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2012 |
Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2012 |
Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial.
Topics: Adenoidectomy; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Double-Blind | 2012 |
The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Blood Loss, Sur | 2013 |
Temporary clamping of drain combined with tranexamic acid reduce blood loss after total knee arthroplasty: a prospective randomized controlled trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2012 |
Temporary clamping of drain combined with tranexamic acid reduce blood loss after total knee arthroplasty: a prospective randomized controlled trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2012 |
Temporary clamping of drain combined with tranexamic acid reduce blood loss after total knee arthroplasty: a prospective randomized controlled trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2012 |
Temporary clamping of drain combined with tranexamic acid reduce blood loss after total knee arthroplasty: a prospective randomized controlled trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2012 |
Can topical application of tranexamic acid reduce blood loss in thoracic surgery? A prospective randomised double blind investigation.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Dou | 2012 |
Tranexamic Acid in on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation: randomized trial and 1-year follow-up.
Topics: Antifibrinolytic Agents; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronar | 2013 |
Less blood loss under concomitant administration of tranexamic acid and indirect factor Xa inhibitor following total knee arthroplasty: a prospective randomized controlled trial.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical | 2013 |
Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Nephrostomy, Percutaneou | 2013 |
Tranexamic acid for cesarean section: a double-blind, placebo-controlled, randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization.
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Dose-Response Relationship, Drug; Female; Humans; Inf | 2002 |
Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Volume; | 2002 |
Tranexamic acid as a means of reducing the need for blood and blood component therapy in children undergoing open heart surgery for congenital cyanotic heart disease.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass; Child; Chi | 2002 |
Tranexamic acid reduces bleeding after off-pump coronary artery bypass grafting.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Female; Humans; Male; Prospec | 2003 |
[Usefulness of tranexamic acid in cranial remodeling surgery].
Topics: Anesthesia Recovery Period; Blood Component Transfusion; Blood Loss, Surgical; Craniosynostoses; Fem | 2003 |
Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: a randomized prospective clinical study.
Topics: Adult; Aged; Anticoagulants; Blood Loss, Surgical; Dental Care for Chronically Ill; Drug Interaction | 2003 |
Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Cell Count; Blood Loss, Surgica | 2004 |
Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Cell Count; Blood Loss, Surgica | 2004 |
Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Cell Count; Blood Loss, Surgica | 2004 |
Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Cell Count; Blood Loss, Surgica | 2004 |
Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass; | 2004 |
Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2003 |
Evaluation of hemorrhage depressors on blood loss during orthognathic surgery: a retrospective study.
Topics: Adolescent; Adult; Anesthesia, Dental; Blood Loss, Surgical; Combined Modality Therapy; Deamino Argi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques.
Topics: Aged; Antifibrinolytic Agents; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Blood Loss, S | 2004 |
Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2004 |
Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2004 |
Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2004 |
Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2004 |
Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2004 |
Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2004 |
Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2004 |
Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2004 |
Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2004 |
Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Intraoperative Period; Male; Middle Age | 2004 |
The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Su | 2004 |
Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Tran | 2005 |
Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Child; Cyanos | 2005 |
[Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery].
Topics: Administration, Cutaneous; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgica | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Binding Sites; Blood Coagulation Tests; Blood Loss, Surgical; C | 2005 |
Tranexamic acid reduces postoperative blood loss in cementless total hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemostatic Tech | 2005 |
The use of tranexamic acid to reduce blood loss during total hip arthroplasty: an observational study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Cohort Studies; Femal | 2005 |
[A dose-response study of tranexamic acid. The effect on nausea and blood loss after total knee replacement].
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Dose-Response | 2005 |
Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo).
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery Bypass, Off-Pump; Cr | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2005 |
Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a "blood transfusion"-free hepatectomy.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distribution; Dou | 2006 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Double-Blind Me | 2005 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation.
Topics: Adult; Aprotinin; Blood Loss, Surgical; Erythrocyte Transfusion; Female; Fibrinolysis; Hemostatics; | 2006 |
Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2007 |
Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2007 |
Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2007 |
Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2007 |
[Effect of tranexamic acid on postoperative bleeding in pediatric heart surgery].
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Blood Proteins; Cardiac Surgical Procedur | 2007 |
Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female | 2008 |
Tranexamic acid and primary coronary artery bypass surgery: a prospective study.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Coro | 2007 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
[Clinical comparative studies on effect of tranexamic acid on blood loss associated with total knee arthroplasty].
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Bl | 2007 |
Effectiveness and safety of tranexamic acid administration during total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
[Comparison of effects of aprotinin and tranexamic acid on blood loss in heart surgery].
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Blood Loss, Surgical; Blood Tran | 1995 |
[Fibrinolytic inhibitors and prevention of bleeding in cardiac valve surgery. Comparison of tranexamic acid and high dose aprotinin].
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Dose-Response Relationship, Drug; D | 1995 |
Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass.
Topics: Aged; Analysis of Variance; Aprotinin; Blood Coagulation Tests; Blood Loss, Surgical; Cardiopulmonar | 1994 |
Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting.
Topics: Aprotinin; Blood Loss, Surgical; Coronary Artery Bypass; Dipyridamole; Female; Hemoglobins; Hemostas | 1995 |
A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery.
Topics: Aged; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cardiac Surgical Procedures; | 1995 |
Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial.
Topics: Analysis of Variance; Blood Coagulation; Blood Coagulation Tests; Blood Loss, Surgical; Cardiopulmon | 1995 |
Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Tests; Blood L | 1995 |
[Use of tranexamic acid for bleeding control in myocardial revascularization].
Topics: Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Extracorporeal Circulation; Female; Hemostasis | 1994 |
Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; Humans; Knee | 1995 |
Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; Humans; Knee | 1995 |
Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; Humans; Knee | 1995 |
Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; Humans; Knee | 1995 |
Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; Humans; Knee | 1995 |
Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; Humans; Knee | 1995 |
Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; Humans; Knee | 1995 |
Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; Humans; Knee | 1995 |
Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; Humans; Knee | 1995 |
The dose-response relationship of tranexamic acid.
Topics: Adult; Aged; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures | 1995 |
Tranexamic acid significantly reduces blood loss associated with coronary revascularization.
Topics: Aged; Blood Coagulation Disorders; Blood Loss, Surgical; Cardiopulmonary Bypass; Erythrocyte Transfu | 1995 |
Tranexamic acid as a mouthwash in anticoagulant-treated patients undergoing oral surgery. An alternative method to discontinuing anticoagulant therapy.
Topics: Anticoagulants; Blood Loss, Surgical; Dental Care for Disabled; Double-Blind Method; Female; Heart V | 1993 |
The effect of preoperative tranexamic acid on blood loss after cardiac operations in children.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiopulmonary Bypass; Child; Child, Pre | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Double-Blind Method; Female; Hemo | 1996 |
Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid.
Topics: Aminocaproic Acid; Aprotinin; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Cardiopulm | 1996 |
Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation.
Topics: Adult; Blood Coagulation Factors; Blood Loss, Surgical; Blood Transfusion; Humans; Liver Transplanta | 1996 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Additional postbypass administration of tranexamic acid reduces blood loss after cardiac operations.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Volume; Cardiopulmonary Bypass; Female; H | 1997 |
Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Extracorporeal Membrane Oxygenatio | 1997 |
The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery.
Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgica | 1997 |
Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery.
Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Blood Volume; C | 1997 |
Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial.
Topics: Aged; Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Coronary | 1997 |
Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery.
Topics: Adult; Aged; Aged, 80 and over; Aprotinin; Blood Loss, Surgical; Double-Blind Method; Female; Heart | 1997 |
Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery | 1998 |
The effectiveness of low dose tranexamic acid in primary cardiac surgery.
Topics: Analysis of Variance; Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Blood Transf | 1998 |
[Comparative effect of tranexamic acid on the reduction of bleeding during and after cardiac surgery].
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmo | 1998 |
[The effect of intraoperative high-dose tranexamic acid on blood loss after operation for acute aortic dissection].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Aortic Aneurysm, Thoracic; A | 1998 |
Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Ar | 1998 |
The effect of three different doses of tranexamic acid on blood loss after cardiac surgery with mild systemic hypothermia (32 degrees C).
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Loss, Surgic | 1998 |
A comparative study of the postoperative allogeneic blood-sparing effect of tranexamic acid versus acute normovolemic hemodilution after total knee replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Volume; | 1999 |
Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Card | 1999 |
Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 1999 |
Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 1999 |
Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 1999 |
Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 1999 |
Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 1999 |
Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 1999 |
Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 1999 |
Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 1999 |
Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 1999 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Doub | 2000 |
Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Aprotinin; Blood Cell Count; Blood Loss, Su | 2000 |
A retrospective survey of fibrinolysis as an indicator of poor outcome after cardiopulmonary bypass and a possible early sign of systemic inflammation syndrome.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiopulmonary Bypass; Female; Fibrinolysis; H | 2000 |
Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation; Blood Component Transfus | 2000 |
Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Proced | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid reduces blood loss in total hip replacement surgery.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Coagulation; Blood Loss, Surgic | 2000 |
Tranexamic acid in aortic valve replacement.
Topics: Aged; Antifibrinolytic Agents; Aortic Valve; Blood Cell Count; Blood Loss, Surgical; Blood Transfusi | 2001 |
A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusio | 2001 |
A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusio | 2001 |
A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusio | 2001 |
A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusio | 2001 |
Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass.
Topics: Aged; alpha-2-Antiplasmin; Analysis of Variance; Antifibrinolytic Agents; Antithrombin III; Blood Lo | 2001 |
A comparative study of the postoperative allogeneic blood-sparing effects of tranexamic acid and of desmopressin after total knee replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2001 |
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Topics: Adult; Antigens; Blood Loss, Surgical; Child; Child, Preschool; Drug Administration Schedule; Electi | 2001 |
Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis?
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass; Coro | 2002 |
Hemostatic effects of tranexamic acid in elective thoracic aortic surgery: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Aged; Aortic Aneurysm, Thoracic; Aortic Dissection; Blood Loss, Surgical; Double-Blind Method; Elect | 2002 |
The effect of warm heart surgery on postoperative bleeding.
Topics: Aminocaproic Acid; Analysis of Variance; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distrib | 1992 |
649 other studies available for tranexamic acid and Blood Loss, Surgical
| Article | Year |
|---|---|
Natural course of hemoglobin level after total knee arthroplasty and the benefit of tranexamic acid injection in the joint.
Topics: Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Hemoglobins; Humans; Injections | 2021 |
[Effectiveness and safety of tranexamic acid combined with intraoperative controlled hypotension on reducing perioperative blood loss in primary total hip arthroplasty].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Hypotension, | 2021 |
Tranexamic acid after cardiopulmonary bypass does not increase risk of postoperative seizures: a retrospective study.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiopulmonary Bypass; Humans; Retrospective | 2022 |
Tranexamic Acid in Patients With Cancer Undergoing Endoprosthetic Reconstruction: A Cost Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Bone Neoplasms; Hospi | 2021 |
[Application of tranexamic acid within the field of dentistry].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Dentistry; Humans; Tranexamic Acid | 2021 |
Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Marfan Syndrome; Scoliosis; Tranexamic Acid | 2022 |
Blood Loss Prophylaxis: Tranexamic Acid Is Safe Even in High-Risk Patients: Commentary on an article by Steven B. Porter, MD, et al.: ''Tranexamic Acid Was Not Associated with Increased Complications in High-Risk Patients with Hip Fracture Undergoing Arth
Topics: Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Humans; Tranexamic Acid | 2021 |
Comment on article by Shodipo et al.: comparison of single versus double tranexamic acid dose regimens in reducing post-operative blood loss following intramedullary nailing of femoral fracture nonunions.
Topics: Blood Loss, Surgical; Femoral Fractures; Fracture Fixation, Intramedullary; Fractures, Ununited; Hum | 2022 |
Comment on Shodipo et al.: comparison of single versus double tranexamic acid dose regimens in reducing post-operative blood loss following intramedullary nailing of femoral fracture nonunions.
Topics: Blood Loss, Surgical; Femoral Fractures; Fracture Fixation, Intramedullary; Fractures, Ununited; Hum | 2022 |
Dose tranexamic acid reduce blood loss associated with simultaneous bilateral distal tibial tubercle-high tibial osteotomy?
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Case-Control Studies; Hu | 2021 |
The Efficiency of Simultaneous Systemic and Topical Use of Tranexamic Acid in Spinal Fusion Surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Hemorrhage; Spinal Fusio | 2022 |
Efficacy of Tranexamic Acid on Blood Loss in Thoracolumbar Spinal Fusion Surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cross-Sectional Studies; Humans; Lumbar Verteb | 2021 |
Tranexamic acid use in simultaneous bilateral total knee arthroplasty : a comparison of intravenous and intra-articular applications, which is more effective?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2021 |
Application of an adjusted patient blood management protocol in patients undergoing elective total hip arthroplasty: towards a zero-percent transfusion rate in renal patients-results from an observational cohort study.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2021 |
Simultaneous Bilateral Total Hip Arthroplasty With Contemporary Blood Management is Associated With a Low Risk of Allogeneic Blood Transfusion.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Fe | 2022 |
Blood conservation outcomes and safety of tranexamic acid in coronary artery bypass graft surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Humans; Re | 2022 |
Blood Management Following Total Joint Arthroplasty in an Aging Population: Can We Do Better?
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Aging; Antifibrinolytic Agents; Arthroplasty, | 2022 |
Letter to the Editor Regarding "Cytotoxicity and Effect of Topical Application of Tranexamic Acid on Human Fibroblast in Spine Surgery".
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Fibroblasts; Humans; Tranexamic Acid | 2022 |
In Reply to the Letter to the Editor Regarding "Cytotoxicity and Effect of Topical Application of Tranexamic Acid on Human Fibroblast in Spine Surgery".
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Fibroblasts; Humans; Tranexamic Acid | 2022 |
Comparison of intra-articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty.
Topics: Adenosine; Administration, Intravenous; Animals; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2021 |
Importance of tranexamic acid in pediatric monosutural craniosynostosis surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; Infant; Retrospectiv | 2022 |
Circulation collapse caused by intracardiac thrombosis associated with tranexamic acid administration: A case report.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Circulation; Blood Loss, Surgical; C | 2021 |
Hip resurfacing and posterior approach total hip arthroplasty have equivalent blood loss when tranexamic acid is used: a propensity score matched cohort analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemoglobins; Humans; | 2022 |
Tranexamic acid use decreases transfusion rate in children with cerebral palsy undergoing proximal femoral varus derotational osteotomy.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cerebral Palsy; Child; | 2022 |
Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hematoma; Humans | 2022 |
The effect of prophylactic use of tranexamic acid for cesarean section.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Hemoglobins; Humans; Infant | 2022 |
Not all patients benefit from the postoperative antifibrinolytic treatment: clinical evidence against the universal use of tranexamic acid following total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2022 |
Clinical outcomes of tranexamic acid in acute hip hemiarthroplasties in frail geriatric patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Frail Elderly; | 2022 |
Local tranexamic acid reduces surgical blood loss.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2022 |
Acute normovolemic hemodilution in combination with tranexamic acid is an effective strategy for blood management in lumbar spinal fusion surgery.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemodilution; Humans; Intraopera | 2022 |
Editorial Commentary: The Current Evidence in Support of Tranexamic Acid in Arthroscopic Surgery Is Poor.
Topics: Antifibrinolytic Agents; Arthroscopy; Blood Loss, Surgical; Humans; Pulmonary Embolism; Tranexamic A | 2022 |
Hypotensive Anesthesia Combined with Tranexamic Acid Reduces Perioperative Blood Loss in Simultaneous Bilateral Total Hip Arthroplasty: A Retrospective Cohort Study.
Topics: Adult; Anesthesia, General; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Sur | 2022 |
Artificial neural networks for the prediction of transfusion rates in primary total hip arthroplasty.
Topics: Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Humans; Neural Networks, Co | 2023 |
Tranexamic acid improves early postoperative mobilization in cancer patients undergoing endoprosthetic reconstruction.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Bone Neoplasms; Humans; Postoperative Hemorrhage; Ret | 2022 |
Avoiding Femoral Canal Instrumentation in Computer-Assisted Total Knee Arthroplasty With Contemporary Blood Management Had Minimal Differences in Blood Loss and Transfusion Rates Compared to Conventional Techniques.
Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Humans; Retro | 2022 |
Variable Response to Antifibrinolytics Correlates with Blood-loss and Transfusion in Posterior Spinal Fusion.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Fibrinolysin; Humans; Prospective Studies; Spinal Fus | 2022 |
Tranexamic acid reduces blood loss in primary total hip arthroplasty performed using the direct anterior approach: a one-center retrospective observational study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Retrospective | 2022 |
[Standard administration of tranexamic acid for prophylaxis in endoprosthetics: a good idea?]
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Plastic Surgery Procedures; Tranexamic Acid | 2022 |
Post-operative tranexamic acid decreases chest tube drainage following vertebral body tethering surgery for scoliosis correction.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Chest Tubes; Drainage; Humans; Scoliosis; | 2022 |
No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2022 |
Perioperative administration of tranexamic acid in hip fracture surgery (The PATHS study): national audit of current practice.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Femoral Neck Fracture | 2023 |
Tranexamic acid protects against implant-associated infection by reducing biofilm formation.
Topics: Animals; Antifibrinolytic Agents; Biofilms; Blood Loss, Surgical; Humans; Mice; Postoperative Compli | 2022 |
Tranexamic acid reduced blood transfusions in acute burn surgery: A retrospective case-controlled trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Burns; Case-Control S | 2022 |
Local Infiltration of Tranexamic Acid During Facelift Improves Operating Room Efficiency: A Matched Patient Study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Case-Control Studies; Humans; Oper | 2022 |
The effect of tranexamic acid on hidden blood loss in total hip arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2022 |
Closed suction drainage is not beneficial in hybrid total hip arthroplasty with intra-articular administration of tranexamic acid: a propensity score-matched cohort study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Cohort Studies; Human | 2022 |
Efficacy and safety of intravenous combined with topical administration of tranexamic acid in reducing blood loss in opening wedge high tibial osteotomy procedure: A retrospective case-control study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Topical; Antifibrinolytic A | 2022 |
Tranexamic acid reduces perioperative bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2022 |
Comparison of weight-based versus standard dosing of tranexamic acid for blood loss and transfusion amount in knee arthroplasty without tourniquet.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Hemoglobins; | 2022 |
Efficacy and safety of tranexamic acid in patients undergoing surgery for bone and soft tissue tumors: a propensity score matching analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Propensity Score; Retrospe | 2022 |
Blood Transfusion can be Avoided in Single-Anesthetic Bilateral Total Knee Arthroplasty.
Topics: Anesthetics; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood T | 2022 |
Safety and efficacy of intravenous or topical tranexamic acid administration in surgery: a protocol for a systematic review and network meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; | 2022 |
Cytotoxicity of tranexamic acid to tendon and bone in vitro: Is there a safe dosage?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Injections, Intra-Articular; Tendons; Tranexa | 2022 |
Impact of gender differences on hemostasis in patients after coronary artery bypass grafts surgeries in the context of tranexamic acid administration.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Coronary Artery Bypass; Female; Hemostasis; Humans; M | 2022 |
Clinical Application Effects of Different Preoperative Blood Management Schemes in Older Patients with Delayed Intertrochanteric Fracture Surgery.
Topics: Aged; Blood Loss, Surgical; Erythropoietin; Hip Fractures; Humans; Iron; Retrospective Studies; Tran | 2022 |
The efficacy and safety of intravenous tranexamic acid on blood loss during total ankle replacement: a retrospective study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Ankle; Blood Loss, | 2022 |
Hidden blood loss of total knee arthroplasty in hemophilia arthritis: an analysis of influencing factors.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blo | 2022 |
Evaluation of the safety of tranexamic acid use in pediatric patients undergoing spinal fusion surgery: a retrospective comparative cohort study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Cohort Studies; Humans; Pulmonary | 2022 |
Comparison of blood loss between tranexamic acid-soaked absorbable Gelfoam and topical retrograde injection via drainage catheter plus clamping in cervical laminoplasty surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Catheters; Constriction; Drainage; Gelatin Sponge, Ab | 2022 |
The Effect of Tranexamic Acid on Operative and Postoperative Blood Loss in Transforaminal Lumbar Interbody Fusions.
Topics: Adult; Blood Loss, Surgical; Child; Humans; Lumbar Vertebrae; Postoperative Hemorrhage; Retrospectiv | 2022 |
Bleeding and Tranexamic Acid in Patients Undergoing Noncardiac Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2022 |
Does tranexamic acid reliably reduce blood loss in proximal femur fracture surgery?
Topics: Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Co | 2023 |
Comparison of trauma-dosed tranexamic acid versus aminocaproic acid in cardiac surgery in the setting of drug shortage.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Human | 2022 |
The effectiveness of a multifaceted, group-facilitated audit and feedback intervention to increase tranexamic acid use during total joint arthroplasty.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2022 |
Combination effect of intraoperative and postoperative intravenous tranexamic acid in hip hemiarthroplasty. A propensity score matched analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiarthroplasty; Hum | 2022 |
Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; I | 2022 |
Fertility-sparing surgery for diffuse adenomyosis: a narrated, stepwise approach to the Osada procedure.
Topics: Adenomyoma; Adenomyosis; Adult; Blood Loss, Surgical; Contraceptive Agents; Female; Hemostatics; Hum | 2022 |
[Effects of oral and intravenous tranexamic acid on perioperative blood loss after lumbar spinal canal decompression and fusion].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Decompression; Humans; Postoperative Hemorrhage; Spin | 2022 |
Reducing transfusion in hip arthroplasty: tranexemic acid diminishes influence of anesthesia administered.
Topics: Anesthesia, General; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; | 2023 |
Tranexamic acid for cesarean delivery: evidence of fibrinolysis?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Fibrinolysis; Humans; Pregn | 2023 |
Tranexamic Acid and Prothrombotic Complications Following Total Hip and Total Knee Arthroplasty: A Population-Wide Safety Analysis Accounting for Surgeon Selection Bias.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2023 |
How does tranexamic acid affect blood transfusion and bleeding amount in pelvis-acetabulum fractures treated with open reduction and internal fixation?
Topics: Acetabulum; Blood Loss, Surgical; Blood Transfusion; Fracture Fixation, Internal; Fractures, Bone; H | 2022 |
Tranexamic Acid in Patients Undergoing Noncardiac Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2022 |
Tranexamic Acid in Patients Undergoing Noncardiac Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2022 |
Tranexamic Acid in Patients Undergoing Noncardiac Surgery. Reply.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2022 |
Tranexamic acid for safer surgery: the time is now.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2022 |
Re: Tranexamic Acid in Patients Undergoing Noncardiac Surgery.
Topics: Blood Loss, Surgical; Blood Transfusion; Humans; Tranexamic Acid | 2022 |
Effect of Topical Administration of Tranexamic Acid on Intraoperative and Postoperative Blood Loss during Posterior Cervical Laminectomy and Fusion Surgery: A Retrospective Study.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemostatics; Humans; | 2023 |
Tranexamic acid for safer surgery: the time is now.
Topics: Blood Loss, Surgical; Clinical Trials as Topic; Humans; Tranexamic Acid | 2022 |
Effectiveness of prophylactic tranexamic acid versus placebo or no intervention for reducing blood loss in healthy patients undergoing orthognathic surgery: a systematic review protocol.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemoglobins; Humans; Meta-Analysis as Topic; Orthogna | 2023 |
Effect of early continuously intravenous tranexamic acid on perioperative blood loss in thoracolumbar burst fractures with neurological symptoms.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Retrospective St | 2022 |
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Humans; Male; Mastectomy; M | 2022 |
Predictors and complications of blood transfusion in rheumatoid arthritis patients undergoing total joint arthroplasty.
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Blood Loss, Surgical | 2023 |
Optimal Release Timing of Drain Clamping to Reduce Postoperative Bleeding after Total Knee Arthroplasty with Intraarticular Injection of Tranexamic Acid.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Constriction; Draina | 2022 |
Comment on: Tranexamic acid for safer surgery: the time is now.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2022 |
Tranexamic Acid and Intraoperative and Postoperative Accumulative Bleeding in Elective Degenerative Spine Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Elective Surgical Procedures; Huma | 2022 |
On Patient Safety: Concerns About Topical Tranexamic Acid in Spine Surgery.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2022 |
Does the clamping method in local and systemic TXA applications in total knee arthroplasty change the game?: A retrospective comparative cohort study.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Cohort Studie | 2022 |
Tranexamic acid is not associated with decreased infection risk after primary shoulder arthroplasty: a cohort study of 9276 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, Surgical; Cohort Stu | 2023 |
Effects of tranexamic acid on vascular occlusive events and perioperative resuscitation in patients with atrial fibrillation undergoing total joint arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Blood Lo | 2022 |
Does living at high altitude increase the risk of bleeding events after total knee arthroplasty? A retrospective cohort study.
Topics: Altitude; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Fibrin Fib | 2023 |
Tranexamic acid in pertrochanteric fractures: a retrospective analysis of perioperative outcomes after fixation with a proximal femoral nail.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Femoral Fractures; Humans; Postoperative Hemorrhage; | 2022 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Comment on Br J Anaesth 2022; 129: 459-61.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Comment on Br J Anaesth 2022; 129: 459-61.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Comment on Br J Anaesth 2022; 129: 459-61.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Comment on Br J Anaesth 2022; 129: 459-61.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Comment on Br J Anaesth 2022; 129: 459-61.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Comment on Br J Anaesth 2022; 129: 459-61.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Comment on Br J Anaesth 2022; 129: 459-61.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Comment on Br J Anaesth 2022; 129: 459-61.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Comment on Br J Anaesth 2022; 129: 459-61.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2023 |
Intravenous Tranexamic Acid Reduces Blood Loss in Multilevel Spine Surgeries.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Lumbar Vertebrae | 2023 |
Intravenous Tranexamic Acid Reduces Blood Loss in Multilevel Spine Surgeries.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Lumbar Vertebrae | 2023 |
Intravenous Tranexamic Acid Reduces Blood Loss in Multilevel Spine Surgeries.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Lumbar Vertebrae | 2023 |
Intravenous Tranexamic Acid Reduces Blood Loss in Multilevel Spine Surgeries.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Lumbar Vertebrae | 2023 |
Is Tranexamic Acid Effective for Hemostasis During Endoscopic Sinus Surgery?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Endoscopy; Hemostasis; Hemostasis, Surgical; Humans; | 2023 |
Is Tranexamic Acid Effective for Hemostasis During Endoscopic Sinus Surgery?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Endoscopy; Hemostasis; Hemostasis, Surgical; Humans; | 2023 |
Is Tranexamic Acid Effective for Hemostasis During Endoscopic Sinus Surgery?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Endoscopy; Hemostasis; Hemostasis, Surgical; Humans; | 2023 |
Is Tranexamic Acid Effective for Hemostasis During Endoscopic Sinus Surgery?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Endoscopy; Hemostasis; Hemostasis, Surgical; Humans; | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Response to Br J Anaesth 2023; 130: e23-e24.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Gastrointestinal Hemorrhage; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Response to Br J Anaesth 2023; 130: e23-e24.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Gastrointestinal Hemorrhage; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Response to Br J Anaesth 2023; 130: e23-e24.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Gastrointestinal Hemorrhage; Humans; Tranexamic Acid | 2023 |
Tranexamic acid for safer surgery: does the evidence support preventative use? Response to Br J Anaesth 2023; 130: e23-e24.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Gastrointestinal Hemorrhage; Humans; Tranexamic Acid | 2023 |
The Effect of Systemic Tranexamic Acid on Blood Loss and Blood Transfusion Requirement in Elective Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2022 |
The Effect of Systemic Tranexamic Acid on Blood Loss and Blood Transfusion Requirement in Elective Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2022 |
The Effect of Systemic Tranexamic Acid on Blood Loss and Blood Transfusion Requirement in Elective Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2022 |
The Effect of Systemic Tranexamic Acid on Blood Loss and Blood Transfusion Requirement in Elective Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2022 |
Topical Tranexamic Acid Can Be Used Safely Even in High Risk Patients: Deep Vein Thrombosis Examination Using Routine Ultrasonography of 510 Patients.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Retrospective St | 2022 |
Combination of Intravenous and Intra-Articular Application of Tranexamic Acid and Epsilon-Aminocaproic Acid in Primary Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
Effect of administration of tranexamic acid on blood loss and transfusion requirements in children undergoing posterior fossa tumor excision: a retrospective cohort study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Brain Neoplasms; Child | 2023 |
High- vs Low-Dose Tranexamic Acid Infusion and Need for Red Blood Cell Transfusion and Adverse Events in Cardiac Surgery-Reply.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Erythrocyte Transfusion; | 2023 |
High- vs Low-Dose Tranexamic Acid Infusion and Need for Red Blood Cell Transfusion and Adverse Events in Cardiac Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Erythrocyte Transfusion; | 2023 |
Predisposing factors for allogeneic blood transfusion in patients with ankylosing spondylitis undergoing primary unilateral total hip arthroplasty: a retrospective study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; He | 2023 |
Tranexamic acid in total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2023 |
Predicting Postoperative Anemia and Blood Transfusion Following Total Knee Arthroplasty.
Topics: Aged; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood | 2023 |
The Administration of Tranexamic Acid For Complex Spine Surgery.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Perioperative Pe | 2023 |
Intravenous Tranexamic Acid Given at Femoral Fragility Fracture Surgery Reduces Blood Transfusion Requirements Fourfold.
Topics: Administration, Intravenous; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Blood Transfus | 2023 |
The Usage of Intravenous Tranexamic Acid in Reduction Mammaplasty Safely Reduces Hematoma Rates.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hematoma; Humans; Mammaplasty; Retrospective | 2023 |
Preliminary outcome of use of parenterally administered tranexamic acid during primary total knee replacement.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
Topical tranexamic acid in intramedullary nailing for the treatment of intertrochanteric fractures in the elderly: A protocol for systematic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Sur | 2023 |
Characteristics and Outcomes of Liver Transplantation Recipients after Tranexamic Acid Treatment and Platelet Transfusion: A Retrospective Single-Centre Experience.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cohort Studies; Humans; Liver Transplantation; Platel | 2023 |
Local Infiltration of Tranexamic Acid in Breast Reduction for Symptomatic Macromastia.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Mammaplasty; Tranexamic Ac | 2023 |
Cost Analysis of Aprotinin Reintroduction in French Cardiac Surgery Centres: A Real-World Data-Based Analysis.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Costs and Cos | 2023 |
The efficacy of aggressive warming combined with tranexamic acid during total hip arthroplasty: a single-center retrospective study from southern China.
Topics: Arthroplasty, Replacement, Hip; Blood Loss, Surgical; China; Humans; Retrospective Studies; Tranexam | 2023 |
The cost effectiveness of tranexamic acid for preventing periprosthetic joint infection following total shoulder arthroplasty: a break-even analysis.
Topics: Antifibrinolytic Agents; Arthritis, Infectious; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2023 |
Topical administration of tranexamic acid reduces postoperative blood loss and inflammatory response in knee arthroscopic arthrolysis: a retrospective comparative study.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroscopy; Blood Loss, Surgical; Hemarthrosis; H | 2023 |
Tranexamic acid as a novel adjunct in the management of vessel perforation complicating Endovascular Clot Retrieval.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Case-Control Studies; Hemorrhage; Humans; Retrospecti | 2023 |
Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children.
Topics: Acute Kidney Injury; Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; C | 2023 |
The efficacy and safety of tranexamic acid in rheumatoid arthritis patients undergoing simultaneous bilateral total knee arthroplasty: a multicenter retrospective study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replaceme | 2023 |
Antifibrinolytic agents and seizure risk in neonates undergoing cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Human | 2023 |
Does the Use of Tranexamic Acid in Patients Who Have Preoperative Coagulopathy Undergoing Total Joint Arthroplasty Normalize Their Risk of Complications? A Matched Equivalence Analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2023 |
Use of Subcutaneous Injection of Epinephrine and Triamcinolone with Tranexamic Acid Reduces Blood Loss, Transfusion Rates, and Length of Stay in Open Sagittal Craniosynostosis Repair.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Bupivacaine; Craniosynostoses; Hemoglobins; Humans; I | 2023 |
Wound Healing Complications With Tranexamic Acid: Not the Silver Bullet After All.
Topics: Administration, Topical; Anesthetics, Local; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; | 2023 |
Topical tranexamic acid reduces postoperative hematomas in reduction mammaplasties.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Cohort Stu | 2023 |
The efficacy and safety of intravenous administration of tranexamic acid in patients undergoing cardiac surgery: Evidence from a single cardiovascular center.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical | 2023 |
Die perioperative Gabe von Tranexamsäure.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Tranexamic Acid | 2023 |
Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Posto | 2023 |
Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Complications; Pulmonary Emboli | 2023 |
FIT for surgery: fractures, iron, and tranexamic acid.
Topics: Blood Loss, Surgical; Blood Transfusion; Humans; Iron; Tranexamic Acid | 2023 |
A prophylactic TXA administration effectively reduces the risk of intraoperative bleeding during open management of pelvic and acetabular fractures.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip F | 2023 |
Outcomes of drain versus no drain in total knee arthroplasty: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2023 |
Risk factors for blood transfusion and postoperative anaemia following total knee arthroplasty.
Topics: Aged; Anemia; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; Female; Hemo | 2023 |
Examining the safety profile of a standard dose tranexamic acid regimen in spine surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Retrospective Studies; Spine; Thromboe | 2023 |
Efficacy of tranexamic acid supplemented with local infiltration analgesia in reducing blood loss in patients undergoing unicompartmental knee arthroplasty.
Topics: Analgesia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; M | 2023 |
Thromboembolic Complications Following Perioperative Tranexamic Acid Administration.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Retrospective Studies; Tranexamic | 2024 |
Is topical tranexamic acid combined with endoscopic hemostasis superior to endoscopic hemostasis alone?
Topics: Administration, Topical; Blood Loss, Surgical; Hemostasis, Endoscopic; Humans; Tranexamic Acid | 2023 |
Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Lumbar Vertebrae | 2023 |
An observational study of an adjusted patient blood management protocol intended to lower rates of transfusion following total knee arthroplasty in patients with preoperative anemia.
Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transf | 2023 |
A Decline in Overutilization of Transfusion after Total Knee Arthroplasty Using Pharmacological Agents for Patient Blood Management in South Korea: An Analysis Based on the Korean National Health Insurance Claims Database from 2008 to 2019.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2023 |
Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Blood Coagulation Factors; Bl | 2019 |
The value of tranexamic acid for patients with preoperative anemia in primary total knee arthroplasty.
Topics: Aged; Anemia; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Chi-Square Distribution; Female | 2019 |
Clinical application of auricular point sticking in perioperative hemostasis for elderly patients with intertrochanteric fractures of the femur.
Topics: Acupuncture Points; Acupuncture Therapy; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Los | 2019 |
Greater Blood Loss in Contemporary Cementless Total Knee Arthroplasty than Cemented Total Knee Arthroplasty despite Tranexamic Acid Use: A Match-Controlled Retrospective Study.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Bone Ce | 2021 |
Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthralgia; Arthroplasty, Replacement, | 2019 |
Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration Schedule; Factor VII | 2019 |
Local Infiltration of Tranexamic Acid With Local Anesthetic Reduces Intraoperative Facelift Bleeding: A Preliminary Report.
Topics: Anesthetics, Local; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Middle Aged; Rhyt | 2020 |
Comparison of the Effects of Intravenous and Oral Tranexamic Acid on Perioperative Hemoglobin Levels During Total Knee Arthroplasty.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Aged; Antifibrinolytic Agents; Arthro | 2020 |
Antifibrinolytic Therapy in Surgery for Adolescent Idiopathic Scoliosis Does the Level 1 Evidence Translate to Practice?
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Cohort Studies; | 2018 |
Tranexamic Acid Administration Is Not Associated With an Increase in Complications in High-Risk Patients Undergoing Primary Total Knee or Total Hip Arthroplasty: A Retrospective Case-Control Study of 38,220 Patients.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2020 |
Postoperative ultrasound evaluation for deep vein thrombosis after knee replacement surgery performed with tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans | 2020 |
Tranexamic acid in cardiac surgery: a systematic review and meta-analysis (protocol).
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Humans; Meta-Analysis as | 2019 |
Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Atrial Fibrillation; Blood Coagulation Factors; B | 2020 |
The impact of patient blood management on blood utilization and clinical outcomes in complex spine surgery.
Topics: Adult; Aged; Blood Loss, Surgical; Blood Transfusion; Female; Humans; Logistic Models; Male; Middle | 2019 |
[Research progress on tranexamic acid in traumatic orthopedic surgery].
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; O | 2019 |
Single dose Intravenous Tranexamic acid may not be adequate to reduce blood loss and blood transfusion requirement in patients undergoing single stage bilateral total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2019 |
The Dangers and Concerns of Intra-articular Tranexamic Acid.
Topics: Anterior Cruciate Ligament Reconstruction; Blood Loss, Surgical; Hemarthrosis; Humans; Injections, I | 2019 |
Tranexamic Acid Is Associated With Reduced Periprosthetic Joint Infection After Primary Total Joint Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2020 |
One Versus Two Doses of Intravenous Tranexamic Acid in Total Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2021 |
Comparison of the Coagulation Profile of Adolescent Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion With and Without Tranexamic Acid.
Topics: Adolescent; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusio | 2019 |
What's New in Adult Reconstructive Knee Surgery.
Topics: Analgesics, Opioid; Anesthesia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2020 |
CORR Insights®: Combined Intravenous and Intraarticular Tranexamic Acid Does Not Offer Additional Benefit Compared with Intraarticular Use Alone in Bilateral TKA: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Cytotoxicity and effect on wound re-epithelialization after topical administration of tranexamic acid.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Cell Culture Techniques; Cel | 2019 |
Intravenous Tranexamic Acid for Reducing Perioperative Blood Loss During Revision Surgery for Vancouver Type B Periprosthetic Femoral Fractures After Total Hip Arthroplasty: A Retrospective Study.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2020 |
Tranexamic Acid Reduces Total Blood Loss and Inflammatory Response in Computer-Assisted Navigation Total Knee Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2019 |
Response to Letter to the Editor on "A Prospective Double-Blind Placebo Controlled Trial of Topical Tranexamic Acid in Total Knee Arthroplasty".
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Double-Blind Method; | 2020 |
Simultaneous Bilateral Total Knee Arthroplasty Becomes Safer after Institution of Optimal Perioperative Management: A Longitudinal Cohort Study.
Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Longitudinal Studies; Postoperative C | 2021 |
Letter to the Editor on "A Prospective Double-Blind Placebo Controlled Trial of Topical Tranexamic Acid in Total Knee Arthroplasty".
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Double-Blind Method; | 2020 |
Reply to the Letter to the Editor: Combined Intravenous and Intraarticular Tranexamic Acid Does Not Offer Additional Benefit Compared with Intraarticular Use Alone in Bilateral TKA: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Tranexamic Acid Utilization in Craniosynostosis Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Craniotomy; Female; Humans; Infant, | 2020 |
Reply to the Letter to the Editor: Combined Intravenous and Intraarticular Tranexamic Acid Does Not Offer Additional Benefit Compared with Intraarticular Use Alone in Bilateral TKA: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
The Use of Tranexamic Acid (TXA) in Neuromuscular Hip Reconstruction: Can We Alter the Need for Blood Transfusion?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Ch | 2020 |
Letter to the Editor: Combined Intravenous and Intraarticular Tranexamic Acid Does Not Offer Additional Benefit Compared with Intraarticular Use Alone in Bilateral TKA: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Letter to the Editor: Combined Intravenous and Intraarticular Tranexamic Acid Does Not Offer Additional Benefit Compared with Intraarticular Use Alone in Bilateral TKA: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Topical Tranexamic Acid Increases Early Postoperative Pain After Total Hip Arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2020 |
Tranexamic acid in emergency care.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Emergency Medical Services; Emergency Treatment; Huma | 2020 |
The efficacy and safety of multiple-dose intravenous tranexamic acid in reducing perioperative blood loss in patients with thoracolumbar burst fracture.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion | 2020 |
Administration of Tranexamic Acid Improves Long-Term Outcomes in Total Knee Arthroplasty.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Safety and efficacy of tranexamic acid in children with cerebral palsy undergoing femoral varus derotational osteotomy: a double cohort study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cerebral Palsy; Child; | 2020 |
Safety and efficacy of tranexamic acid with epinephrine for prevention of blood loss following surgery for trochanteric femoral fractures.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Epinephrine; Female; Fractur | 2020 |
The effect of topical and systemic tranexamic acid on fracture healing in rats.
Topics: Administration, Topical; Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration | 2020 |
Comment on the article "The antifibrinolytic and anti-inflammatory effects of a high initial-dose tranexamic acid in total knee arthroplasty: a randomized controlled trial".
Topics: Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surg | 2020 |
[A comparative study of Taylor spatial frame and unilateral external fixator in treatment of tibiofibular open fractures].
Topics: Blood Loss, Surgical; External Fixators; Fracture Fixation, Internal; Fracture Healing; Fractures, O | 2020 |
Perioperative anesthetic management in a patient with factor XI deficiency undergoing coronary artery bypass graft surgery.
Topics: Acute Coronary Syndrome; Aged; Blood Loss, Surgical; Cardiopulmonary Bypass; Coronary Artery Bypass; | 2020 |
How treatment delay may lead to loss of effectiveness of tranexamic acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Time-to-Treatment; Tranexamic Acid; Treatment | 2020 |
Venous thromboembolism after tranexamic acid administration: legitimate risk or statistical confounder?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Tranexamic A | 2020 |
Perspectives on tranexamic acid in surgery.
Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Hemorrhage; Humans; Publications; | 2020 |
Tranexamic acid administration during total joint arthroplasty surgery is not associated with an increased risk of perioperative seizures: a national database analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Seizures; Tra | 2020 |
Tranexamic acid with a pre-operative suspension of anticoagulation decreases operative time and blood transfusion in the treatment of pelvic and acetabulum fractures.
Topics: Acetabulum; Anticoagulants; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans | 2020 |
A protocol of situation-dependent transfusion, erythropoietin and tranexamic acid reduces transfusion in fronto-orbital advancement for metopic and coronal craniosynostosis.
Topics: Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Erythropoietin; Humans; Infant; Retrospec | 2021 |
Tranexamic Acid Does Not Reduce the Risk of Transfusion in Rheumatoid Arthritis Patients Undergoing Total Joint Arthroplasty.
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2020 |
In the Era of Tranexamic Acid, are Type and Screens for Primary Total Joint Arthroplasty Obsolete?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2020 |
Effect of the application of the "Patient blood management" programme on the approach to elective hip and knee arthroplasties.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2020 |
Postoperative Intravenous Iron Supplementation Does Not Improve Hemoglobin Level and Transfusion Rate Following Staged Bilateral Total Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Cohort Studies; Diet | 2020 |
Peri-operative administration of tranexamic acid in lower limb arthroplasty: a multicentre, prospective cohort study.
Topics: Aged; Aged, 80 and over; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement; Arthroplasty, R | 2020 |
Letter to the Editor on "In the Era of Tranexamic Acid, Are Type and Screens for Primary Total Joint Arthroplasty Obsolete?"
Topics: Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Humans; Tranexamic Acid | 2020 |
Response to Letter to the Editor on "In the Era of Tranexamic Acid, Are Type and Screens for Primary Total Joint Arthroplasty Obsolete?"
Topics: Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Humans; Tranexamic Acid | 2020 |
Intravenous tranexamic acid vs. topical thrombin in total shoulder arthroplasty: a comparative study.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, S | 2021 |
Letter to the Editor on "Topical Tranexamic Acid Increases Early Postoperative Pain After Total Hip Arthroplasty".
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Pain, Postope | 2020 |
Author Response to Commentary on "Topical Tranexamic Acid Increases Early Postoperative Pain After Total Hip Arthroplasty".
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Pain, Postope | 2020 |
The impact of tranexamic acid on administration of red blood cell transfusions for resection of colorectal liver metastases.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Colorectal Neoplasms; Erythrocyte Transfusion; Hepate | 2021 |
Prospective Study Assessing the Effect of Local Infiltration of Tranexamic Acid on Facelift Bleeding.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Case-Control Studies; Female | 2021 |
Effect of Tranexamic Acid on Wound Complications and Blood Loss in Total Ankle Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Ankle; Blood Loss, Surgical; Cohort Studie | 2020 |
[Analysis of hemostatic effect and safety of tranexamic acid in primary simultaneous bilateral total hip arthroplasty].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemostatics; Humans; | 2020 |
Efficacy of intravenous tranexamic acid administration in revision hip arthroplasty.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2021 |
Tranexamic acid in hip hemiarthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Hemiarthropla | 2020 |
Administration of tranexamic acid during total shoulder arthroplasty is not associated with increased risk of complications in patients with a history of thrombotic events.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, Surgical; Databases, | 2021 |
One Dose Versus Two Doses of Intravenous Tranexamic Acid in Total Joint Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2021 |
Intraoperative coagulopathy during cesarean section as an unsuspected initial presentation of COVID-19: a case report.
Topics: Adult; Antifibrinolytic Agents; Betacoronavirus; Blood Coagulation Disorders; Blood Loss, Surgical; | 2020 |
Finding the optimal control level of intraoperative blood pressure in no tourniquet primary total knee arthroplasty combine with tranexamic acid: a retrospective cohort study which supports the enhanced recovery strategy.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Pressure | 2020 |
Higher doses of topical tranexamic acid safely improves immediate functional outcomes and reduces transfusion requirement in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2020 |
Efficacy of topical versus intravenous tranexamic acid in spinal deformity.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Hu | 2020 |
Effectiveness of administering tranexamic acid to high-risk hip and knee arthroplasty patients: a systematic review protocol.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2020 |
Effect of 3 different anticoagulants on hidden blood loss during total hip arthroplasty after tranexamic acid.
Topics: Administration, Intravenous; Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2020 |
Efficacy and safety of tranexamic acid in unilateral major revision total hip arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Retrospective | 2020 |
The effects of intravenous and local tranexamic acid on bone healing: An experimental study in the rat tibia fracture model.
Topics: Administration, Intravenous; Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Rats; Tibia; Ti | 2020 |
Does tourniquet use decrease blood loss following primary total knee arthroplasty in Jehovah's Witness patients?
Topics: Aged; Anesthesia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Fe | 2020 |
Is tranexamic acid effective on hidden blood loss in patients during total knee arthroplasty?
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Component Transfusion; Blood L | 2020 |
Is continuation of anti-platelet treatment safe for elective total hip arthroplasty patients?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Blood Los | 2020 |
Effectiveness of Multi-Modal Blood Management in Bernese Periacetabular Osteotomy and Periacetabular Osteotomy with Proximal Femoral Osteotomy.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hip Dislocation, Congenital | 2020 |
Does intraoperative transfusion during total knee arthroplasty reduce the need for transfusion after surgery?: A preliminary retrospective cohort study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2021 |
Tranexamic acid in non-elective primary total hip arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; Male; | 2021 |
Tranexamic Acid Administration is Associated With a Decreased Odds of Prosthetic Joint Infection Following Primary Total Hip and Primary Total Knee Arthroplasty: A National Database Analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2021 |
Tranexamic Acid in Infantile Craniosynostosis Surgery: Friend or Foe?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Female; Humans; | 2020 |
The Utility of Obtaining a Complete Blood Count After Total Knee Arthroplasty in the Era of Tranexamic Acid.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Cell | 2021 |
[Acute Limb Ischemia after Total Hip Arthroplasty in a High-Risk Patient - Is Tranexamic Acid to Blame?]
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2020 |
Intravenous tranexamic acid for reducing perioperative blood loss during revision hip arthroplasty: A retrospective study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2020 |
Effectiveness of pre-operative anaemia screening and increased Tranexamic acid dose policies on outcomes following unilateral primary, elective total hip or knee replacement: a statistical analysis plan for an interrupted time series and regression discon
Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bl | 2020 |
Effectiveness of pre-operative anaemia screening and increased Tranexamic acid dose policies on outcomes following unilateral primary, elective total hip or knee replacement: a statistical analysis plan for an interrupted time series and regression discon
Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bl | 2020 |
Effectiveness of pre-operative anaemia screening and increased Tranexamic acid dose policies on outcomes following unilateral primary, elective total hip or knee replacement: a statistical analysis plan for an interrupted time series and regression discon
Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bl | 2020 |
Effectiveness of pre-operative anaemia screening and increased Tranexamic acid dose policies on outcomes following unilateral primary, elective total hip or knee replacement: a statistical analysis plan for an interrupted time series and regression discon
Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bl | 2020 |
Does the correction angle affect hidden blood loss in HTO?
Topics: Aged; Blood Loss, Surgical; Female; Humans; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Ost | 2020 |
Comparison of the effectiveness and safety of intravenous and topical regimens of tranexamic acid in complex tibial plateau fracture: a retrospective study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Simultaneous Bilateral Primary Total Knee Arthroplasty With TXA and Restrictive Transfusion Protocols: Still a 1 in 5 Risk of Allogeneic Transfusion.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2021 |
[Progress on the application of tranexamic acid in adolescent spine corrective surgery].
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Postoperative | 2020 |
Factors associated with blood loss in ankylosing spondylitis patients with hip involvement undergoing primary total hip arthroplasty: a cross-sectional retrospective study of 243 patients.
Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Sedimentation; Cross-Sectio | 2020 |
Routine Postoperative Complete Blood Counts Are Not Necessary After Most Primary Total Hip and Knee Arthroplasties.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Cell | 2021 |
[Efficacy and safety of tranexamic acid in total hip arthroplasty via direct anterior approach].
Topics: Aged; Antifibrinolytic Agents; Antiviral Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgica | 2020 |
[Analysis of hemostatic effect of intra-articular injection of tranexamic acid after minimally invasive unicompartmental knee arthroplasty].
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Hemost | 2020 |
Does tranexamic acid influence activated clotting time values in patients undergoing cardiac surgery?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Humans; Tranexamic Acid | 2022 |
[Comparison of hemostatic effect and safety in primary unilateral total hip arthroplasty receiving different anticoagulants after anti-fibrinolysis with tranexamic acid].
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemos | 2020 |
[Perioperative blood management for total hip/knee arthroplasty].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2020 |
Combined treatment of intraoperative cell-salvage and tranexamic acid for primary unilateral total hip arthroplasty: Are there added benefits?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2022 |
Tourniquetless Total Knee Arthroplasty: History, Controversies, and Technique.
Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Knee Joint; Tourniquets; Tranexamic A | 2021 |
Use of tranexamic acid is not associated with complications following bipolar hemiarthroplasty for metastatic disease.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Femoral Neoplasms; Femur Neck; Follow-Up Stud | 2021 |
Lysine analogue use during cancer surgery: a survey from a Canadian tertiary care centre.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Humans; Lysine; Neoplasms; Ontario; Surveys and Questionnai | 2020 |
Impact of Obesity on Tranexamic Acid Efficacy in Adult Patients With Major Bleeding.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Obesity; Retrospective Stu | 2021 |
Is there a role of tranexamic acid in rheumatoid arthritis with total knee arthroplasty? Findings from a multicenter prospective cohort study in China.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2021 |
Can Tranexamic Acid Be Safely Administered during Microsurgery in the Era of COVID-19?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; COVID-19; Humans; Microsurgery; Tranexamic Acid | 2021 |
Local Infiltration of Tranexamic Acid (TXA) in Liposuction: A Single-Surgeon Outcomes Analysis and Considerations for Minimizing Postoperative Donor Site Ecchymosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Humans; Lipectomy; Postoperative Hemorrha | 2021 |
Intravenous tranexamic acid is associated with safe reduced blood loss and transfusion rate in one-stage exchange for infected hip arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2021 |
Intra-operative local plus systemic tranexamic acid significantly decreases post-operative bleeding and the need for allogeneic blood transfusion in total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2021 |
The efficacy of intravenous tranexamic acid administration at induction in definitive hip fracture surgery: Is there a role?
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Hum | 2021 |
Does Not Use of Closed Suction Drainage in Total Knee Arthroplasty with Tranexamic Acid Reduce Blood Loss?
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drainage; Female; Hu | 2020 |
Do all cardiac surgery patients benefit from antifibrinolytic therapy?
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; | 2021 |
Variation in prophylactic tranexamic acid administration among anesthesiologists and surgeons in orthopedic surgery: a retrospective cohort study.
Topics: Adult; Anesthesiologists; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgi | 2021 |
Clinical Outcomes and Experience of a Multiyear Consecutive Case Series of Total Knee Arthroplasty Procedures Conducted with a Bipolar Sealer System for Hemostasis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Hemostasis; Humans; | 2022 |
Predictors for blood loss and transfusion frequency to guide blood saving programs in primary knee- and hip-arthroplasty.
Topics: Aged; Anemia; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bioma | 2021 |
The efficiency and safety of intravenous tranexamic acid administration in open reduction and internal fixation of pelvic and acetabular fractures.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Pelvis; Tranexamic Acid | 2022 |
Is tranexamic acid use in patients with a hip fracture safe?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; | 2021 |
Comparing the effect of tourniquet and tranexamic acid on the tibial cement mantle thickness in total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoperativ | 2022 |
Commentary on: Local Infiltration of Tranexamic Acid (TXA) in Liposuction: A Single-Surgeon Outcomes Analysis and Considerations for Minimizing Postoperative Donor Site Ecchymosis.
Topics: Blood Loss, Surgical; Ecchymosis; Humans; Lipectomy; Surgeons; Tranexamic Acid | 2021 |
Associations of preoperative stroke and tranexamic acid administration with convulsive seizures in valvular open-heart surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Humans; Retrospective St | 2021 |
A New Low Dose of Tranexamic Acid for Decreasing the Rate of Blood Loss in Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Humans; Kyphosi | 2021 |
Impact of tranexamic acid on blood loss and transfusion rate in children with cerebral palsy undergoing hip reconstruction with two or more osteotomies.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Ce | 2022 |
Topical tranexemic acid reduces intra-operative blood loss and transfusion requirements in spinal deformity correction in patients with adolescent idiopathic scoliosis.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Humans; Scolio | 2021 |
Tranexamic acid does not affect intraoperative blood loss or in-hospital outcomes after acetabular fracture surgery.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Hospitals; Humans; Middle Aged; | 2022 |
Effect of administration of tranexamic acid on reduced risk of red blood cell transfusion after resection for colorectal liver metastases.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Colorectal Neoplasms; Erythrocyte Transfusion; Humans | 2021 |
Prophylactic tranexamic acid use in non-cardiac surgeries at high risk for transfusion.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Canada; Humans; Retrospective Studies; Tranexamic Aci | 2021 |
Safety and Efficacy of Topical Administration of Tranexamic Acid in High-Risk Patients Undergoing Posterior Lumbar Interbody Fusion Surgery.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiovascular Disease | 2021 |
Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2021 |
Tranexamic acid and the burden of early neurologic complications in valvular open-heart surgery: A propensity matched analysis in 3227 patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Humans; Tranexamic Acid | 2021 |
ε-Aminocaproic acid versus tranexamic acid in children undergoing complex cranial vault reconstruction for repair of craniosynostosis.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; R | 2021 |
Risk Factors for Increased Surgical Drain Output After Transforaminal Lumbar Interbody Fusion.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Lumbar Verteb | 2021 |
Tranexamic Acid in High-risk Arthroplasty Patients: How Will We Adapt to Evolving Evidence?
Topics: Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Humans; Tranexamic Acid | 2021 |
[Tranexamic acid and arthroplasty: between off-label use and evidence-based medicine].
Topics: Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Evidence-Based Medicine; Humans; Off-La | 2021 |
Low blood transfusion rate after implementation of tranexamic acid for fast- track hip- and knee arthroplasty. An observational study of 5205 patients.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2021 |
Efficacy of repeated intravenous tranexamic acid in reducing perioperative bleeding of acetabular fractures.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Retrospective Studies; Tranexa | 2021 |
Blood management in direct anterior versus posterior primary total hip arthroplasty using tranexamic acid: a matched cohort study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Cohort Studies; Human | 2023 |
Efficacy and safety of tranexamic acid in hip fracture surgery: A comparative study of 613 patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2022 |
Benefits of Tranexamic Acid in Total Knee Arthroplasty: A Classification and Regression Tree Analysis in Function of Instrumentation, BMI, and Gender.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
Efficacy and Safety of Tranexamic Acid in Resection and Endoprosthetic Reconstruction of Distal Femoral Osteosarcomas in Children: A Retrospective Cohort Study.
Topics: Administration, Intravenous; Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Femal | 2021 |
The Use of Tranexamic Acid in Facial Cosmetic Surgery Procedures: A Technical Note.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Humans; Surgery, Plastic; Tranexamic Acid | 2021 |
Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2022 |
The Efficacy and Safety of Tranexamic Acid Treatment in Orthopaedic Trauma Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Orthopedics; Tranexamic Acid | 2021 |
High- versus low-dose tranexamic acid as part of a Patient Blood Management strategy for reducing blood loss in patients undergoing surgery for adolescent idiopathic scoliosis.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Retrospective | 2022 |
[Study on the safety and effectiveness of low-dose tranexamic acid in operation of multi-level continuous thoracic ossification of ligament flavum].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Ligaments; Osteogenesis; Postoperative Hemorr | 2021 |
[Application of tranexamic acid in the treatment of intertrochanteric fracture of femur].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Femur; Hip Fractures; Humans; Postoperative Hemorrhag | 2021 |
Tranexamic acid is safe and effective in patients with heterozygous factor V Leiden mutation during total joint arthroplasty.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2023 |
Effectiveness of using tranexamic acid in total hip and total knee arthroplasty: Single tertiary center experience.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2021 |
Effect of administration of tranexamic acid on reduced risk of red blood cell transfusion after resection for colorectal liver metastases - Reply.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Colorectal Neoplasms; Erythrocyte Transfusion; Humans | 2021 |
Efficacy and Safety of Locally Injected Tranexamic Acid in Hip Fracture Patients: A Retrospective Review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Retrospective Studies; Tranexa | 2022 |
Thrombotic activation before and after total hip arthroplasty. A prospective cohort study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; | 2021 |
Comparison of topical and intravenous Tranexamic acid for high tibial osteotomy: A retrospective study.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Follow- | 2021 |
In reply to the letter to the editor regarding "The efficacy and safety of tranexamic acid in high tibial osteotomy: a systematic review and meta-analysis".
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Osteotomy; Tranexamic Acid | 2021 |
Significantly reducing blood loss via a peri-articular injection of tranexamic acid during total knee arthroplasty: a retrospective study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2021 |
Tranexamic Acid is Associated With Decreasing the Risk of Complications in Patients Undergoing Arthroplasty With Preoperative Coagulopathy.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Human | 2021 |
Effect and safety of topical application of tranexamic acid to reduce perioperative blood loss in elderly patients with intertrochanteric fracture undergoing PFNA.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blo | 2021 |
Anaphylactic reaction to tranexamic acid in an adolescent undergoing posterior spinal fusion.
Topics: Adolescent; Anaphylaxis; Anesthesia, General; Anesthesia, Intravenous; Antifibrinolytic Agents; Bloo | 2017 |
Effect of Tranexamic Acid on Transfusion Rates Following Total Joint Arthroplasty: A Cost and Comparative Effectiveness Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2017 |
CORR Insights
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Tranexamic A | 2017 |
Process Improvement Project Using Tranexamic Acid Is Cost-Effective in Reducing Blood Loss and Transfusions After Total Hip and Total Knee Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2017 |
Tranexamic Acid and Computer-Assisted Surgery in Cemented and Cementless Total Knee Arthroplasty: Are the Effects Additive for Blood Conservation?
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Bloodle | 2017 |
Invited Commentary related to: Tranexamic Acid Safely Reduced Blood Lossin Hemi- and Total Hip Arthroplasty for Acute Femoral Neck Fracture: A Randomized Clinical Trial.
Topics: Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Femoral Neck Fractures; Humans; Tranexamic Aci | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Antifibrinolytic Agents; Arteries; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Antifibrinolytic Agents; Arteries; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Antifibrinolytic Agents; Arteries; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Antifibrinolytic Agents; Arteries; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Antifibrinolytic Agents; Arteries; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; | 2017 |
Tranexamic Acid Effectively Reduces Blood Loss and Transfusion Rates during Simultaneous Bilateral Total Knee Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2018 |
Tranexamic Acid Reduces Blood Loss in Craniosynostosis Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Critical Care; H | 2017 |
An Aprotinin Containing Fibrin Sealant Does Not Reduce Blood Loss in Total Hip Arthroplasty.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Aprotinin; Arthroplasty, Replacement, Hip; Blo | 2017 |
Tranexamic Acid: What Is Known and Unknown, and Where Do We Go From Here?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2017 |
Oral Tranexamic Acid Reduces Transfusions in Total Knee Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2017 |
What Should Define Preoperative Anemia in Primary THA?
Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Blood Loss, Surgical; | 2017 |
Limitations of Preoperative PFA-200 as a Predictor of Postoperative Blood Loss in Total Knee Arthroplasty: According to Use of Tranexamic Acid.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Blood Loss, Surgical; Blood Tr | 2017 |
Use of a Tourniquet in Total Knee Arthroplasty Causes a Paradoxical Increase in Total Blood Loss.
Topics: Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Su | 2017 |
A new topical hemostatic agent TT-173 reduces blood loss in a sheep model of total knee arthroplasty.
Topics: Animals; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2017 |
Periarticular Injection of Tranexamic Acid Reduces Blood Loss and the Necessity for Allogeneic Transfusion After Total Knee Arthroplasty Using Autologous Transfusion: A Retrospective Observational Study.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2018 |
[Local Application of Tranexamic Acid in Total Hip Arthroplasty Decreases Blood Loss and Consumption of Blood Transfusion].
Topics: Administration, Cutaneous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss | 2017 |
Tranexamic Acid Should be Considered in Fracture Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration Routes; Fracture Fixation; Fractu | 2017 |
Epsilon Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Hip and Total Knee Arthroplasty.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Comparison of Oral and Intravenous Tranexamic Acid for Prevention of Perioperative Blood Loss in Total Knee and Total Hip Arthroplasty.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl | 2018 |
Topical use of tranexamic acid can effectively decrease hidden blood loss during posterior lumbar spinal fusion surgery: A retrospective study.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusi | 2017 |
Can Tranexamic Acid Reduce Blood Loss during Major Cardiac Surgery? A Pilot Study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Valve Annuloplasty; Corona | 2017 |
Perioperative Blood Loss and Transfusion in Craniosynostosis Surgery.
Topics: Adolescent; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Craniotomy; Female; Hematocri | 2018 |
High-dose Versus Low-dose Tranexamic Acid to Reduce Transfusion Requirements in Pediatric Scoliosis Surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Dose-Response R | 2017 |
High-dose Versus Low-dose Tranexamic Acid to Reduce Transfusion Requirements in Pediatric Scoliosis Surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Dose-Response R | 2017 |
High-dose Versus Low-dose Tranexamic Acid to Reduce Transfusion Requirements in Pediatric Scoliosis Surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Dose-Response R | 2017 |
High-dose Versus Low-dose Tranexamic Acid to Reduce Transfusion Requirements in Pediatric Scoliosis Surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Dose-Response R | 2017 |
Evaluating the Effect on Mortality of a No-Tranexamic acid (TXA) Policy for Cardiovascular Surgery.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiovascular Surgical Procedures; Cohort Stud | 2018 |
Craniosynostosis Surgery and the Impact of Tranexamic Acid Dosing.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Craniosynostoses; Dr | 2018 |
Risk Factors for Reaching the Post-Operative Transfusion Trigger in a Community Primary Total Knee Arthroplasty Population.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2018 |
Benefits of Tranexamic Acid Not Debatable but Leave Tourniquet Use to Surgeon's Discretion: Commentary on an article by ZeYu Huang, MD, PhD, et al.: "Intravenous and Topical Tranexamic Acid Alone Are Superior to Tourniquet Use for Primary Total Knee Arthr
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2017 |
Tranexamic Acid Use in Cardiac Surgery: Hemostasis, Seizures, or a Little of Both.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Hemostasis; Humans; Seiz | 2018 |
Clinical Research of Combined Intravenous Administration and Topical Application of Tranexamic Acid to a Surgical Wound During Posterior Lumbar Fusion.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Sur | 2018 |
Comment on Chiem J, Ivanova I, Jimenez N. Anaphylactic reaction to tranexamic acid in an adolescent undergoing posterior spinal fusion.
Topics: Adolescent; Anaphylaxis; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Scoliosis; Spinal Fu | 2018 |
From Foundation to Demolition: The Influence of Perioperative Tranexamic Acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemostasis; Humans; Perioperative Care; Tranexamic Ac | 2018 |
Tranexamic acid may result in small decrease in blood loss in patients undergoing orthognathic surgery.
Topics: Blood Loss, Surgical; Double-Blind Method; Humans; Orthognathic Surgery; Orthognathic Surgical Proce | 2018 |
The effect of tranexamic acid in unilateral and bilateral total knee arthroplasty in the South Asian population: A retrospective cohort study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Asian People; Blood Loss, Surgical; | 2018 |
Evidence appraisal of Kim C, Park SS, Dhotar HS, Perruccio AV, Zywiel MG, Davey JR. Topical tranexamic acid reduces transfusion rates in simultaneous bilateral total knee arthroplasty: a retrospective case series. Can J Surg. 2017;60(5):311-315.
Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; Humans; Retrospective Stud | 2018 |
Effectiveness and safety of an optimized blood management program in total hip and knee arthroplasty: A large, single-center, retrospective study.
Topics: Administration, Intravenous; Administration, Topical; Adult; Aged; Anemia; Antifibrinolytic Agents; | 2018 |
Additional Dose of Intravenous Tranexamic Acid after Primary Total Knee Arthroplasty Further Reduces Hidden Blood Loss.
Topics: Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans; Male; Middle Aged; Pilo | 2018 |
Incidence and Risk Factors for Blood Transfusion in Simultaneous Bilateral Total Joint Arthroplasty: A Multicenter Retrospective Study.
Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; | 2018 |
Improved Early Postoperative Range of Motion in Total Knee Arthroplasty Using Tranexamic Acid: A Retrospective Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control Studies | 2019 |
Matched cohort study of topical tranexamic acid in cementless primary total hip replacement.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2018 |
[A case report of tranexamic acid associated epilepsy in spine surgery].
Topics: Blood Loss, Surgical; Epilepsy; Humans; Orthopedic Procedures; Spine; Tranexamic Acid | 2018 |
Pharmacologic Hemostatic Agents in Total Joint Arthroplasty-A Cost-Effectiveness Analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Supportive topical tranexamic acid application for hemostasis in oral bleeding events - Retrospective cohort study of 542 patients.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood | 2018 |
Aprotinin and coronary artery bypass surgery.
Topics: Aprotinin; Blood Loss, Surgical; Coronary Artery Bypass; Humans; Tranexamic Acid | 2018 |
Intravenous tranexamic acid only versus combined intravenous and intra-articular tranexamic acid for perioperative blood loss in patients undergoing total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2018 |
Effect of Tranexamic Acid on Blood Loss, D-Dimer, and Fibrinogen Kinetics in Adult Spinal Deformity Surgery.
Topics: Antifibrinolytic Agents; Blood Component Transfusion; Blood Loss, Surgical; Female; Fibrin Fibrinoge | 2018 |
Minimizing Blood Loss and Transfusions in Total Knee Arthroplasty.
Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; Epoetin Alfa; Fibrin Tissu | 2018 |
[Effect on time of temporarily-closed wound drainage on blood loss of primary total knee arthroplasty after intravenous and intra-articular injection of tranexamic acid].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; D | 2017 |
Tranexamic acid administration to older patients undergoing primary total hip arthroplasty conserves hemoglobin and reduces blood loss.
Topics: Age Factors; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood | 2018 |
Blood Loss Reduction with Tranexamic Acid and a Bipolar Sealer in Direct Anterior Total Hip Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2018 |
Effectiveness of a patient blood management protocol on reduction of allogeneic red blood cell transfusions in orthopedic surgery.
Topics: Aged; Aged, 80 and over; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplas | 2019 |
Transfusion rate using intravenous tranexamic acid in hip revision surgery.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2018 |
Intravenous Tranexamic Acid before and after Tourniquet Use Can Reduce Blood Loss and Blood Transfusion after Total Knee Arthroplasty
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2016 |
When Should Complete Blood Count Tests Be Performed in Primary Total Hip Arthroplasty Patients?
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blo | 2018 |
Tranexamic acid is associated with selective increase in inflammatory markers following total knee arthroplasty (TKA): a pilot study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Blood Coagulation; Blood | 2018 |
Response to Letter to the Editor on "The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis".
Topics: Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Humans; Tranexamic Acid | 2018 |
Letter to the Editor on "The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis".
Topics: Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Humans; Tranexamic Acid | 2018 |
Reply: The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Blood Loss, Surgical; Humans; Plastics; Tranexamic Acid | 2018 |
The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations.
Topics: Blood Loss, Surgical; Humans; Plastics; Tranexamic Acid | 2018 |
One Dose of Intravenous Tranexamic Acid Is Equivalent to Two Doses in Total Hip and Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthropl | 2018 |
Should we use prophylactic tranexamic acid in orthognathic surgery to decrease blood loss?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Orthognathic Surgery; Tranexamic Acid | 2018 |
The effect of different dosage regimens of tranexamic acid on blood loss in bimaxillary osteotomy: a randomized, double-blind, placebo-controlled study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Osteotomy; Tranexamic Ac | 2018 |
Combined use of topical intraarticular tranexamic acid and rivaroxaban in total knee arthroplasty safely reduces blood loss, transfusion rates, and wound complications without increasing the risk of thrombosis.
Topics: Administration, Topical; Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2018 |
Comment on: "Efficacy of preoperative administration of single high dose intravenous tranexamic acid in reducing blood loss in total knee arthroplasty: A prospective clinical study".
Topics: Administration, Intravenous; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Postoper | 2018 |
Patients With Infected Total Hip Arthroplasty Undergoing 2-Stage Exchange Arthroplasty Experience Massive Blood Loss.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Infectious; Arthroplasty, Replacement, Hip; Blood Loss, S | 2018 |
The Effect of Preoperative Administration of Intravenous Tranexamic Acid During Revision Hip Arthroplasty: A Retrospective Study.
Topics: Acetabulum; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood | 2018 |
Tranexamic Acid Reduces Perioperative Blood Loss and Hemarthrosis in Total Ankle Arthroplasty.
Topics: Aged; Ankle Joint; Antifibrinolytic Agents; Arthroplasty, Replacement, Ankle; Blood Loss, Surgical; | 2018 |
Tranexamic acid is effective for blood management in open-wedge high tibial osteotomy.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Case-Control Studies | 2018 |
Early morbidity and mortality after single-stage bilateral total knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2018 |
The key role of tranexamic acid in Patient Blood Management programmes.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Tranexamic Ac | 2018 |
Ulnar Artery Thrombosis Following Tranexamic Acid Administration for Craniosynostosis Repair.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child, Preschool; Craniosynostoses; Female; Humans; T | 2019 |
Topical Tranexamic Acid in Revision Total Knee Arthroplasty Reduces Transfusion Rates and May Be Associated With Earlier Recovery.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2019 |
Effect of pharmacist intervention on blood conservation therapy in total knee arthroplasty: A retrospective, observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2019 |
Transfusion rates with intravenous tranexamic acid in total hip arthroplasty performed using the direct anterior approach.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Antiviral Agents; Arthroplasty, Replacem | 2019 |
Comparison of three routes of administration of tranexamic acid in primary unilateral total knee arthroplasty: Analysis of a national database.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2019 |
The efficacy and safety of tranexamic acid in reducing perioperative blood loss in patients with multilevel thoracic spinal stenosis: A retrospective observational study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Bone Transplantation; China; Decom | 2018 |
Routine Postoperative Laboratory Tests Are Not Necessary After Primary Total Hip Arthroplasty.
Topics: Acute Kidney Injury; Aged; Anemia; Arthroplasty, Replacement, Hip; Blood Chemical Analysis; Blood Lo | 2019 |
Blood loss of total knee arthroplasty in osteoarthritis: an analysis of influential factors.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2018 |
[Preliminary analysis of the effect of different administration routes of tranexamic acid on blood loss after total hip arthroplasty for female femur neck fractures].
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Reducing Blood Loss in Revision Total Hip and Knee Arthroplasty: Tranexamic Acid Is Effective in Aseptic Revisions and in Second-Stage Reimplantations for Periprosthetic Infection.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; | 2018 |
Total Knee Arthroplasty Is Safe in Jehovah's Witness Patients-A 12-Year Perspective.
Topics: Aged; Aged, 80 and over; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Los | 2020 |
Tranexamic acid is effective in lower doses with infusion in total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2019 |
Does Prophylactic Administration of TXA Reduce Mean Operative Time and Postoperative Blood Loss in Posterior Approach Lumbar Spinal Fusion Surgery Performed for Degenerative Spinal Disease?
Topics: Blood Loss, Surgical; Female; Humans; Intervertebral Disc Degeneration; Lumbar Vertebrae; Male; Oper | 2019 |
Role of intravenous tranexamic acid in reducing blood loss during caesarean section: Study at tribal-dominated area hospital in Chhattisgarh, India.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2019 |
The Efficacy and Safety of Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Patients Treated with Posterior Lumbar Interbody Fusion.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Autologous; Body Mass Index; Bone | 2019 |
Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.
Topics: Aged; Blood Loss, Surgical; Carcinoma, Hepatocellular; Dabigatran; Humans; Infusions, Intravenous; L | 2019 |
Perioperative intravenous tranexamic acid reduces blood transfusion in primary cementless total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2019 |
Do tourniquet and drainage influence fast track in total knee arthroplasty? Our results on 151 cases.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2019 |
Tranexamic Acid Reduces Transfusion Rates in Obese Patients Undergoing Total Joint Arthroplasty.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgica | 2019 |
Letter to the Editor Regarding "The Efficacy of Tranexamic Acid on Blood Loss of Lumbar Spinal Fusion Surgery: A Meta-Analysis of Randomized Controlled Trials".
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Randomized Controlled Trials as Topic; Spinal | 2019 |
Topics: Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Pyrazines; Retrospective Studies; Tran | 2019 |
[Case-control study on effect of early intermittently closing drainage tube for blood loss after total knee arthroplasty].
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2019 |
Postoperative thrombotic effects of tranexamic acid in open heart surgery.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Ca | 2019 |
A survey of anaesthetists' use of tranexamic acid in noncardiac surgery.
Topics: Anesthetists; Antifibrinolytic Agents; Australia; Blood Loss, Surgical; Humans; New Zealand; Randomi | 2019 |
[Effect of tranexamic acid on blood loss and soft-tissue swelling following cemented total hip replacement].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Length of Sta | 2019 |
Effects of topical tranexamic acid during open reduction and internal fixation of acetabular fractures: A retrospective study.
Topics: Acetabulum; Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusio | 2019 |
Reducing transfusion requirements following total knee arthroplasty: effectiveness of a double infusion of tranexamic acid.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2019 |
The effects of tranexamic acid on blood loss and transfusion rate in colorectal surgery.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Colectomy; Drug Admin | 2019 |
Rotational thromboelastometry-guided transfusion during lumbar pedicle subtraction osteotomy for adult spinal deformity: preliminary findings from a matched cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Co | 2019 |
Clinical Impact of Routine Complete Blood Counts Following Total Knee Arthroplasty.
Topics: Aged; Aged, 80 and over; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Cel | 2019 |
Utilization and Real-world Effectiveness of Tranexamic Use in Shoulder Arthroplasty: A Population-based Study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, Surgical; Blood Tran | 2019 |
[Evaluation of Efficacy of Systemic Administration of Tranexamic Acid (Exacyl) in Total Hip and Knee Arthroplasty - Prospective Cohort Study].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2019 |
Topical tranexamic acid in elderly patients with femoral neck fractures treated with hemiarthroplasty: efficacy and safety? - a case-control study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Case-Cont | 2019 |
Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2019 |
Minimizing transfusion in sagittal craniosynostosis surgery: the Children's Hospital of Minnesota Protocol.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Clinical Protocols; Cranios | 2019 |
Short-term safety of tranexamic acid use in posterior cervical decompression and fusion surgery.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Ce | 2019 |
Tranexamic Acid in Thoracic and Lumbar Fusions and Perioperative Blood Loss.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Dose-Response Relationship, Drug; | 2019 |
Tibial cement mantle thickness is not affected by tourniquetless total knee arthroplasty when performed with tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Bone Cements; | 2020 |
Blood loss and perioperative transfusions related to surgery for spinal tumors. Relevance of tranexamic acid.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Decompression, Surgic | 2019 |
The use of tranexamic acid in adult spinal deformity: is there an optimal dosing strategy?
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Humans; Male; Middl | 2019 |
Implementation of tranexamic acid reduces red blood cell utilization in orthopedic surgeries.
Topics: Academic Medical Centers; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgi | 2019 |
Optimal route for administering tranexamic acid in primary unilateral total hip arthroplasty: Results from a multicenter cohort study.
Topics: Administration, Intravenous; Administration, Topical; Aged; Anticoagulants; Antifibrinolytic Agents; | 2019 |
Efficacy and safety of tranexamic acid in geriatric hip fracture with hemiarthroplasty: a retrospective cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Erythrocyte Tra | 2019 |
The efficacy and safety of tranexamic acid for reducing blood loss following simultaneous bilateral total knee arthroplasty: a multicenter retrospective study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2019 |
Intraarticular use of tranexamic acid reduces blood loss and transfusion rate after primary total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2019 |
Balancing thrombotic and bleeding risks related to antiplatelet therapy in coronary bypass surgery: Comment on "Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting".
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Female; Humans; | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2013 |
[Intravenous administration of tranexamic acid to decrease bleeding and transfusion in knee and hip prosthetic surgery: is it safe and cost-effective?].
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Cost-Benefit | 2013 |
Inadequate methodology renders results on the use of tranexamic acid inconclusive.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans; Male | 2013 |
Tranexamic acid for reducing blood transfusions in arthroplasty interventions: a cost-effective practice.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2014 |
Reply to Letter to the Editor: Inadequate methodology renders results on the use of tranexamic acid inconclusive.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans; Male | 2013 |
The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2014 |
The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2014 |
The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2014 |
The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Repl | 2014 |
Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplast | 2014 |
Economic impact of tranexamic acid in healthy patients undergoing primary total hip and knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2013 |
Cerebrovascular infarction following bilateral total knee arthroplasty and tranexamic acid administration.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Cerebral Infar | 2013 |
Tranexamic acid and thrombosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hematuria; Hemorrhage; Humans; Menorrhagia; R | 2013 |
One dose of tranexamic acid is safe and effective in revision knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2013 |
Trauma and tranexamic acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Thrombosis; Tranexamic Acid; Woun | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Tranexamic acid decreases risk of haematomas but not pain after hip arthroplasty.
Topics: Adult; Aged; Analgesics, Opioid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss | 2013 |
Evaluation of the efficacy and safety of tranexamic acid for reducing blood loss in bilateral total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2014 |
Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2014 |
Tranexamic Acid Tamponade to Control Postoperative Surgical Hemorrhage.
Topics: Anticoagulants; Blood Loss, Surgical; Humans; Postoperative Hemorrhage; Tooth Extraction; Tranexamic | 2015 |
[Percutaneous nephrolithotomy - tranexamic acid reduces blood loss].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Nephrostomy, Percutaneous; Tran | 2013 |
Tranexamic acid reduces surgical bleeding: does one size fit all?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2014 |
Blood transfusion after primary total knee arthroplasty can be significantly minimised through a multimodal blood-loss prevention approach.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2014 |
[Intravenous tranexamic acid in primary total knee arthroplasty].
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Hemostatics; | 2014 |
Blood conservation.
Topics: Anesthesia; Antifibrinolytic Agents; Arthritis, Infectious; Arthroplasty, Replacement; Blood Loss, S | 2014 |
Can tranexamic acid and hydrogen peroxide reduce blood loss in cemented total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2014 |
Usefulness of intraoperative continuous infusion of tranexamic acid during emergency surgery for type A acute aortic dissection.
Topics: Acute Disease; Aged; Antifibrinolytic Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Blood Lo | 2015 |
Cost benefit analysis of topical tranexamic acid in primary total hip and knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty | 2014 |
Tranexamic acid and trauma.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injur | 2014 |
Tranexamic acid and trauma.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injur | 2014 |
Tranexamic acid and trauma.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injur | 2014 |
Healthy ethical conduct is vital.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; China; Comorbidity; Computer | 2014 |
Single perioperative dose of tranexamic acid in primary hip and knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplast | 2015 |
Perioperative tranexamic acid in day-case paediatric tonsillectomy.
Topics: Adolescent; Ambulatory Surgical Procedures; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Ch | 2014 |
What is the evidence for tranexamic acid in burns?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Burns; Hemorrhage; Humans; Tranexamic Acid | 2014 |
Use of tranexamic acid in infants undergoing choroid plexus papilloma surgery: a report of two cases.
Topics: Blood Loss, Surgical; Blood Volume; Choroid Plexus Neoplasms; Female; Hemostatics; Humans; Infant; I | 2014 |
Tranexamic acid reduces intraoperative blood loss in orthognathic surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Orthognathic Surgical Procedures; Randomized | 2014 |
The effects of Amicar and TXA on lumbar spine fusion in an animal model.
Topics: Aminocaproic Acid; Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Calcification, Physiologi | 2014 |
Decreased blood transfusion following revision total knee arthroplasty using tranexamic acid.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2014 |
Eliminating transfusion in primary joint arthroplasty-an achievable goal.
Topics: Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Blood Transfusion; Goals; Humans; Trane | 2014 |
Comparison of intra-operative regimes of tranexamic acid administration in primary total hip replacement.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid for surgical bleeding.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2014 |
Efficacy and safety of tranexamic acid versus ϵ-aminocaproic acid in cardiovascular surgery.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiopul | 2014 |
Does tranexamic acid improve outcomes in patients undergoing urgent or emergency surgery?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Emergencies; Humans; Tranexamic Acid | 2015 |
Cost analysis of use of tranexamic Acid to prevent major bleeding complications in hip and knee arthroplasty surgery.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2014 |
Assessment of the introduction of a blood management program in orthopaedic surgery.
Topics: Aged; Anemia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biomarkers; Blood Ban | 2015 |
Topical versus intravenous tranexamic acid in total knee arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2015 |
Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child, Preschool; Cohort Studies; | 2015 |
Topical tranexamic Acid does not affect electrophysiologic or neurovascular sciatic nerve markers in an animal model.
Topics: Administration, Topical; Animals; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Los | 2015 |
[Blood loss during total knee-joint replacement: a combination of anticoagulant and hemostatic techniques].
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Etha | 2014 |
[Effectiveness of tranexamic acid in total knee arthroplasty].
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2014 |
Topical tranexamic acid was noninferior to intravenous tranexamic acid in controlling blood loss during total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans; Male | 2015 |
Eliminating the use of allogeneic blood products in adolescent idiopathic scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemoglobins; H | 2015 |
Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
Does Tranexamic Acid Reduce Blood Loss and Transfusion Requirements Associated With the Periacetabular Osteotomy?
Topics: Acetabulum; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Dru | 2015 |
Tranexamic Acid Benefits Total Joint Arthroplasty Patients Regardless of Preoperative Hemoglobin Value.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
The value of tranexamic acid during fronto-orbital advancement in isolated metopic craniosynostosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Female; Humans; | 2015 |
[The Use of Thromboelastometry and Tranexamic Acid Reduces Blood Loss and Transfusion Requirements in Cardiac Surgery under Cardiopulmonary Bypass].
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Cardiopulmonary Bypass; | 2015 |
The efficacy of tranexamic acid in hip hemiarthroplasty surgery: an observational cohort study.
Topics: Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemiarthroplasty; Hip Frac | 2015 |
Tranexamic Acid Decreases Incidence of Blood Transfusion in Simultaneous Bilateral Total Knee Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2015 |
Universal tranexamic acid therapy to minimize transfusion for major joint arthroplasty: a retrospective analysis of protocol implementation.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2015 |
CORR Insights(®): Does Tranexamic Acid Reduce Blood Loss and Transfusion Requirements Associated With the Periacetabular Osteotomy?
Topics: Acetabulum; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hip Dislocatio | 2015 |
Minimizing Blood Transfusion in Total Hip and Knee Arthroplasty Through a Multimodal Approach.
Topics: Aged; Aged, 80 and over; Algorithms; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip | 2016 |
The Use of Intravenous Tranexamic Acid in Patients Undergoing Total Hip or Knee Arthroplasty: A Retrospective Analysis at a Single Military Institution.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2015 |
Intravenous administration of tranexamic acid effectively reduces blood loss in primary total knee arthroplasty in a 610-patient consecutive case series.
Topics: Administration, Intravenous; Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Hu | 2016 |
An In Vivo Study of Low-Dose Intra-Articular Tranexamic Acid Application with Prolonged Clamping Drain Method in Total Knee Replacement: Clinical Efficacy and Safety.
Topics: Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drainage; Female; Humans; Injections, I | 2015 |
Cost Analysis of Tranexamic Acid in Anemic Total Joint Arthroplasty Patients.
Topics: Aged; Anemia; Antifibrinolytic Agents; Arthroplasty; Blood Loss, Surgical; Blood Transfusion; Cost-B | 2016 |
Tranexamic acid reduces the blood loss and blood transfusion requirements following peri-acetabular osteotomy.
Topics: Acetabulum; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Fem | 2015 |
Tranexamic acid decreases blood loss after total shoulder arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Blood Transfusion; Female; | 2016 |
Intra-articular tranexamic acid wash during bilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2015 |
Comparison between topical and intravenous administration of tranexamic acid in primary total hip arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2016 |
Does tranexamic acid reduce blood loss and transfusion rates in unicompartmental knee arthroplasty?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; F | 2016 |
"Topical vs Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Double-Blind, Randomized Controlled Trial".
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
Cost-effectiveness of post-operative cell salvage in total knee arthroplasty. Should we continue to recommend its use today?
Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; Blood Transfusion, Autolog | 2016 |
Topical vs Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Double-Blind, Randomized Controlled Trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
Is there a need for routine post-operative hemoglobin level estimation in total knee arthroplasty with tranexamic acid use?
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Tranexamic acid: optimal blood loss management in surface replacement arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2016 |
Low dose tranexamic acid reduces blood transfusion rate after total knee arthroplasty: A population-based study in Taiwan.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
Beware of using tranexamic acid in parturients with eclampsia.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Critical Care; Eclampsia; Fe | 2016 |
In Reply: Tranexamic Acid Benefits Total Joint Arthroplasty Patients Regardless of Preoperative Hemoglobin Value.
Topics: Antifibrinolytic Agents; Arthroplasty; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood | 2016 |
Letter to the Editor on "Tranexamic Acid Benefits Total Joint Arthroplasty Patients Regardless of Preoperative Hemoglobin Value".
Topics: Antifibrinolytic Agents; Arthroplasty; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood | 2016 |
Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty; Aspirin; Blood Loss, Surgical; Cohort Studies; Female; | 2016 |
A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Blood Component Transfusion; Blood Loss, Surgical; Cytoreduction Surgical Procedures; Factor VIII; F | 2016 |
Tranexamic acid in total joint arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Post | 2016 |
Low-volume formulation of intra-articular tranexamic acid, 25-ml tranexamic acid (2.5 g) plus 20-ml saline, is effective in decreasing blood transfusion rate in primary total knee replacement even without preoperative haemoglobin optimization.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2016 |
Bleeding complications during cardiac electronic device implantation in patients receiving antithrombotic therapy: is there any value of local tranexamic acid?
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Chi-Square Distributio | 2016 |
Tranexamic acid decreases blood loss in total shoulder arthroplasty and reverse total shoulder arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Shoulder; Blood Loss, S | 2016 |
Announcing the winner of the John J. Sciarra IJGO Prize Paper Award for 2015.
Topics: Awards and Prizes; Blood Loss, Surgical; Cesarean Section; Female; Gynecology; History, 21st Century | 2016 |
Efficacy of tranexamic acid in reducing allogeneic blood products in adolescent idiopathic scoliosis surgery.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Humans; Male; | 2016 |
Commentary: Clinical and financial benefits of intra-articular tranexamic acid in total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2016 |
Letter to the Editor: Intra-articular tranexamic acid wash during bilateral total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2016 |
Letter to the Editor: Intra-articular tranexamic acid wash during bilateral total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2016 |
Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2016 |
Multimodal blood loss prevention approach including intra-articular tranexamic acid in primary total knee arthroplasty for patients with severe haemophilia A.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control Studies | 2016 |
Comparison of ε-Aminocaproic Acid and Tranexamic Acid in Reducing Postoperative Transfusions in Total Hip Arthroplasty.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
Controversy in Tranexamic Acid Administration Route Continues: Commentary on an article by Zeng Yi, MD, et al.: "Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial of Intravenous Combined with Topical Versus Si
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Tranexamic acid in hip fracture patients: a protocol for a randomised, placebo controlled trial on the efficacy of tranexamic acid in reducing blood loss in hip fracture patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2016 |
Effect of Antifibrinolytic Therapy on Complications, Thromboembolic Events, Blood Product Utilization, and Fusion in Adult Spinal Deformity Surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; | 2016 |
Intravenous versus topical tranexamic acid administration in primary total knee arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
The Efficacy Comparison of Tranexamic Acid for Reducing Blood Loss in Total Knee Arthroplasty at Different Dosage Time.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
Blood-Sparing Efficacy of Oral Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Sur | 2017 |
Tranexamic Acid in Anesthetic Management of Surgical Procedures.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Contr | 2016 |
Prophylactic use of tranexamic acid combined with thrombelastogram guided coagulation management may reduce blood loss and allogeneic transfusion in pediatric hemispherectomy: case series.
Topics: Algorithms; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschoo | 2016 |
Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Hemorrhage; Humans; Infant; Postope | 2016 |
Effects of tranexamic acid on coagulation indexes of patients undergoing heart valve replacement surgery under cardiopulmonary bypass.
Topics: Adolescent; Blood Coagulation; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary By | 2016 |
Topical Tranexamic Acid in Total Knee Arthroplasty Patients with Increased Thromboembolic Risk.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2017 |
The Michigan Experience with Safety and Effectiveness of Tranexamic Acid Use in Hip and Knee Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2016 |
Tranexamic acid use and risk of thrombosis in regular users ofantithrombotics undergoing primary total knee arthroplasty: a prospectivecohort study.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Fibrinolytic Agents; | 2018 |
Influence of single-dose intravenous tranexamic acid on total hip replacement : A study on transfusions, collateral complications, and readmissions.
Topics: Aged; Antifibrinolytic Agents; Argentina; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Bloo | 2017 |
Re: Efficacy and Safety of Intraoperative Tranexamic Acid Infusion for Reducing Blood Transfusion during Open Radical Cystectomy.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cystectomy; Humans; Tranexamic Aci | 2016 |
Rapid hemostasis in a sheep model using particles that propel thrombin and tranexamic acid.
Topics: Animals; Blood Loss, Surgical; Carotid Artery Injuries; Disease Models, Animal; Hemostatic Technique | 2017 |
High-dose tranexamic acid reduces intraoperative and postoperative blood loss in posterior lumbar interbody fusion.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Case-Cont | 2017 |
Lower red cell transfusion rates with use of tranexamic acid in single-stage bilateral total knee arthroplasty: A retrospective audit.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2016 |
Topical Tranexamic Acid is Equivalent to Targeted Preoperative Autologous Blood Donation in Total Hip Arthroplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anemia; Antifibrinolytic Agents; Arthroplas | 2017 |
Prospective observational study of the effect of dual antiplatelet therapy with tranexamic acid treatment on platelet function and bleeding after cardiac surgery.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Platelets; Card | 2016 |
Intraarticular Administration of Tranexamic Acid is Safe and Effective in Total Knee Arthroplasty Patients at High-Risk for Thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2016 |
[Intra-Articular Application of Tranexamic Acid Significantly Reduces Blood Loss and Transfusion Requirement in Primary Total Knee Arthroplasty].
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; | 2016 |
Tranexamic acid versus fibrin sealant in primary total hip replacement: a comparative study.
Topics: Aerosols; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood | 2017 |
Can tranexamic acid reduce blood loss in cervical laminectomy with lateral mass screw fixation and bone grafting: a retrospective observational study.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Bone Screws; Bone Transplantation; Cervical Ver | 2017 |
The Effectiveness and Safety of Tranexamic Acid in Orthotopic Liver Transplantation Clinical Practice: A Propensity Score Matched Cohort Study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Databases, Factual; Erythrocyte Transfusion; Female; | 2017 |
Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery.
Topics: Aged; Antifibrinolytic Agents; Area Under Curve; Blood Loss, Surgical; Coronary Artery Bypass; Creat | 2017 |
Tranexamic acid: still far to go.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2017 |
Safety of antifibrinolytics in cranial vault reconstructive surgery: a report from the pediatric craniofacial collaborative group.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Cooperati | 2017 |
Reply to letter to the editor on "Intravenous versus intra-articular tranexamic acid in total knee arthroplasty: A double-blinded randomised controlled noninferiority trial".
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2017 |
Letter to editor "Intravenous versus intra-articular tranexamic acid in total knee arthroplasty: A double-blinded randomized controlled noninferiority trial".
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2017 |
Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.
Topics: Acute Kidney Injury; Aged; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Case-Control Studies; | 2008 |
Perioperative coagulation management and blood conservation in cardiac surgery: a Canadian Survey.
Topics: Anticoagulants; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Heparin; Human | 2008 |
A questionnaire-based survey of perioperative blood conservation practice for revision hip arthroplasty in Scotland.
Topics: Anesthesia; Anesthesiology; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Sur | 2008 |
Routine preoperative coagulation screening detects a rare bleeding disorder.
Topics: Antifibrinolytic Agents; Blood Component Transfusion; Blood Loss, Surgical; Child; Factor X Deficien | 2009 |
Bleeding in liver surgery: prevention and treatment.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Fibrin Tissue Adhesive; Hemostatics; Hepat | 2009 |
Bleeding in liver surgery: prevention and treatment.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Fibrin Tissue Adhesive; Hemostatics; Hepat | 2009 |
Bleeding in liver surgery: prevention and treatment.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Fibrin Tissue Adhesive; Hemostatics; Hepat | 2009 |
Bleeding in liver surgery: prevention and treatment.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Fibrin Tissue Adhesive; Hemostatics; Hepat | 2009 |
Bleeding in liver surgery: prevention and treatment.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Fibrin Tissue Adhesive; Hemostatics; Hepat | 2009 |
Bleeding in liver surgery: prevention and treatment.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Fibrin Tissue Adhesive; Hemostatics; Hepat | 2009 |
Bleeding in liver surgery: prevention and treatment.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Fibrin Tissue Adhesive; Hemostatics; Hepat | 2009 |
Bleeding in liver surgery: prevention and treatment.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Fibrin Tissue Adhesive; Hemostatics; Hepat | 2009 |
Bleeding in liver surgery: prevention and treatment.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Fibrin Tissue Adhesive; Hemostatics; Hepat | 2009 |
Living without aprotinin: the results of a 5-year blood saving program in cardiac surgery.
Topics: Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Blood Loss, Surg | 2009 |
Antifibrinolytic therapy in complex spine surgery: a case-control study comparing aprotinin and tranexamic acid.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion | 2009 |
Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
Optimization of recovering shed blood when performing blood salvage.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Autologous; Cardiac Surgical Proce | 2009 |
[Type A hemophilia in a man undergoing liver resection for metastasis: implications for anesthetic management].
Topics: Adenocarcinoma; Aged; Anesthesia, General; Blood Loss, Surgical; Colorectal Neoplasms; Deamino Argin | 2009 |
[Tranexamic acid and dentoalveolar surgery].
Topics: Anticoagulants; Blood Loss, Surgical; Fibrinolytic Agents; Hemostatics; Humans; Oral Surgical Proced | 2009 |
eComment: A comparison of the safety of aprotinin and tranexamic acid in cardiac surgery.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Proced | 2009 |
Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.
Topics: Alleles; Blood Loss, Surgical; Factor VIIa; Factor XI; Factor XI Deficiency; Female; Hemophilia A; H | 2009 |
Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation.
Topics: Angioplasty, Balloon, Coronary; Antifibrinolytic Agents; Blood Loss, Surgical; Coagulants; Coronary | 2009 |
Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Spine 2008; 33: 2577-80.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Orthopedic Procedures; P | 2009 |
The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiop | 2010 |
Pneumatic wound compression after hip fracture surgery.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Bandages; Blood Loss, Surgical; Fracture Fi | 2009 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2010 |
Can we safely reduce blood loss during lumbar pedicle subtraction osteotomy procedures using tranexamic acid or aprotinin? A comparative study with controls.
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Female; Hemostatics; Humans; | 2010 |
Can we safely reduce blood loss during lumbar pedicle subtraction osteotomy procedures using tranexamic acid or aprotinin? A comparative study with controls.
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Female; Hemostatics; Humans; | 2010 |
Can we safely reduce blood loss during lumbar pedicle subtraction osteotomy procedures using tranexamic acid or aprotinin? A comparative study with controls.
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Female; Hemostatics; Humans; | 2010 |
Can we safely reduce blood loss during lumbar pedicle subtraction osteotomy procedures using tranexamic acid or aprotinin? A comparative study with controls.
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Female; Hemostatics; Humans; | 2010 |
A single centre experience in circumcision of haemophilia patients: Izmir protocol.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Circumcision, Male; Factor I | 2010 |
Tranexamic acid reduces allogenic transfusion in revision hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2011 |
Tranexamic acid: how much is enough?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Dose-Response Relationsh | 2010 |
Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiop | 2010 |
Tranexamic acid: an alternative to aprotinin as antifibrinolytic therapy in pediatric congenital heart surgery.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Proced | 2011 |
Efficient strategy for controlling postoperative hemorrhage in total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Arthroplasty, Replacement, Knee; Blood Loss, Surgical | 2011 |
ε-Aminocaproic acid and clinical value in cardiac anesthesia.
Topics: Algorithms; Aminocaproic Acid; Anesthesia; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; | 2011 |
Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients.
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Endarterectomy; Female; Hemos | 2010 |
Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion | 2011 |
Blood conservation and pain control in scoliosis corrective surgery: an online survey of UK practice.
Topics: Adolescent; Analgesia, Epidural; Analgesics, Opioid; Anesthesia; Anticoagulants; Antifibrinolytic Ag | 2011 |
Blood conservation in cardiac surgery.
Topics: Algorithms; Aprotinin; Blood Loss, Surgical; Blood Substitutes; Blood Transfusion; Cardiac Surgical | 2010 |
The post-BART anti-fibrinolytic dilemma?
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2011 |
Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid.
Topics: Aged; Aminocaproic Acid; Anesthesia; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical | 2011 |
Conference discussion: Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass; | 2011 |
Comparison of blood-sparing efficacy of ε-aminocaproic acid and tranexamic acid in newborns undergoing cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgica | 2011 |
Use of tranexamic acid is a cost effective method in preventing blood loss during and after total knee replacement.
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgica | 2011 |
rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency.
Topics: Adolescent; Adult; Blood Loss, Surgical; Factor VII Deficiency; Factor VIIa; Female; Hemostasis, Sur | 2011 |
Is tranexamic acid really an alternative to aprotinin?
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Female; Heart | 2012 |
Use of tranexamic acid as a rescue measure to achieve hemostasis after massive blood loss in a pediatric neurosurgical patient.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Choroid Plexus Neoplasms; Female; Hemostasis; Humans; | 2011 |
Comparative analysis of tranexamic acid use in minimally invasive versus open craniosynostosis procedures.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Chi-Square Distribution; Child; Craniosynostoses; Fem | 2011 |
Use of tranexamic acid to reduce bleeding in burns surgery.
Topics: Bandages; Blood Loss, Surgical; Burns; Craniocerebral Trauma; Humans; Male; Middle Aged; Neck Injuri | 2012 |
Are antifibrinolytics helpful in decreasing blood loss and transfusions during spinal fusion surgery in children with cerebral palsy scoliosis?
Topics: Adolescent; Aminocaproic Acid; Analysis of Variance; Antifibrinolytic Agents; Blood Loss, Surgical; | 2012 |
Efficacy of tranexamic acid in reducing blood loss in posterior lumbar spine surgery for degenerative spinal stenosis with instability: a retrospective case control study.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Decompression, Surgical; Dose-Response Relation | 2011 |
Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery.
Topics: Age Factors; Analysis of Variance; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac | 2012 |
Randomised surgical trials need good surgical outcomes in the control arm.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Male; Prostatectomy; Tranexamic Acid | 2011 |
Use of tranexamic acid in pediatric cardiac surgery: we really need more.
Topics: Blood Loss, Surgical; Cardiac Surgical Procedures; Female; Humans; Male; Postoperative Hemorrhage; T | 2012 |
[Tranexamic acid reduces blood loss after major elective orthopaedic operations].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2012 |
Reducing blood losses and transfusion requirements in craniosynostosis surgery: an endless quest?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Elective Surgica | 2012 |
Comparison of aprotinin and tranexamic acid in adult scoliosis correction surgery.
Topics: Adolescent; Adult; Aged; Aprotinin; Blood Loss, Surgical; Female; Hemostasis, Surgical; Hemostatics; | 2012 |
Effectiveness of tranexamic acid in revision total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2012 |
Tranexamic acid for reduction of blood loss during total hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; | 2012 |
Tranexamic acid for reduction of blood loss during total hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; | 2012 |
Tranexamic acid for reduction of blood loss during total hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; | 2012 |
Tranexamic acid for reduction of blood loss during total hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Female; Humans; | 2012 |
Does the intraoperative tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of adolescent idiopathic scoliosis?
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Female; Humans; | 2012 |
Tranexamic acid reduces blood loss and financial cost in primary total hip and knee replacement surgery.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplast | 2012 |
Tranexamic acid reduces blood transfusion in surgical patients while its effects on thromboembolic events and mortality are uncertain.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Tranexamic Acid | 2013 |
Antifibrinolytic agents reduce blood loss during pediatric vertebral column resection procedures.
Topics: Adolescent; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfus | 2012 |
[Pharmacological reduction of bleeding during hip endoprosthetic replacement].
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2012 |
A retrospective analysis of blood loss with combined topical and intravenous tranexamic acid after coronary artery bypass graft surgery.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cohort Studies; Corona | 2013 |
Coronary artery bypass grafting after aprotinin: are we doing better?
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary B | 2013 |
The risks associated with aprotinin use: a retrospective study of cardiac cases in Nova Scotia.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical | 2013 |
Does tranexamic acid reduce blood loss and blood transfusion requirement in knee arthroplasty?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; F | 2012 |
The routine use of tranexamic acid in hip and knee replacements.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biom | 2012 |
[Perioperative management based on kinetics of bleeding during total primary arthroplasty].
Topics: Aged; Anesthesia, General; Anesthesia, Spinal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthr | 2013 |
Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2013 |
[Anesthetic management of a patient with congenital plasminogen activator inhibitor-1 deficiency].
Topics: Adult; Anesthesia, General; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Male; Molar, Thir | 2003 |
[Protocol for adapting treatment with vitamin K antagonists before dental extraction].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Blood Loss, Sur | 2003 |
[Tranexamic acid versus aprotinin for the prevention of bleeding during mitral valve surgery ].
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiopulmonary Bypass; Dose-Respon | 2003 |
[Acute normovolemic hemodilution combined with inhibition of fibrinolysis and use of cell saver in total hip arthroplasty].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Bl | 2003 |
The use of tranexamic acid to reduce blood loss during total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Bone Cements; | 2003 |
Comment on "Clinical observation of blood loss reduced by tranexamic acid during and after cesarian section: a multi-center, randomized trial (Eur J Obstet Gynecol Reprod Biol 2004; 112: 154-57)".
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Multicenter Studies | 2004 |
More information on patients with factor XI deficiency.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Factor XI Deficiency; Hemostasis; Humans; Postoperati | 2004 |
Identifying patients at risk of intraoperative and postoperative transfusion in isolated CABG: toward selective conservation strategies.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Anticoagulants; Blood Component Transfusion; Bloo | 2004 |
Continuous infusion of factor VIIIc during heart surgery in a patient with haemophilia A.
Topics: Anticoagulants; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Coronary | 2004 |
Antifibrinolytic use and bleeding during surgery on the descending thoracic aorta: a multivariate analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aortic Aneurysm, Thoracic; Blood Loss, Surgical; D | 2005 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
[Hemostatic drugs in a patient with antiphospholipid syndrome and clinically significant perioperative bleeding].
Topics: Adult; Aminocaproic Acid; Antiphospholipid Syndrome; Aprotinin; Blood Coagulation Tests; Blood Loss, | 2006 |
Management of the dental patient on anticoagulant medication.
Topics: Anticoagulants; Bleeding Time; Blood Coagulation Disorders; Blood Loss, Surgical; Dental Care for Ch | 2006 |
[The "Seville" Consensus Document on Alternatives to Allogenic Blood Transfusion. Sociedades españolas de Anestesiología (SEDAR), Medicina Intensiva (SEMICYUC), Hematología y Hemoterapia (AEHH), Transfusión sanguínea (SETS) Trombosis y Hemostasia (SETH)].
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Substitutes; Bloo | 2006 |
Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
Topics: Aminocaproic Acid; Animals; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Drug Hyper | 2006 |
Antifibrinolytic therapy use to mitigate blood loss during staged complex major spine surgery: Postoperative visual color changes after tranexamic acid administration.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Chordoma; Color Perception; Color Vision Defects; Hum | 2006 |
Topical use of tranexamic acid to control perioperative local bleeding in gynaecology patients with clotting disorders: two cases.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Blood Coagulation Diso | 2007 |
Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann's thrombasthenia for nasal polipectomy.
Topics: Adult; Aminocaproic Acid; Anesthesia, General; Antifibrinolytic Agents; Blood Loss, Surgical; Drug T | 2007 |
Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome.
Topics: Adolescent; Blood Loss, Surgical; Blood Platelet Disorders; Drug Administration Schedule; Factor VII | 2007 |
Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusions for duchenne muscular dystrophy scoliosis.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Child; E | 2007 |
Practice pearl: a novel use of tranexamic Acid for decreasing the blood loss of aneurysmal bone cyst ablation.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Bone Cysts, Aneurysmal; Humans; Tranexamic Acid | 2008 |
[Antifibrinolytic agents and repeat open-heart surgery: a comparison of tranexamic acid and low dose aprotinin].
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical | 2007 |
[A Jehovah's Witness child with hemophilia B and factor IX inhibitors undergoing scoliosis surgery].
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Dietary Supplements; Epoetin Alfa; Erythr | 2008 |
Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surg | 2008 |
Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients?
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Female; Follow-Up Studies; Graft Re | 2008 |
Re: Shapiro F, Zurakowski D, Sethna NF. Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusion for Duchenne muscular dystrophy scoliosis. Spine 2007;32:2278-83.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Child; E | 2008 |
[Effectiveness of tranexamic acid in routine performance of total knee replacement surgery].
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2008 |
[Drugs to reduce transfusion needs during surgery].
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Blood Transfusion, Auto | 2008 |
Does tranexamic acid reduce blood loss in knee arthroplasty?
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distribution; Fem | 1995 |
Drugs for surgical blood loss.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Humans; Serine Proteinase Inhibitors; Tranexamic Acid | 1993 |
Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass; Coronary Artery | 1993 |
Tranexamic acid use during coronary artery bypass grafting.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Chi-Square Distribution; Coronary Artery Bypass; Fibr | 1996 |
Cost/benefit analysis of pharmacologic hemostasis.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Cost- | 1996 |
Tranexamic acid reduces blood loss after knee arthroplasty.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Knee Prosthesis; Postoperative Complications; | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
[Mouth-washing with tranexamic acid in patients treated with oral anticoagulants subjected to oral surgery procedures].
Topics: Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Dental S | 1998 |
[Can drugs reduce the need for blood transfusion in the course of surgery?].
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Deamino Arginine Vasopr | 1999 |
Tranexamic acid applied topically to achieve haemostasis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Hemostasis, Surgical; | 2000 |
Is tranexamic acid indicated for total knee replacement surgery?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Hemodilution; Humans | 2000 |
Antifibrinolytic therapy reduces blood loss in knee replacement surgery.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Hemodilution; Humans | 2000 |
Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases.
Topics: Adult; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Factor VIIa; Factor VIII; Hemophilia A; | 2000 |
Preservation of collagen-induced whole blood platelet aggregation by tranexamic acid therapy in primary cardiac valve surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiopulmonary Bypass; Collagen; Female; Hear | 2000 |
Plasma tranexamic acid concentrations during cardiopulmonary bypass.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary B | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
The use of technologies to decrease peri-operative allogenic blood transfusion: results of practice variation in Israel.
Topics: Aprotinin; Attitude of Health Personnel; Biomedical Technology; Blood Loss, Surgical; Blood Transfus | 2001 |
Intramedullary multiple hematomas in siblings with congenital alpha-2-plasmin inhibitor deficiency: orthopedic surgery with protection by tranexamic acid.
Topics: Adolescent; alpha-2-Antiplasmin; Blood Loss, Surgical; Bone Diseases; Child; Female; Femur; Hematoma | 1991 |